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ABSTRACT 
Background: Tuberculosis is a leading cause of morbidity and mortality in several low- and 
middle income countries (LMICs). Despite a decline in the burden of tuberculosis (TB) over the 
last century in many high-income countries (HICs), including the United Kingdom, emerging 
evidence in the last 10 years reveals an increasing burden attributed mainly to immigration, 
particularly from countries with high TB incidence like Nigeria.  
Methods: Based on Nigeria, this study explores the cost-effectiveness of three TB control 
strategies on reducing the potential burden of TB among Nigerian migrants to the United 
Kingdom.  The three strategies explored were: i) Chest X Ray (CXR) Screening of Nigerian 
migrants at United Kingdom airports; ii) Interferon Gamma Release Assay (IGRA) Screening 
at airports; and iii) ‘enlighten self-interest’ investment of the UK government by supporting 
Nigeria to scale-up her country-based TB control programme. A decision analysis model was 
developed to estimate the cumulative probabilities of TB-related outcomes and the cost-
effectiveness of each strategy. Quality Adjusted Life Years (QALYs) were used as the utility 
measure, and a 3% discount was applied to all future costs. 
Results: Over 91,000 Nigerian migrants were estimated to come to the United Kingdom 
annually over the 20 years modelled. 21.62% of these migrants were likely to be screened for 
TB based on the current practice (or selection) of TB screening. The average cost of TB 
treatment in Nigeria was estimated at US $227. The median out-of-pocket patient cost for 
hospitalized cases was US$166.11, while ambulatory patients paid an estimated median cost of 
US$94.16, equivalent to about 9-38% of their average annual income. Delay in diagnosis of TB 
across various settings in Nigeria was attributable to the estimated high direct and indirect costs 
from TB. The mean cost, to the UK government, for investment (paying the whole funding gap) 
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in scaling up TB control in Nigeria was estimated at £253.78 (SD £25.84) per Nigerian migrant 
coming into the UK, CXR screening at £293.41 (£102.95), IGRA screening at £690.93 
(£113.45), while not doing anything ‘Nothing’ will still cost the UK government £70.29 (£31.52) 
per Nigerian migrant. The incremental cost-effectiveness ratio (ICER) for strategies – 
Investment in the Nigerian TB control, CXR, and IGRA –  compared to strategy ‘Nothing’ was 
estimated at £2,964/QALY, £15,712/QALY and £11,429/QALY, respectively. 
Conclusions : Relative to the Nigerian GDP, this study reveals a high cost of TB treatment in 
Nigeria, suggesting a disproportionate expenditure on TB at the expense of other competing 
health needs in the Nigerian health sector. The study suggests, albeit with important limitations, 
a potential benefit to the United Kingdom when the WHO Stop TB Strategy program is fully 
scaled up in Nigeria. There is potential application of the findings of this study in other high-
income countries that receive large numbers of migrants, and the low-income, but higher TB 
incidence, countries like Nigeria.
 1 
1. INTRODUCTION 
1.1. OVERVIEW 
This chapter presents the background information and approach to this thesis. It provides the 
general motivation, problem statement and justification of the research. The chapter also covers 
the research aim, objectives and anticipated outcomes. The thesis structure is also given in the 
concluding section of the chapter. 
1.2. RESEARCH BACKGROUND 
Tuberculosis (TB) has been among the top global health crisis for several decades (1). In the 
2016 World Health Organization (WHO) global TB report (2), there were an estimated 10.4 
million incident (new) cases and 1.4 million deaths from TB worldwide in 2015, with people 
living with HIV accounting for about 1.2 million (11%) of all new cases of TB globally. Cur-
rently, more than 2 billion people, about one-third of the world’s population are infected with 
TB, with this accounting for almost 26% of all preventable deaths globally (1-3). Across world 
regions, the burden is unevenly distributed, with several regions disproportionately affected (3, 
4). According to the WHO, six countries—India, Indonesia, China, Nigeria, Pakistan and South 
Africa—accounted for about 60% of the new cases of TB in 2015 (2). Africa has the highest TB 
incidence and mortality worldwide, with this accounting for about one-fourth of TB burden 
globally (1, 5). The response to the rising burden has also been a major challenge, especially in 
resource-constrained settings. Estimates suggest that in several world regions, about three mil-
lion people were consistently not diagnosed, not treated, or possibly not officially covered by 
local or national TB programmes (6, 7). Indeed, many affected persons in this category will 
continue to be a source of infection to others, with this pointing to the need for a comprehensive 
global response (8). 
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One largely under-researched aspect of TB, especially in Africa, is the economic impact, given 
the size of the problem in the region (8, 9). Many affected persons are actually in the economi-
cally active and productive population age groups (10). In fact, the disease no longer affects 
only the poor, with many affected persons now having moderate education, and moderate in-
comes (10, 11). The direct costs to patient, family and several governments have been tremen-
dously huge. In fact, one significant indirect cost of TB to a sick patient is income lost from the 
inability to go to work, with this estimated to about 20-30% income of a household yearly (12). 
Families and carers are also affected, especially among the inpatients (13). These all point to a 
large economic burden in settings with high TB incidence. 
Tuberculosis (TB) is an infectious disease caused by a bacterium from the Mycobacterium 
tuberculosis complex. These comprise M. tuberculosis, M. bovis, M. africanum and M. microti 
(14). Depending on national guidelines for TB diagnosis and management, the case definition 
of TB varies slightly across countries (14).  However, in most instances, it is necessary to isolate 
one of the M. tuberculosis complex organisms from the affected organ(s) for a case to be 
confirmed (15). M. tuberculosis complex is usually transmitted as an infectious aerosol, but also 
by ingestion of contaminated milk (usually Mycobacterium bovis), or less commonly through 
direct inoculation (16). Humans, and rarely primates, are the primary reservoir (16). Sharing 
breathing space with an infectious (i.e. sputum smear-positive) person is the most important risk 
factor for acquiring infection (14).  The transmission of a disease among persons depend on the 
clinical presentation of the TB, smear status, age of the infected person, proximity and duration 
of exposure to an infectious aerosol (from cough or sneeze), and if early diagnosis and prompt 
treatment were instituted (14). Except for rare conditions, for example a draining skin sinus, 
extra-pulmonary TB (other than laryngeal) is generally not communicable (16). 
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Generally, TB is a highly complex and poorly understood disease, having persistently infected 
people for several years, and even nowadays, despite the availability of antibiotics (17). There 
are many unanswered questions on the natural history, and impact of current interventions (17). 
This has prompted several debates among authors on the need to improve the understanding of 
the dynamic epidemiology of TB, especially regarding measures to control the spread of the 
disease across international borders (17, 18). 
As already noted, TB disproportionately affects poor and marginalized populations, especially 
those who do not have access to health care and social support. This has been particularly 
observed in populations with high prevalence of HIV, which also shares links with poor socio-
economic status (19). Evidence shows that HIV co-infection increases the risk of developing 
TB significantly (20). It specifically targets cell-mediated immunity, impairing its functions and 
processes (21). It can be understood that countries in sub-Saharan Africa with high prevalence 
of HIV, have continued to report an increasing trend in new TB cases over the last two decades 
(21, 22).  
Although there has been a steady decline in the prevalence of TB in developed countries, recent 
evidence has shown a rise in both TB incidence and prevalence in these countries from the mid-
1980s onward (23). This has been attributed mainly to immigration patterns (24). The lack of 
capacity of the health systems in developing countries to respond to the disease may have been 
an underlying factor. Hence, due to increasing migration from these settings with high TB 
incidence, high-income countries have now continued to witness a rising number of new TB 
cases (18).  
Based on historical evidence, human migration has played important roles in the spread of TB 
worldwide (25, 26). In the seventeenth century, the first epidemic of TB—White plague—
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occurred in Europe, with TB becoming the leading cause of death for several years (27). 
Subsequently, this spread to other continents, resulting in major TB epidemics across the world 
(28). With high-income countries tackling the disease, and substantial gaps existing in low-
income settings, coupled with increased migration to high-incomes countries from low-income 
settings, increased TB prevalence has been reported in immigrants-receiving countries (29). 
Experts have estimated the proportion of TB patients that were foreign-born at 85% across low-
incidence countries (29, 30). In the UK, TB notifications have increased over the last 30 years, 
increasing by about 50% to 9040 cases between 1998 and 2009 (31). Foreign-born individuals 
account for over 70% of TB notifications in the country, with a 22-fold increase in incidence 
rate at 89 cases per 100000, compared to 4 cases per 100000 in UK-born persons (31).   
Reports show that several of these TB cases were due to reactivation of latent TB infection 
(LTBI) in the migrant population, which has been acquired before arriving the low-incidence 
countries, enhanced by high levels of migration from sub-Saharan Africa and India, which have 
high TB burdens (32). The International Union Against TB and Lung Diseases has already 
indicated a strong relationship between TB incidence and international migration, which need 
to be comprehensively reviewed to optimize control (29, 33). 
In the last three decades, several developed countries have spent millions of United States 
Dollars (US$) annually for TB treatment in their respective countries (34). Despite the huge 
costs committed to the management of TB in these countries, more cases have continued to be 
imported by immigrants (28, 35). According to Pareek and colleagues, TB control in several 
high-income settings have historically targeted early identification and treatment of active TB 
cases with strict contact tracing (32). However, due to high TB loads in migrant populations, it 
still remains doubtful how best to identify (or contract-trace) TB in these groups (36).  
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Meanwhile, in developing countries, there is still a complex pathway required to be navigated 
by every patient to ensure effectiveness of TB control measures (37, 38). This involves 
presenting at local health centres, suspicion of TB by a clinician, ordering appropriate diagnostic 
investigations, making accurate diagnosis and commencement of the right medications (37). 
The loss of patients along this line can affect the epidemiological impact of a diagnostic 
intervention. 
According to the WHO, population-wide improvements in the ability to detect TB, especially 
in resource-constrained settings, must be ensured (39). This is because TB is grossly under-
diagnosed across world regions, with just about 67% of TB cases currently detected, and 57% 
with confirmed bacteriologic diagnosis (40). Insufficient laboratory capacity in several settings 
and relative costs of TB diagnosis, coupled with poor sensitivity and specificity of available 
diagnostic tools may have contributed to these challenges (41). It has been suggested that 
established market economies need to be carried along with new technological innovations to 
help address the cost of TB interventions, particularly because they eventually share in TB 
burden as a result of migration (42, 43). Besides, the current uncertainties surrounding the 
commitments of several governments also need to be addressed, possibly through a strong WHO 
backing of current and emerging interventions (44).   
Largely, high-income countries have adopted two broad approaches to tackling TB—identifying 
active TB pre- or post-arrival in migrants, or identifying LTBI in migrants from TB endemic 
settings (45). Some observers have also stated that investments in TB control in high TB burden 
countries by providing targeted LTBI screening and treatment may be of huge benefits to 
migrants-receiving high-income countries, with this however requiring addressing inherent 
(country-based) challenges and barriers to successful implementation of these interventions (46, 
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47).  
However, in the diagnosis of TB, an antecedent contact with a TB case has been found to be a 
significant clinical history in ensuring an accurate TB diagnosis, and also useful for contact 
tracing (48). A Chest X Ray (CXR) may be helpful but can also be misleading, as this requires 
other confirmatory tests and appropriate clinical history (49). A positive tuberculin skin test 
(TST) is useful, but a negative test does not exclude disease (48). However, many believe 
sputum microscopy for Acid Fast Bacilli (AFB) identification and culture remain the gold 
standard for detection of Mycobacterium tuberculosis (49). Some authors still suggest 
combination of these conventional methods with advanced diagnostic methods to enhance 
sensitivity and specificity, as detection of Mycobacterium specie may be sometimes difficult 
(50). In several advanced settings, multiplex polymerase chain reaction (PCR), or multiplex 
PCR- reverse cross blot hybridization is now being used as a confirmation assay, particularly 
for negative results from smear and culture (51-53). 
A more recent diagnostic test, Interferon-Gamma Release Assays (IGRA), has several 
advantages over the TST and CXR (54). A two-step strategy is usually employed in LTBI-
screening, with an initial TST, followed by IGRA if the TST is positive (55). One major 
advantage of IGRA over TST is the fact that it is an in-vitro test and does not require the 
subjective measurement of skin reactions, and only a single visit is necessary (56). These 
advantages therefore make IGRA an attractive alternative to replace the widely-adopted practice 
of CXR screening of migrants for TB at Port of Arrival (PoA) (56). 
Over the years, migrants have been identified and screened through the PoA channels in the UK, 
but this system has been found to be relatively ineffective with only a small proportion of 
entrants screened annually, out of which only few have active TB at the time of entry (32, 57).  
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This has raised several debates on immigrant screening exercise. The UK National Institute for 
Health and Clinical Excellence (NICE) also noted that in addition to the use of CXR at points 
of arrival, the focus should be on adult immigrants from sub-Saharan Africa, with a combination 
of  TST and a confirmatory IGRA (58). This guideline however received varying levels of 
adherence following reports suggesting the economic analyses on this guideline lacked relevant 
data on LTBI prevalence among migrants (29). There have been further reviews suggesting 
countries with TB incidence greater than 40 cases per 100000 should be screened with TST and 
a confirmatory IGRA (58). Again, these have also been debated by economists pointing out that 
the reviews were mainly based on scenarios rather than empirical data, with this failing to 
address the challenges on the preferred and cost-effective methods of TB screening among 
migrants (44, 45). Sanneh and colleagues did report that active PoA screening has significant 
benefits especially in identifying high risk groups, reducing periods of infectiousness and 
instituting early commencement of treatment (57). However due to high costs of some of the 
proposed interventions and challenges with implementation, it is still important to conduct a 
comprehensive assessment of the costs and associated benefits (45, 57). The next section gives 
insights into the main approaches to screening of TB in the UK. 
1.3. APPROACH TO SCREENING OF TUBERCULOSIS IN THE UK 
Tuberculosis screening for migrants before or when arriving developed countries started dec-
ades ago, particularly after the Second World War (59). CXR screening was the primary 
method adopted by these countries (60). At some time, general screening of the population 
was advocated but stopped when the burden of the disease significantly declined in these 
countries (59). In an 18-point questionnaire based survey to 31 member countries of the Or-
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ganization for Economic Cooperation and Development, including the UK, 86% screened im-
migrants for active TB, and 55% screened for LTBI, with marked variations in populations 
covered (45). The report reveals most developed countries used TST (68%) and IGRA (38%) 
following a positive TST performed LTBI screening, mostly conducted with random selec-
tions and varying policies and guidelines (45). 
In the UK, there is a ‘Collaborative TB Strategy for England 2015-2020’, which aims to 
achieve a yearly decrease in incidence of TB, address health inequalities occasioned by the 
disease, and ultimately eliminate TB as a public and global health problem in England (61). 
Targets have been set out in key areas to achieve this, including improving access to health 
services, ensuring early and high quality diagnostics, facilitating comprehensive contact trac-
ing, and particularly systematically implementing immigrants’ latent TB screening (61). There 
is growing evidence that active case detection, contact tracing and treatment of both active and 
latent cases are essential in effective control of TB (62). Migrants from high TB burden coun-
tries account for over 70% cases of TB in the UK (61, 63). Generally, immigrants planning to 
stay in the country for longer than 6 months undergo radiographic screening at international 
ports during first arrival, and if found or suspected to have active TB are referred to appropri-
ate facilities for more investigations and care (64).  
In the recently launched TB strategy in the UK, Latent TB infection (LTBI) screening is a key 
component. This is supported by the National Health Service (NHS) and Public Health England 
(61). Targeted population include all migrants aged 16-35 years entering the UK from a TB high 
incidence country (150 per 100,000 and over or from sub-Saharan Africa) within the last five 
years (46). The general approach is an Interferon Gamma Release Assay (IGRA) based 
screening, which will be conducted in a primary health centre, with positive individuals referred 
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to specialty infectious units (56). The programme may also provide opportunities for other 
health check initiatives. The launch of the strategy along with a clear vision and identified 
resources for a national LTBI screening programme would ensure that this intervention is 
properly implemented. The programme has a clear vision and identified needed resources, 
including a budget GB £10 million by NHS England for systematically implementing LTBI 
screening of new entrants (61). It is however still subject to further evaluation and economic 
analyses regarding the overall cost and effectiveness of the intervention. The next sections 
describe the three screening methods (CXR, TST and IGRA) in detail. 
1.4.  CHEST X-RAY (CXR) SCREENING 
Legal immigrants and visitors planning to stay longer than 6 months in the UK undergo radio-
logical screening for tuberculosis at least at the point of entry (64). However, adoption of other 
alternative screening methods, with treatment of latent tuberculosis infection, have been recom-
mended by several experts (44, 65). Ideally, CXR can be suggestive of typical TB case with the 
classic unilateral lymphadenopathy, or lung field shadows (cavitations) indicating infiltration 
(66). However, there have been challenges in categorizing TB patients especially with the in-
crease HIV prevalence and immunocompromised patients, with this subsequently increasing the 
number of atypical X-rays (67). It is important to note that the chance of any screening to diag-
nose a TB case is expressed by the sensitivity and specificity of the test, clinical presentation 
and severity of the disease, which in turn are influenced by a range of other factors (Table 1.1). 
Hence, the prevailing argument on the effectiveness of CXR screening is that it is limited by 
poor predictive value and several administrative and follow-up challenges (68). The specificity 
of CXR in detection of latent TB has been generally assumed to be very low (67).   Other limi-
tations include the fact that some migrants and visitors might not be screened based on the 
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screening eligibility guidelines that consider the ‘migrant-declared’ intended length of stay in 
the country (68), and exposure of foreign born residents who often visit their countries of birth 
(69).  
Table 1.1. Sensitivity, specificity and predictive values of Chest X Ray (CXR) screening for 
pulmonary TB 
 Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
PPV (95% CI) NPV (95% CI) 
TB cases  91 (88–93) 67 (62–71) 0.78 (0.74–
0.81) 
0.84 (0.81–.088) 
Any CXR pathology 92 (90–94) 63 (58–67) 0.76 (0.73–
0.79) 
0.86 (0.82–0.90) 
 
Source: MRA van Cleeff et al. The role and performance of chest X-ray for the diagnosis of tuberculosis: A cost-effectiveness 
analysis in Nairobi, Kenya. BMC Infectious Diseases 2005, 5:111.(70) 
PPV: Positive Predictive Value, NPV: Negative Predictive Value 
 
1.5. TUBERCULIN SKIN TEST (TST) 
 
As noted earlier, a CXR may be helpful but can also be misleading, as this requires other con-
firmatory tests and appropriate clinical history (49). A positive tuberculin skin test (TST) is 
useful, but a negative test does not exclude disease (48).  Many have stated that an accurate 
diagnosis of LTBI depends on a positive TST, especially among contacts and groups likely to 
progress to active TB (71). But, TST may sometimes give false positive results due to a rela-
tively poor specificity, owing to several antigens it shares with Bacille Calmette-Guerin (BCG) 
(72, 73). In fact, TST has been suggested as the most cost-effective diagnostic measure for pre-
venting new cases of TB on a short-term basis (48).  
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1.6. INTERFERON GAMMA RELEASE ASSAYS (IGRA) 
IGRA test is based on the detection of mycobacterium tuberculosis specific region of difference 
(RD1) antigen (56). It has been found to be effective in detecting latent TB, even in those that 
had BCG vaccine (73). IGRAs are whole-blood tests used in diagnosing M. tuberculosis infec-
tion (74). It specifically measures a person’s immune response to M. tuberculosis. Fresh blood 
samples are obtained and mixed with antigens and controls. The principle for this test is based 
on the fact that T-cells (a class of white blood cells responsible for immunity against bacteria), 
once sensitized with tuberculosis antigens, produce immunoglobulin called interferon gamma 
(IFN-y) when in contact mycobacterial antigens (75). A significant elevation of this IFN-y is 
therefore presumed to be suggestive of TB (75, 76).  
Recent systematic reviews show that in contrast to TST, IGRA has higher specificity and better 
correlation when exposed to M. tuberculosis (or active TB), and less cross-reactivity with BCG 
vaccine and other non-tuberculous mycobacterium (36, 37, 77, 78).  In some clinical settings, 
Interferon Gamma Release Assays (IGRAs) have now been introduced, as it is broadly regarded 
as a more specific whole-blood tests in the diagnosis of LTBI (54, 76).  
Largely, immigrant screening in the UK has been found to be useful in reducing the burden of 
TB in the country (29, 66). However, given several other factors that have affected the imple-
mentation of recommended strategies, especially with growing TB incidence in several low-
income settings, it is important to comprehensively re-appraise the available options, and pro-
vide an evidence-based cost-effective strategy that meets contextual needs, and can be feasibly 
implemented across affected settings. 
1.7. RESEARCH QUESTION 
Although there have been several studies done to assess the cost effectiveness of contact tracing 
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and TST for detecting TB among migrants over the conventional CXR screening. To the best of 
the author’s knowledge, no study has yet compared the cost effectiveness of a proactive 
approach of reducing TB burden among migrants coming into the UK from high TB incidence 
country as against the cost-effectiveness of the conventional CXR screening, nor with the cost-
effectiveness of IGRA screenings for TB among migrants entering the UK from these high TB 
incidence countries. 
In view of the aforementioned, this study seeks to answer the question:  
What is the relative cost-effectiveness of ‘doing nothing’ as an alternative TB control strategy 
by the UK government to some selected alternative interventions. The selected alternatives are: 
i) Investment in scale-up of TB control programmes in high TB incidence country like Nigeria 
(as a proactive approach to reduce influx of TB cases from the country); ii) IGRA for screening 
of all migrants entering the UK from the high incidence country, or iii) CXR screening for 
migrants at points of entry. 
1.8. RESEARCH JUSTIFICATION 
Nigeria is the most populous country in Africa, and with high incidence and overall burden of 
TB. The influx of Nigerians to the UK has increased in the last three decades, as many are in 
pursuit of higher degrees, employment, seeking asylum, or in search better opportunities.  
Hence, there is a relative chance for decrease in TB incidence in the UK with a potential 
reduction in TB imports from Nigeria if appropriate control measures are applied. 
Implementation of the WHO strategy is a proven approach to limit the incidence and prevalence 
of TB in countries with a high prevalence of the disease (79, 80); thus, reducing the burden 
amongst entrants coming to UK from those countries.  However, due to reasons primarily 
attributed to inadequate funding and a host of contextual factors, the implementations of these 
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strategies in those countries remain far from complete (81). These countries, therefore, act as 
reservoirs for TB, and adding burden to countries where the disease has hither-to been 
controlled. This is particularly due to significant international travels and migrations from high 
incidence to low incidence countries. It is therefore worthwhile to compare control strategies 
with regards to the cost of these interventions and their effectiveness, towards providing 
evidence-based options that can be implemented in affected settings. The research has been 
largely motivated by the relative knowledge gap on the potential returns in donor countries (i.e. 
anticipated accrued savings from cases and deaths averted in donor countries) obtainable from 
investments in disease control programmes in low-income countries. 
1.9. AIM AND OBJECTIVES 
The main aim of this research is to evaluate the cost-effectiveness of ‘doing nothing’ as an 
alternative TB control strategy by the UK government to some selected alternative interventions. 
These alternatives are: i) Investment in scale-up of TB control programmes in high TB incidence 
country like Nigeria (as a proactive approach to reduce influx of TB cases from the country); ii) 
IGRA for screening of all migrants entering the UK from the high incidence country, or iii) CXR 
screening for migrants at points of entry. 
However, to quantify the cost of the ‘enlighten self interest spending’ in scaling up the TB 
control program in Nigeria it is necessary to also evaluate the cost of TB detection and 
treatment in Nigeria, the burden of TB in the country and the funding deficit (gap) that when 
provided the country will able detect and treat target cases of TB over a period of time.  
Thus, the first 6 objectives of this research aims to evaluate the cost, burden and funding gap 
for TB detection, treatment and care in Nigeria while the 7th objective aims to address the 
primary study goal of evaluating the cost effectiveness of the alternatives under consideration. 
 14 
These objectives are as follows: 
1. To estimate the provider cost for the treatment of TB in Nigeria. 
2. To estimate the patient (direct and indirect) cost associated with TB treatment 
in Nigeria. 
3. To estimate the total cost attributable to TB control programme in Nigeria. 
4. To estimate the total cost that will be required to scale up TB control 
programme in Nigeria from the present level to a coverage rate of 100%, case 
detection rate of 80% and treatment success rate of 80%. 
5. To estimate the funding gap for scaling up TB control programme in Nigeria 
6. To estimate the impact of scaling up TB control programme in terms of number 
of latent and active TB cases averted in Nigeria and amongst migrants coming to the 
UK. 
7. To compare the cost-effectiveness of ‘doing nothing’ to the three (3) proposed 
alternatives interventions (Investment to scale up TB control programme in Nigeria, 
IGRA screening, or CXR screenings for migrants at points of entry). 
1.10. STUDY EXPECTATIONS 
It is intended that this research will provide a guide for policy makers and other stakeholders in 
Nigeria and internationally on the cost attributable to TB burden and overall management in 
Nigeria. It will also provide evidence for or against investment in TB control interventions in 
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high TB incidence countries (as a cost- effective approach) to mitigate influx of TB cases from 
these countries to low incidence countries.	
1.11. THESIS STRUCTURE 
This thesis is presented in 7 distinct but interrelated chapters.  
A literature search was conducted to aid the discussion of findings in the thesis. As this was not 
a systematic review, there were no distinct inclusion or exclusion criteria, and no systematic 
extraction or synthesis of findings obtained in the literature. Studies were mainly scoped for 
three key words (cost-effectiveness/ economic analysis; Tuberculosis; and Developing 
countries). The Table 1.2 gives a summary of the search terms and results of the searches 
conducted in MEDLINE and EMBASE. Searches were conducted in December 2016, and 
related findings have been included under relevant chapters and sections of the thesis. 
Table 1.2. Literature search terms and results 
#	 Searches	 MEDLINE 
Results	
EMBASE Re-
sults	
1	 ((Low- and middle-income countr*) or Developing Countr* 
or Developing Nation* or Least Developed Countr* or 
Less-Developed Countr* or Less-Developed Nation* or 
Third-World Countr* or Third-World Nation* or Under-De-
veloped Countr* or Under-Developed Nation* or resource 
limited setting*).af.	
122905	 134501	
2	 (Costs or Cost analysis or Cost Benefit Analysis or Cost Ef-
fectiveness or Cost-Benefit Data or Cost-Effectiveness 
Analysis or Cost-Utility Analysis or (Costs and Benefits) or 
Economic Evaluation or Marginal Analysis or Incremental 
cost-effectiveness ratio or Economic analysis or Quality-ad-
justed life years or Disability-adjusted life years or Adjusted 
Life Years).af.	
286548	 389837	
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3	 (Tuberculosis or TB or Mycobacterium tuberculosis).af.	 253847	 268453	
4	 1 and 2 and 3	 399	 536	
 
▪ Chapter 1 describes the problem background, research justification, aim and 
objectives of the study and the study expectations; 
▪ Chapter 2 (addresses the 1st Objective of the study) describes the method, 
assumptions, descriptions and evaluation of the provider cost of TB treatment in 
Nigeria; 
▪ Chapter 3 (addresses the 2nd Objective of the study) describes the method, 
assumptions, descriptions and evaluation of the direct cost incurred by TB patients 
in Nigeria attributable to TB treatment; 
▪ Chapter 4 (also addresses the 2nd Objective of the study) describes the method, 
assumptions, descriptions and evaluation of the indirect cost (valued time lost and 
productivity lost) incurred by TB patients in Nigeria attributable to TB disease and 
treatment; (NB:  although both the ‘direct’ and ‘indirect’ patient costs due to TB are 
estimated in Chapters 3 and 4 respectively, these estimates have not been factored 
in the CEA model in Chapter 7 primarily because the perspective of the CEA is for 
the UK Government and only captured the provider cost of treatment of TB in 
Nigeria. However, this analysis is included in the thesis to highlight some of the 
positive externalities (humanitarian) of the ‘Investment in Nigerian TB Control” as 
an alternative. 
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▪ Chapter 5 (address the 3rd, 4th, 5th and 6th Objectives of the study) describes the 
method, assumptions, descriptions and evaluation of the total cost of TB control 
programme in Nigeria and the cost of scaling up the programme as well as impact 
and the required funding gap for the scale up; 
▪ Chapter 6 (addresses the 7th Objective of the study) describes the method, 
assumptions, descriptions and evaluation of the cost effectiveness analysis model 
comparing three alternative strategies for TB control among migrants from Nigeria 
to the UK; and 
▪ Chapter 7 covers the thesis synthesis, contribution to body of knowledge and 
recommendations for further research.
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2. PROVIDER COST OF TUBERCULOSIS TREATMENT IN NIGE-
RIA 
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2.1. BACKGROUND 
Nigeria, like most third world countries, is severely resource constrained in the provision of 
health care services (51). Nigeria has the fourth highest burden of tuberculosis (TB) in the world 
after India, Indonesia, and China, with an incidence rate of 322 per 100,000, prevalence at 521 
per 100,000, and mortality at 99 per 100,000 populations, respectively in 2015 (2). Despite 
Nigeria’s gross domestic product (GDP) per capita at US$ 1376 in 2008 (53), only about 6.6% 
of GDP per capita was spent on health in that year (82), most of which was spent on staff wages 
(83). 
Underfunding, resource leakage and wastage due to corruption and incompetence were seen by 
several experts as the main reasons behind the prevalent misdiagnosis and low case detection 
rates of TB in the country over past decades despite the enormous resources invested by both 
the government and international development partners (84, 85). 
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The complexity and cost of treating TB has increased in recent years due to emergence of multi 
drug resistant TB (MDR-TB) strains, significant proportion of TB patients co-infected with HIV, 
high rates of both TB and HIV infections in difficult-to-reach populations, and the delays in 
diagnosis (86). 
Walker and colleagues noted that the role of the provider of care is to ensure accurate diagnosis 
and correct treatment of TB in the population within the limited resources available (66). 
However, incorrect diagnosis, among several other factors, has contributed to high overall cost 
of provider care in many low-income settings (43). For instance, under-diagnosis of TB may 
likely aid further spread of the disease, as several people remain undiagnosed and are at risk of 
spreading the disease to others (66). Over-diagnosis leads to a waste of limited resources in these 
settings due to commencement of inappropriate medications (43, 66). 
Although significant work has been done in evaluating the economic burden of TB among 
patients, society and providers in several developed and developing countries, some 
methodological challenges have been reported during these appraisals (87). Essentially, the 
specifications of appropriate alternative interventions, the need to measure and consider relevant 
costs that need to be avoided, and the difficulties of measuring and comparing outcomes across 
populations, are among the main challenges towards estimating provider cost of TB treatment 
in developing countries (87).  
Moreover, these challenges may have contributed to a paucity of comprehensive studies on 
provide costs evaluation in sub-Saharan Africa (sSA) (88). Besides, experts have noted it is 
worthwhile to identify newer provider-based approaches to tuberculosis treatment that are 
effective, contextually adaptable, and put less demand on limited health resources in developing 
countries (89). There is a clear need for such provider data and research for evidence-based 
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planning and efficient management of TB control programs in Nigeria. To address this and 
contribute to existing knowledge, this study aimed to evaluate the provider cost of TB diagnostic 
and treatment services in Bauchi State, Nigeria. 
2.2. STUDY AREA AND SETTING 
Bauchi State is in the North-Eastern region of Nigeria and is the 7th most populous state in the 
country. It occupies a land mass area of 49,259 sq. Km with a total population of 4,676,465 
inhabitants (90). The population of the State are served by about 950 government health 
facilities (two tertiary hospitals, 19 secondary hospitals, 81 primary health care centers, 213 
maternity and child health centers, 636 dispensaries/health posts) (91). However, only 67 of 
these government facilities provide tuberculosis care facilities. These include the two tertiary 
hospitals, 18 general hospitals, one infectious diseases hospital, 14 primary healthcare with 
diagnostic (smear microscopy) capacity, 25 treatment centers (also primary healthcare centers. 
Three privately owned clinics in the state provide tuberculosis services (91). 
Nigeria also run a National Tuberculosis Control Programme, which is based on the 
internationally recommended WHO Stop TB strategy. It provides free investigations quality 
drugs to aid diagnosis and treatment of TB. The programme also allows decentralized treatment 
services to be offered close to patients’ residence under direct observation with the help of 
government health workers and community volunteers (92).  
In health facilities, clinicians, community health officers, nurses and other hospital staff attend 
to these patients in either outpatient department, where suspected TB patients are initially seen, 
diagnosed or followed up, or in general medical wards, where inpatient care is provided to 
patients with serious conditions requiring closer clinical attention. Patients suspected of having 
TB are usually asked to submit three early morning sputum for acid-fast bacilli tests in three 
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consecutive days. Diagnosis is either based on sputum positive smear or clinical and radiological 
judgment when the sputum result is negative (92). 
Directly observed therapy (DOT) is carried out in the first two months of treatment for those 
patients who live close to the clinics. However, family members and friends are usually relied 
on to give or make sure patients take medications in those that live far from the clinic or are 
stable but too weak to reach the clinic. Generally, during the remaining six months of treatment, 
patients only come in once every two weeks for refills. The DOT clinics are designated rooms 
in the hospitals for patients coming in to be weighed, reviewed, and receive treatment or pick 
their refills. The DOT clinic is also the place where the TB register is kept and TB notifications 
are made. A nurse or a community health officer usually oversees these clinics. Any patient 
diagnosed with TB is usually referred for HIV voluntary testing and counselling, and if positive 
is referred to the nearest anti-retro viral therapy (ART) clinic where free HIV treatment is usually 
available.	
2.3. STUDY DESIGN 
This is a cross sectional study where a questionnaire was used to assess the provider cost of TB 
diagnosis and treatment. The questionnaire used was developed using the WHO cost analysis 
guidelines (93). The methodology used in estimating this cost is primarily a ‘Bottom-up 
estimation approach’ breaking down composite services into different cost dimensions which 
are then summarized or "rolled up" to determine an overall cost estimate for the cost of care per 
patient. This type of estimate is generally more accurate than other methods (parametric, 
analogous or expert judgement estimations) since it is looking at costs from a more granular 
perspective. 
Questionnaire was piloted in 2 facilities in May 2008, and was found to be practical and reliable. 
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Between June and August 2008, a total of 27 facilities were stratified and randomly sampled out 
of the 67 facilities providing TB services in the state. 
Ethical approval was sought and granted for this research from the Bauchi State Ministry of 
Health.	
2.4. DATA COLLECTION 
All sampled facilities were visited and questionnaires administered with the help of relevant 
members of staff. There were no outpatient attendance records, or reliable inpatient registers or 
patient records in all the facilities. However, the records from the TB notification and DOT 
register showed no pattern in weekly, monthly or annual incidence or proportion of TB cases in 
all except one treatment center that reportedly sees fewer patients in rainy season due to bad 
road conditions. Based on this information, and in the absence of a reference proportion of TB 
patient population, this study assumed the average patient counts done on the 3 randomly 
selected days in 12 consecutive clinic days, considered to represent the daily patient population 
in the hospital. However, Mondays were excluded because of possible bias resulting from higher 
patients coming in following weekend closure. Based on the number of both TB and total 
populations on these days, the proportions of TB patients receiving inpatient and outpatient care 
were calculated and used to allocate weigh costs for inpatient and outpatient services per patient 
receiving TB service in the facility. Overhead and general cost was also allocated based on 
proportion of TB patient in the overall facility patients’ population from the total overhead spent 
in the facility. 
Staff costs were mostly shared; hence, costs were calculated using proportional time allocation 
(proportion of staff time). Additional 29% fringe was added to staff cost based on the rate used 
by the state Ministry of Budget and Planning. Building cost was estimated from a cost per square 
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meter estimation made from recently built facilities in the state. The average lifespan of 
buildings was assumed to be 30 years based on an unpublished report from the Ministry of 
Works.  
The annual inflation rate in the country was 10.9% in 2008 and 12.6% in 2009 (94). Real time 
deposit interest rate was 9.87% in 2008 and 12 months’ deposit rate was 12.6% in 2008 and 
13.6% in 2009 (95). Based on these economic indices, depreciation method of discounting was 
applied on the assumption that the net effect of both inflation and interest rates will be mini-
mal. Thus, the annual discount rates for buildings was assumed to be 3.5% based on a 30-year 
lifespan, and 10% for general office and medical equipment based on a 10-year lifespan. The 
replacement cost of equipment was also estimated from contract documents for supplies of 
equipment made for the government for the facilities in the state. All currency value reported 
in the study was based on the US $ PPP as at November 2008 value. Amounts quoted in UK 
Pound Sterling (£) is a based-on November 2008 $/£/Naira exchange rate. 
The drug cost for 2 months’ treatment with Rifampicin, Isoniazid, Ethambutol Pyrazinamide 
and 6 months of Ethambutol and Isoniazid (2RHZE/6EH) as first line TB drugs per patient was 
assumed to be (in 2008) US$ 19. The second line drugs treatment with 2 months of 
Streptomycin, Rifampicin, Isoniazid, Ethambutol, Pyrazinamide and a month of Rifampicin, 
Isoniazid, Ethambutol Pyrazinamide followed by 5 months of Rifampicin, Isoniazid, 
Ethambutol (2SRHZE/1RHZE/5RHE) per patient was estimated at (in 2008) US$ 46, all based 
on WHO estimates (96). 
To estimate the cost of a sputum acid fast bacilli (AFB) test, the average cost was estimated 
from the market prices rates in 4 independent laboratories across the state, less by 35% (assumed 
profit margin). Another assumption made was that each TB patient would have at least 3 sputum 
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AFB tests during diagnosis and treatment. Each TB patient was also assumed to be screened for 
HIV at the point of TB diagnosis or while on treatment, and the cost of HIV screening was also 
by same method from 4 independent laboratories across the state. Another assumption made in 
the study is that only patients that are sputum negative get CXR, at least once during TB 
diagnosis and treatment. This assumption is based on the practice reported in all the diagnostic 
centers. The cost of CXR was also estimated from the average, less by 35%, of price quotations 
from 4 independent x-ray facilities across the state.	
2.5. ANALYSIS 
The Nigerian Naira amounts were subsequently converted to US dollar based on the currency 
exchange rate (Official rate from Central Bank of Nigeria in November, 2008) of NGR 118.5 to 
1 US in 2008 (95). The estimated cost attributable to TB treatments per facility was calculated 
from the summation of all TB attributable to the cost elements in each center.  
The average proportions of TB patients in outpatient, inpatients and general patient populations 
were estimated and dispersion of the measurement described. The WHO Choice programme 
(service delivery) costs template was adopted (including administrative support, training, 
building costs, electricity, water etc). Differences in costs between levels of service provision 
and urban rural divide were assessed and reported. Diagrams were also drawn to appreciate 
these differences. Student t-test was done to test the significance of the differences of mean.	
2.6. RESULTS 
Seventeen out of 50 Primary care centers TB services in the state were randomly sampled. Out 
of these 17 facilities, 11 provide treatment services only, while the remaining 6 treatment centers 
sampled provide both diagnostics and treatment services. Nine facilities are secondary care 
providers and one is a tertiary service provider. Four treatment centers sampled have less than 
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10 bed capacities, 5 other treatment centers have between 10 and 20 bed capacities, the 
remaining two treatment centers and six of the diagnostics primary care centers have between 
20 and 50 bed capacities. All secondary care providers have between 100 and 180 bed capacities 
and the tertiary care Centre has about 600 bed capacity.	
2.6.1. Proportions of tuberculosis patients in facilities 
The proportion of TB patients in the total patient population on the day of the research visit 
varied slightly between facilities. The mean of proportions for the total TB patient population 
within the patient populations in the facilities was 0.034 (SD 0.016; 95% CI 0.028-0.041). Non-
parametric one-way ANOVA (Kruskal-Wallis Test) showed no significant (P=0.2578) deviation 
in the ratio TB patients/total patient population among the facilities sample in the study. 
The proportion of TB inpatients in inpatient population in all the facilities was estimated at 0.33 
(SD 0.037; 95% CI 0.019-0.048) and the proportion of TB outpatients in outpatient population 
was 0.03 1 (SD 0.013; 95% CI 0.026-0.036). Kruskal-Wallis Test showed significant (P=0.0036) 
difference in the ratio of hospitalized TB patients to the total hospitalized patient population 
among the facilities sample in the study.  
However, by taking out the ‘infectious diseases hospital’, a hospital designated as a referral 
hospital to treat infectious diseases with much higher proportion of TB patients, the variability 
became statistically insignificant (P=0.3212).  
The ratio TB cases to total outpatient population in all the facilities was 0.031, and the variation 
among facilities, tested by Kruskal-Wallis Test in the sample was not significant (P=0.3948) 
(Table 2.1; Figures 2.1, 2.2 and 2.3). 
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Table 2.1. The proportions of TB patients in the whole facility patient population as well as 
in outpatients and inpatients population by facility level 
Facility Level Prop. of all TB 
patients in facility 
patient population 
(SD) 
Av. Prop. of TB 
inpatients in facility 
inpatient population 
(SD) 
Av. Prop. of TB 
outpatients in facility 
outpatient 
population (SD) 
Tertiary Hospital 0.03 (0) 0.03 (0) 0.03 (0) 
Infectious Disease 
Hospital 
0.11 (0) 0.19 (0) 0.08 (0) 
General Hospitals 0.036 (0.011) 0.041 (0.014) 0.03 (0.08) 
PHC (D) 0.04 (0.02) 0.038 (0.0147) 0.027 (0.01) 
PHC (T) 0.029 (0.009) 0.015 (0.013) 0.032 (0.014) 
For all facilities 0.034 (0.019) 0.033 (0.037) 0.031 (0.013) 
 
PHC: primary health centre 
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Figure 2.1. Histogram showing the (total) proportion of TB patients by facility types 
 
	
Figure 2.2. Histogram showing the (inpatient) proportion of TB patients by facility types 
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Figure 2.3. Histogram showing the (outpatient) proportion of TB patients by facility types 
	
2.6.2. The cost of tuberculosis treatment per patient 
The average provider cost attributable to TB diagnosis and treatment in Bauchi State was 
estimated at US $206.22 per patient treated. These total and all cost elements, except for DOT 
services, were observed to be highest in the tertiary center and least expensive in the infectious 
diseases hospital. However, the variation between facility type in the cost per patient, using 
Kruskal-Wallis method, was not significant (P=0.1407).  
Of all the cost elements estimated, the costs of providing DOT services contribute highest in all 
the facilities, ranging from US$ 148 (61% of the total cost) in Primary Healthcare treatment 
centers to US$ 21 (23% of total cost) in the Infectious Diseases hospital. This could be due to 
the lower number of patients in those facilities despite the human and other resources stationed 
to provide the DOT. The difference in the cost of DOT services between facilities was found to 
be statistically not significant, with a P value of 0.1407 (Kruskal-Wallis χ2-test).  
The average overhead cost estimate for all the centers in this study was US$ 30.89 per TB patient 
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(SD 16.55; 95% CI 24.35- 37.44). The estimated overhead cost was only about US$ 11 (12% of 
the total cost) in the ‘infectious diseases’ hospital, but as high as US$ 74 (29% of total cost) in 
the ‘tertiary hospital’ though these observed differences between the centers was also found to 
be statistically not significant (P=0.1281) by Kruskal-Wallis χ-test. Sensitivity analysis may not 
be necessary to explore the robustness of the analysis, and reasons behind the high differential 
in costs between different institutions in Nigeria, because the cost drivers are very predictable. 
For instance, the low overhead cost, high patients’ turnover and high proportion of TB patients 
in ‘infectious disease’ hospital makes the attributable cost of TB care in infectious disease 
hospital very low contrary to what was observed in ‘tertiary hospital’.  
The average cost of hospitalization for TB patients was estimated at US$ 16.95 per TB patient 
(SD 13.99; 95% CI 11.41- 22.48). The average cost of follow-up visits was estimated at US$ 
6.26 (SD US$ 4.02; 95% CI US$ 4.67- $7.85) and the cost of DOT services estimated at $119.27 
(SD US$ 67.81; 95% CI US$ 92.45- US$ 146.10). There is significant variance in the cost of 
DOT services per patient between by facility type, P value of 0.0273 (Kruskal-Wallis χ-test).  
Ninety-one percent of patients in all the facilities were assumed to be on first line drugs and 9% 
on second lines based on the reported prevalence resistance to first line anti TB drugs resistance. 
A weighted estimation of the cost of anti TB drugs was US$ 21.43 per patient treated in any 
facility and the cost estimate for AFB sputum tests, HIV screening and chest X-rays for sputum 
negative patients was US$ 23.20 per TB patient (Table 2.2; Figures 2.4, 2.5, 2.6 and 2.7). 
 30 
 
Table 2.2. The average cost of TB services per patient by facility type 
Facility 
Level	
Average Over-
head cost/Pt 
(SD) in US $	
Inpatient ser-
vices cost/Pt 
(SD) in US $	
Outpatient ser-
vices cost/Pt 
(SD) in US $	
Total cost of TB 
care/pt (inc drugs and 
tests) (SD) in US $	
Tertiary 
Hospital	
$74 (0)	 $25 (0)	 $111 (0)	 $256 (0)	
Infectious 
Disease 
Hospital	
$11 (0)	 $13 (0)	 $24 (0)	 $93 (0)	
General 
Hospitals	
$32 (14.2)	 $22.88 (12.8)	 $96.38 (63.42)	 $197 (83.75)	
PHC (Diag-
nostic)	
$22.67 (7.26)	 $22 (15.84)	 $134.5 (30.65)	 $225.67 (43.42)	
PHC (Treat-
ment)	
$32.45 (16.76)	 $9.45 (12.27)	 $171.55 (80.99)	 $259.45 (84.82)	
For all fa-
cility	
$30.89 (16.55)	 $16.95 (13.99)	 $133.34 (72.92)	 $227.14 (80.34)	
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Figure 2.4. Histogram showing the general administrative overhead cost/patient by facility 
types 
	
	
Figure 2.5. Histogram showing the average inpatient cost/patient by facility types 
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Figure 2.6. Histogram showing the average DOT services cost/patient by facility types 
	
	
Figure 2.7. Histogram showing the average follow-up visits cost/patient by facility types 
	
2.7. DISCUSSION 
Tuberculosis cases constitute about 3.4% of all patients, 3.3% of all inpatients and 3.1% of all 
outpatients receiving care in government health care facilities across Bauchi State, Nigeria. The 
average cost for treating a patient with TB was estimated at US $206.22, with inpatient cost 
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estimated at US $16.95/patient, outpatient cost including the direct observed therapy short-
course (DOTS) services at US $133.34/patient, and average overhead cost per patient estimated 
at US $30.89/patient treated.  
The high cost of DOTS (and outpatient management) has been observed by some authors, 
possibly due to the longer periods of treatment and monitoring involved (97). But, on the long-
term, DOTS has been adjudged cost-effective and was relatively linked to the achievement of 
the then millennium development goals in developing countries (before it was abolished in 
2015) (98). DOTS is particularly cost-effective in the treatment of smear-negative, extra-
pulmonary and multidrug resistant TB cases (98). In Tanzania, Wandwalo et al. also noted that 
from all perspectives, including providers’, patients’ and supervisors’, community-based 
approach to delivery of DOTS was more cost-effective compared to other facility-based 
treatment options (4). It was estimated to reduce the cost of treating a patient by over 33% in 
the settings (4). 
Primary health care diagnostic centers were observed to spend less overhead cost per patient 
than that the general hospitals and primary health care treatment centers. This is probably due 
to inadequate staffing and lower budget for recurrent spending in primary health care diagnostic 
centers with higher proportion of TB patients and higher patient population. While a higher 
overhead cost per patient in general hospitals and primary health care treatment centers with 
lower proportion of TB patients and lower patient population is due to more staffing and 
recurrent spending.  
The ‘Infectious Diseases’ hospital had the lowest cost of all cost components per patient treated, 
probably due to a lower marginal cost that result from economies of scale. The inpatients 
services cost per patient was slightly higher in the tertiary hospital probably because of the 
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higher cost of staff and more recurrent spending.  
The study also showed that the cost of inpatient service care per patient in the primary health 
care treatment centers was much less than in general hospitals and primary health care diagnostic 
centers. Inadequate staffing and low inpatient capacity or lower recurrent spending in primary 
health care treatment centers with higher proportion of TB patients may also be responsible for 
this. It may also be attributed to more staffing and higher recurrent spending in general hospitals 
and primary health care diagnostic centers with lower proportion of TB patients.  
Contrary to the inpatient cost, the outpatients’ services cost per patient was highest in both 
primary health care treatment and diagnostic centers. This is probably because of higher 
proportion of TB patients in a low outpatient population. However, ‘Infectious Diseases’ 
hospital spent least compared to general hospitals and tertiary centers. This could be due to 
inadequate staffing and recurrent spending in the infectious disease hospital with higher 
proportion of TB patients and higher patient population. As noted earlier, it may also be due to 
more staffing and recurrent spending in general hospitals and tertiary centers with lower 
proportion of TB patients and lower patient population.  
In a country where the GDP per capita is only US$ 1370 (83), government total expenditure on 
social amenities at US$50 per capita, and government total expenditure on health constituting 
only 4.1% of GDP (84), the cost of tuberculosis treatment reported in this study could be 
described as relatively high and probably one of the major reasons for the low case detection 
rate for TB in the country. In such instances, many would prefer to visit cheaper alternative 
(non-medical) sources of care when they are sick, meaning that several TB cases visiting such 
services may remain undiagnosed (99).  Besides, due to low levels of diagnosis and delays in 
treatment, there is higher morbidity and mortality from the disease, with many eventually 
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presenting at government health facilities with severe advanced TB, which is particularly more 
difficult and expensive to manage (100). 
In some other studies, varying estimates and conclusions on the cost of treating TB in different 
countries were reported.  In the Tanzanian study, the authors concluded that Community based 
DOTs provides an economically attractive option to complement health facility based DOTs, 
especially in resource-poor settings where provider TB clinics are working at extreme capacity 
under limited resources (4). Using cost inputs from South Africa, Abimbola and colleagues 
reported higher provider costs in South Africa, estimated at US $850 per TB patient (101). 
However, this was relatively higher that the reported estimate ($206.22) in this study possibly 
because the provider cost covers diagnostics, treatment and anti-retrovirals (ART). Variations 
have however been observed in reported estimates across studies owing differing models, 
assumptions, study periods, and the overall economic situation of the study location. For 
instance, a study conducted in Thailand estimated the provider cost for treating tuberculosis at 
US $373 in 1995 (102), while another study from India reported lower mean cost at Rupees 
1587 (92), which was equivalent to US $35.98 in 2006. These explains the difficulties in arriving 
at estimates that are representative of the population. There is definitely a need for improved 
approach and guidelines to estimating the economic burden from TB across countries. 
2.8. STUDY LIMITATIONS  
This study has several limitations arising from the methods and the actual conduct of the study. 
The following are the limitations noted. 
1. Exclusion of some staff under the government payroll but were not accounted for in the 
analysis because there were never available at the facilities. There engagements was seen 
more as a ‘favor to them’ rather than call to serve. These unaccounted costs makes the 
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estimates in this study an underestimation.  
The assumption used in the estimation of the proportions of TB patients based on 3 days’ patient 
turnover was a major limitation, as the patients’ daily turnover was neither consistent nor 
predictable. However, because there were no patient records in any of the facilities, this 
assumption was necessary. Besides, averaging the daily turnover from 3 randomly selected days 
over a period of 3 weeks was considered to provide reasonable estimation. 
2. Another major limitation of this study also from the fact that in this study it was assumed 
that where there was no TB patient in a clinic or facility on all the three days selected, but  
at least between 1 and 3 TB patients were said to be seen in the facilities every week, a 
proportion of 0.005 for TB service burden was used. This could also account for some 
considerable degree of costs underestimation or over estimation.  
3. Other assumptions were also made in estimating the replacement costs and life spans of 
buildings and equipment, and in estimating other cost components based on personal 
experience of some technical persons working in the field. There could be significant bia in 
reporting these estimates. 
4. Selection bias: although the study sample was randomly selected but the fact that the 
selection and implementation was done solely by the investigator could have led to bias and 
preferential selection of health facilities. Effort were made during the selection to blind  
names of the facilities during the random selection process. 
5. Observational bias: there could observational bias and errors in measurements or estimates 
during the data collection due to the imperfection of the observer and the subjective human 
judgement. Efforts were made standardize the procedure for collection of the data. 
6. Generalization: A major limitation of this study is the fact that although significant number 
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of health facilities were sampled, due to the heterogeneity of the settings and other factors in 
Nigeria, and financial limitations of the investigator, it was difficult to sample as much health 
facilities across the country.   
7. Sensitivity analysis was not done to assess the effect of these assumptions in the study. 
However, because all major parameters had normal distribution curves, these assumptions 
were accepted as reasonable estimates of the real values. 
2.9. CONCLUSION 
The result of this study is suggestive of wide differential costs in overall provider cost per patient 
attributable to TB treatment across facilities in Nigeria. Relative to the national health 
expenditure in Nigeria over the years (less than 5% of total budget), it is uncertain if efforts will 
be directed towards addressing the basic challenges across centres. Based on the current finding, 
there is a need to improve the local capacity (financial, health workforce and infrastructural) of 
several health or designated infectious diseases (or TB) centres in the country to receive and 
adequately cater for more TB cases. This may also help to address the relative low turnout of 
TB patients in the specialized (infectious diseases) centres. It is hoped that this study may 
contribute to improved policy and public health response to TB in the country.  
The next chapter provides the direct patient cost on TB treatment in Nigeria.
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3. PATIENT (DIRECT) COST OF TB TREATMENT IN NIGERIA 
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3.1. BACKGROUND 
Estimates show that over 25% of TB cases and 31% of TB related deaths occur in sub-Saharan 
Africa, a region with only about 11% of the world’s population (103). Nigeria, the most 
populous country in Africa, has the fourth largest burden of tuberculosis (TB) worldwide (after 
India, Indonesia and China), with incidence rate at 322 per 100 000 population, prevalence of 
521 per100 000 population, and 99 deaths per 100,000 in 2015 (2). The estimated adult (15–45 
years) human immuno-deficiency virus (HIV) prevalence rate in Nigeria is 3.6%, a condition 
that has contributed to increased incidence of TB in the country (104). It has been estimated that 
about 26% of notified TB patients are HIV-positive, which is one of the highest TB/HIV co-
infection rates in the world (105). Over the years, this has contributed to a considerably high 
economic burden from TB in Nigeria (106, 107).  
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The health care system in Nigeria, which also fully integrates TB control, is constrained by 
several factors including finances, health workforce, access to health care, and difficulties in 
rendering TB outreach services particularly in rural area (105). There are also challenges with 
integrating the private health sector into the TB services, due to poor regulation, high costs and 
inconsistencies in the quality of care provided by this sector (105). Hence, Nigeria still has the 
4th largest burden of TB globally, despite a reported 99%, albeit debatable, coverage of DOTs 
(39). Besides, direct medical costs, and indirect costs from lost income, productivity and time 
spent in hospital have been other major individual and household economic barriers limiting the 
response to TB in Nigeria (108). The WHO, in its Stop TB Strategy, recommended universal 
access to care and reduction in socio-economic related burden from TB as key objectives toward 
global control of TB (96). There is no social protection against cost of illness in Nigeria, which 
is an important policy objective of the post-2015 Global Strategy for Tuberculosis (10).  
Nigeria has a per capita gross domestic product (GDP) of US$1376 (83), with about 50% of the 
population living below US$ 1.25 per day (109). Approximately 41% of women and 18% of 
men aged 15– 45 years are unemployed, and with over 50% living below the poverty index of 
$1.25 per day (83, 110). In fact, over 34% of people in the country do not obtain the required 
daily calorie intake, even if they spent all their income on food (109). Both TB and HIV have 
been associated with poverty (111, 112). Difficult financial circumstances are more likely to 
expose the poor to conditions favorable for infection with M. tuberculosis (113), and progression 
to a full-blown disease (114). The poor also face geographic and economic difficulties (barrier) 
in accessing TB services (12, 115), leading to delays in diagnosis, higher mortality and 
morbidity, and continued transmission of TB in the community (116). TB also has significant 
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socio-economic impact on patients, families and community, particularly due to a predominant 
infection of the most economically productive age groups (117, 118). 
The Nigerian National Tuberculosis Control Programme (NTP) is based on the internationally 
recommended World Health Organization Stop TB strategy and provides free diagnostic testing 
as well as quality anti-tuberculosis drugs free of charge to all TB patients (119). This strategy 
also recommends decentralized treatment services and community TB care, thereby taking 
treatment closer to patients’ homes under direct observation with the help of government health 
workers and community volunteers (119). However, for patients to access care, they must bear 
certain out-of-pocket expenditure or direct costs for transport, drugs and services that are not 
provided free (120, 121). Although anti-tuberculosis treatment is provided free of charge, 
considering the level of poverty in the country, and particularly among most TB patients, other 
associated costs and trade-offs could limit patients’ access to TB services. Aspler and colleagues 
also noted that the level of cost patients incur are also indirectly a function of the health system 
structure (120). For example, significant delays have been reported in arriving at definitive TB 
diagnosis in health care settings in sub-Saharan Africa (122), with this leading to patients 
incurring costs from repeated misdiagnosis and indirect costs from hospital visits and time lost 
in the process.  
There is need to understand the varying dimensions to economic burden and personal costs 
associated with the management of TB in Nigeria, as this is also central to planning and 
identifying appropriate control measures specific for different population settings (10). There is 
however limited understanding of the economic burden of TB in Nigeria, especially due to 
paucity of studies describing out-of-pocket costs of TB across Nigeria, even though such 
information is essential for improving case detection and treatment success rates in the country. 
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For the few studies that do exists in Africa (10, 123), a number of bottlenecks have been 
identified in the methods and approach employed that limited a detailed systematic synthesis of 
results. This study therefore aimed to review and describe out-of-pocket costs incurred by TB 
patients and their households in accessing TB-related diagnosis and treatment in Bauchi State, 
Nigeria.  
3.2. MATERIAL AND METHODS 
The study area and setting have been described in Chapter 2.	
3.2.1. Study design and sampling  
A cross-sectional study was conducted to assess the direct costs of TB on patients from the onset 
of the illness to end of the treatment. Sampling was randomly done, but stratified based on 
facility type, patients’ HIV status and sex. A total of 255 TB patients were randomly sampled 
across 27 facilities in the state: 40 from the Infectious Disease Hospital, 40 from the Specialist 
Hospital (a tertiary centre), 10 each from nine selected General Hospitals, six each from five 
selected primary health care diagnostic centers, and five each from 11 selected PHCs. Only 
patients with an established TB diagnosis (based on sputum smear results and in some cases 
CXR with clinical judgment), who had completed at least 3 months of treatment, were included. 
Those with disabilities and other debilitating conditions, such as leprosy, were excluded from 
the study. In all the sampled facilities, standard first-line treatment consisted of 2RHZE/6EH, 
while second-line treatment consisted of 2SRHZE/1RHZE/5RHE.* 
The methodology used in estimating this cost is the ‘Bottom-up estimation approach’ breaking 
down composite services into different cost dimensions which are then summarized or "rolled 
up" to determine an overall cost estimate for the cost of care per patient. This type of estimate 
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is generally more accurate than other methods (parametric, analogous or expert judgement es-
timations) since it is looking at costs from a more granular perspective. All currency value re-
ported in the study was based on the US $ PPP as at November 2008 value. Amounts quoted 
in UK Pound Sterling (£) is a based-on November 2008 $/£ exchange rate. 
Its also important to note here that although both the ‘direct’ and ‘indirect’ patient costs due to 
TB are estimated in Chapter 3 and 4, these estimates have not been factored in the CEA model 
in Chapter 7 primarily because the perspective of the CEA is for the UK Government and only 
captured the provider cost of treatment of TB in Nigeria. However, this analysis is included in 
the thesis to highlight some of the positive externalities (humanitarian) of the ‘Investment in 
Nigerian TB Control” alternative. 
3.2.2. Questionnaire  
A standardized questionnaire, similar to what was employed in a study in Zambia was used for 
this study (120), with permissions from the principal investigator. Through the questionnaire, 
the direct costs for patients in accessing TB diagnosis and treatment services during the pre-
diagnostic, diagnostic and post-diagnostic period, as well as during hospitalization, where 
applicable, were estimated.  
3.2.3. Defining direct patient cost of Tuberculosis 
Direct costs (out-of-pocket) in this study refer to money spent by, or for, patients to access drugs, 
commodities, paid services and any other items used for TB care. Self-reported total annual 
income for both patients and their households (excluding patient’s income) from the 
questionnaire was used to estimate patient and household income. For ease of recall, a table with 
columns for each month of a year, and rows for income elements captured in local currency 
value (cash, kind, other produce, e.g., farm produce) was used. For patients working on family 
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farms or businesses, the value of the business or farm produce was only included in their income 
if they were in the primary business or farm owners, otherwise it was added to the household 
income. Cost was captured in Nigerian Naira and converted to USD equivalent based on the 
Central Bank of Nigeria USD-Naira exchange rate as at 01 November 2008.  
3.2.4. Data collection and analysis  
Questionnaires were administered to each of the 255 patients individually. In most cases, 
information had to be sought or verified from relatives or friends who accompanied the patient 
to the clinic. All the patients sampled were in between months 3 and 8 of treatment. Based on 
the assumption that patients were treated for a total of 8 months, the monthly cost of the 
remaining treatment period was estimated from the number of monthly visits patients would 
have to make from the follow-up and re-fill schedules, and using the average patient 
expenditures for all the cost elements to extrapolate the expenditure in the remaining months.  
The patient level costs of the WHO Choice costing templates (40)were employed including 
hospital bed days, health centre visits, diagnostic tests, and drugs. The study took place from 
May to December 2008. Data was analyzed using IBM SPSS version 19.0 software (Statistical 
Package for the Social Sciences Inc., Chicago, IL, USA). 
3.3. RESULTS 
Of the 255 patients, 112 (43.9%) were hospitalized within the period from 6 months before TB 
diagnosis to end of the second month of TB treatment, and the remaining 143 (56.1%) were 
never hospitalized during this period. One hundred and fifteen (45.1%) were female and 140 
(54.9%) were male, 230 (90.2%) were new cases, 25 (9.8%) were retreatment cases. Twenty-
one (84%) of the retreatment cases were relapses’ 3 (12%) were due to default and 2 (8%) to 
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treatment failure. One hundred and fifteen (45.1%) of the sampled population were HIV-
negative, 124 (48.6%) were HIV-positive, while 16 (6.3%) did not know or refused to declare 
their HIV status (Table 3.1).  
Seventy-six (29.8%) were unemployed, 18 (7.1%) were students, 55 (21.6%) were small- scale 
businessmen and women, 42 (16.5%) farmers, 26 (10.2%) were drivers, laborers, security 
guards or menial workers, 10 (3.9%) were commercial sex workers, and 28 (11.6%) patients 
were civil servants and other professionals. The mean age of the sample population was 31.9 
years (range 9–67). 
Table 3.1. Characteristics of the sampled population 
Description Number (%) 
History of hospitalization at least 6 months before 
diagnosis, during diagnosis and after diagnosis 
     Hospitalized 
     Not hospitalized 
 
 
112 (43.9%) 
143 (56.1%) 
Gender 
     Female  
     Male 
 
115 (45.1%) 
140 (54.9%) 
History of prior TB illness 
     New TB cases,  
     Retreatment 
 
230 (90.2%) 
25 (9.8%) 
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Reasons for retreatment 
                      - Relapse 
                      - Default 
                      - Treatment failure 
 
21 (81% of the retreated) 
3 (11% of the retreated ) 
2 (8% of the retreated) 
HIV status 
      HIV negative 
      HIV positive   
      Unknown HIV status 
 
115 (45.1%) 
124 (48.6%) 
16 (6.3%) 
Employment 
       Un-employed 
       Students 
       Small scale business men and women 
       Farmers 
       Drivers, Labourers, Security guards or Menial 
workers 
       Commercial sex workers 
 
76 (29.8%) 
18 (7.1%) 
55 (21.6%) 
42 (16.5%) 
26 (10.2%) 
10 (3.9%) 
Mean annual income 
       Female 
       Male 
 
$445/annum 
$942/annum 
The mean age of the sample population 32 yr (min. 9 yrs, max. 
67yrs) 
Average number of facilities visited before diagnosis.  3 facilities 
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Patients visited an average of three facilities before diagnosis, and had completed on average 5 
of 8 months of treatment at the time of the interview. There was a significant difference in 
median household income (χ2 P < 0.0001), but there was no statistically significant difference 
in the median patients’ income between patients from different facility types (see Table 3.2). 
 
Table 3.2. Median Patients’ and Households’ income by type of health facility attended 
 Tertiary Hos-
pital	
IDH	 General hos-
pital	
PHC (Diag-
nostic)	
PHC (Treat-
ment)	
Patient in-
come prior to 
diagnosis 
Median 
(IQR)	
 
$281.88 
($161.07-
604.04)	
 
$604.03 
($281.88-
1208.05)	
 
$604.03 
($161.07-
1208.05)	
 
$281.88 
($161.07-
604.03)	
 
$281.88 
($161.07-
604.03)	
Household 
income prior 
to diagnosis 
Median 
(IQR)	
 
$604.03* 
($362.42-
2818.79)	
 
$2013.42* 
($604.03-
3020.12)	
 
$604.03* 
($604.03-
1409.40)	
 
$604.03*  
($281.88-
604.03)	
 
$604.03* 
($281.88-
1208.05)	
 
 
 
*Median test (Pearson’s X2), p<0.05 
 
3.3.1. Analysis based on hospitalization 
Among patients hospitalized during the period at least 6 months before diagnosis or during 
treatment (the hospitalized group), median out-of-pocket expenditure was estimated at 
US$166.11 (range $33.52– 417.92). For patients who were never hospitalized during this period 
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(the ‘non-hospitalized’ group), the median out-of-pocket expenditure was estimated at $94.16 
($30.87–284.63).	
3.3.2. Analysis based on HIV status  
The median out-of-pocket expenditures did not vary significantly between HIV-positive and 
HIV-negative patients in both the hospitalized and non-hospitalized patient groups. Median test 
P values were respectively 0.849 and 0.933 for the non-hospitalized and hospitalized groups 
(see Table 3.3).	
Table 3.3. Median Direct Cost based on patients’ HIV status and hospitalization 
 Hospitalized Not hospitalized 
HIV+ HIV- HIV+ HIV- 
Total (Median) out of pocket cost, US$ $166.48 $166.11 $82.95 $83.96 
IQR $127.25-
$203.99) 
$131.55-
$207.30 
$58.52-
$114.36 
$55.67-
$111.21 
Median test (Pearson’s X2)for 
difference based on HIV status 
 
P value = 0.933 
 
P value = 0.0.849 
 
 
3.3.3. Analysis based on sex  
Non-hospitalized female patients spent a median 16% more on out-of-pocket expenses than their 
male counterparts, while among the hospitalized patient group, females incurred 11% less costs 
than male patients. However, these differences were not statistically significant (respectively P 
= 0.185 in non-hospitalized and 0.252 in hospitalized patient groups). Females spent a 
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statistically significantly higher proportion of their income than males in both the hospitalized 
and non-hospitalized groups (χ2 P both < 0.0001) (Table 3.4).  
Table 3.4. Direct costs based on patients’ sex and hospitalization 
 Hospitalized Not hospitalized 
Female Male Female Male 
Total (Median) out of pocket cost, US$ $158.52 $178.58 $94.46 $79.80 
IQR $125.60-
$213.12) 
$137.25-
$204.16 
$55.54-
$122.97 
$59.93-
$104.55 
Median test (Pearson’s X2)for difference 
based on HIV status 
 
P value = 0.253 
 
P value = 0.185 
% of self-reported annual income 38%* 19%* 21%* 9% 
 
*p<0.0001 (Z test for difference in proportion of income)	
3.3.4. Analysis based on period of illness (pre/post-diagnosis, diagnosis 
and hospitalization period)  
The median out-of-pocket cost paid by and for patients before TB diagnosis was US$28.99. 
During diagnosis and during treatment, the estimated median cost for all patients was 
respectively US$31.01 and US$17.45. The median out-of-pocket cost incurred during 
hospitalization was US$73.83.  
There were no significant differences between males and females in out-of-pocket costs incurred 
before, during and after TB diagnosis in both the HIV- positive and HIV-negative groups. The 
median out- of-pocket expenditure during hospitalization was 11% higher for HIV-positive 
 49 
males than HIV-negative females, and 5% lower in HIV-positive males than for HIV-positive 
females (P > 0.05) (Table 3.5)  
Table 3.5. Median direct cost based on period before, during or after diagnosis by HIV and 
gender of patients 
 HIV Positives	 HIV Negatives	
Period of illness	 Male	 Female	 Male	 Female	
Pre-diagnosis/ care 
seeking*  
 Median (IQR)	
$33.56 
 ($16.29-
$51.41)	
$26.21 
($8.79-
$46.43)	
$35.57 
($17.35-
$46.85)	
$28.79 
($12.75-
$55.96)	
Diagnosis period* 
Median (IQR)	
$31.61  
($23.58-
$37.00)	
$31.18 
($22.95-
$43.29)	
$29.66 
($22.05-
$44.06)	
$31.01 
($23.19-
$45.00)	
Post diagnosis/treatment 
period* 
Median (IQR)	
$19.46 
 ($10.99-
$32.92)	
$22.49 
($11.41-
$40.10)	
$19.33 
($11.08-
$34.03)	
$16.78 
($9.67-
$35.57)	
Total out of pocket per 
patient not hospitalized* 
Median (IQR)	
$79.06 
($58.82-
$103.36)	
$97.32 
($56.11-
$124.83)	
$88.12 
($61.81-
$111.74)	
$88.26 
($53.70-
$117.07)	
Hospitalization* 
Median (IQR)	
$69.93 
 ($53.02-
95.30)	
$73.83 
($54.70-
94.96)	
$70.81 
($55.30-
101.18)	
$63.56 
($49.66-
$83.89)	
Total out of pocket per 
patient hospitalized*  
Median (IQR)	
$178.52 
(147.05-
$204.16)	
$158.52 
($120.57-
$213.49)	
$177.25 
($132.03-
$209.27)	
$157.09 
($131.28-
$208.32)	
 
*Median test (Pearson’s X2), p>0.05	
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The median out-of-pocket expenditures incurred in the different periods of the disease also vary 
across the different types of facilities sampled. The pre- diagnosis median out-of-pocket costs 
range from US$23.02 for PHC patients to US$26.92 in general hospitals to $41.91 for patients 
at the infectious dis- eases hospital (median P = 0.008). The median out-of- pocket cost during 
diagnosis ranged from US$24.30 in infectious diseases hospital patients to US$37.72 in 
diagnostic PHCs (median test P < 0.05). Post-diagnosis (treatment) varied from US$10.74 in 
general hospital patients to US$32.2 in PHCs (median test P < 0.001). Out-of-pocket 
expenditures did not vary significantly between patients sampled from the different types of 
facilities. In both the hospitalized and the non-hospitalized patient groups, the median total out- 
of-pocket expenditures varied statistically significantly among patients from different types of 
health care facilities (median test P < 0.05) (Table 3.6, Figure 3.1).  
Table 3.6. Median direct cost based on period before, during or after diagnosis by type of fa-
cility attended 
Period of illness Tertiary 
Hospital 
IDH General 
Hospital 
PHC 
(Diagnostic) 
PHC 
(Treatment) 
Pre-diagnosis/ 
care seeking* 
Median (IQR) 
$33.29 
($17.05-
$51.45) 
$41.91 
($28.39-
$64.73) 
$26.92 
($8.32-
$45.10) 
$29.87 
($14.83-
$43.76) 
$23.02 
($10.74-
$47.85) 
Diagnosis period* 
Median (IQR) 
$28.99 
($20.57-
$35.97) 
$24.30 
($19.00-
$32.69) 
$32.62 
($24.83-
$43.76) 
$37.72 
($28.59-
$41.01) 
$31.68 
($24.97-
$43.09) 
Post 
diagnosis/treatmen
t period* 
Median (IQR) 
$15.57 
($11.41-
$21.65) 
$22.82 
($17.45-
$38.25) 
$10.74 
($7.79-
$21.74) 
$27.05 
($16.11-
$53.69) 
$32.20 
($18.79-
$48.32) 
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Total out of 
pocket per patient 
not hospitalized* 
Median (IQR) 
$72.68 
($58.52-
$93.42) 
$104.73 
($88.26-
$128.76) 
$67.53 
($51.61-
$87.49) 
$101.34 
($67.85-
$163.29) 
$86.78 
($63.49-
$109.46) 
Hospitalization* 
Median (IQR) 
$63.09 
($48.99-
$75.84) 
$74.19 
($56.72-
$116.28) 
$73.83 
($60.40-
$91.95) 
$83.22 
($51.68-
$93.96) 
$70.47 
($53.69-
$94.63) 
Total out of 
pocket per 
patient 
hospitalized* 
Median (IQR) 
$149.87 
($123.56-
$289.85) 
$176.58 
($147.72-
$201.04) 
$70.54 
($121.48-
211.95) 
$153.96 
($127.65-
$204.16) 
$196.10 
($158.52-
225.77) 
 
*Median test (Pearson’s X2), p>0.05
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Figure 3.1. Total mean out-of-pocket spending during the prediagnosis, diagnosis and post 
diagnosis periods (all in US dollars) grouped by type of health care facility 
	
3.3.5. Analysis based on cost elements  
In both the hospitalized and the non-hospitalized groups, there was no significant difference 
between HIV-negative and HIV-positive patients in median costs of transportation, 
registration/consultation fees, medications, tests/X-rays and food (median test P > 0.05) (see 
Table 3.7).  
 
Table 3.7. Cost elements (Median) by hospitalization and HIV status 
 Hospitalised Non-Hospitalised 
Cost elements HIV 
negatives 
HIV positives HIV 
negatives 
HIV positives 
Travel* 
Median (IQR) 
$24.03 
($15.44-
$35.57) 
$24.83 
($14.93-
$35.57) 
$8.05 
($3.89-
$16.11) 
$9.40 
($4.30-
$17.58) 
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Registration/consultation* 
Median (IQR) 
$0.81 
($0.20-$5.17) 
$0.87 
($0.27-$1.85) 
$0.34 
($0.13-$0.67) 
$0.40 
($0.13-$0.67) 
Medications* 
Median (IQR) 
$72.15 
($1.34-
$92.28) 
$71.74 
($54.03-
$89.77) 
$38.07 
($23.49-
$47.65) 
$37.58 
($24.16-
$45.64) 
Investigations including 
X-Rays* 
Median (IQR) 
$24.30 
($18.12-
$32.89) 
$25.50 
($16.61-
$33.22) 
$16.11 
($12.08-
$20.13) 
$16.11 
($11.07-
$22.15) 
Food/drinks while at 
facility* 
Median (IQR) 
$20.13 
($12.42-
$25.17) 
$20.13 
($10.74-
31.54) 
$0 
($0-$0.67) 
$0 
($0-$1.34) 
Food supplements and 
paid help* 
Median (IQR) 
$12.75 
($5.37-
$26.17) 
$13.42 
($6.71-28.86) 
$6.71 
($0-$22.82) 
$10.74 
($0.$21.48) 
 
 
 
*Median test (Pearson’s X2), p>0.05	
However, there were statistically significant differences in the amount spent on transport and 
registration/consultation by patients’ facility types (median test P < 0.05). The out-of-pocket 
expenditure on food, tests/X-rays and registration/ consultations did vary slightly; however, 
these differences were not statistically significant (median test P > 0.05) (see Table 3.8, Figure 
3.2).	
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Table 3.8. Cost elements (Median) by type of facility attended 
Cost elements Tertiary 
Hospital 
IDH General 
Hospital 
PHC 
(Diagnostic) 
PHC 
(Treatment) 
Travel* 
Median (IQR) 
$12.21 
($5.10-
$20.47) 
$23.22 
($10.87-
$36.24) 
$12.08 
($5.37-
$21.21) 
$18.79 
($13.42-
$30.87) 
$19.80 
($8.02-
$36.51) 
Registration/consultation* 
Median (IQR) 
$0.80 
($0.20-
$2.21) 
$0.60 
($0.27-
$2.92) 
$0.27 
($0.13-
$0.87) 
$0.37 
($0.13-
$0.87) 
$0.70 
($0.27-
$1.01) 
Medications* 
Median (IQR) 
$52.18 
($38.73-
$81.54) 
$57.38 
($44.46-
$79.53) 
$42.95 
($29.53-
$69.13) 
$43.62 
($32.21-
$53.02) 
$43.49 
($30.54-
$71.14) 
Investigations including 
X-Rays* 
Median (IQR) 
$21.31 
($15.10-
$28.54) 
$15.50 
($11.41-
$22.82) 
$18.79 
($14.77-
$26.85) 
$20.81 
($12.75-
$26.84) 
$18.12 
($12.75-
$24.83) 
Food/drinks while at 
facility* 
Median (IQR) 
$3.36 
($0-
$12.08) 
$6.71 
($0-
$25.13) 
$3.36 
($0-
$20.13) 
$3.02 
($0-$13.43) 
$3.69 
($0-$22.15) 
Food supplements and 
paid help* 
Median (IQR) 
$10.74 
($5.37-
$22.82) 
$15.44 
($10.74-
$28.19) 
$12.08 
($4.08-
$29.53) 
$8.72 
($0.0-
$20.13) 
$6.71 
($0-$23.49) 
 
 
 
*Median test (Pearson’s X2), p>0.05 
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Figure 3.2. Median expenditure on travel, registration, clinical tests and food 
	
3.4. DISCUSSION 
The median total out-of-pocket spending by patients for seeking TB diagnosis and treatment in 
Bauchi State Nigeria was respectively US$166.11 and US$94.16 for hospitalized and non-
hospitalized patients during their illness.  
The study also found that, among patients hospitalized for TB, median out-of-pocket 
expenditure was US$166.48 and US$166.11 for HIV-positive and HIV-negative patients, 
respectively. Among non-hospitalized patients, it was respectively US$82.95 and $83.96 for 
HIV-positive and HIV-negative patients.  
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The median total out-of-pocket expenditure for hospitalized female and male patients during 
their illness was respectively US$158.52 and US$178.52. That of non-hospitalized female and 
male patients during their illness was respectively US$94.46 and US$79.80. 
Females were found to spend significantly higher proportions of their income in seeking 
diagnosis and treatment. This could be due to delayed health seeking behavior among females. 
Generally, in an African setting a woman may not be able to seek medical attention even in 
emergencies, unless approved by her husband (116, 124). Even after such, she still depends on 
her husband for the cost of medical expenses, which she may not even get on the long-run (124). 
Hence, female patients tend to present late at health facilities, with an advanced disease and 
widespread complications, usually abandoned and requiring more of their personal income to 
offset hospital bills (125). However, the differences in out-of-pocket expenditure based on sex 
and HIV status were not statistically significant. 
Similar studies have been published in sub-Saharan African and other resource limited 
developing countries (99, 126). These studies reported relatively lower overall costs than 
observed in this study. For instance, in Zambia, $7 was reported as the median direct cost of 
anti-tuberculosis treatment per patient in 2006, which was implausibly low, suggesting some 
inaccuracies with the costing methods employed (120).  Another study conducted in 2002 
reported the average direct cost for TB patients in Dar es Salaam, Tanzania, at $22 per patient, 
which is also low (4). While in Bangladesh and India, the estimates were slightly higher but still 
lower than the estimate in this study at US$ 130 and US$ 100, respectively (126). These 
differences could partly be explained by the differences in the purchasing powers of the US 
dollar between these countries and/or due to omission of some cost elements in these studies 
and/or due to bias resulting from inflation of self-reported expenditure, possibly in expectation 
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of refunds or compensation. Another major reason for these low estimates is because direct TB 
costs are often related to only health system costs, hence leading to an underestimation in most 
cases (100). Indeed, health system costs may be the smallest component of treatment costs in 
most settings, as observed in rural Uganda (99). Across most developing countries, many 
patients with tuberculosis would have sought assistance from traditional/herbal healers or 
alternative health care providers, incurring some costs in the process (99). A report in Malawi 
revealed that TB patients patronized traditional healers for an average of four weeks before 
presenting at standard health facilities (99). Initially the costs may be low, but due to repeated 
visits, the cumulative expenses incurred may eventually be high (126). This direct health cost is 
quite difficult to measure and often not included in several TB cost estimates (9, 96). 
As noted in Chapter 2, one of the major reasons for the high cost of care in Nigeria as observed 
in this study may be due to delayed diagnosis, as it generally takes above four weeks before a 
definitive diagnosis is made. In the process, several expenses would have been incurred on 
irrelevant investigations, palliative drugs and expensive nutritional supplements (100). Foster 
and colleagues also affirmed this, describing the period of delays (prior to commencing 
treatment) as contributing the greatest to TB treatment costs Aspler et al. also explained that the 
three major predictors of patient costs in Zambia included patient delays in seeking care, an 
over-bearing male gender which affects the choice of seeking health care, and the DOTs 
supervision approach (120, 126).  
Another important finding of this study is the fact that although anti-tuberculosis drugs are 
provided to patients free of charge in Nigeria, HIV-negative and -positive patients respectively 
spent a median of US$38.07 and US$37.58 (non-hospitalized patient group) and US$72.15 and 
US$71.74 (hospitalized group) for other medications from the period before diagnosis and up 
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to the end of treatment. Although several studies have reported that HIV co-morbidity increased 
the cost of TB (121, 127, 128). However, in this study HIV co-morbidity did not affect costs.  
Some disparities were also observed between cost elements in expenditures incurred by patients 
in the different facility types. Expenditure on non-TB medication was higher in patients 
attending the tertiary hospital and the infectious disease hospital, whereas these facilities have 
the highest physician/patient ratio.  These are mostly specialty physicians who are expected to 
give appropriate medications for TB. This raises a fundamental question as to whether 
physicians are over-prescribing non-TB medications in these facilities, possibly due to incorrect 
or delayed diagnosis. In addition, patients attending the infectious diseases hospital spent more 
on transportation than those attending other types of facilities, while those that attend to the 
primary health care treatment centers incurred higher transportation expenditure than those in 
the diagnostic PHCs. The higher travel costs among patients attending the infectious disease 
hospital could be due to the fact that there is only one such hospital in the whole State, and 
patients travel long distances to this hospital, which is known to provide the best TB services in 
the State. The higher travel costs among patients from the primary health care treatment centres 
may be due to the fact that such patients have to travel to other facilities not only for diagnostic 
services and follow-up visits but also for emergency and other ‘non-treatment’ services 
throughout the duration of their illness.  
As already identified in this study that delay in diagnosis of TB is a major determinant of patient 
costs, interventions that bring diagnosis of TB closer to patients where they live, like 
community-based enhanced case finding, have been recommended (120). This may involve 
promoting TB symptom awareness in communities, encouraging early presentations, and an 
expert guided sputum collection form suspected TB cases in the communities (100, 120). This 
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possibly may address the high economic costs on patients currently experienced before 
diagnosis. 
3.5. STUDY LIMITATIONS 
The cost estimate in this study was based on self-reported expenditure by patients, which may 
have been biased. Besides, it could have been underestimated due to failure to recall certain 
expenditures by patients or informants, or overestimated from inflated self-reported expenditure. 
Another major limitation is the estimation of future expenditures by extrapolation for patients 
yet to complete treatment. Every effort was made to minimize bias and ensure projection of 
future costs. 
Other limitations are:- 
1.  Selection bias: although the study sample was randomly selected but the fact that the 
selection and implementation was done solely by the investigator could have led to bias and 
preferential selection of participants. Effort were made during the selection to blind  names 
of the facilities during the random selection process. 
2. Observational bias: there could observational bias and errors in measurements or estimates 
during the data collection due to the imperfection of the observer and the subjective human 
judgement. Efforts were made standardize the procedure for collection of the data. 
3. Sensitivity analysis was not done to assess the effect of these assumptions in the study. 
However, because all major parameters had normal distribution curves, these assumptions 
were accepted as reasonable estimates of the real values. 
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3.6. CONCLUSION 
This study reveals the relatively high economic burden faced by TB patients in Nigeria, 
particularly due to delayed diagnosis of TB cases in these settings. Yet, worrying is the fact that 
patients have to pay out-of-pocket costs to get drugs, though anti-tuberculosis treatment is 
supposedly free in Nigeria. In a country where the per capita GDP is only US$1376, the per 
capita gross national income is only US$1160, and about 46% of the urban population lives 
below the poverty line, patient expenditure of 9–39% of annual income on TB diagnosis and 
treatment could be described as too expensive and potentially catastrophic for many patients 
and their families. The high cost of TB diagnosis and treatment poses significant barrier to care, 
resulting in further delays in diagnosis, poor treatment outcomes, and poor TB case detection 
rates, leading to continued spread of the infection in the community. The poorest group of 
patients have incurred higher costs due to delayed diagnosis, poor awareness on TB and lack of 
government support, thus pushing these set of people further down the poverty line. It is 
important that appropriate measures are taken to address this economic challenge in Nigeria, 
sub-Saharan Africa and several low-income settings to ensure sustained control of TB burden 
globally. To give a broader perspective on the impact of direct patient out-of-pocket expenditure, 
an insight into the indirect patient expenditure in the country is worthwhile.  The next chapter 
describes this in detail.
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4. PATIENT (INDIRECT) COST OF TUBERCULOSIS TREATMENT 
IN NIGERIA 
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4.1. BACKGROUND  
As already described in Chapter One, about one-third of the world’s population are currently 
infected with Mycobacterium Tuberculosis, with 1.4 million deaths attributable to tuberculosis 
each year despite the availability of effective antibiotics {WHO, 2016 #2106}. Experts believe 
efforts to control TB globally is facing great opportunities, as well as, great challenges 
worldwide (129). Widespread opportunities have been reported owing to relatively better 
commitments of the governments of many developing countries, and the support they get from 
international donors and funding agencies (130). This has also led to a situation where many of 
these governments are unable to increase their local capacity to sustain the increasing 
opportunities they receive (68). Hence, many governments and international donors are finding 
it difficult to direct resources to the most pressing needs in developing countries, despite the 
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rising burden of TB in these settings (130). Consequently, this has translated into several indirect 
costs borne by patients, families and their carers. 
Indirect costs constitute major health costs attributable to TB in any settings. Most economic 
analyses of TB burden have traditionally focused on direct out-of-pocket expenditure (foster). 
Across Africa and low- and middle-income countries (LMICs), patient and house-hold out-of-
pocket costs of TB have been assessed, including cost-effectiveness analyses of different 
approaches to TB treatment in many countries (4, 12, 120). While this is important (as noted in 
Chapter Three), it has quite a number of limitations, in that there is little insight on the social 
impact of the illness, jobs lost, opportunities missed, time spent in hospital, and national 
economic loss, especially because TB predominantly affects the productive age groups (114). 
TB care and services are increasingly becoming reliant on informal care, with associated costs 
shifted from the health care sector to the communities through early discharge programmes 
(114). Besides, substitution of inpatient care with ambulatory care and the move toward 
community care of tuberculosis have been widely reported in several communities (119). This 
clearly demonstrates that the social networks of a TB patient play important economic roles, 
which become affected as a result of an illness. An appropriate understanding of this may be 
helpful for experts and policy makers working on TB control and prevention. Generally, it is 
quite difficult to describe with certainty time lost by patients or being unable to work due to 
sickness. This thus makes the estimation of indirect costs quite difficult, with this resulting in 
the paucity of related data and information across world regions (10). This study therefore seeks 
to estimate the indirect costs to patients, households, and communities with tuberculosis, 
particularly in terms of hours spent by TB patients and/or their households, and the associated 
productivity lost.  
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4.2. METHODS 
Study area and setting have been described in Chapter Two. 
4.2.1. Study objective  
This study aimed to estimate, based on the United States Dollar (US$) value, the indirect cost 
of TB regarding the time spent and productivity lost by patients, families and others due to TB 
illness in Bauchi State, Nigeria.  
4.2.2. Study design and methods  
This is a cross sectional study in which the time spent by patients and other household members 
for tuberculosis (TB) diagnosis and treatment was assessed as well as the income lost (both the 
patients and households) due to the illness.  
A total of 242 (initially 255 but 13 were excluded based on age criteria of less than 15 years or 
older than 59 years of age) TB patients were sampled from 27 out of 67 facilities providing TB 
services in the state. The sample size was allocated based on facility type and patients were 
randomly selected in each facility. Selection was stratified based on patients’ HIV status and 
gender. The stratification was done during the selection, and where randomly selected number 
of patients in a stratum got at least half of the allocated sample size, the subsequent random 
selections will only be valid if is for the other stratum. A total of 40 patients were selected from 
the Infectious Disease Hospital, 40 from the Specialist hospital (tertiary hospital), 10 patients 
each from 9 General Hospitals, 6 patients each from 5 PHC diagnostic centers, 5 patients each 
from PHC treatment centers.  
Only patients with ‘confirmed’ TB diagnosis were included. Most of these patients had at least 
one sputum smear positive test and few had only sputum negative results but had CXRs strongly 
suggestive of TB with history of significant clinical improvement after initiation of TB 
treatment.  
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Ethical approval was sought and granted for this research by the Bauchi State Ministry of 
Health. The study was conducted between May and August, 2008.  
The methodology used in estimating the cost in this Chapter is the ‘Bottom-up estimation 
approach’ breaking down composite services into different cost dimensions which are then 
summarized or "rolled up" to determine an overall cost estimate for the cost of care per patient. 
This type of estimate is generally more accurate than other methods (parametric, analogous or 
expert judgement estimations) since it is looking at costs from a more granular perspective. 
Its also important reinstate here that although both the ‘direct’ and ‘indirect’ patient costs due 
to TB are estimated in Chapter 3 and 4, these estimates have not been factored in the CEA 
model in Chapter 7 primarily because the perspective of the CEA is for the UK Government 
and only captured the provider cost of treatment of TB in Nigeria. However, this analysis is 
included in the thesis to highlight some of the positive externalities (humanitarian) of the 
‘Investment in Nigerian TB Control” alternative. 
4.2.3. Questionnaire 
A standardized questionnaire (with the permission of the original developers (120)) was used to 
estimates the indirect costs of TB on patients, their families and other carers for seeking and 
accessing TB treatment during pre-diagnostic, diagnostic and post-diagnostic period, as well as 
during hospitalization where applicable. The questionnaires were administered to the all patients 
individually.  
4.2.4. Defining indirect patient cost of Tuberculosis 
The indirect cost in this study was estimated from:  
i) The average time spent by patients, their relatives, friends and other unpaid carers 
on travel, waiting time for consultation, treatment and hospitalization by TB patients 
and persons who accompanied patients during the period (starting from the onset of 
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illness that lead to TB diagnosis to the time TB treatment was completed). The 
monetary value of the time was calculated from the hourly wage value estimated at 
US$0.56/hr based on the 2008 annual gross national income per capita in Nigeria, 
which is $1169 (68). Annual working hours per capita used in this estimate was 2080 
hours (40 hours per week for 52 weeks); 
And 
ii) Income lost by TB patients and their households due to the period of TB illness or 
complication resulting from TB or treatment, as estimated from the difference in 
self-reported monthly patients and household income in the periods before and 
during TB illness.  
4.2.5. Data analysis 
Based on the definitions above, semi-structured questionnaire was employed (Appendix 21). 
Descriptive data analysis was conducted. A univariate general linear modeling for test of 
between subject effects of some demographic and socioeconomic variables on the total indirect 
cost was also conducted. All statistical analyses were conducted in IBM SPSS version 19 
software.   
4.3. RESULTS  
About 104 (43.0%) of the patients in this study were hospitalized within the period from 6 
months before TB diagnosis through the period of TB treatment (Table 4.1).  
One hundred and thirty-two (54.5%) of the patients were male, average age of the sample was 
32.8 (±9.8 SD) years. Only 24 (9.9%) of the patients in this study had history of previous TB 
infections. Twenty (83.3%) of the retreatment cases were reportedly due to relapse, 2 (8.3%) 
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due to default and another 2 (8.3%) due to treatment failure. Only 22 (9.1%) of the patients had 
all sputum AFB tests negative.  
About 106 (43.8%) of the patients were HIV negative, 122 (50.4%) were HIV positive and 14 
(5.8%) did not declare their HIV status. Ninety-three (38.4%) of the patients had no formal 
education, 52 (21.5%) had primary school certificates, 18 (7.4%) had junior secondary school 
certificates, 60 (24.8%) had secondary school certificates, 15 (6.2%) had undergraduate 
certificates, and 4 (1.7%) had graduate degrees and above. Seventy-six (29.8%) of the patients 
were unemployed, 18 (7.1%) were students, 55 (21.6%) were small scale business men and 
women, 42 (16.5%) are farmers, 26 (10.2%) were either drivers, laborers, security guards or 
menial workers and 10 (3.9%) were commercial sex workers.  
Average number of people living in the patient’s household was 6.43 (±5.37 SD). Average delay 
in diagnosis was estimated at 5.61 (±2.67 SD) weeks and the average number of facilities visited 
before diagnosis was 2.74 (Table 4.1).  
Table 4.1. The characteristics of the study population 
Description Number (%) 
History of hospitalization at least 6 months before diagnosis, 
during diagnosis and after diagnosis 
     Hospitalized 
     Not hospitalized 
 
 
104 (43.0%) 
138 (57.0%) 
Gender 
     Female  
     Male 
 
110 (45.5%) 
132 (54.5%) 
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History of prior TB illness 
     New TB cases  
     Retreatment 
 
218 (90.1%) 
24 (9.9%) 
Reasons for retreatment 
                      - Relapse 
                      - Default 
                      - Treatment failure 
 
20 (83.3% of the retreated) 
2 (8.3% of the retreated) 
2 (8.3% of the retreated) 
HIV status 
      HIV negative  
      HIV positive   
      Unknown HIV status 
 
106 (43.8%) 
122 (50.4%) 
14 (5.8%) 
Employment 
       Un-employed 
       Students 
       Civil servants 
       Small scale businesses 
       Farmers 
       Drivers, Labourers, Security guards or Menial workers 
       Commercial sex workers. 
 
75 (31.0%) 
10 (4.1%) 
28 (11.6%) 
53 (21.9%) 
40 (16.5%) 
26 (10.7%) 
10 (4.1%) 
Mean annual income 
       Female 
       Male 
 
$449.90/year 
$960.65/year 
The mean age of the sample population 32.8 years (15 – 59 years) 
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4.3.1. Income lost  
The income lost among the hospitalized group was estimated at $156/patient and about $114 in 
the non-hospitalized patients group (Table 4.2). The income lost varied by history of 
hospitalization, gender and HIV status of the patients (Table 4.3 and 4.4, Figures 4.1 and 4.2).  
Table 4.2. Income lost by hospitalization status 
Description Hospitalized Not hospitalized 
Average income lost by 
patient throughout the TB 
illness 
$75.09 
(min. -$53.69; max. 
$1100.08;  
SD $164.97 
$69.62  
(min. -$77.18; max. 
$1107.38;  
SD $167.24) 
Average income lost by 
other household members 
throughout the TB illness 
$80.87 
(min. -$161.07; max. 
$1436.24; SD $224.02) 
$43.89 
(min. -$268.46; 
max.$2805.37;  
SD $266.24) 
Total $155.96  $113.51 
 
	
Table 4.3. Income lost by gender and hospitalization 
Gender	 Hospitalized	 Not hospitalized	
Income 
lost in US 
$	
Value of 
time spent 
in US$ 	
Total	 Income 
lost in US 
$	
Value of 
time spent 
in US$	
Total	
Female	 $75.45	 $125.2	 $200.65	 $38.2	 $79.0	 $117.2	
Male	 $114.32	 $112.4	 $226.72	 $82.8	 $79.3	 $162.1	
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Table 4.4. Income lost by HIV status and hospitalization 
	
HIV status	 Hospitalized	 Not hospitalized	
Income 
lost in US 
$	
Value of 
time spent 
in US$ 	
Total	 Income 
lost in US 
$	
Value of 
time spent 
in US$	
Total	
HIV +	 $110.32	 $118.72	 $229.04	 $72.57	 $84.0	 $156.57	
HIV-	 $79.52	 $119.67	 $199.19	 $57.59	 $75.55	 $133.14	
 
 
 
 
 
	
Figure 4.1. Average Income lost by patients and their households by gender and hospitaliza-
tion history 
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Figure 4.2. Average Income lost by patients and their households by HIV status and hospi-
talization history 
	
4.3.2. Time spent by patients and household 
Patients with history of hospitalization during the TB illness spent an average time of 924.98 
hours for seeking diagnosis and treatment whereas the non-hospitalized group spent an average 
of 141.29 hours. The estimated US dollar valued for these hours based on the US0.56/hour GNI 
assumption was US517.98 and US $79.13 for hospitalized and non-hospitalized patient groups, 
respectively (Table 4.5).  
Hospitalization and facility of diagnosis were statistically significant (p-value <0.05), and 
associated with the total time (patients and household) spent on TB (Table 4.5, Figures 4.3, 4.4 
and 4.5).  
 
 71 
Table 4.5. Time spent by patients and ‘others’ in hours and value in US dollars by hospitali-
zation status 
Description	 Hospitalized	 Not hospitalized	
Time (Hrs)	 Cost in US$	 Time (hrs)	 Cost in US$	
Average time patients used 
for diagnosis and care 
throughout the TB illness	
 
517.33 Hrs	
$289.70	 120.37 Hrs	 $67.41	
Average time spent by others 
on a TB patient throughout 
the TB illness	
407.65 Hrs	 $228.28	 20.92 Hrs	 $11.72	
TOTAL	 924.98 Hrs	 $517.98	 141.29 Hrs	 $79.13	
 
 
Expectedly, both the time spent on TB illness and income lost by patients themselves and 
relatives varied based on whether patient was hospitalized or not during the TB illness.  
The income lost among the hospitalized group was estimated at $156/patient and about $114 in 
the non-hospitalized group. This difference is mainly from the higher income lost among the 
friends and relatives of patients that were hospitalized group, which was also found to be 
statistically significant (p-value < 0.001). 
The US dollar valued average time spent throughout the TB illness for seeking diagnosis and 
treatment varied between $518 and $79 between the hospitalized and non-hospitalized groups 
and was also found to be statistically significant (p-value < 0.001).  
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Figure 4.3. Average time spent by patients and ‘others’ on tuberculosis diagnosis and treat-
ment by hospitalization history 
	
Figure 4.4. Average time spent by patients and ‘others’ on tuberculosis diagnosis and treat-
ment by the occupation of the patient 
 73 
	
Figure 4.5. Average time spent by patients and ‘others’ on tuberculosis diagnosis and treat-
ment by educational attainment of the patient 
	
Univariate General Linear Model showed that age, gender, facility of diagnosis, level of 
education and occupation were statistically significant (p-values <0.05) predictors of the total 
(both patients and their households) income lost. However, AFB sputum-smear result and HIV 
status had no significant effects on the income lost (Table 4.6).  
 
Table 4.6. Test of Between-Subject Effects (Univariate General Linear Model) 
 Total time spent by patients and 
households in Hours	
Total Income lost by patients and 
households in US Dollars	
Df	 F	 p-value	 Df	 F	 p-value	
Age	 36	 1.268	 0.158	 36	 1.673	 0.015**	
Gender	 1	 0.613	 0.435	 1	 6.309	 0.013**	
Facility of 
Diagnosis	
4	 3.950	 0.004**	 4	 2.873	 0.024**	
Sputum Smear 
test	
1	 1.687	 0.195	 1	 2.793	 0.096	
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Level of 
Education	
5	 0.510	 0.769	 5	 4.459	 <0.001**	
HIV status	 3	 1.342	 0.264	 3	 1.084	 0.340	
Occupation	 6	 0.681	 0.665	 6	 6.268	 <0.001**	
History of 
Hospitalization	
1	 23.803	 <0.001**	 1	 3.181	 0.076	
 
4.4. DISCUSSION  
The study estimated the average total income lost by TB patients and their household for the 
hospitalized and non-hospitalized patients groups at US$156.96 and US$113.51 respectively.   
Income lost in individual patient incomes did not vary much based-on history of hospitalization 
(US$75.09 vs. US$69.62 for the hospitalized and non-hospitalized patient groups respectively). 
However, average income lost to household members was observed to be much higher in the 
hospitalized patients group (US$80.87 vs. US$43.89 for the hospitalized and non-hospitalized 
patient groups respectively).  
Age, gender, type of facility, level of education and occupation were found to be significant 
predictors of the total income lost (by patients and household) due to TB. AFB sputum-smear 
test result and hospitalization were not significantly associated with the total income lost.  
In this study, we also found that TB patients and their household spent an average of 924.98 
hours in the hospitalized and 141.29 hours in the non-hospitalized patients’ groups seeking TB 
diagnosis and treatment. These times were valued at US$517.98 and US$79.13 for hospitalized 
and non-hospitalized patients respectively.  
According to the WHO, income lost as a result of illness and death from TB are generally much 
more than the direct costs of TB (9, 96). In rural Uganda, it was estimated that 70% of costs to 
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TB patient are due income lost from work time, which can be either traced to loss of work or 
reduced productivity due to the illness (96, 131).  
Hospitalization during the TB illness and the facility of diagnosis were found to be significant 
predictors of the total time spent. Age, gender, AFB sputum-smear results, level of education, 
HIV status and occupation were not significant predictors of the total time spent on TB illness.  
While there are no comparable estimates in Nigeria, some studies have reported income lost due 
to Tuberculosis in some African countries. A study in Zambia reported an average of 48 days’ 
loss of income due to TB illness (132), while Aspler and colleagues reported US$ 15.27 as the 
median total indirect cost of TB treatment in Zambia in 2006 (98).  Another study conducted in 
Dar es Salaam, Tanzania in 2002 reported a median estimate of about US$431 as the household 
productivity lost due to Tuberculosis (123). In other separate reviews in sub-Saharan Africa, a 
short assessment of patients revealed household income grossly reduced among TB patients 
over time, increasing proportion of people classified as poor from 54% to 79%, with patients 
borrowing money and selling assets to cope with the cost of care (105, 131). Foster and 
colleagues stated that the indirect costs of TB on households could drive a ‘medical poverty 
trap’, as they adopt devastating coping strategies in the face considerable payments and assets 
losses during the illness (10). Considering the average annual income of TB patients in the study 
($449.90 and $960.65 for female and male patients respectively), the income lost due to TB as 
reported in this study could be described as catastrophic (more than 10% of the annual income 
(114)) to many patients and their households. As most indirect costs are due to lost income and 
time, it is important for experts working on TB control to factor these into potential research 
and interventions, with emphasis on the contextual needs of the poor who are actually the most 
affected in several settings.  
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4.5. STUDY LIMITATIONS 
There were several limitations that affected this study. As with questionnaires and interviews, 
recall biases may have led to inaccurate cost estimates. Although several questions on costs, 
income and time lost and job losses were linked to memorable events in the history of the pa-
tient, this was still difficult to ascertain, this giving the results presented wide uncertainties. 
Some authors have recommended that to attain some degree of accuracy, there may be need to 
estimate direct costs first, and then link this using some sets of scores and guidelines to arrive 
at losses of time and potential income as a result of the illness (105). This is rather hypothetical, 
as there is yet a standard guideline that best integrates this simulation. The results in this study 
are therefore presented against these limitations. Other general limitations such as selection bias, 
observational bias discussed in the previous Chapter also applies. 
4.6. CONCLUSION  
This study suggests a high indirect cost attributable to TB in Nigeria. Tuberculosis poses 
tremendous burden in terms of time and productivity lost to both patients and their households 
that could be catastrophic to many patients and their families whom are mostly impoverished 
and economically very vulnerable. Indirect cost of household members was particularly high in 
hospitalized patients, suggestive of prolonged hospital stay, poor state at presentation, and 
challenges with the capacity of health facilities to promptly respond to patient needs. There is 
need for resources to be directed towards prevention, early diagnosis and treatment, and better 
health service delivery in Nigeria and indeed across several African settings. Incorporating 
patients’ nutrition into national treatment plans may help reduce feeding costs on households, 
particularly among patients that are HIV positive who need more nutritional supplements. For 
those on treatment already, it may also be helpful that treatment support be given at community 
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levels as this reduces the impact on the household particularly during the intensive first two 
month of treatment. Largely, it is important that local, national and global TB policies and 
interventions be directed at early identification of TB patients and community-based support of 
patients in ways that reduces poverty and ensures quick recovery. Having highlighted the 
provider cost implications, and patients’ direct and indirect attributable cost due to TB in Nigeria 
(as contained in Chapters 2-4), it is important to highlight the cost and impact of TB control 
programme and interventions in Nigeria, towards an informed policy driven and public health 
response to TB in the country.
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5. THE COST AND IMPACT OF SCALING UP OF THE TB CON-
TROL PROGRAMME IN NIGERIA 
This Chapter describes the cost and impact regarding the number of TB cases detected and 
treated in Nigeria, and cases potentially averted among migrants coming into the UK in the 
next 20 years.   
5.1. BACKGROUND 
Poor case detection, treatment and coverage on existing interventions for TB have been widely 
reported in Nigeria (108). In 2015 alone, the incidence of multidrug resistance TB in Nigeria 
was 16 per 100,000 population accounting for over 29000 new cases (2).  With increasing cases 
of drug resistant TB and high prevalence of HIV infection amidst a rapidly-growing population, 
migrating Nigerians, and indeed migrants from other similar developing countries, remain the 
main importers of TB to UK and several developed countries (133).  
In 2009, the World Health Organization (WHO) estimated the cost of improving health systems 
in 49 developing countries, as a measure to scale up health service delivery for top causes of 
morbidity and mortality in these settings (6). Based on country prices and using a normative 
approach, the total additional cost of scaling up health service provision in these countries was 
US$ 251 billion spanning 7 years (134). Interestingly, sub-Saharan Africa (sSA) account for 
over 60% of this estimate at US$ 151 billion. It is expected that if these funds are efficiently 
utilized, mortality would reduce significantly across the 49 countries, particularly in sSA, 
averting 23 million deaths over the period 2009-2015 (134). Indeed, due to fragile health 
systems in sSA, the need to invest in top causes of mortality remain one of the major strategies 
towards alleviating the disease burden on these settings. 
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Arguably, ‘investment’ by developed countries, to scale up TB control programme in Nigeria 
and other countries in sSA through provision of funds (towards bridging the gaps for full 
implementation of all the activities recommended by the WHO Stop TB Strategy (96)) could be 
seen as not only an investment to help humanity, but also a preemptive approach to avert influx 
of TB cases from these countries.  However, despite the seemingly worthwhile initiative, there 
is yet a detailed assessment of the cost and impact of such scale-up investment in a Nigerian 
setting (5, 82). Generally, economic analysis of TB in Nigeria has been a challenge over the 
years, due to the paucity of data and lack of a standard mechanism for routine collation of data 
on health financing, and other related building blocks of the health system (135). 
Even in settings with limited data, designing a simple decision analysis model remain difficult. 
For example, Dowdy and colleagues explained that cost-effectiveness analysis may be 
misleading if applied only to scale-up of TB diagnostics (136). In such instances, the costs of 
false positive or negative diagnoses are often poorly defined and underestimated, and the 
operational and clinical impact of the diagnostics are mostly not accounted for (136). Besides, 
as a result of the challenges in determining accuracy (sensitivity and specificity) of diagnoses, 
several investigations are ordered, which rather results in the diagnostic activities competing 
with available resources when specific TB treatments are needed (137).  This often makes it 
difficult to specify standardized cost-effectiveness thresholds for specific aspects of TB 
management.  
Hence, this chapter provides an opportunity to examine the projected cost of an ‘investment’ in 
TB management (including scale-up of diagnosis, treatment, prevention and control) over a 
period of 20 years in Nigeria. It also describes how this can fit into the ‘funding gap’, 
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prospectively estimated from the difference between what is required for full implementation 
and the resources that are likely going to available over the next 20 years.  
5.2. METHODS 
A Microsoft Excel™ based model was developed to extrapolate disease and treatment burden 
of TB in Nigerian population over a period of 20 years, with the cost estimated element by ele-
ment. For instance, per patient TB control programme, cost elements were estimated from the 
World Health Organization TB control planning and budgeting tools multiplied by unit pa-
tients accessing services calculated (8, 138). The products were finally summed up to give the 
total expected programme expenditure. All currency value reported in the study was based on 
the US $ PPP as at November 2008 value. Amounts quoted in UK Pound Sterling (£) is also 
based on November 2008 $/£ exchange rate. 
The driver of the programme cost was regarded as the number of patients accessing services, 
including the coverage, case detection and treatment success rates.	
5.2.1. General Assumptions 
US Dollar was used as the currency for all TB diagnostics and treatment expenditures in Nige-
ria which was subsequently converted to Great Britain Pound sterling based November 2008 
exchange rate £1.00=$1.55=NGR 148.00, as this was an investment expected from the UK to 
Nigeria (120). All future costs were discounted by 3.5%. It was assumed that by full scale up 
of TB control programme in Nigeria, the TB incidence in the country will be declining by 
about 6% annually. This assumption is based on a study conducted in Peru that showed a 6% 
annual decline in TB incidence following full scale up of DOTS (79). It is understandable that 
there are distinct contextual differences between Nigeria and Peru, as the latter has a much 
lesser incidence of Tuberculosis. However, as noted, there are no comparable comprehensive 
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study in sSA, with the study in Peru as identified from the literature search conducted (Table 
1.2), being a developing economy providing a relatively comparable estimate. However, a sen-
sitivity analysis and apparent limitation of this assumption have been included, and discussed 
extensively in Chapter 6. 
Meanwhile, at the present level of TB service coverage in Nigeria, the incidence rate of TB 
has been declining over the past few year at a rate of 2.7% and 2.6% were reported between 
2006-2007 and 2007-2008, respectively (8). Hence, in the first three years of implementing 
the scale up, the incidence rate was assumed to remain 2.7% annually and subsequently 6% 
annually for the remaining 17 modeled years. Achieving a full scale-up was considered a rea-
sonable target based on the Peru experience within the first 3 years. All currency value re-
ported in the study was based on the US $ PPP as at November 2008 value. Amounts quoted 
in UK Pound Sterlings (£) is also based on November 2008 $/£ exchange rate. 
 
5.2.2. The cost elements and assumptions 
• National and State TB control programme logistics and overhead- The cost per patient 
for national and state TB control programme logistics and overhead was estimated at 
US $43 per patient based on the WHO Budget estimate in 2006 (8).  
• Routine programme management, supervision activities- The cost per patient treated 
for routine programme management, supervision activities, meetings, equipment and 
training was estimated at US $72 per patient, also based on the WHO Budget estimate 
in 2006. 
• Private-Public Mix (PPM)- The cost for PPM activities was estimated. A sum of US 
$171,054 will be needed in 2012 for PPM activities, US $178,532 in 2013, US 
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$188,595 in 2014 and US $196,846 in 2015. In this study, the 2015 figure was 
assumed to be the annual requirement from 2015 to 2031.  
• Practical Approach to Lung Health (PAL) - The estimated cost for PAL activities was 
US $207,941 annually from 2012 to 2031.  
• Communities TB care (CTBC)- The estimated cost for CTBC activities was US 
$271,353 in 2012, US $285,288 in 2013, US $299,889 in 2014 and US $315,175 in 
2015, and assumed (in this study) to remain so annually up to 2031. 
• Advocacy, Communication and Social Mobilization (ACSM) – The cost of ACSM 
activities was estimated at US $20,143,067 in 2012, US $21,177,500 in 2013, US 
$22,261,413 in 2014 and US$ 23,396,071 in 2015, and assumed to remain same up to 
2031.  
• Technical support- The cost for technical assistance by staff and consultants in country 
based and International organizations was also estimated at US $320,000 annually 
from 2012 to 2031.  
• Monitoring, Evaluation, Surveillance and Operational Research (M&E, S, O.R)- The 
cost of activities was estimated at US $1,012,000 in 2012, US $1,000,000 in 2013, US 
$1,058,400 in 2014, and US $1,101,000 annually from 2015 to 2031.  
• Multi-Drug Resistant TB (MDR TB) treatment cost- The cost of treating a case of 
MDR TB in Nigeria was estimated at US $3,106 per MDR-TB patient and assumed 
not to be affected throughout the 20 years’ model period. This cost includes the cost of 
MDR TB drugs, hospitalization for MDR TB patients, outpatient and DOT visits by 
MDR TB patients, sputum smear, culture, DST and X rays, MDR TB programme and 
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data management, provision of food parcels to MDR TB patients, services for adverse 
drug effects, and other costs relevant for MDR TB patients.  
• The cost of TB/HIV collaboration activities was estimated at US $0.42 per HIV patient 
screened for TB, treatment for latent TB in HIV patient at US $33 per patient 
completing IPT, HIV counseling and testing at US $22 per patient tested and 
counseled, cost of HIV prevention activities at US $24 per TB patient treated, cost of 
care and support for HIV+ TB patients at US $66 per patient treated for 6 months, cost 
of ART for HIV+TB patients at US $1363 per patient for 6 months, and cost of CPT 
per HIV+ TB patient for 6 months at US $71.  
5.2.3. Modeled impact in the United Kingdom 
5.2.3.1. Characteristics of migrants/entrants population coming into the UK 
The age and gender composition of Nigerian migrants into the UK, based on data from Labor 
Forces Survey (conducted by the Office of National Statistics in 2006), are reported below. 
Nigerian migrants in the UK were estimated to be 146,300 first generation population of 
Nigerian migrants (133, 139). The survey reported the gender and age composition of this 
population as: 
Gender composition: 52% were male 
                                                                                    48% were female 
Age composition:       8% were aged 0-15 years  
                                                       12% were aged 16-24 years  
                                                     53% were aged 25-44 years 
                                                     23% were aged 45-64 years 
                                                   4% were aged 65+ years 
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Based on this age distribution, entrants’ exposure to Tuberculosis and estimated burden was 
calculated. A projection was made for the 20-year model period for both intervention (CXR, 
IGRA and Investment to scale-up TB control in Nigeria, and the hypothetical no intervention 
‘doing nothing’ scenarios. Based on these projections, numbers and proportions of entrants 
coming into the UK in each TB state were estimated. 
5.2.3.2.  Economic and legal status of entrants 
Most of the Nigerians who enter the UK are legal entrants, i.e. work permit holders, students, 
and refugees and asylum seekers (133, 139).  Among the long-term migrants, about 76% were 
employed, 7% were unemployed and 17% were inactive, 50% either own a property outright 
or have bought a home with a mortgage (140). There was no information about the income of 
Nigerian migrants in the UK. There was also no published information on the income of 
visitors and other short term entrants from Nigeria in the UK. It was however assumed that no 
visitor works while in the UK. All children under the age of 15 years were assumed not to be 
working. 
5.3. RESULTS 
5.3.1. Drugs sensitive patients’ hospitalizations, outpatient 
care, investigations and drugs 
With a potential implementation of the proposed scale-up intervention, the annual cost of 
treatment for all expected drug sensitive TB cases in Nigeria raised from GBP 12,717,947 in 
2012 to a peak level of GBP 43,848,666 in 2015, before declining to GBP 15,124,897 by 
2031. However, in a scenario where the intervention is not implemented, the annual cost of 
treatment for all expected drug sensitive cases in Nigeria will slightly reduce from GBP 
12,717,947 in 2012 to GBP 12,098,635 by 2031 (Figure 5.1). 
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Figure 5.1. Line diagram showing total cost of drug sensitive patients’ hospitalizations, out-
patient care, investigation and drugs through the model years 
	
5.3.2. Drugs resistant patients’ hospitalizations, outpatient 
care, investigations and drugs 
With the proposed intervention implemented, annual cost of treatment for all expected drug 
resistant TB cases in Nigeria will rise from GBP 3,542,755 in 2012 to a peak level of GBP 12, 
214, 634 in 2015 before declining to GBP 4,213,243 by 2031. However, in a scenario where 
the intervention is not implemented, the annual cost of treatment for all expected drug resistant 
TB cases in Nigeria slightly reduces from GBP 3,542,755 in 2012 to GBP 3,370,237 by 2031 
(Figure 5.2). 
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Figure 5.2. Line diagram showing total cost of drug resistant patients’ hospitalizations, out-
patients’ care, investigation and drugs through the model years 
 
5.3.3. National and State TB control programme 
With the proposed intervention, annual cost of national and state general TB control 
programme in Nigeria is expected to rise from GBP 62,282,420 in 2012 to peak at GBP 
151,429, 071 in 2015 and subsequently decline slightly annually to GBP 110,331,044 by 2031. 
However, in a scenario where the proposed intervention is not implemented, this cost element 
was assumed to remain at the 2012 estimate of 2012 throughout the 20 model years (Figure 
5.3).  
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Figure 5.3. Line diagram showing general programme management cost through the model 
years 
 
5.3.4. Total programme (scale-up) management 
When the proposed intervention is implemented, the total programme scale up cost in Nigeria 
will to rise from GBP 76,822,658 in 2012 to a peak level of GBP 203,890,020 in 2015 before 
declining to GBP 144,685,342 by 2031. However, in a scenario where the intervention is not 
implemented, the total annual cost of TB control programme will rise from GBP 76,822,658 in 
2012 to a peak of GBP 106,885,183 by 2019 decline to GBP 93,636,754 in 2031 (Figure 5.4). 
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Figure 5.4. Line diagram showing total programme (scale-up) cost, with and without pro-
posed intervention through the model years 
 
 
5.3.5. Total cost of scaling up and the funding gap 
The total annual funding gap for scaling up TB programme in Nigeria was estimated to raise 
from GBP 0 in 2012 to peak at GBP 97,380,987 (GBP 94,459,558 discounted) in 2015 and 
subsequently reduced to GBP 51,048,588 (GBP 49,517,130 discounted) in 2031 (Figure 5.5). 
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Figure 5.5. Line diagram showing total funding gap for scaling up TB control programme in 
Nigeria through the model years 
 
5.3.6. Projected impact of intervention in Nigeria TB control 
5.3.6.1. In Nigeria 
Incidence rate of TB cases in Nigeria decline over the 20 years study period, from 311/100,000 
in 2012 to 189/100,000 (without proposed intervention) or 66/100,000 (with the proposed 
intervention) in 2031. In other words, the intervention will hasten the observed decline in TB 
incidence from the expected cumulative 122% reduction based on the present 2.6% annual 
decline rate to 245% reduction in 2031. 
A similar trend will be observed in both sputum smear positive and negative TB patients.  Over 
the 20-year period, sputum smear negative incidence rate declined from 180/100,000 to 
109/100,000 without proposed intervention and 38/100,000 with the intervention in the country 
and sputum positive incidence rate declined from 131/100,000 to 79/100,000 without the 
intervention and to 28/100,000 with the intervention (Figure 5.6). 
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Figure 5.6. Line diagram showing decline of projected incidence rates of sputum smear neg-
ative and positive TB in Nigeria through the model years 
 
Total number of new TB cases in Nigeria: Thus, the total number of new TB cases in the country 
is expected to decline, from 519,211 in 2012 to 493,928 without intervention and 172,252 with 
the intervention in 2031 as shown in the line diagram (Figure 5.7) below: 
 
	
Figure 5.7. Line diagram showing decline of projected number of new cases of TB, with and 
without scale-up intervention, in Nigeria through the model years 
Total number of TB patients to be treated in Nigeria: The number of TB patients to be treated is 
expected to increase sharply, from 101,388 in 2012 over the first few years to a peak at 349,564 
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in 2015 then declines to 120, 576 without and 96,451 with the proposed intervention by 2031 
as the burden of the disease significantly decrease in the country (Figure 5.8).  
 
	
Figure 5.8. Line diagram showing decline of projected total number of TB to be treated an-
nually in Nigeria through the model years 
Total number of TB patients that would not get treated: The number of TB patients expected not 
to get treated decreased from 417,823 in 2012 to 397,477 without the proposed intervention, 
and sharply to 51,676 with the intervention by 2031, mirroring similar reduction in the total 
burden of the disease decrease in the country. The decline with intervention was steeper in the 
first 3 years but slows down after the case detection rate peaked at 70% and remained so through 
the remaining period in the model (Figure 5.9). 
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Figure 5.9. Line diagram showing decline in the total number of TB that will not be treated 
annually in Nigeria through the model years 
 
Annual number of TB infections averted increased from 0 in 2012 to 321,676 per annum with 
the intervention and 170, 006 per annum without intervention in 2031. Cumulatively, about 
3,171,261 lives and about 2,470,196 lives will be saved with and without the proposed 
intervention, respectively over the 20-year period (See Figure 5.10). 
 
	
Figure	5.10.	Line	diagram	showing	total	number	of	TB	cases	and	deaths	that	will	be	averted	
with	the	intervention	annually	in	Nigeria	from	2012	to	2031 
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5.3.6.2. Amongst Nigerian migrants in the UK 
A major assumption in the study is that there will be corresponding decline in the burden of TB 
among Nigerian migrants with decline in the disease burden in Nigeria. The total annual burden 
of TB will decline from 21,608 in 2012 to 15,858 in 2031 if there is no intervention in Nigeria, 
and 5,246 with the proposed intervention. The cumulative number of all the TB infections 
coming into the UK from Nigeria over the 20 years was estimated at 370,135 without the 
intervention and 267,149 when there is intervention. Thus, the intervention will avert about 
102,986 cases of all forms of TB among migrants/entrants from Nigeria in the UK (Figure 5.11, 
Table 5.1). 
 
	
Figure 5.11. Line diagram showing the annual and cumulative TB cases among Nigerian 
migrants entering the UK with and without the intervention in Nigeria through the model 
years 
Active TB cases entering UK from Nigeria: The annual number of active TB cases among 
migrants coming to the UK from Nigeria will decrease from 283 in 2012 to 172 without 
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intervention and 60 with proposed intervention by 2031 as the burden of the disease in Nigeria 
proportionately decreased over the 20-year period (Figure 5.12, Table 5.1).  
 
	
Figure 5.12. Line diagram showing decline in the number of active TB cases entering the UK 
from Nigeria, through the model years 
0
75
150
225
300
1 3 5 7 9 11 13 15 17 19
ACTIVE	TB-Intervention
ACTIVE	TB-No	intervention
 95 
 
Table 5.1. Projections annual influx of TB cases from Nigeria into the UK 
Year	 No investment in Nigeria TB control	 Investment in Nigerian TB control	
Active 
TB	
Recent 
latent TB	
Longstanding 
latent TB	
Total	 Active 
TB	
Recent 
latent TB	
Longstanding 
latent TB	
Total	
2012	 283	 1246	 20079	 21608	 283	 1246	 20079	 21608	
2013	 276	 1220	 19733	 21228	 276	 1220	 19733	 21228	
2014	 269	 1195	 19395	 20859	 266	 1185	 19265	 20716	
2015	 262	 1170	 19067	 20498	 254	 1142	 18690	 20086	
2016	 255	 1146	 18746	 20148	 238	 1089	 17974	 19301	
2017	 248	 1123	 18435	 19806	 222	 1030	 17188	 18440	
2018	 242	 1100	 18131	 19473	 204	 968	 16354	 17526	
2019	 235	 1078	 17835	 19149	 186	 904	 15490	 16579	
2020	 229	 1057	 17547	 18833	 169	 811	 13807	 14787	
2021	 223	 1036	 17266	 18526	 154	 741	 12655	 13549	
2022	 218	 1016	 16993	 18226	 140	 677	 11606	 12423	
2023	 212	 996	 16727	 17935	 127	 611	 10417	 11155	
2024	 206	 977	 16467	 17650	 116	 556	 9479	 10151	
2025	 201	 958	 16215	 17374	 105	 506	 8626	 9238	
2026	 196	 939	 15969	 17104	 96	 461	 7850	 8406	
2027	 191	 922	 15729	 16842	 87	 419	 7143	 7650	
2028	 186	 904	 15496	 16586	 62	 381	 6500	 6943	
2028	 181	 887	 15269	 16337	 72	 347	 5915	 6335	
2030	 176	 871	 15047	 16094	 66	 316	 5383	 5765	
2031	 172	 855	 14832	 15858	 60	 287	 4898	 5246	
 4461	 20696	 344978	 370135	 3182	 14897	 249052	 267132	
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Recent’ latent TB cases entering UK from Nigeria: The annual number of ‘recent’ latent TB 
cases among migrants and other entrants coming to the UK from Nigeria also decreased from 
1246 in 2012 to 855 (with intervention) and 287 (without intervention) by year 2031 (Table 
5.1, Figure 5.13). 
 
	
Figure 5.13. Line diagram showing decline in the number of ‘recent’ latent TB cases entering 
the UK from Nigeria, through model years 
Longstanding’ latent TB cases entering UK from Nigeria: The annual number of ‘longstanding’ 
latent TB cases among migrants coming to the UK from Nigeria decreased from 20079 in 2012 
to 14832 (without the proposed intervention) and 4898 (with the proposed intervention) by 2031 
as shown in the line diagram below (Table 5.1, Figure 5.14). 
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Figure 5.14. Line diagram showing decline in the number of ‘longstanding’ latent TB cases 
entering the UK from Nigeria, 2012 to 2031 
5.4. DISCUSSION  
The study found that although total of about GB £3.34 billion is required for implementation of 
full scale TB control program in Nigeria over the next 20 years, but based on the current 
spending by Nigerian government and other funders (8), its estimated that only about GB£ 1.99 
billion is likely going to be available over the 20-year period.(8). This leaves a gap of about 
GB£ 1.35 billion (about 40%) over the next 20 years. An estimated funding gap of US$ 251 
billion dollar will be needed over seven years to scale-up the health system of 49 low-income 
studies enlisted in the WHO costing exercise. This amounts to an average of US$ 5.1 billion per 
country included in the costing. This is relatively higher than the GB£ 1.35 (US$ 1.70) estimated 
in this study, possibly because this was not a disease-specific scale-up, but targets the entire 
sector. It may therefore still be assumed to be comparable with the estimate in this study. The 
cost-effectiveness of this investment is examined in detail in Chapter Six, with the model based 
on the assumption that the UK government may ‘invest’ as much as 25% of this gap over 20 
years as a proactive strategy to reduce the influx of TB from Nigeria. The implications of this 
assumption and other related assumptions are also critically examined and discussed. 
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The WHO clearly stated that realizing desired outcomes in health indices strictly depends on 
the availability of more resources allocated for health in developing countries, and ensuring 
there is capacity to effectively utilize these funds to meet targeted health needs (141) Indeed, 
implementation of the WHO strategy has been proved to be effective in substantially reducing 
the incidence and prevalence of TB in countries with a high TB burden (96). However, due to 
inadequate funds and several contextual factors, the implementations of this strategy in many 
developing countries remain far from complete. These countries act as reservoirs for TB, adding 
burden to countries where the disease has been hither-to controlled, particularly owing to 
significant international travels and migrations from the high TB incidence countries to low TB 
incidence countries.  
This study reported a decline in the incidence rate of TB in Nigeria over the 20-year study 
period, from 311/100,000 in 2012 to either 189/100,000 (without proposed intervention) or 
66/100,000 (with the proposed intervention) in 2031. Thus, the total number of new TB cases 
in the country is expected to decline, from 519,211 in 2012 to 493,928 without the intervention 
and 172,252 with the intervention in 2031. In the 2009 WHO report, some specific health sector 
benefits were also potentially identified following health systems strengthening and scale-up of 
specific health interventions. It was estimated that country-specific total expenditure for health 
among the 49 low-income countries would increase to an average of US$54 per capital, with 
hospital beds increasing to about 21 per 10000 population, and nurses and midwives to 1.9 per 
1000 population (134).  
Meanwhile, the cumulative number of all the TB infections coming in to the UK from Nigeria 
was estimated at 370,135 without the intervention and 267,149 when there was the intervention, 
thus, the intervention may avert about 102,986 cases of all forms of TB among migrants/entrants 
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from Nigeria in the UK over the 20-year study period. However, despite an apparent reduction 
in TB burden following investment in TB control in Nigeria, the potential impact among the 
rural and hard-to-reach populations who are relatively poor and without the needed resources to 
access urban health facilities remain uncertain. It is unclear how these interventions would 
improve living conditions of an average rural dweller infected with TB. This challenge was also 
raised by the WHO, suggesting that most health system scale-up exercise and the estimated 
costs may not produce the “ideal” health system with evenly spread resources and service 
delivery across all settings, but may only offer a reasonable leverage for the local capacity to 
respond to pressing population health needs (134).  
5.5. STUDY LIMITATIONS 
One important limitation of this study is that the probability of TB cases among migrants was 
calculated based on the expected prevalence of TB in Nigeria after full scale up of TB. This 
probability was estimated at 0.0017, which was based on the assumption that with TB control 
strategies in Nigeria, there may be a decline of about 6% annually in the incidence of TB in 
the country, as observed in Peru, which provides a developing country comparison with Nige-
ria. Unfortunately, the plausibility of this argument is highly debatable, particularly because of 
the contextual differences between Nigeria and Peru. However, sensitivity analysis testing the 
robustness of this assumption was done and reported in the later section of this chapter. The 
probability active TB among migrant was doubled to about 0.0034 and was lowered by about 
half ( to 0.0010) to find whether the cost effectiveness analysis result would be significantly 
changed but found that the order of effectiveness haven't changed. 
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Other major limitation of this study includes the assumption that there would be proportionate 
decline in the prevalence of TB among Nigerian coming to UK with decrease in the preva-
lence of TB in Nigeria. This possibility like likely makes our estimation of the Utility (QALY) 
gain among migrants an over estimation, however, the unity gain in Nigeria will be signifi-
cant, although not estimated in this study. 
Some cost estimated of some commodities and services in this study were drawn from other 
studies and validity of some of these estimates weren't ascertained. This also posed a limita-
tion on the significance of this study. Efforts were made to critically appraise the validity of 
evidence before inclusion in this study.  
The estimates provided in this study should therefore be interpreted against this limitation.  
5.6. CONCLUSION 
This study has suggested potential benefits in the scale-up of TB control in Nigeria, but with 
some uncertainties and limitations (already described). In the next chapter, cost-effectiveness 
analysis of selected TB control strategies among Nigerians migrants/entrants in the UK will be 
conducted. This builds essentially on the results already presented in this chapter. To test the 
robustness of the key assumptions from this chapter (and other assumptions in the next chap-
ter), sensitivity analyses will be conducted to find if the results will significant vary. 
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Table 6.17. Sensitivity analysis for variable ‘Proportion of entrants/migrants chest x ray 
screened at point of entry’ (pScr) 
	
pScr	 STRATEGY	 COST	 EFF	 C-E	 I-C	 I-E	 ICE	 Remark	
0	 NOTHING	 72.02958	 17.24974	 4.17569	 0	 0	 0	  
0	 Present practice (Chest x ray screening 
at the airport)	
72.15578	 17.24856	 4.18329	 0.1262	 -
0.00118	
-106.54554	 Dominated	
0	 Investment in Nigeria TB control	 255.8446
4	
17.30379	 14.78547	 183.81506	 0.05405	 3401.06238	  
0	 IGRA	 717.7416
6	
17.30225	 41.48257	 461.89702	 -
0.00154	
-
299503.4286	
Dominated	
0.25	 NOTHING	 72.02958	 17.24974	 4.17569	 0	 0	 0	  
0.25	 Present practice (Chest x ray screening 
at the airport)	
250.3863
9	
17.26573	 14.50193	 178.3568	 0.01599	 11157.54379	  
0.25	 Investment in Nigeria TB control	 255.8446
4	
17.30379	 14.78547	 5.45826	 0.03806	 143.40793	  
0.25	 IGRA	 717.7416
6	
17.30225	 41.48257	 461.89702	 -
0.00154	
-
299503.4286	
Dominated	
0.5	 NOTHING	 72.02958	 17.24974	 4.17569	 0	 0	 0	  
0.5	 Investment in Nigeria TB control	 255.8446
4	
17.30379	 14.78547	 183.81506	 0.05405	 3401.06238	  
0.5	 Present practice (Chest x ray screening 
at the airport)	
428.6169
9	
17.2829	 24.80006	 172.77234	 -
0.02089	
-8270.08465	 Dominated	
0.5	 IGRA	 717.7416
6	
17.30225	 41.48257	 461.89702	 -
0.00154	
-
299503.4286	
Dominated	
0.75	 NOTHING	 72.02958	 17.24974	 4.17569	 0	 0	 0	  
0.75	 Investment in Nigeria TB control	 255.8446
4	
17.30379	 14.78547	 183.81506	 0.05405	 3401.06238	  
0.75	 Present practice (Chest x ray screening 
at the airport)	
606.8475
9	
17.30007	 35.07776	 351.00294	 -
0.00372	
-94319.3783	 Dominated	
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0.75	 IGRA	 717.7416
6	
17.30225	 41.48257	 461.89702	 -
0.00154	
-
299503.4286	
Dominated	
1	 NOTHING	 72.02958	 17.24974	 4.17569	 0	 0	 0	  
1	 Investment in Nigeria TB control	 255.8446
4	
17.30379	 14.78547	 183.81506	 0.05405	 3401.06238	  
1	 IGRA	 717.7416
6	
17.30225	 41.48257	 461.89702	 -
0.00154	
-
299503.4286	
Dominated	
1	 Present practice (Chest x ray screening 
at the airport)	
785.0781
9	
17.31724	 45.33507	 529.23354	 0.01345	 39352.95046	  
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Figure 6.39. Sensitivity analysis for variable ‘Proportion of entrants/migrants chest x ray 
screened at point of entry’ (pScr) (in Figures)
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5.6.1.5. Proportion of entrants/migrants screened using IGRA at point of entry 
(pScrIGRA) 
The sensitivity of this cost-effectiveness model to changes in the proportion of Nigerian 
migrants/entrants screened at the airport using IGRA method was evaluated.   
As shown in Table 6.18 below, when 0% of entrants undergo IGRA screening, the most cost 
effective alternatives when none of the migrants is IGRA screened are strategies 1 (investment 
in Nigerian TB control) and strategy 2 (Chest x ray screening) and strategy 3 (IGRA) were 
dominated. 
When 10% of migrants are IGRA screened, the most cost effective strategy is strategy 1 
(Investment in Nigeria control); next strategy 2 (chest x ray screening) followed by strategy 3 
(IGRA) in that order.  
When 20% of migrants are screened, the most cost-effective strategy is strategy 1 (Investment 
in Nigeria control) followed by strategy 2 (chest X ray screening) then 3 (IGRA) in that order. 
When 30% of migrants are screened, the most cost-effective strategy is strategy 1 (Investment 
in Nigeria control) followed by strategy 2 (chest X ray screening) in that order. Strategy 3 
(IGRA) is dominated. 
When 40% of migrants are screened, the most cost-effective strategy is strategy 1 (Investment 
in Nigeria control) followed by strategy 2 (chest X ray screening) in that order. Strategy 3 
(IGRA) is dominated. 
When 50% of migrants are screened, the most cost-effective strategy is strategy 1 (Investment 
in Nigeria control) followed by strategy 2 (chest X ray screening) in that order. Strategy 3 
(IGRA) is dominated. 
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When 60% of migrants are screened, the most cost-effective strategy is strategy 1 (Investment 
in Nigeria control) followed by strategy 2 (chest X ray screening) in that order. Strategy 3 
(IGRA) is dominated. 
When 80% of migrants are screened, the most cost-effective strategy is strategy 1 (Investment 
in Nigeria control) followed by strategy 2 (chest X ray screening) in that order. Strategy 3 
(IGRA) is dominated. 
When all migrants are screened, the most cost-effective strategies is strategy 1 (Investment in 
Nigeria control) followed by strategy 2 (chest X ray screening) then strategy 3 (IGRA) (see 
Table 6.18, and group of figures below—Figure 6.40)	
	
	
pScr 
IGRA	
STRATEGY	 COST	 EFF	 C-E	 I-C	 I-E	 ICE	 Remark	
0	 NOTHING	 72.02958	 17.24974	 4.17569	 0	 0	 0	  
0	 IGRA	 72.15578	 17.24856	 4.18329	 0.1262	 -0.00118	 -106.546	 (Dominated
)	
0	 Present practice (Chest X ray 
screening at the airport)	
228.9987	 17.26367	 13.26478	 156.9691	 0.01392	 11272.52	  
0	 Investment in Nigeria TB 
control	
255.8446	 17.30379	 14.78547	 26.84593	 0.04012	 669.1169	  
0.1	 NOTHING	 72.02958	 17.24974	 4.17569	 0	 0	 0	  
0.1	 IGRA	 143.8876	 17.25452	 8.33912	 71.85797	 0.00478	 15030.2	  
0.1	 Present practice (Chest X ray 
screening at the airport)	
228.9987	 17.26367	 13.26478	 85.11116	 0.00914	 9307.841	  
0.1	 Investment in Nigeria TB 
control	
255.8446	 17.30379	 14.78547	 26.84593	 0.04012	 669.1169	  
0.2	 NOTHING	 72.02958	 17.24974	 4.17569	 0	 0	 0	  
0.2	 IGRA	 215.6193	 17.26049	 12.49207	 143.5897	 0.01075	 13361.77	  
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0.2	 Present practice (Chest X ray 
screening at the airport)	
228.9987	 17.26367	 13.26478	 13.3794	 0.00318	 4209.182	  
0.2	 Investment in Nigeria TB 
control	
255.8446	 17.30379	 14.78547	 26.84593	 0.04012	 669.1169	  
0.3	 NOTHING	 72.02958	 17.24974	 4.17569	 0	 0	 0	  
0.3	 Present practice (Chest X ray 
screening at the airport)	
228.9987	 17.26367	 13.26478	 156.9691	 0.01392	 11272.52	  
0.3	 Investment in Nigeria TB 
control	
255.8446	 17.30379	 14.78547	 26.84593	 0.04012	 669.1169	  
0.3	 IGRA	 287.3511	 17.26645	 16.64216	 31.50643	 -0.03733	 -843.893	 (Dominated
)	
0.4	 NOTHING	 72.02958	 17.24974	 4.17569	 0	 0	 0	  
0.4	 Present practice (Chest X ray 
screening at the airport)	
228.9987	 17.26367	 13.26478	 156.9691	 0.01392	 11272.52	  
0.4	 Investment in Nigeria TB 
control	
255.8446	 17.30379	 14.78547	 26.84593	 0.04012	 669.1169	  
0.4	 IGRA	 359.0828	 17.27242	 20.78938	 103.2382	 -0.03137	 -3291.06	 (Dominated
)	
0.5	 NOTHING	 72.02958	 17.24974	 4.17569	 0	 0	 0	  
0.5	 Present practice (Chest X ray 
screening at the airport)	
228.9987	 17.26367	 13.26478	 156.9691	 0.01392	 11272.52	  
0.5	 Investment in Nigeria TB 
control	
255.8446	 17.30379	 14.78547	 26.84593	 0.04012	 669.1169	  
0.5	 IGRA	 430.8146	 17.27839	 24.93373	 174.97	 -0.0254	 -6887.54	 (Dominated
)	
0.6	 NOTHING	 72.02958	 17.24974	 4.17569	 0	 0	 0	  
0.6	 Present practice (Chest X ray 
screening at the airport)	
228.9987	 17.26367	 13.26478	 156.9691	 0.01392	 11272.52	  
0.6	 Investment in Nigeria TB 
control	
255.8446	 17.30379	 14.78547	 26.84593	 0.04012	 669.1169	  
0.6	 IGRA	 502.5464	 17.28435	 29.07522	 246.7017	 -0.01944	 -12691.4	 (Dominated
)	
0.7	 NOTHING	 72.02958	 17.24974	 4.17569	 0	 0	 0	  
0.7	 Present practice (Chest X ray 
screening at the airport)	
228.9987	 17.26367	 13.26478	 156.9691	 0.01392	 11272.52	  
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0.7	 Investment in Nigeria TB 
control	
255.8446	 17.30379	 14.78547	 26.84593	 0.04012	 669.1169	  
0.7	 IGRA	 574.2781	 17.29032	 33.21386	 318.4335	 -0.01347	 -23634.9	 (Dominated
)	
0.8	 NOTHING	 72.02958	 17.24974	 4.17569	 0	 0	 0	  
0.8	 Present practice (Chest X ray 
screening at the airport)	
228.9987	 17.26367	 13.26478	 156.9691	 0.01392	 11272.52	  
0.8	 Investment in Nigeria TB 
control	
255.8446	 17.30379	 14.78547	 26.84593	 0.04012	 669.1169	  
0.8	 IGRA	 646.0099	 17.29628	 37.34964	 390.1653	 -0.00751	 -51969.3	 (Dominated
)	
0.9	 NOTHING	 72.02958	 17.24974	 4.17569	 0	 0	 0	  
0.9	 Present practice (Chest X ray 
screening at the airport)	
228.9987	 17.26367	 13.26478	 156.9691	 0.01392	 11272.52	  
0.9	 Investment in Nigeria TB 
control	
255.8446	 17.30379	 14.78547	 26.84593	 0.04012	 669.1169	  
0.9	 IGRA	 717.7417	 17.30225	 41.48257	 461.897	 -0.00154	 -299503	 (Dominated
)	
1	 NOTHING	 72.02958	 17.24974	 4.17569	 0	 0	 0	  
1	 Present practice (Chest X ray 
screening at the airport)	
228.9987	 17.26367	 13.26478	 156.9691	 0.01392	 11272.52	  
1	 Investment in Nigeria TB 
control	
255.8446	 17.30379	 14.78547	 26.84593	 0.04012	 669.1169	  
1	 IGRA	 789.4734	 17.30821	 45.61265	 533.6288	 0.00442	 120643.2	  
	
Table 6.18. Sensitivity analysis table for variable ‘Proportion of entrants/migrants screened 
using IGRA at point of entry’ (pScrIGRA) 
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Figure 6.40. Sensitivity Analysis plot showing the total cost (,000) in US Dollars of the 4 al-
ternative interventions by proportion of migrants screened using IGRA at the POE 
 
	
Figure 6.41. Sensitivity Analysis plot showing the Effect/migrant in QALYs of the 4 alterna-
tive interventions by proportion of migrants screened using IGRA at the POE	
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Figure 6.42. Sensitivity analysis for variable ‘Proportion of entrants/migrants screened us-
ing IGRA at point of entry’ (pScrIGRA) (in Figures)
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5.6.1.6. Proportion of entrants/migrants that are HIV positives (ppHIV) 
The sensitivity of this CE model to change in the proportion of Nigerian migrants/entrants that 
HIV positive was evaluated.   
When 0% of entrants are HIV positive, the most cost effective alternatives is strategies 1 
(investment in Nigerian TB control) with ICER of £3465.45/QALY followed by strategy 3 
(IGRA) with ICER of £48847.19/QALY. Strategy 2 (Chest X ray screening) was dominated. 
When 25% of entrants are HIV positive, the most cost effective alternatives is strategies 1 
(investment in Nigerian TB control) with ICER of £3433.14/QALY followed by strategy 3 
(IGRA) with ICER of £139785.74/QALY. Strategy 2 (Chest X ray screening) was dominated. 
When 50% of entrants are HIV positive, the most cost effective alternatives is strategies 1 
(investment in Nigerian TB control) with ICER of £3401.06/QALY. Strategy 2 (Chest X ray 
screening) and 4 (IGRA) were dominated. 
When 75% of entrants are HIV positive, the most cost effective alternatives is strategies 1 
(investment in Nigerian TB control) with ICER of £3,369.22/QALY. Strategy 2 (Chest X ray 
screening) and 4 (IGRA) were dominated. 
When all entrants are HIV positive, the most cost effective alternatives is strategies 1 
(investment in Nigerian TB control) with ICER of £3337.60/QALY. Strategy 2 (Chest X ray 
screening) and 4 (IGRA) were dominated (see group of figures below—Figure 6.41)
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Figure 6.43. Sensitivity Analysis plot showing the total cost (,000) in US Dollars of the 4 
alternative interventions by prevalence of HIV infection among migrants from Nigeria. 
 
	
	
Figure 6.44. Sensitivity Analysis plot showing the Effect/migrant in US QALY for the 4 al-
ternative interventions by prevalence of HIV among Nigeria migrants coming into the UK.	
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Figure 6.45. Senasitivity analyses for proportion of entrants/migrants that are HIV positives 
(ppHIV) (in Figures)
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5.6.1.7. Proportion of entrants/migrants that have drug resistant TB (pDRA) 
The sensitivity of this CE model to changes in the proportion of Nigerian migrants/entrants 
entering the UK with drug resistant TB was evaluated.   
As shown in Table x below, when 0% of entrants have drug resistant TB, the most cost 
effective strategy is strategies 1 (investment in Nigerian TB control) ICER £671.05/QALY 
followed by strategy 2 (Chest X ray screening) ICER £11320.65/QALY. Strategy 3 (IGRA) is 
dominated. 
When 2% of entrants have drug resistant TB, the most cost effective strategy is strategies 1 
(investment in Nigerian TB control) ICER £668.90/QALY followed by strategy 2 (Chest X ray 
screening) ICER £11320.65/QALY. Strategy 3 (IGRA) is dominated. 
When 4% of entrants have drug resistant TB, the most cost effective strategy is strategies 1 
(investment in Nigerian TB control) ICER £666.76/QALY followed by strategy 2 (Chest X ray 
screening) ICER £11213.79/QALY. Strategy 3 (IGRA) is dominated. 
When 8% of entrants have drug resistant TB, the most cost effective strategy is strategies 1 
(investment in Nigerian TB control) ICER £662.45/QALY followed by strategy 2 (Chest X ray 
screening) ICER £11107.23/QALY. Strategy 3 (IGRA) is dominated. 
When 12% of entrants have drug resistant TB, the most cost effective strategy is strategies 1 
(investment in Nigerian TB control) ICER £658.19/QALY followed by strategy 2 (Chest X ray 
screening) ICER £11000.98/QALY. Strategy 3 (IGRA) is dominated. 
When 16% of entrants have drug resistant TB, the most cost effective strategy is strategies 1 
(investment in Nigerian TB control) ICER £653.92/QALY followed by strategy 2 (Chest X ray 
screening) ICER £10895.03/QALY. Strategy 3 (IGRA) is dominated. 
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When 18% of entrants have drug resistant TB, the most cost effective strategy is strategies 1 
(investment in Nigerian TB control) ICER £651.78/QALY followed by strategy 2 (Chest X ray 
screening) ICER £10842.16/QALY. Strategy 3 (IGRA) is dominated (see group of figures 
below—Figure 6.42) 
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Figure 6.46. Sensitivity Analysis plot showing the total cost (,000) in US Dollars of the 4 al-
ternative interventions by probability of DRA among Nigerian migrants.	
	
Figure 6.47. Sensitivity Analysis plot showing the Effect/migrant in QALYs for the 4 alter-
native interventions by probability of DRA among Nigerian migrants.	
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Figure 6.48. Sensitivity analyses for probability of DRA among entrants/migrants (in Fig-
ures) 
The above (subsections 6.3.6.1-6.3.6.7) are the main sensitivity analyses conducted in the 
study. However, there are other sensitivity analyses that were conducted along with these main 
ones. For details of other sensitivity analyses, please refer to Appendix 19.  
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5.4. DISCUSSION 
This study has compared the costs and utilities (effectiveness) of three main alternatives for 
Tuberculosis control among Nigerian migrants and their contacts in the United Kingdom. The 
study shows that the proposed alternative that UK government invests in Nigerian DOTS 
scale-up is the most cost-effective strategy for mitigating the impact of influx of TB from Ni-
geria to the UK.  The prevalence of active and latent TB among migrants coming to the UK 
from Nigeria was estimated as 0.24% and 20% respectively. This study also shows that among 
those screened, 0.24% and only about 0.22% true positive active and latent TB respectively 
will be detected with CXR screening and 0.20% (active TB), 19% (latent TB) will be true pos-
itives when IGRA screening used. 
Although about 99.76% and 80% of migrants do not have active and latent TB respectively, 
CXR screening estimates 66.84% and 0% as true negative active and latent TB respectively 
while IGRA estimates about 98.76% and 79.12% true negative active and latent TB 
respectively. The study also found that with CXR screening, about 32.92% and 79.92% are 
likely going to be false positive for active and latent TB respectively, but with IGRA screening 
only about 1% and 0.8% of active and latent TB respectively will be false positive. However, 
false negative results were reported in 0% and 17.78% for active and latent TB, respectively, 
using CXR. While it was 0.4% and 1% active and latent TB respectively when IGRA was 
used. This suggests a relatively better specificity and sensitivity of IGRA compared to CXR. 
This finding has been reported by several authors, with IGRA highly recommended and 
approved for immigrant screening in many countries over the years (77, 155). However, some 
studies have been conducted recently with apparently contradictory findings reported (77). In 
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a 2011 systematic review, Nienhaus and colleagues reported that there is no substantial 
difference in the effectiveness of some selected strategies, including CXR and IGRA, to 
screening LTBI (155). They specifically noted that the contradictions in results across studies 
could have been due to methodological issues, which has already been identified in the cost-
effectiveness analyses of IGRA screening (155).  While guidelines have been published to 
standardize analyses, a host of factors, often related to population and relevance, have 
prevented researchers from following these guidelines. Researchers have recommended the 
development of standard input parameters and assumptions in economic modeling studies. 
e. Moreover, in the reported estimates in this study, about three hundred and five 
thousand (305,000) Nigerians were estimated to come to the UK for varying 
reasons and durations annually and are estimated to spend a total of 91,052 per-
son years every year through the 20 years modeled. Only about 21.62% annu-
ally are estimated to be screened by CXR at present and is assumed to remain 
same in the next 20 years if there is no intervention. All currency value re-
ported in the study was based on the US $ PPP as at November 2008 value. 
Amounts quoted in UK Pound Sterlings (£) is also based on November 2008 
$/£ exchange rate. 
The mean cost, to the UK government, for investment (paying the whole funding gap) in 
scaling up TB control in Nigeria (strategy 1) was estimated as £253.78 (SD £25.84) per 
Nigerian migrants coming into the UK, the cost of CXR screening was estimated at £293.41 
(£102.95), IGRA screening at £690.93 (£113.45) and not doing anything ‘do nothing’ will still 
cost the UK government £70.29 (£31.52). The mean effectiveness, to the UK government, for 
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investment (paying the whole funding gap) in scaling up TB control in Nigeria (strategy 1) 
was estimated at 17.327 QALY (SD 0.172 QALY) per Nigerian migrants coming into the UK, 
CXR screening was 17.279 QALY (0.189 QALY), IGRA screening 17.319 QALY 
(0.188QALY) and not doing anything was estimated at 17.265 QALY (0.177 QALY). 
The study found investment in scaling up Nigerian TB control as the most cost effective 
strategy with ICER of £2,964/QALY followed by IGRA screening strategy with an ICER of 
£11,430/QALY and CXR screening with ICER of £15,713/QALY. Investment in scaling up 
Nigerian TB control as an alternative was found to remain most cost effective. It was 
independent of proportion of migrants screening by both IGRA and CXR at the airports, the 
proportion of migrants with HIV infection, and proportion with drug resistant TB infection. 
Some findings have been reported which are in keeping with the results presented in this 
study. For instance, Dasgupta and colleagues stated specifically that the ideal long term TB 
control strategy lies in a global investment in strategies to improving TB control in high 
incidence countries, as this has the most likely probability of reducing transmission of TB 
across international borders by human migrants from high TB incidence countries (29). This, 
according to the authors, would be more humanitarian and cost-effective than other 
approaches (29). In Norway, Haukaas, reported that the combining TST and IGRA may not be 
a cost-effective strategy at any willingness-to-pay threshold, but rather the focus should be on 
targeting immigrants before arrival, which requires some level of investment in TB control in 
their respective countries (156, 157). Nienhaus et al. elaborated further on the need to have 
standard criteria on willingness-to-pay threshold with this clearly stated before a strategy is 
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labelled cost-effective (155). In sub-Saharan Africa, most cost-effectiveness studies have been 
silent on this. 
Meanwhile, Schwartzman et al. explained that the cost-effectiveness of any strategy can be 
greatly improved if it is dependent on strict-adherence to medications, stating that rather than 
only screening immigrants, some level of investment should be directed at identifying and 
treating them in their home country (68). However, Zammarchi and colleagues, opined that 
LTBI control strategies may only be effective if they focus on young persons in high incidence 
countries, as most people affected in these settings are in the young and productive age groups 
(158).  
Meanwhile, in two separate systematic reviews, the authors reported that CXR and TST 
screening programmes for LTBI have little impact and are in fact not cost-effective, stating 
that embarking on LTBI treatments based on these two may require coercion to ensure 
maximum impacts in population covered (29, 44). These finding were due to some operational 
problems and acceptance of the strategies and the treatment plans. The authors further stated 
that screening with sputum cultures improved cost-effectiveness marginally, especially when 
this was followed by contact-tracing within the communities (29). Pareek et al. stated in their 
report that screening for LTBI should be able to identify most migrants with LTBI and prevent 
future cases of active TB for it to be cost-effective (31). 
Finally, very few studies employed QALY as their measure of effectiveness, hence this could 
not allow direct comparisons with the estimates reported in this study. This was identified as 
major challenges in a 2015 systematic review by Campbell et al, further emphasizing that 
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varying parameters, study designs and assumptions have limited the comparability of different 
studies’ findings (37).  
5.6. STUDY LIMITATIONS 
The main limitation of the study is the uncertainty resulting from some of the major 
assumptions in the analysis. The assumption of 6% decline in both incidence and prevalence 
of TB in Nigeria after full scale-up TB program is largely debatable.  This was based on 
studies conducted in South America, a setting with distinct contextual differences from 
Nigeria and indeed sub-Saharan Africa. This is even further challenged by the current decline 
in TB in Nigeria, estimated at 2.7%. As there are no country-based projections suggesting an 
increase to 6% in the coming years, the assumption thus raises further questions. However, as 
noted in Chapter 5, studies assessing the decline in TB incidence following documented 
population-wide interventions in sub-Saharan Africa are largely unavailable, meaning that the 
study in Peru and Chile, a developing setting, may provide some relative comparisons to 
Nigeria. 
Another example is the assumption that the patterns of migration from Nigeria would remain 
same throughout the 20 years. This is yet a definitive assumption, which has not taken into 
consideration several confounders, including demographic and epidemiological transitions in 
these settings. Africa, and indeed, Nigeria is experiencing the fastest rate of population growth 
worldwide. With seemingly poor socio-economic status and standards of living, internal 
migration from rural to urban, and international migration to developed countries, may not be 
unexpected. Besides, there may also be strict immigrations laws and controls from both the 
UK and Nigeria that may increase or reduce the number of migrants entering the UK. This 
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may be due to diplomatic reasons or some emerging political interests. This obviously limits 
the assumption of a constant pattern of migration in the country. In fact, the implication here is 
that if the number of migrants decrease in future years, then the scaling up of TB control in 
Nigeria would become least cost saving. But, if the number increases, the cost spent per 
migrant becomes much higher, then the investment in Nigeria’s TB control produces greater 
savings. 
Another sensitive assumption is the proportion of unscreened migrants which is difficult to 
ascertain due to operational challenges. The guidelines for screening migrants may change 
depending on several factors, including epidemiological or clinical variations, or possibly due 
to competing political interests. In such instances, the number of screened and unscreened 
migrants maybe affected. However, this may not significantly affect both the cost and 
effectiveness of the alternative ‘Investment in Nigeria’ strategy. 
A meta-analysis would have also added to the evidence provided in this study. However, as 
meta-analysis is dependent on data available with emphasis on the degree of heterogeneity 
from study designs and sample population, this becomes relatively difficult to conduct in a 
sub-Saharan African setting. 
Largely, the representativeness of the estimates provided remain uncertain, as it is clearly 
based on several assumptions, especially due to paucity of data on some cost elements. As 
explained in the introduction to this chapter, Braithwaite and colleagues noted that it may be 
difficult to “trust” decision analytic models as it is often based on wide range study designs, 
opinions, and not clearly defined population parameters, which rather makes the evidence 
presented weak (142). Given the evidence available in this study, it has been noted that cost-
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effectiveness analyses vary considerably across studies. The usefulness of these analyses 
therefore become subject of debate if they continue to provide unclear and contradictory 
results on how to invest the rather “limited” funds. This calls for more research, and agreed 
standards and guidelines in the conduct of such, particularly in sub-Saharan Africa and 
developing countries. 
 
However, having conducted a wide range of sensitivity analyses around the assumptions 
included in this study, a better understanding of the cost-effectiveness of the four strategies in 
the Nigerian migrant population to the UK may have been presented, and possibly could 
prompt further vital research. 
5.7. CONCLUSION 
The Stop TB strategy is a cost-effective approach of TB control globally, particularly in the 
high TB burden countries that are relatively poor. Despite the reported benefits, the full 
implementation of this strategy has not been achieved in most of these countries primarily due 
to poor funding, and several other health system challenges, particularly in low-income 
settings. Notwithstanding the limitations stated above, this study suggests a potential benefit to 
the United Kingdom when the WHO Stop TB Strategy program is fully scaled up in Nigeria 
and other counties where most TB cases come from. There may be need for more 
comprehensive and comparative studies in other ‘migrants originating’ and ‘migrants-
receiving’ countries for more evidence-based findings, and particularly towards a potential 
application of the current findings between high-income countries that receive large numbers 
of migrants, and poor but higher TB incidence countries like Nigeria. 
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7. SUMMARY OF FINDINGS AND CONCLUSION 
7.1. OVERVIEW 
A series of distinct but interrelated research activities were carried out and reported in this 
thesis, with the principal aim of evaluating the cost-effectiveness of ‘doing nothing’ as an 
alternative TB control strategy by the UK government to other alternative interventions vis-à-
vis ‘Investment to scale up TB control programme in Nigeria as a means of reducing the 
passive follow of cases to the UK’; ‘Interferon Gamma Release Assay (IGRA) screening at the 
point of entry’; or  ‘CXR screenings for migrants at points of entry’ (Chapter 6). 
The measure of outcome (QALY) was estimated from the literature and similarly the estimates 
for the cost of CXR screening at the POA, IGRA screening, and treatment of TB in the UK 
estimated from the review of literature (Chapter 1). However, due to paucity of literature 
about cost of TB treatment in Nigeria, data had to be collected and analyzed from Nigeria to 
estimate the provider cost for the treatment of TB (Chapter 2), as well as the direct cost, and 
the valued time and productivity lost to TB patients because of their illness and treatment in 
Nigeria (Chapter 3 and Chapter 4). 
Data on the programme management component of the TB control programme was deduced 
from WHO estimates and was used together with provider cost of treatment and consumables 
to estimate the total cost of TB control programme, the cost of scaling up the TB programme 
(towards a coverage rate of 100%, case detection rate of 80% and treatment success rate of 
80%), and funding gap estimate (Chapter 5). The impact of scaling up TB control programme 
in terms of number of latent and active TB cases averted in Nigeria and amongst migrants 
coming to the UK was also estimated (Chapter 5). 
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7.2. THESIS SYNTHESIS 
In this concluding chapter, I review the overall research undertakings reported in the thesis to 
ascertain if the research problems and hypothesis guiding the study have been addressed 
adequately. As described earlier [in Chapter 1], the research has been largely motivated by the 
relative knowledge gap on the potential returns in donor countries (anticipated accrued savings 
from cases and deaths averted in donor countries) from investments in disease control 
programmes in low-income countries. This is particularly important in this study because most 
of the TB cases in the UK are either migrants or contacts of migrants from high TB incidence 
country. 
Accordingly, this thesis contributes towards improved understanding of the cost effectiveness 
of other TB control strategies in addressing the problem of influx of TB cases from high-
incidence countries to UK and other developed countries. It may also serve as a resource 
material for enlightening policy- and decision-makers, and the public on the benefits that 
could directly or indirectly accrue in the donating countries, rather than just being a diplomatic 
or humanitarian gesture. 
In Chapter 1, the research problems, study background, main motivations, fundamental 
principles and significance of the research work were presented. This Chapter also introduced 
some of the fundamental assumptions in this study and the basis for the use of some estimates 
as parameters in the study models. Chapter 2 outlined the methodology, assumptions, analysis 
and results for estimation of the provider cost of Tb-treatment in Nigeria. This addressed the 
first objective of the thesis.   In Chapters 3 and 4, the methodology, assumptions, analysis and 
results for estimation of the direct and indirect cost of TB treatment in Nigeria (from the 
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patients’ perspectives) were presented. This addressed the second objective of the thesis.  
Chapter 5 described the methodology, assumptions, descriptions and evaluation of the total 
cost of Tb-control programme in Nigeria (addressed objective 3), the cost of scaling up the 
programme (addressed objective 4), the impact of the scale up in terms of cases averted in 
Nigeria and among migrants coming to the UK (addressed objective 5), and the required 
funding gap for the scale up (addressed objective 6). 
Chapter 6 described the method, assumptions, descriptions and evaluation results of the cost 
effectiveness analysis model (objective 7)	
7.3. SUMMARY OF KEY FINDINGS 
It is noteworthy that the cost analysis reported in this thesis, to the best of my knowledge, is 
the first ever conducted in Nigeria focusing on TB control and Nigerian migrants to the UK.  
Based on the key findings of the study [as discussed in Chapters 2, 3, 4 and 5], the following 
findings were reported: 
1) The average proportion of TB patients in facilities was 3.4% in overall, 3.3% among 
inpatients and 3.1% in the outpatient population. The average cost spent to treat a 
patient with TB was estimated at US $227.14. The cost of inpatient care averaged 
$16.95/patient; DOT and outpatient services was $133.34/patient, while the overhead 
cost per patient was $30.89. The overall cost and all computed cost elements, except 
for DOT services, were highest in the tertiary center, and least expensive in the 
‘infectious diseases’ hospital. This, partly, could be due to the higher administrative 
and other overhead recurrent spending in the tertiary health facility, while the lower 
overhead cost in ‘infectious diseases’ hospital could be due to the economy of scale 
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because of the relative higher number of TB cases seen in the facility operating with 
relatively same level of resources as other facilities in the state. 
2) The median out-of-pocket cost for hospitalized patients was estimated at US$166.11, 
while ambulatory patients paid an estimated median cost of US$94.16, equivalent to 
about 9-38% of their average annual income. Female patients spent a higher proportion 
of their income on diagnosis and treatment than males (p < 0.0001). The median out-
of-pocket costs borne by patients before, during and after diagnosis were estimated at 
US$35.23, US$27.12 and US$23.43 respectively for ambulatory patients, and 
additional average out-of-pocket spending of US$66.44 for patients hospitalized 
during their illness. Pre-diagnosis, diagnosis and post-diagnosis out-of-pocket 
spending did not vary significantly by human immunodeficiency virus status (p > 0.05) 
and sex (p > 0.05). 
3) The income lost among the hospitalized group was estimated at $156/patient, and 
about $114 in the non-hospitalized patients group. Age, gender, facility of diagnosis, 
level of education and occupation were significantly (p-values <0.05) associated with 
total (both patients and their households) income lost. However, AFB sputum-smear 
result and HIV status had no significant effects on the income lost. Hospitalized 
patients spent an average time of 924.98 hours for diagnosis and treatment whereas the 
non-hospitalized spent an average of 141.29 hours. The estimated US-dollar value of 
these hours was US517.98 and US$79.13 for hospitalized and non-hospitalized patient 
groups, respectively. Hospitalization and the facility of diagnosis were statistically 
significant (p <0.05) predictors of the time the patients and household spent on TB. 
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4) The ICER for strategies ‘Investment in Nigeria TB control’, ‘CXR screening’, and 
‘IGRA screening’ compared to strategy ‘nothing’ was estimated as £2,964/QALY, 
£15,712/QALY and £11,429/QALY respectively., suggesting the ‘Investment in 
Nigeria TB control’ was a more cost-effective strategy. 
7.4. POLICY IMPLICATIONS 
One major purpose of a cost-effectiveness analysis is to contribute to decision making process. 
Hanrahan and Shah described economic evaluations of health interventions as guide to assist 
policy-makers in allocating available resources amidst other competing needs (159). Most de-
cision analytic tools in health have been able to describe the scope of disease burden and how 
best to intervene. Unfortunately, in Africa and several developing countries, such analyses 
have only had minimal impacts on the population, owing to poor implementation or inaccura-
cies in the predictions of the economic models. This is a major concern for researchers and 
policy makers, hence the need for an in-depth painstaking review (and re-review if need be) of 
results of cost-effectiveness analyses towards ensuring the population gains maximally and an 
efficient utilization of the limited resources available.  
In this study, late detection of TB was identified as an underlying factor for the high costs of 
TB care to providers, patients and households. The implication for policymakers therefore is 
towards ensuring TB cases are detected early. It is now clear that no matter how cost-effective 
the intervention is, it probably amounts to nothing when cases are diagnosed late. In most de-
veloping countries, estimates reveal only two-thirds of new cases are detected each year (43). 
There is a potentially large market for TB diagnostics, given the large number of undetected 
cases who continue to be the main sources of ongoing and new TB transmissions. To ensure 
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resources are well-directed from the increasing number of diagnostic strategies before clini-
cians and implementers, there is need for considerable thorough investment and collaboration 
spreading across the developers, researchers, policymakers, national government and interna-
tional regulatory bodies. 
In the action of policymakers, it is not just only to direct resources at detecting active TB 
cases, as reactivation of latent TB infection (LTBI) was also major source of transmission of 
TB among migrants. It is therefore important that the investment and collaboration should be 
targeted at identification and treatment of LTBI in high-incidence countries, while ongoing in-
terventions may continue for early diagnosis and treatment of active cases (45). 
Still on investment and collaboration among all parties, Sinanovic and colleagues highlighted 
the possibility of strong economic gains in achieving this through public private partnerships 
(PPPs) in TB treatment (160). In such cases, they recommended that PPPs can be tailored to 
target groups (e.g organizations, churches, mosques, trade unions) affected with TB in the 
community and supported by the public sector (160); the sharing of resources and a relative 
sense of ownership it brings may allow the scaling-up of interventions to be achieved at much 
lower costs. Besides, some other findings also reveal that TB treatments conveyed through 
PPPs were more accessible and convenient for patients, and that the various target groups took 
responsibility of the needs of their members (or employees), with this also reducing the impact 
of the indirect costs attributable to TB (161, 162). 
One other important policy consideration is to direct investments toward improved research on 
TB and cost-effectiveness analyses in Nigeria, and across several low-and middle-income 
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countries (LMICs). From the literature search conducted in this study, using broad search 
terms, there were 399 hits on MEDLINE, and 536 hits on EMBASE, however, narrowing the 
search to only migrant’s population the number of hits reduced to only 17 and 22 from MED-
LINE and EMBASE respectively. This shows the low level of research on this topic in 
LMICs, and further highlights the major concerns and limitations of this thesis regarding the 
paucity of data on economic analyses of TB interventions in Nigeria. To really address the 
problems and guide policy-makers in making the right decisions, there is need for robust evi-
dence-based research. Several authors have stated the lack of routine health data on the Afri-
can continent (163). This can be the starting point of actions for the decision-maker—ensuring 
regular up-to-date data on TB and other priority health issues in Nigeria, spreading across the 
various levels of health care and administration in the country. Policies on this will need to be 
developed in line with national health needs, while considering the impact it may have on 
neighboring countries, frequently visited countries by the citizens (as in the case of TB), and 
the larger international society. In fact, to get policy recommendations and endorsements of 
relevant international organizations (e.g. the WHO), proposed interventions and implementa-
tion plans must have been examined by multiple studies focusing on the test performance and 
utility stretch of such interventions in various settings and among key population groups in the 
country (32). This therefore underscore the importance of robust research findings in the im-
plementation of any health intervention. 
7.5. SUMMARY OF KEY CONCLUSIONS 
1) Because the Nigerian GDP per capita is only about US$ 1160, of which only about 
$8.4 per capita is spent on health, the $227 cost attributable to TB services found in the 
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study suggests that TB disproportionately use resources in the health sector at the 
expense of other competing health needs. This further points the deplorable health 
indices in the country. 
2) Although anti-tuberculosis treatment is supposed to be free in Nigeria, patients must 
pay significant out-of-pocket costs to access diagnosis and treatment services. The 
costs of anti-tuberculosis treatment found in this study are expensive and potentially 
catastrophic for many patients and their families. 
3) Tuberculosis poses causes tremendous burden in terms of time and productivity lost to 
both patients and their households that could also be catastrophic to many patients and 
their families, whom are mostly impoverished and economically highly vulnerable. 
4) The study suggests, albeit with important limitations, a potential benefit to the United 
Kingdom when the WHO Stop TB Strategy program is fully scaled up in Nigeria. 
There may be need for more comprehensive and comparative North-South studies for 
more evidence-based findings, particularly towards a potential application of the 
findings of this study in high-income countries that receive large numbers of migrants, 
and the low-income, but higher TB incidence, countries like Nigeria. 
	
	
  
6. COST-EFFECTIVENESS ANALYSIS OF TB CONTROL STRATE-
GIES AMONG NIGERIAN MIGRANTS IN UK 
6.1. OVERVIEW 
This chapter describes the cost effectiveness analysis model, the assumptions underlying this 
model, and the results evaluating the cost and outcome of three main interventions—CXR 
screening for migrants at point of entry into the UK, IGRA screening at point of entry into the 
UK, and ‘investment’ towards scale-up of Nigerian TB control programme. These three were 
each compared with a hypothetical strategy— “doing nothing”—where Nigeria sustains the 
present level of coverage, migrants enter UK without screening, and the UK government bears 
cost of diagnosis and treatment when TB is imported into the UK by Nigerian migrants. This 
approach is an adaptation of the WHO CHOICE approach in which a “null” was used as a 
common comparator, which implies that in the cost-effectiveness analysis prospective 
interventions for different diseases had “doing nothing” as the main comparator (40).  
As noted in Chapter Five, several cost-effectiveness analyses may give misleading results 
when not properly conducted and if the assumptions are implausibly achievable. Dowdy and 
colleagues did note that cost-effectiveness analyses need be designed taking into consideration 
a variety of implementation bottlenecks to ensure policy makers make choices that are likely 
to patient and population health across world regions (136).  Braithwaite et al. also shared this 
opinion, emphasizing that the quality of evidence and realistic approach to decision analytic 
models largely determine positive outcomes of an intervention when implemented (142). 
There are widespread concerns that several cost-effectiveness analyses have not really been 
impactful as these incorporate data from all sources regardless of the quality of the evidence. 
Thus, the precision or otherwise of several decision analytic models have been subject of 
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debates over the years (142). 
In sub-Saharan Africa however, it is understandable the data sources are limited and of varying 
quality. This implies that over the years, experts have only been able to develop sophisticated 
analytical models, often with questionable assumptions, and a very unlikely representation of 
current economic trends (143). However, given the increasing burden of TB in Nigeria and the 
possible threat this poses to countries that receive large number of Nigerian immigrants, it is 
important to make use of the available data to conduct a cost-effectiveness analysis of a range 
of TB interventions that are applicable to the settings. This chapter therefore seeks to conduct 
a cost-effectiveness analysis of three main TB interventions (CXR, IGRA and Investment in 
Nigerian TB control by the UK) and a hypothetical “doing nothing”, and subsequently provide 
a critical discussion of the findings, especially with regard to the major assumptions the 
analysis was based on.  
Although the cost effectiveness analysis in this study particularly evaluates cost and 
effectiveness of TB control strategies among Nigerian migrants, the perspective of the study is 
for the United Kingdom which bears the burden ion imported TB from Nigeria. In other 
words, this study attempts to evaluate evidence that could support for decision makers in the 
United Kingdom on what could be the most cost-effective alternative (either proactive 
intervention in Nigeria, screening using chest x-ray or IGRA) to control TB inflow from 
Nigeria compared to not doing anything at all.    
6.2. METHODS 
6.2.1. Background about the model 
This is a decision-analysis model developed on TreeAge software, and incorporating multiple 
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Markov processes to estimate the cumulative probabilities of active and latent TB mortality and 
morbidity. It also estimates the associated costs among Nigerian migrants to the United 
Kingdom through a hypothetical period of 20 years in which the number, age characteristics, 
and types of migrants entering the United Kingdom annually is assumed to remain unchanged 
during the period. This model provides a platform for assessment of cost-effectiveness of four 
alternatives strategies for control of TB among immigrants from Nigeria into the United 
Kingdom. A Quality Adjusted Life Year (QALY) calculation was used to measure outcome. The 
model evaluated costs and outcomes from the UK government perspective. Future costs 
discounted at 3% (90).  
Health states and transition dynamics in the model were assumed to be determined by the 
prevalence of TB in Nigeria at the time of entry and the health state transition probabilities, 
respectively. A separate Excel™ based model was also developed to extrapolate number of 
migrants coming into the UK over a period of 20 years.  
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Figure 6.1. Simplified diagram of the state transitions in the model 
6.2.1.1. Model framework and decision tree 
The approach employed is the use of Main decision branches. A decision-analysis model incorpo-
rating multiple Markov processes using TreeAge™ Software. A decision node compares the 
four competing alternative strategies (Figures 6.24). 
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Figure 6.24. A decision-analysis model incorporating multiple Markov processes 
 
 
Box 6.1. Decision analysis tree 
A decision tree describes graphically how all possible interventions relate stochastically to the 
relatively ideal or possible outcome. Standard methods are applied on different parameters, 
which are labelled as probability distributions (refers to a range of probabilities in which some 
inputted parameters may be more likely that others) (Braithwaite).  In cost-effectiveness anal-
ysis, it also helps the analysts to easily identify the cost elements and data needed for the anal-
ysis, with this offering a flexible and transparent frame to conduct the analyses. The limita-
tions lie in the fact that different data from varying sources (to test probability) are likely to be 
incorporated in the analyses. However, the robustness of the findings can be assessed by al-
lowing changes in the key parameters using sensitivity analysis (66).  
 
Refer to Appendix 19 for more details on this. 
 
6.2.2. Assumptions underlying the Interventions and model 
6.2.2.1. Alternative 1: ‘Investment’ by the UK government to scale up Nigerian TB 
Control Programme. 
Evidence shows that implementation of the World Health Organization (WHO) strategy of 
directly observed treatment, short course (DOTS), can substantially reduce the incidence and 
prevalence of tuberculosis in countries with high incidence of the disease (80). However, 
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because of inadequate funding, global implementation of the DOTS program remains far from 
complete. One strategy to reduce the incidence of TB in high-income countries is to strengthen 
tuberculosis control through the expansion of the DOTS program in high incidence countries 
with key migrant population in the developed countries (144). Thus, a hypothetical preemptive 
TB control in the UK will be by reducing the influx of TB cases from Nigeria to the UK through 
a scale-up of TB control in Nigeria from the present 23% detection rate, 91% coverage rate and 
76% treatment success rate, to the WHO benchmark of 70% case detection, 100% coverage and 
85% treatment success rates over three years (8, 96). This target is considered reasonable based 
on the Peru and Chilean experience where full scale up was achieved within 3 years (79). After 
the full scale-up of TB services, the incidence and prevalence of both active and latent TB is 
assumed to decline by 6 percent annually in the general Nigerian population as well as among 
the departing migrants, based on the experience in these two countries. As noted in the previous 
chapter, in the absence of a similar detailed study in sub Saharan Africa (sSA), these two 
countries, albeit with distinct contextual differences from Nigeria, provide relatively 
comparative indices that the assumptions can be based on. The limitations of this are explained 
further in the discussion. 
It was also assumed that treatment success and failure rates, case fatality, and prevalence of drug 
resistant TB will remain the same in both Nigeria and United Kingdom throughout the 20-year 
period. 
Nigerian government and partners were also assumed to maintain the current annual spending 
on TB control through the next 20 years (as already described in Chapter 5), and will provide 
the facilities and personnel for the scale-up the TB services.  
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If all the proposed activities are implemented accordingly, it is assumed that the following 
targets will be achieved in 3 years, i.e. from 2012 to 2015: 
- Case detection rate of at least 75%   
- Treatment success rate of at least 85%. 
In Nigeria, the incidence rate of TB has been observed to be declining over the last few years. 
Over the last couple of years the decline rates of 2.7% and 2.6% were reported between 2006-
2007 and 2007-2008 respectively (5). Based on this, it was assumed that the incidence, 
prevalence and death rate will go down by at least 2.7% annually in the first 3 years of 
implementing the proposed programme and subsequently by at least 6% annually for at least 
the remaining 17 modelled years (based on the Peru and Chilean experience).  
Although only about 10% of Nigeria emigrants go to the UK (133, 139), in this study, it was 
proposed that the UK Government, based on an ‘enlighten self-interest’, invests in the TB 
control in Nigeria by providing an estimated 25% of the total funding gap for the full scale-up 
implementation of Stop TB strategy in Nigeria. This is relatively ‘fair’ because the other 
countries hosting Nigerian migrants are mostly poor African countries, except the United States 
which receives only about 14% of this emigrant populations.  
6.2.2.2. Alternative 2: CXR at the point of entry (POE). 
This practice is what was obtainable some year ago all the international airports in the UK (64).  
So, in this study a hypothetical scenario is assumed, that there will be CXR screening for 
migrants coming to the country the first time and declared their intention of staying for more 
than 3 months in the country. When the CXR is indicative of active pulmonary TB, entrants are 
referred to appropriate facility for further investigation and treatment.  
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6.2.2.3. Alternative 3: Interferon Gamma Release Assay (IGRA) screening at point of 
entry 
This has been recommended by several authors due to the reported advantages of this new 
screening method in detecting the latent form of TB (56, 77, 130). In this study, it was assumed 
that proportion of entrants coming to the country the first time would have to be screened at the 
point of entry. 
The cost of CXR or IGRA screening at the airport, and the cost of diagnostics and treatment 
services for both migrants and their contacts are assumed to be shouldered by the UK 
government. These costs were estimated from available literature after critical appraisals of the 
reporting research methodology (77). 
 
6.2.3. Other major assumptions      
6.2.3.1. Number of Nigerian migrants and visitors (and length of stay) in the UK 
There are about 146,300 Nigerian migrants residing in the UK (120) and it is assumed in this 
model that about half of this population travel and spend 30 days in Nigeria annually. It was 
also assumed that there will be about 11,900 students in the UK that will spend 11 months in 
the country annually. About 165,000 visitors were assumed to be visiting the UK from Nigeria 
annually staying for an average of 21 days. Other entrants with work permit, all dependents of 
work permit holders, all migrants admitted based on other point based system, all those admitted 
as husband, wife, fiancé or fiancée, all refugees/exceptional leave cases and their dependents, 
and all others given leave to enter and any migrant granted settlement on arrivals were all 
assumed to stay in the country longer than 6 month. It was also assumed that there are no illegal 
entrants into the UK from Nigeria within the reference period. 
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To test the robustness of these important assumptions, sensitivity analyses were conducted 
evaluating the outcomes in different scenarios (this is discussed further under Study 
Limitations).   
Person years of visitors’ and other migrants’ time (Table 6.1) in the UK was calculated from 
the expected total number of entrants each year and the expected average length of stay for 
different sub-groups. Inherent in the person-year method is the assumption that the daily risk 
of a person developing tuberculosis in visitors (for instance staying in the UK for 3 weeks) is 
the same daily risk with a person who stays a full year.  
Table 6.1. Person’s years spent by Nigerian migrants and visitors in the UK from Septem-
ber, 2008 to August, 2009 
Purpose for entry to the 
UK	
Number	 Average 
length of stay	
Person days 
spent	
Person years 
spent	
Ordinary visitors	 165,000*	 21 days *	 3,465,000	 9493	
Business visitors	 25,600*	 12*	 307,200	 842	
Students	 11,900*	 335 days **	 3,986,500	 10,922	
Work permit- Employed for 
12 months or more	
275*	 335 days **	 92,125	 252	
Work permit- Employed for 
less than 12 months	
155*	 170 days**	 26350	 72	
Dependents of work permit 
holders	
560*	 335 days**	 187,600	 514	
Point Bases System	 240*	 170 days**	 40800	 112	
Admitted as a husband or 
fiancé	
635*	 335 days**	 212725	 583	
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Admitted as wife or fiancée	 705*	 335 days**	 236175	 647	
Passengers in transit	 21,400*	 0	 0	 0	
Passengers returning after a 
temporary absence abroad	
71,700*	 335 days**	 24,019,500	 65807	
Refugees, exceptional leave 
cases and their dependents	
5	 365 days**	 1825	 5	
Others given leave to enter	 7,040	 90 days**	 633,600	 1736	
Granted settlement on arrival	 140	 180 days**	 25200	 69	
TOTAL	 305,000	  33,234,125 
(Person days)	
91052 
(Person years)	
*Sourced from: Travel Trend 2008, Publication of Office of National statistics (145). 
http://www.statistics.gov.uk/downloads/theme_transport/Travel_Trends_2008.pdf . Accessed on 6th February, 2009. ** Assumption  
 
6.2.3.2. TB states of migrants/entrants population coming into the UK 
Approximately 91,052 Nigerians are expected to enter the UK from Nigeria annually through-
out the 20-year cycle of the model (refer to Chapter Five, Table 5.1 and Appendixes 4-12). 
Based on the entrants’ age distribution, exposure to TB was computed, and TB burden among 
this migrant population was estimated (Table 6.2).  
Table 6.2. Numbers of proportion of Nigerian migrants coming to UK by TB state 
 Number (Proportion)	 Number (Proportion)	
Recent drug sensitive latent TB 
(DSLTBr)	
24464 
(0.013434120402)	
14629 
(0.008033388985)	
Recent drug resistant latent TB 
(DRLTBr)*	
448 (0.000246246606)	 268 (0.000147251529)	
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Longstanding drug sensitive latent TB 
(DSLTBL)	
394356 
(0.216555209238)	
244569 
(0.134301824798)	
Longstanding drug resistant latent TB 
(DRLTBL)**	
7229 (0.003969443754)	 4483 (0.002461744243)	
Drug sensitive active TB (DSATB)	 5561 (0.003054020000)	 3125 (0.001716078076)	
Drug resistant active TB (DRATB)*** 	 102 (0.000055980000)	 57 (0.000031455606)	
No TB infection (NO TB)	 1388880 
(0.762684980000)	
1553908 
(0.853308256763)	
TOTAL	 1821040 (1)	 1821040 (1)	
 
*1.8% of all recent latent TB infections based on drug resistance prevalence rate. 
**1.8% of all longstanding latent TB infections based on drug resistance prevalence rate. 
***1.8% of all active TB infections based on drug resistance prevalence rate. 
	
6.2.3.3. Screening for TB at the Point of Entry (POE) 
Migrants that declared their intention to stay for more than 3 months in the country are assumed 
to be most likely going to be CXR screened based on the current practice (Table 6.3). 
Table 6.3. Classification and number of Nigerians migrant and visitors to U.K from Septem-
ber 2008 to August 2009 and likelihood of screening for TB based on the present practice 
  Purpose for entry to the UK	 Number	 Number probably 
staying longer 
than 3 month	
% likely screened 
for TB before arrival 
or at point of entry	
Ordinary visitors	 165,000	 16,500 (10%)	 0 % (0)	
Business visitors	 25,600	 2560 (10%)	 0 % (0)	
Students*	 11,900	 11,900 (100)	 100 % (11,900)	
Work permit- Employed for 12 
months or more	
275	 275 (100%)	 100 % (275)	
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Work permit- Employed for less 
than 12 months	
155	 155 (100%)	 100 % (155)	
Dependents of work permit 
holders	
560	 560 (100%)	 100 % (560)	
Point Bases System	 240	 240 (100%)	 100 % (240)	
Admitted as a husband or fiancé	 635	 635 (100%)	 100 % (635)	
Admitted as wife or fiancée	 705	 705 (100%)	 100 % (705)	
Passengers in transit	 21,400	 0 (0%)	 0 % (0)	
Passengers returning after a 
temporary absence abroad	
71,700	 71,700 (100%)	 10 % (Assumption) 
(7,170)	
Refugees, exceptional leave 
cases and their dependents**	
5	 5 (100%)	 100 % (5)	
Others given leave to enter***	 7,040	 3,520 (50%)	 50 % (Assumption) 
(1,760)	
Granted settlement on 
arrival****	
140	 140 (100%)	 100% (140)	
TOTAL	 305,000	 108895	 21.62% (23,545)	
 
 
 
* Includes Student visitors, but excludes dependents which are included under 'Others given leave to enter'. 
** Excludes such persons given temporary admission.   
*** Includes 46,700 journeys made in 2008 for which the category of admission is unknown 
**** Excludes asylum-related cases given indefinite leave to enter; these are included in 'Refugees, exceptional 
leave cases and their dependents'.  
Migrants are either: 
 
i) Screened Immigrants – this group include entrants who were screened at the point of 
entry into the UK. It was estimated that about only about 21.62% of entrants will be 
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screened (which agrees with the Home Office 10-40% estimated range (33)), or 
ii) Unscreened immigrants - this group include entrants who were not screened at the 
point of entry into the UK, estimated at about 78.38% of entrants.  
6.2.3.4. Tuberculosis prevalence among the model migrant population  
We assumed the TB and HIV burden among all entrants’ categories in the UK to be the same 
as in the general populations of Nigerians in Nigeria, as estimated in 2009 WHO report (52) 
(see Table 6.4). 
Table 6.4. Tuberculosis epidemiological detail of Nigerian population (64) 
Description	 Estimates in 2007	
Number of all forms of TB (New cases)	 460,000/year	
Incidence of all forms of TB (New cases)	 311/100,000 pop/year	
Number of new ss+ cases 	 195,000/year	
Incidence of new ss+ cases 	 131/100,000 pop/year	
 
HIV+ incident TB cases (%)	
27% of all TB cases	
Number of all forms of TB (New and old)	 772,000/year	
Prevalence of all forms of TB 	 521/100,000 pop/year	
Multidrug-resistant TB (MD R-TB) 
MDR-TB among all new TB cases (%)	
1.8%	
MDR-TB among previously treated TB cases (%)	 9.4%	
Percentage of extra pulmonary cases	 5%	
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In this model, it was assumed that every migrant fall in one of a finite number of discrete 
health states. 
The following are the states used:  
  Uninfected: Neither active, no latent nor previous active TB.  
  Recent latent TB infection: TB infection less than 2 years. 
  Longstanding latent TB infection: TB infection more than 2 years.  
  Active TB disease. 
  Previous active disease (recovered). 
  Dead from either from TB infection or other cause  
Based on estimates of disease burden in Nigeria, proportional burden among entrants/migrants 
was assumed to be:  
1) Active tuberculosis: 
Based on the prevalence rate of TB in Nigerian population estimated at 521/100,000 
population, the number migrants with active TB among the Nigerian entrants (91,052 
persons’ years) is estimated as 
                                           = 521*(91,052/100,000) person years 
                                           = 474 cases of Active TB in the first year 
2) Latent tuberculosis infection (LTBI), was estimated based on the Styblo’s rule (125) 
that says for every 50 cases of incidence of smear positive active TB per 100,000 
population, the Annual Risk of Infection (ARI) in that population is 1%.  
Thus, the ARI in Nigeria, where the incidence of smear positive TB is estimated at 
131/100,000 is estimated as: 
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    = (131/50) %  
= 2.62 % 
It was also assumed that 30% of those exposed to TB get the infection, out of which about 5% 
develop active disease while the remaining 95% remain with the infection as a latent TB (5,6, 
18).  
Based on these estimates, the number of migrants/entrants with latent TB was estimated as 
shown in Table 6.5 below: 
Table 6.5. Estimate of the number of latent TB cases among Nigerian migrants in the UK 
grouped by age 
Age 
(yrs)	
Midpoint 
(yrs)	
% of  
migrants	
Number	 ARI (%)	 Exposed 
to TB 
<2 yrs	
Exposed 
to TB 
>2 yrs	
Latent 
TB 
<2years	
Latent 
TB 
>2years	
0-15	 8 	 8%	 7284	 2.62%/yr	 379	 1148	 108	 327	
16-24 	 20 	 12%	 10926	 2.62%/yr	 573	 5152	 163	 1468	
25-44 	 34 	 53%	 48258	 2.62%/yr	 1264	 41724	 360	 11891	
45-64 	 54 	 23%	 20942	 2.62%/yr	 1097	 19845	 313	 5656	
65+ 	 65	 4%	 3642	 2.62%/yr	 191	 3451	 54	 984	
TOTAL	   91052	  3504	 71320	 998	 20326	
 
Thus,  
3) Number of entrants/migrants with recent latent TB (acquired < 2 years) = 998 persons 
/year 
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4) Number of entrants/migrants with longstanding latent TB (acquired > 2 years) = 20326 
persons/year 
5) No tuberculosis;  
                                 = Total person years-Active cases-Latent cases-Healed cases 
                                = 91052 – 474 – 998 – 20326 
                                = 69254 persons/ year	
6.2.3.5. HIV prevalence  
HIV prevalence in adult (15-49 years) population in Nigeria is .3.1% (126) 
Proportion that of HIV positive patients that have AIDS among the people living with HIV in 
the population is estimated at about 39% (126). 
The number of HIV positive persons entering the UK from Nigeria within the first year  
                        = 3.1%*91052 
                        = 2823 persons/year 
Out of which; 
i) Late infection - clinical AIDS: 
                                             = 39%*2823 
                                             = 1101 persons 
ii) Early (asymptomatic) HIV infection: 
                                = 61%*2823 
                                = 1722 persons 
iii) No HIV infection: 
                               = 91052 – 1101 – 1722  = 88229 persons. 
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6.2.3.6. Treatment outcome for Active TB cases 
Based on the annual report on TB surveillance in the UK (17), 84.5% of TB cases completed 
treatment successfully within 12 months, about 2.7% died while on treatment, 4.4% were lost 
to follow-up, 0.9% treatment was stopped mainly because TB was a wrong diagnosis, 4.9% 
were reported as still on treatment, 1.2% transferred out, 0.4% treatment not completed for 
unknown reasons, and the outcome was reported as unknown in 1.2%. 
However, to account for the outcome of those still on treatment (4.9%), treatment not 
completed for unknown reasons (0.4%), treatment stopped for wrong diagnosis (0.9 %), those 
that transferred out (1.2%), and those reported as unknown outcome (1.2%), an adjustment 
was made to make the proportion all-inclusive (61) (Table 6.6). 
Table 6.6. Tuberculosis treatment outcomes at 12 months for Black Africans, UK, 2007 
	
Treatment outcome	 Proportion (%) 
 N=1711	
Adjusted proportion (%)	
Treatment completed	 84.5% (1446)	 92% (1446)	
Died	 2.7% (46)	 3% (46)	
Still on treatment	 4.9% (84)*	 -	
Lost to follow up	 4.4% (75)	 5% (75)	
Treatment stopped	 0.9% (15)*	 -	
Transferred out	 1.2% (21)*	 -	
Treatment not completed (Unknown 
reason)	
0.4% (7)*	 -	
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Outcome reported Unknown	 1.2% (21)*	 -	
TOTAL	 100 % (1711)	 100% (1567)	
 
Sourced from Table 3.5 in the article titled: Tuberculosis in the UK: Annual report on tuberculosis surveillance in 
the UK, 2007. London, Health Protection Agency, July 2007 (17)   
 
6.2.3.7. Treatment outcome for latent TB cases 
The proportion of entrants completing at least 6 months of ‘Latent TB’ Isoniazid treatment 
was estimated from studies that reported proportions of foreign-born migrants completing at 
least 4 months of treatment with Isoniazid for treatment of latent TB (44, 146-149) and based 
on the estimates from these studies, proportion completing treatment of latent TB with 4 
months Isoniazid was assumed to be 62% of patients with latent TB (both ‘recent’ and 
‘longstanding’) that started the Isoniazid regimen. 
6.2.3.8. Reactivation of latent TB and other clinical outcomes 
The probability of having any clinical outcome largely depends on TB and HIV status of the 
migrants/entrants.  Incidence of tuberculosis among migrants is highest in the first two years 
after entry or re-entry (69, 150). There is evidence that this is primarily due to recent infection, 
or re-infection (69, 150). In HIV negatives, the risk of reactivation of latent infection was 
assumed at 5% throughout the first 2 years (69, 150-153). It was also assumed that this risk 
reduces to annual rate of 0.1% (69). 
Estimates for clinical outcome following treatment assumes that, once diagnosed, all 
categories of migrants would receive UK standard of care for their tuberculosis and therefore 
achieve UK national average cure rates (61).  
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For patients who defaulted after two months or less of therapy, cure rate is assumed to be 25% 
which is the same as in untreated patients. For those who defaulted therapy, risk of relapse and 
failure is higher, but cure rates were assumed to be 62% (69).  
Patients who completed five months or more of therapy were considered to have the same cure 
rate as those who completed a full course and the risk of acquiring TB infection while in the 
UK was assumed to be negligible (154).  
Treatment outcomes were also determined by underlying drug sensitivity (the probability of 
which was taken from published studies of prevalence of drug resistant TB in the countries of 
origin), and HIV infection. Co-infection with HIV did not alter probability of diagnosis, nor 
the treatment outcomes of cure, or relapse. However, mortality among HIV infected persons 
with active TB was 2.25 times higher during treatment, and was 100% if TB was undiagnosed 
(69). Latent and active TB were modeled as drug-sensitive and drug resistant (Table 6.7). 
 Base	 Range	
Reactivation from LTBI 
‘Longstanding’ LTBI 
- HIV- Uninfected 
- HIV infected – Asymptomatic 
- HIV infected – AIDS	
 
 
0.1%/ year 
3.4%/year 
33%/year	
 
 
0.1% -0.2%/yr 
3.4% - 8.7%/yr 
33% - 67%/yr	
 ‘Recent’ LTBI 
- HIV uninfected 
- HIV infected – asymptomatic 
- HIV infected – AIDS	
 
5% 
33% 
100%	
 
2% - 15% 
33% - 100% 
50% - 100%	
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Re-infection within 2 years  
- HIV uninfected – Protective effect 80% 
- HIV infected – No protective effect	
 
1% 
33% - 100%	
 
TB cases, HIV Negative 
(Untreated smear positive):  
- Mortality - 1 year, & 2 years 
- Spontaneous remission 
- Relapse after spontaneous remission	
 
 
33%, & 50% 
25% 
2.5%/year	
 
 
 
 
1.3% - 2.5%/yr	
(Treated smear positive): 
- Relapse after cure (total over next 2 years) 
- Cure rate if default (SDR or drug sensitive) 	
 
3.0% 
62.4%	
 
1.5% - 5%	
- Effect of drug sensitivity or treatment outcomes 
- RR of failure (SDR) 
- RR of failure (MDR) 
- RR of death (SDR) 
- RR of death (MDR) 
- In MDR – Probability of cure with treatment 
                 – Probability of death with treatment	
 
 
2.0 
10.5 
1.0 
4.5 
48% 
12%	
 
 
 
 
 
 
48%-73% 
12%-26%	
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TB, HIV Positive 
-  Av. Duration of HIV infection   
- Av. Duration as HIV (AS) 
- AR of progress: HIV (AS) to AIDS 
- AR of death from HIV (AS) 
- AR of death from AIDS 
- Effect of prior active TB on RR of death from HIV 
- Effect of HIV infection on RR of death during TB 
treatment (DS or SDR) 
- Relapse after successful TB treatment (cured)	
 
9.8 years 
9.0 years 
7% 
4.6% 
22% 
2.2 
 
 
2.25 
3.1%	
 
7.3-9.8 yrs 
 
7%-9% 
 
 
(2.2 – 4.0) 
 
 
 
3.1% - 6.4%	
	
Table 6.7. Some of the transition probabilities and parameters used in the model 
Sourced from the Supplementary appendix of the article ‘Kevin Schwartzman, et al. Domestic returns from 
investment in the control of tuberculosis in other countries. N Engl J Med 353;10, 09/2005 (68) 
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6.2.3.9. Predictive values of the screening tests 
Probabilities of positive and negative results for detection of active and latent TB were estimated 
from the sensitivity and specificity of the screening test (Figure 6.3). 
 
 
i) True Positives: 
(True Positivea,l = Prevalencea,l*Sensitivitya,l) 
a) CXR: 
- True positiveactive TB= 0.002449456477 (i.e. proportion with active TB)*1 (i.e. 100% 
sensitivity)= 0.002449456477 
- True Positivelatent TB=0.200805089(i.e. proportion with latent TB)*0.11(i.e. 11% 
sensitivity)= 0.022088559806 
b) IGRA: 
- True positiveactive TB= 0.0024494565 (i.e. proportion with active TB)*0.82 (i.e. 82% 
sensitivity)=0.002008554311 
- True Positivelatent TB=0.200805089(i.e. proportion with latent TB)*0.95 (i.e. 95% 
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sensitivity)= 0.190764834687 
ii) True Negatives:  
(True Negativea,l = (1-Prevalencea,l)*Specificitya,l) 
a) CXR: 
- True negativeactive TB= 0.997550543523 (i.e. proportion WITHOUT active TB)*0.67(i.e. 
67% specificity)= 0.668358864161 
- True negativelatent TB= 0.799194910855(i.e. proportion WITHOUT latent TB)*0.0 (i.e. 
0% specificity)= 0 
b) IGRA: 
- True negativeactive TB= 0.997550543523 (i.e. proportion WITHOUT active TB)*0.99(i.e. 
99% specificity)= 0.987575038088 
- True negativelatent TB= 0.799194910855(i.e. proportion WITHOUT latent TB)*0.99 (i.e. 
99% specificity)= 0.791202961747 
iii) False Positives:  
(False Positivea,l = (1-Prevalencea,l)*(1-Specificitya,l)) 
a) CXR: 
- False positiveactive TB= 0.997550543523 (i.e. proportion WITHOUT active 
TB)*0.33(i.e.100- 67% specificity)=0.329191679363 
- False positivelatent TB= 0.799194910855(i.e. proportion WITHOUT latent TB)*1 (i.e. 
100-0% specificity)= 0.799194910855 
Note: In this model, it was assumed that only about a quarter (25%) of the false positives will 
be followed up as often clinical judgment improves the accuracy of diagnosis. 
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b) IGRA: 
- False Positiveactive TB= 0.997550543523 (i.e. proportion WITHOUT active TB)* 
0.01(i.e.100- 99% specificity)= 0.009975505435 
- False Positivelatent TB= 0.799194910855(i.e. proportion WITHOUT latent TB)* 0.01 (i.e. 
100-99% specificity)= 0.007991949109 
iv. False Negatives:  
(False Negativea,l = Prevalencea,l*(1-Sensitivitya,l)) 
a) CXR: 
- False Negativeactive TB= 0.002449456477 (i.e. proportion with active TB) *0.0(i.e.100-
100% sensitivity)=0.0 
- False negativelatent TB= 0.200805089 (i.e. proportion with latent TB) *0.89 (i.e. 100-11% 
sensitivity)= 0.178716529339 
a) IGRA: 
- False negativeactive TB= 0.0024494565 (i.e. proportion with active TB)*0.18 (i.e. 100-
82% specificity)= 0.000440902166 
- False negativelatent TB=0.200805089(i.e. proportion with latent TB)*0.05 (i.e. 100-95% 
specificity)= 0.010040254457 
However, for each test result, the probability of being active or latent TB depends on the 
proportional prevalence of active and latent TB in the population.  
6.2.3.10. Hypothetical separate populations 
Separate populations, N1 and N2, were assumed for active and latent TB. These hypothetical 
populations were assumed to be mutually exclusive, i.e. N3 is a hypothetical population 
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N1+N2. (Tables 6.8 and 6.9) 
Table 6.8. Hypothetical separate populations TBa, TBl and combined TBa+l (CXR) 
 TBN1	 TBN2	 TBN3	 pTBa	 pTBl	 pTBa+l	
TP	 4461	 40224	 44685	 0.099822921
6	
0.900177078
4	
0.012269008
1	
FP	 599471	 1455366	 2054837	 0.291736610
7	
0.708263389
3	
0.564193295
1	
TN	 1217108	 0	 1217108	 1.000000000
0	
0.000000000
0	
0.334179432
1	
FN	 0	 325450	 325450	 0.000000000
0	
1.000000000
0	
0.089358264
7	
 1821040 (N1)	 1821040(N2)	 3642080(N3)	   1	
 
	
Table 6.9. Hypothetical separate populations TBa, TBl and combined TBa+l (IGRA) 
 TBN1	 TBN2	 TBN3	 pTBa	 pTBl	 pTBTB	
TP	 3658	 347390	 351048	 0.0104192509	 0.9895807491	 0.0963866945	
FP	 18166	 14554	 32719	 0.5551985904	 0.4448014096	 0.0089837273	
TN	 1798414	 1440812	 3239226	 0.5551985904	 0.4448014096	 0.8893889999	
FN	 803	 18284	 19087	 0.0420661747	 0.9579338253	 0.0052405783	
 1821040	 1821040	 3642080	   1	
 25 
 
 
 
 
 
 
 
 
 
6.2.3.11. Model Time-frame 
Cohort simulation of TB-related events and outcomes for migrants/entrants from Nigeria to 
the UK was done, through a period 20 years, beginning from 2012 to 2031. 
Migrants’ health status at the beginning of each cycle depend on the events in the previous 
cycle, vis-a vis: treatment or not treated, treatment completed or defaulted, survived or died, 
etc. Since the risk of new TB infection was much lower after entry into the UK, the likelihood 
of development of active TB fell considerably after the first two years in the UK. A mortality 
rate from all other causes among entrants in the UK was assumed to be the same as for the UK 
general population. 
 
6.3. RESULTS 
6.3.1. Cost Analysis 
Following Monte Carlo simulation, 1000 trials, the average cost for the ‘investment in 
Nigerian TB control’ per Nigerian migrant in the UK was estimated at £253.78, and average 
cost per migrant for chest x ray, IGRA screening or when ‘Nothing’ is done is £293.41 or 
£690.93 or £72.29 respectively (Table 6.10, Figures 6.4-6.7). 
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Table 6.10. The Mean, Median and dispersion of the costs of the 4 strategies in a Monte 
Carlos simulation 
 
Cost in 2008 GB £	
Investment in 
Nigeria TB 
control in GBP	
Present 
practice (Chest 
x ray screening 
at the airport) 
in GBP	
IGRA in GBP	 NOTHING in 
GBP	
Mean + SD	 253.78 + 25.84	 293.41 + 
102.95	
690.93 + 
113.45	
70.29 + 31.52	
Median	 247.90	 263.99	 680.22	 65.91	
Minimum	 225.04	 153.47	 501.48	 26.96	
Maximum	 388.83	 572.18	 1019.47	 211.79	
2.5%	 228.41	 166.46	 511.65	 27.698	
10%	 233.11	 188.46	 565.553	 39.392	
90%	 276.41	 469.97	 850.792	 110.991	
97.5%	 313.01	 520.60	 997.388	 147.153	
Size (n)	 100	 100	 100	 100	
Variance	 667.84	 10598.02	 12870.52	 993.55	
Variance/Size	 6.68	 105.98	 128.71	 9.94	
SQRT[Variance/Size
]	
2.58	 10.29	 11.34	 3.15	
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Figure 6.4. Probability distribution of the cost of investment in Nigerian TB control per mi-
grant entering the UK 
 
  
	
Figure 6.5.  Probability distribution of the cost of present practice of x ray screening per mi-
grant entering the UK 
 
 
	
Figure 6.6. Probability distribution of the cost of IGRA screening per migrant entering the 
UK 
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Figure 6.7. Probability distribution of the cost of ‘nothing’ per migrant entering the UK 
  
 
6.3.2. Effectiveness Analysis 
 
Following Monte Carlo simulation, 1000 trials, average QALY per Nigerian migrant in the 
UK when UK government invested in scaling up Nigerian TB control was estimated at 17.33 
QALY, and for chest x ray, or IGRA screening or when ‘Nothing’ is done the QALYs are 17.23 
or 17.32 or 17.26 respectively (Table 6.11, Figures 6.8-6.11). 
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Table 6.11. The Mean, Median and dispersion of the QALYs of the 4 strategies in a Monte 
Carlos simulation 
 
Effectiveness in 
QALY	
Investment in 
Nigeria TB 
control	
Present 
practice (Chest 
x ray screening 
at the airport)	
IGRA	 NOTHING	
Mean + SD	 17.3266 + 
0.1721	
17.2789 + 
0.1885	
17.3190+0.188
1	
17.2647 + 
0.1770	
Median	 17.3526	 17.2736	 17.3332	 17.2756	
Minimum	 16.8766	 16.7390	 16.8488	 16.7735	
Maximum	 17.7814	 17.6986	 17.7436	 17.6907	
2.5%	 16.9724	 16.9065	 16.9426	 16.9009	
10%	 17.0982	 17.0791	 17.0728	 17.0152	
90%	 17.5391	 17.5045	 17.5579	 17.4650	
97.5%	 17.6717	 17.6675	 17.6614	 17.5815	
Size (n)	 100	 100	 100	 100	
Variance	 0.029608107	 0.035536022	 0.035364236	 0.031327102	
Variance/Size	 0.000296081	 0.000355360	 0.000353642	 0.000313271	
SQRT[Variance/Size]	 0.017207007	 0.018851000	 0.018805381	 0.017699464	
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Figure 6.8. Probability distribution of the QALYs of investment in Nigerian TB control per 
migrant entering the UK 
 
	
 	
	
Figure 6.9. Probability distribution of the QALYs of present practice of x ray screening per 
migrant entering the UK 
  
 
	
Figure 6.10. Probability distribution of the QALYs of IGRA screening per migrant entering 
the UK 
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Figure 6.11. Probability distribution of the QALYs of ‘nothing’ per migrant entering the UK 
	
6.3.3. Cost-Effectiveness Analysis 
 
Following Monte Carlo simulation, 1000 trials, average cost and utility for strategy ‘invest-
ment in Nigerian TB control’ per Nigerian migrant in the UK was estimated at GB £253.78 
and 17.33 QALYs respectively. Cost and utility for the CXR screening strategy was estimated 
at 2008 GB £293.41 and 17.28 respectively. Cost and utility for IGRA screening estimated at 
GB £690.93 and 17.32 QALYs while strategy ‘Nothing’ cost on average of GB  
 
Table 6.12. The Mean Cost and QALYs of the 4 strategies in a Monte Carlos simulation 
Strategy Name	 Cost (UK 
£)	
Effectiveness (QALY)	
NOTHING	 70.29	 17.2647	
Investment in Nigeria TB control	 253.78	 17.3266	
Present practice (Chest x ray screening at the 
airport)	
293.41	 17.2789	
IGRA	 690.93	 17.3190	
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Figure 6.12. Cost-Effectiveness Analysis plot 
 
6.3.4. Incremental Cost Effectiveness Ratio (ICER) 
 
The incremental costs for strategy 1 (investment in Nigeria), strategy 2 (CXR), and strategy 3 
(IGRA) when all are compared to strategy 4 (‘nothing’) are £183.49, £223.12, and £620.64 
respectively and incremental effectiveness compared to strategy ‘nothing’ are 0.0619 QALY, 
0.0142 QALY and 0.0543 QALY respectively. Hence ICER (compared to strategy ‘nothing’) 
was estimated as £2,964/QALY, £15,712/QALY and £11,429/QALY for strategies Investment 
in Nigeria TB control, Present practice (CXR screening at the airport) and IGRA respectively 
(Table 6.13). 
Table 6.13. Cost, Effectiveness and ICER for strategies 1, 2, 3 compared to strategy 4 
Strategy Name	 Cost (£)	 Eff. (QALY)	 Incr. Cost	 Incr. Eff	 ICER	
NOTHING	 70.29	 17.2647	 0.00	 0.0000	 0.00	
Investment in Nigeria TB 
control	
253.78	 17.3266	 183.49	 0.0619	 2964.19	
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Present practice (Chest x 
ray screening at the 
airport)	
293.41	 17.2789	 223.12	 0.0142	 15712.68	
IGRA	 690.93	 17.3190	 620.64	 0.0543	 11429.83	
 
However, the incremental cost and incremental effectiveness for strategy 2 (investment in 
Nigeria) when compared to strategy 1 (‘nothing’) was estimated at GB £183.47 and 0.0619 
QALYs. Strategy 3 (X ray screening), and strategy 4 (IGRA) when compared to strategy 2 
(investment in Nigeria) are £39.63/-0.0477, and £437.15/-0.0077 respectively. The ICER for 
strategy 2 (Investment in Nigeria TB control) compared to strategy 1(‘nothing’) was estimated 
as £2,964.19/QALY gained but ICER for strategy 3 (X ray screening) and strategy 4 (IGRA) 
compared to strategy 2 (Investment in Nigeria TB control) showed dominance of strategy 2 
(investment in Nigeria) over both two strategies (Table 6.14).  
Table 6.14. Cost, Effectiveness and ICER for strategy 1 compared to strategy 4 and strate-
gies 2, 3 compared to strategy 1 
Strategy Name	 Cost 
(£)	
Eff. 
(QALY)	
Incr. 
Cost	
Incr. Eff	 ICER	 Remark	
NOTHING	 70.29	 17.2647	 0.00	 0.0000	 0.00	  
Investment in 
Nigeria TB 
control	
253.78	 17.3266	 183.49	 0.0619	 2964.19	  
Present practice 
(Chest x ray 
screening at the 
airport)	
293.41	 17.2789	 39.63	 -0.0477	 -830.06	 (Dominated
)	
 34 
IGRA	 690.93	 17.3190	 437.15	 -0.0077	 -
57062.40	
(Dominated
)	
The next nine diagrams (Figures 6.13-6.21) displays the incremental cost and effectiveness, 
and the probability distribution for the incremental costs, with each diagram comparing the 
four strategies (CXR, IGRA, Investment and Nothing) in turn.  
 
 
	
 
Figure 6.13. Incremental cost and effectiveness scatter plots comparing Investment in Nige-
ria (Strategy 1) verses Chest X ray screening (Strategy 2) 
Figure 6.13 shows increasing incremental effectiveness as incremental cost also increases. 
 
 
	
Figure 6.14. Probability distribution for the incremental cost comparing Investment in Ni-
geria (Strategy 1) verses Chest X ray screening (Strategy 2) 
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Figure 6.15. Probability distribution for the incremental effectiveness comparing Invest-
ment in Nigeria (Strategy 1) verses Chest X ray screening (Strategy 2) 
 
  
	
Figure 6.16. Incremental cost and effectiveness scatter plots comparing Investment in Nige-
ria (Strategy 1) verses IGRA (Strategy 3). 
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Figure 6.17. Probability distribution for the incremental cost comparing Investment in Ni-
geria (Strategy 1) verses IGRA (Strategy 3) 
 
	
Figure 6.18. Probability distribution for the incremental effectiveness comparing Invest-
ment in Nigeria (Strategy 1) verses IGRA (Strategy 3) 
 
	
Figure 6.19. Incremental cost and effectiveness scatter plots comparing Investment in Nige-
ria (Strategy 1) verses ‘nothing’ (Strategy 4) 
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Figure 6.20. Probability distribution for the incremental cost comparing Investment in Ni-
geria (Strategy 1) verses ‘nothing’ (Strategy 4) 
	
 
  
	
Figure 6.21. Probability distribution for the incremental effectiveness comparing Invest-
ment in Nigeria (Strategy 1) verses ‘nothing’ (Strategy 4) 
  
 
6.3.5. Acceptability Curve 
At £1000 threshold ‘willingness to pay’, the strategy ‘nothing’ has the highest iteration 
percentage of almost 90%, which falls to about 60% when the WTP threshold increased to 
£2,000.  At about £3,000 WTP threshold, the strategy ‘investment in Nigeria TB control’ has 
the highest percentage iteration of about 45% then strategy ‘IGRA’ with iteration percentage 
of about 35% (Figures 6.22-6.23). 
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Figure 6.22. Acceptability curves for all the alternative strategies on scale of ‘willingness to 
pay £0-10,000 
  
  
	
Figure 6.23. Acceptability curves for all the alternative strategies on scale of ‘willingness to 
pay £0-35,000 
 
6.3.6. Sensitivity Analysis	
Sensitivity analysis assesses the robustness of the findings from the decision analysis model 
by varying key parameters and assumptions to assess the effect in the model outputs. 
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Favorable and unfavorable scenarios with respect to the PPV and NPV of CXR, IGRA 
screenings and the baseline prevalence of LTBI and HIV infection, and the probability of INH 
resistance and MDR-TB as well as the proportion of migrants screened at the point of entry 
evaluated. This section explores the sensitivity of the cost effectiveness to assumptions about 
four key parameters.  
6.3.6.1. The total number of migrants coming into the UK from Nigeria over the 
model 20 years 
The economic model assumes that about 1.8 million people will come to the UK over the 20 
years included in the model. This was calculated based on the estimates of the number of dif-
ferent categories of migrants entering the UK from Nigeria and their length of stay in the UK, 
as obtained from the immigration data (see Tables 6.1 and 6.2). This implies about 90,000 
immigrants from Nigeria will enter the UK annually and stay for at least 30 days.  This esti-
mate is one of the core parameters used in this model. Hence, to establish the validity of the 
results, the sensitivity analysis aimed to test the robustness of this model to varying scenarios 
(figures) of this key assumption.  
Therefore, the outcome was evaluated based on varied assumptions on the number of Nigeri-
ans coming into the UK annually from only 25,245 immigrants, including about 11,900 stu-
dents (that is 504,905 Nigerian immigrants in 20 years) to 38,407 annually (768,132 in 20 
years), 51,568 annually (1,031,358 in 20 years), 64,729 annually (1,294,586 in 20 years), 
77,891 annually (1,557,813), 91,051 annually (1,821,040 in 20 years). These were all based on 
inclusion of 10%, 20%, 30%, 40% and 50%, respectively, of Nigerian population living in the 
UK that travel to Nigeria annually to spend significant time (at least 30 days) in Nigeria.  
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‘Investment in Nigeria TB Control’ strategy remains the most cost-effective alternative in the 
model either when only about 504,905 or over 1.8 million Nigerians come into the country. In 
fact, it was observed that the more the migrants coming into the UK, the more cost-effective 
the ‘Investment in Nigerian TB control’ compared to the other alternatives. Hence, this implies 
that even if the estimate used in the model is an overestimation of the number of Nigerian Mi-
grants coming into the country, the result of the model could still be valid because the range of 
possible variability of this parameter couldn't significantly affect the result (Table 6.15, Fig-
ures 6.25-6.32). 
Nigeria 
Migrants 
coming 
into the 
UK	
STRATEGY	 COST	 EFF	 CE	 INCRCOST	 INCREFF	 INCRCE	 DOMI-
NATED	  
504905	 NOTHING	 72.030	 17.250	 4.176	 0.000	 0.000	 0.000	  -72.030	
504905	 Present practice 
(Chest x ray screen-
ing at the airport)	
294.283	 17.263	 17.047	 222.254	 0.014	 16213.135	  -294.283	
504905	 Investment in Nige-
ria TB control	
708.947	 17.304	 40.971	 414.664	 0.040	 10279.704	  -708.947	
504905	 IGRA	 717.742	 17.302	 41.483	 8.794	 -0.002	 -5702.466	 (Domi-
nated)	
-717.742	
768132	 NOTHING	 72.030	 17.250	 4.176	 0.000	 0.000	 0.000	  -72.030	
768132	 Present practice 
(Chest x ray screen-
ing at the airport)	
294.283	 17.263	 17.047	 222.254	 0.014	 16213.135	  -294.283	
768132	 Investment in Nige-
ria TB control	
480.727	 17.304	 27.782	 186.444	 0.040	 4622.028	  -480.727	
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768132	 IGRA	 717.742	 17.302	 41.483	 237.014	 -0.002	 -153684.920	 (Domi-
nated)	
-717.742	
1031359	 NOTHING	 72.030	 17.250	 4.176	 0.000	 0.000	 0.000	  -72.030	
1031359	 Present practice 
(Chest x ray screen-
ing at the airport)	
294.283	 17.263	 17.047	 222.254	 0.014	 16213.135	  -294.283	
1031359	 Investment in Nige-
ria TB control	
369.002	 17.304	 21.325	 74.718	 0.040	 1852.295	  -369.002	
1031359	 IGRA	 717.742	 17.302	 41.483	 348.740	 -0.002	 -226130.190	 (Domi-
nated)	
-717.742	
1294586	 NOTHING	 72.030	 17.250	 4.176	 0.000	 0.000	 0.000	  -72.030	
1294586	 Present practice 
(Chest x ray screen-
ing at the airport)	
294.283	 17.263	 17.047	 222.254	 0.014	 16213.135	  -294.283	
1294586	 Investment in Nige-
ria TB control	
302.710	 17.304	 17.494	 8.426	 0.040	 208.896	  -302.710	
1294586	 IGRA	 717.742	 17.302	 41.483	 415.032	 -0.002	 -269114.997	 (Domi-
nated)	
-717.742	
1557813	 NOTHING	 72.030	 17.250	 4.176	 0.000	 0.000	 0.000	  -72.030	
1557813	 Investment in Nige-
ria TB control	
258.821	 17.304	 14.957	 186.792	 0.054	 3456.137	  -258.821	
1557813	 Present practice 
(Chest x ray screen-
ing at the airport)	
294.283	 17.263	 17.047	 35.462	 -0.040	 -879.125	 (Domi-
nated)	
-294.283	
1557813	 IGRA	 717.742	 17.302	 41.483	 458.920	 -0.002	 -297573.334	 (Domi-
nated)	
-717.742	
1821040	 NOTHING	 72.030	 17.250	 4.176	 0.000	 0.000	 0.000	  -72.030	
1821040	 Investment in Nige-
ria TB control	
227.621	 17.304	 13.154	 155.591	 0.054	 2878.842	  -227.621	
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1821040	 Present practice 
(Chest x ray screen-
ing at the airport)	
294.283	 17.263	 17.047	 66.663	 -0.040	 -1652.605	 (Domi-
nated)	
-294.283	
1821040	 IGRA	 717.742	 17.302	 41.483	 490.121	 -0.002	 -317804.50	 (Domi-
nated)	
-717.742	
 
Table 6.15. Sensitivity analysis: Effect of assumed probability of Nigerians immigrants com-
ing to the UK on cost effectiveness estimates 
	
	
 
Figure 6.25. Cost-Effectiveness Analysis (CEA) plot assuming about 504,905 Nigerian mi-
grants will live in the UK over the 20 years 
Figure 6.25 is the Cost-Effectiveness Analysis (CEA) plot assuming about 504,905 Nigerian 
migrants will live in the UK over the 20 years (the estimate in the model is that 1.8 million Ni-
gerian migrants will enter the UK over the 20 years modelled). ‘Investment in Nigerian TB 
control’ is most cost-effective. IGRA, ’Nothing’ and ‘Chest X ray’ are dominated. 
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Figure 6.26. CEA plot assuming about 768,132 Nigerian migrants will live in the UK over 
the 20 years 
Figure 6.26 is the CEA plot assuming about 768,132 Nigerian migrants will live in the UK 
over the 20 years (the estimate in the model is that 1.8 million Nigerian migrants will live in 
the UK over the 20 years). The ‘Investment in Nigerian TB control’ is also most effective, 
slightly more effective than IGRA, but significantly less expensive. IGRA, ‘Nothing’ and ‘Chest 
X ray’ are dominated. 
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Figure 6.27. CEA plot assuming about 1,031,359 Nigerian migrants will live in the UK over 
the 20 years 
Figure 6.27 is the CEA plot assuming about 1,031,359 Nigerian migrants will live in the UK 
over the 20 years (the estimate in the model is that 1.8 million Nigerian migrants will live in 
the UK over the 20 years). ‘Investment in Nigerian TB control’ is most effective, significantly 
more effective than IGRA and less expensive. IGRA, ‘Nothing’ and ‘Chest X ray’ are dominated. 
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Figure 6.28. CEA plot assuming about 1,294, 586 Nigerian migrants will live in the UK over 
the 20 years 
Figure 6.28 is the CEA plot assuming about 1,294, 586 Nigerian migrants will live in the UK 
over the 20 years (the estimate in the model is that 1.8 million Nigerian migrants will live in 
the UK over the 20 years). ‘Investment in Nigerian TB control’ is most effective, significantly 
more effective than IGRA and less expensive. IGRA, ‘Nothing’ and ‘Chest X ray’ are dominated. 
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Figure	6.29.	CEA	plot	assuming	about	1,557,813	Nigerian	migrants	will	live	in	the	UK	over	
the	20	years 
Figure 6.29 is the CEA plot assuming about 1,557,813 Nigerian migrants will live in the UK 
over the 20 years (the estimate in the model is that 1.8 million Nigerian migrants will live in 
the UK over the 20 years). ‘Investment in Nigerian TB control’ is most effective, significantly 
more effective than IGRA and less expensive IGRA, ‘Nothing’ and ‘Chest X ray’ are dominated. 
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Figure 6.30. CEA plot assuming about 1,821,040 Nigerian migrants will live in the UK over 
the 20 years 
Figure 6.30 is the CEA plot assuming about 1,821,040 Nigerian migrants will live in the UK 
over the 20 years (the estimate in the model is that 1.8 million Nigerian migrants will live in 
the UK over the 20 years). ‘Investment in Nigerian TB control’ is most effective, significantly 
more effective than IGRA and less expensive. IGRA, ‘Nothing’ and ‘Chest X ray’ are dominated. 
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Figure 6.31. Sensitivity Analysis plot showing the annual Net Monetary Benefit in GB 
Pounds of the 4 alternative interventions, depending on assumed number of Nigerian mi-
grants 
Figure 6.31 is the Sensitivity Analysis plot showing the annual Net Monetary Benefit in GB 
Pounds of the 4 alternative interventions on varied assumptions on number of Nigerian mi-
grants coming into the UK. The range between 100,000 - 1.8million migrants over 20 years 
(the estimate in the model is 1.8 million). ‘Willingness to Pay’ pegged at 32,000 GBP per 
QALY, the ‘Investment in TB control in Nigeria’ shows the highest Net Monetary Benefit 
when the number of migrants living in the UK gets above 448,000 and above.  
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Figure 6.32. Sensitivity Analysis plot showing the incremental effectiveness (QALYs) of the 4 alter-
native interventions depending on assumed number of Nigerian migrants 
 
Figure 6.32 is the Sensitivity Analysis plot showing the incremental effectiveness (QALYs) 
of the 4 alternative interventions on varied assumption of the number of Nigerian migrants 
coming into the UK. The range between 504,905 - 1.8million migrants over 20 years (the esti-
mate in the model is 1.8 million). ‘Investment in TB control in Nigeria’ is most cost effective. 
 
6.3.6.3. The probability of active TB among migrants coming in to the UK from Nige-
ria based on the TB prevalence in Nigeria 
The base case analysis is based on the assumption that the prevalence and incidence of latent 
TB in Nigeria remain unchanged in the model. The probability of TB was calculated based on 
the expected prevalence of TB in Nigeria after full scale up of TB. This probability was esti-
mated as 0.0017. This is further based on the assumption that with TB control strategy, there 
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will be a decline of about 6% annually in the incidence of TB in the country, as observed in 
the studies in Peru and Chile. As already noted in the Study Limitations in Chapter 5, the 
plausability, or otherwise, of this assumption is particularly because of the contextual differ-
ences between Nigeria and these countries, and the results should be interpreted with this limi-
tation. 
The sensitivity analysis conducted aimed to test the robustness of this key assumption, if the 
result from the model will significant vary based on the possible inaccuracy in this extrapola-
tion. 
 As observed in the previous sensitivity analyses, ‘Investment in Nigeria TB Control’ strategy 
remains the most cost-effective alternative in the model either when the probability (preva-
lence) of TB is very low or when the prevalence is high. This invariably implies that even if 
the estimated prevalence of TB in Nigeria is an overestimation of the impact of the ‘Invest-
ment in Nigeria TB Control’, i.e. the actual prevalence is higher than the model assumed prev-
alence, the CEA results from the model will still be valid because the range of possible varia-
bility of this parameter would not significantly affect the result (refer to Table 6.16, Figures 
6.33-6.38 for details). 
Table 6.16. Probability of active TB among Nigerian migrants 
Probability of active 
TB among Nigeria 
Migrants STRATEGY COST EFF CE 
INCR-
COST INCR-EFF INCR-CE DOMINATED NMB 
0 NOTHING 72.030 17.250 4.176 0.000 0.000 0.000  -72.030 
0 
Investment in Nige-
ria TB control 214.324 17.306 12.384 142.294 0.056 2526.667  
-
214.324 
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0 
Present practice 
(Chest x ray 
screening at the air-
port) 294.283 17.263 17.047 79.960 -0.043 -1876.611 (Dominated) 
-
294.283 
0 IGRA 717.742 17.302 41.483 503.418 -0.004 -132035.693 (Dominated) 
-
717.742 
0.001144 NOTHING 72.030 17.250 4.176 0.000 0.000 0.000  -72.030 
0.001144 
Investment in Nige-
ria TB control 223.188 17.305 12.898 151.158 0.055 2758.198  
-
223.188 
0.001144 
Present practice 
(Chest x ray 
screening at the air-
port) 294.283 17.263 17.047 71.096 -0.041 -1730.031 (Dominated) 
-
294.283 
0.001144 IGRA 717.742 17.302 41.483 494.554 -0.002 -215105.468 (Dominated) 
-
717.742 
0.002288 NOTHING 72.030 17.250 4.176 0.000 0.000 0.000  -72.030 
0.002288 
Investment in Nige-
ria TB control 232.052 17.303 13.411 160.022 0.053 3002.880  
-
232.052 
0.002288 
Present practice 
(Chest x ray 
screening at the air-
port) 294.283 17.263 17.047 62.231 -0.040 -1572.240 (Dominated) 
-
294.283 
0.002288 IGRA 717.742 17.302 41.483 485.690 -0.001 -618316.644 (Dominated) 
-
717.742 
0.003432 NOTHING 72.030 17.250 4.176 0.000 0.000 0.000  -72.030 
0.003432 
Investment in Nige-
ria TB control 240.916 17.302 13.925 168.887 0.052 3261.869  
-
240.916 
0.003432 
Present practice 
(Chest x ray 
screening at the air-
port) 294.283 17.263 17.047 53.367 -0.038 -1401.901 (Dominated) 
-
294.283 
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Figure 6.33. CEA plot with the probability of TB among migrants at 0.001 
Figure 6.33 is the CEA plot with the probability of TB among migrants at 0.001 (the estimate 
in the model is 0.0017). ‘Investment in TB control in Nigeria’ is most effective, slightly more 
effective than IGRA but significantly less expensive. Both IGRA and CXR are dominated. 
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Figure 6.34.CEA plot with the probability of TB among migrants at 0.002 
Figure 6.34 is the CEA plot with the probability of TB among migrants at 0.002 (the estimate 
in the model is 0.0017). ‘Investment in TB control in Nigeria’ is most effective, slightly more 
effective than IGRA but significantly less expensive. Both IGRA and CXR are dominated. 
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Figure 6.35. CEA plot for the probability of TB among migrants at 0.003 
Figure 6.35 is the CEA plot for the probability of TB among migrants at 0.003 (the estimate 
in the model is 0.0017). ‘Investment in TB control in Nigeria’ is most effective, the same as 
IGRA but significantly less expensive. Chest X ray alternative is dominated.  
 
 55 
 
Figure 6.36. Sensitivity Analysis plot showing the effectiveness (QALYs) of the 4 alternative 
interventions 
Figure 6.36 is the Sensitivity Analysis plot showing the effectiveness (QALYs) of the 4 alter-
native interventions on varied probabilities of TB among migrants. The probability range be-
tween 0.0010 - 0.0030 (the estimate in the model is 0.0017). ‘Investment in TB control in Ni-
geria’ is most effective. When the probability of TB among migrants gets to about 0.0027, 
IGRA becomes most effective. 
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Figure 6.37. Sensitivity Analysis plot showing the annual Net Monetary Benefit in US Dol-
lars of the 4 alternative interventions 
Figure 6.37 is the Sensitivity Analysis plot showing the annual Net Monetary Benefit in US 
Dollars of the 4 alternative interventions on varied probabilities of TB among migrants. The 
probability range between 0.0010 - 0.0030 (the estimate in the model is 0.0017). ‘Investment 
in TB control in Nigeria’ shows the highest Net Monetary Benefit across the probability scale. 
The NMB declines gradually with increasing probability of active TB. 
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Figure 6.38. Sensitivity Analysis plot showing the incremental effectiveness (QALYs) of the 
4 alternative interventions 
Figure 6.38 is the Sensitivity Analysis plot showing the incremental effectiveness (QALYs) 
of the 4 alternative interventions on varied assumption of the number of Nigerian migrants 
coming in to the UK. The range between 100,000 - 1.8million migrants over 20 years (the esti-
mate in the model is 1.8 million). ‘Investment in TB control in Nigeria’ is most cost effective 
when the number of migrants living in the UK gets above 596,000 and above. 
 
6.3.6.4. Proportion of entrants/migrants chest X ray screened at point of entry (pScr) 
The sensitivity of this CE model to changes in the proportion of Nigerian migrants/entrants 
screened at the airport by chest x ray was evaluated.   
As shown in Table 6.17 below, when 0% of entrants are chest x ray screened, the most cost-
effective alternatives when none of the migrants X ray screened are strategies 1 (investment in 
Nigerian TB control) and strategy 4 (‘nothing’). Strategy 2 (CXR) and strategy 3 (IGRA) were 
dominated. 
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When 25% of migrants are screened, the Most cost-effective strategies are strategy 1 
(Investment in Nigeria control), and strategy 2 (CXR screening), followed by strategy 4 
(‘nothing’) in that order. Strategy 3 (IGRA) was dominated. 
When 50% of migrants are screened, the most cost-effective strategies is strategy 1 
(Investment in Nigeria control) followed by strategy 4 (‘do nothing’) in that order. Strategies 2 
(chest x ray screening) and 3 (IGRA) are dominated. 
When 75% of migrants are screened, the cost and effectiveness of strategy 2 (CXR screening) 
is £607 and 17.30 QALYs respectively.  Most cost-effective strategies is strategy 1 
(Investment in Nigeria control) followed by strategy 4 (‘do nothing’) in that order. Strategies 2 
(CXR) and 3 (IGRA) are dominated. 
When all migrants are screened, the cost and effectiveness of strategy 2 (CXR screening) is 
£785 and 17.32 QALYs respectively.  Most cost-effective strategy is strategy 1 (Investment in 
Nigeria control) followed by strategy 2 (CXR) then strategy 4 (‘nothing’) in that order. 
Strategy 3 (IGRA) is dominated (see Table 6.17, and group of figures below—Figure 6.39) 
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APPENDIX 1: PROJECTED DEMOGRAPHICS AND BURDEN OF TB IN NI-
GERIA OVER A PERIOD OF 20 YEARS 
 
 
2012	 2013	 2014	 2015	 2016	 2017	 2018	 2019	 2020	 2021	
Demographics	           
Population esti-
mate	
166,949,000	 170,955,776	 175,058,715	 179,260,124	 183,562,367	 187,967,864	 192,479,092	 197,098,590	 201,828,957	 206,672,852	
Annual growth 
rate (%)	
2.40	 2.40	 2.40	 2.40	 2.40	 2.40	 2.40	 2.40	 2.40	 2.40	
Projected Bur-
den of TB in 
Nigeria	           
A- When there 
is no any exter-
nal intervention	           
Incidence rate 
new ss+ (per 
100 000 pop)	
131	 128	 124	 121	 118	 115	 112	 109	 106	 103	
Incidence rate 
new ss- (per 
100 000 pop)	
180	 175	 171	 166	 162	 158	 154	 150	 146	 142	
Total incidence 
per 100,000 
population	
311	 303	 295	 287	 280	 273	 266	 259	 252	 245	
Proportion of 
MDR-TB in 
population (%)	
1.8	 1.8	 1.8	 1.8	 1.8	 1.8	 1.8	 1.8	 1.8	 1.8	
Number of 
deaths due to 
all forms of TB	
221,078	 220,498	 219,920	 219,342	 218,767	 218,193	 217,620	 217,049	 216,480	 215,912	
 71 
B- With exter-
nal intervention	           
Incidence rate 
new ss+ (per 
100 000 pop)	
131	 128	 123	 117	 110	 103	 94	 86	 78	 71	
Incidence rate 
new ss- (per 
100 000 pop)	
180	 175	 169	 161	 152	 141	 130	 118	 107	 98	
Total incidence 
per 100,000 
population	
311	 303	 292	 279	 262	 244	 224	 204	 186	 169	
Proportion of 
MDR-TB in 
population (%)	
1.8	 1.8	 1.8	 1.8	 1.8	 1.8	 1.8	 1.8	 1.8	 1.8	
Number of 
deaths due to 
all forms of TB	
221,078	 197,403	 158,468	 116,854	 112,479	 107,116	 100,912	 94,034	 87,624	 81,652	
Projected Dis-
ease Control 
indices	           
A- When there 
is no any exter-
nal intervention	           
Case detection 
rate new ss+ 
(%)	
23	 23	 23	 23	 23	 23	 23	 23	 23	 23	
Case detection 
rate new ss- 
(%)	
17	 17	 17	 17	 17	 17	 17	 17	 17	 17	
Treatment suc-
cess rate (%)	
76	 76	 76	 76	 76	 76	 76	 76	 76	 76	
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B- With exter-
nal intervention	           
Case detection 
rate new ss+ 
(%)	
23	 33	 50	 70	 70	 70	 70	 70	 70	 70	
Case detection 
rate new ss- 
(%)	
17	 30	 50	 70	 70	 70	 70	 70	 70	 70	
Treatment suc-
cess rate (%)	
76	 76	 76	 80	 80	 80	 80	 80	 80	 80	
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APPENDIX 2: PROJECTED DEMOGRAPHICS AND BURDEN OF TB IN NI-
GERIA OVER A PERIOD OF 20 YEARS 
 
 2022	 2023	 2024	 2025	 2026	 2027	 2028	 2029	 2030	 2031	
Demographics	           
Population 
estimate	
211,63
3,000	
216,71
2,192	
221,91
3,285	
227,23
9,204	
232,69
2,944	
238,27
7,575	
243,99
6,237	
249,85
2,147	
255,84
8,598	
261,98
8,964	
Annual growth 
rate (%)	 2.40	 2.40	 2.40	 2.40	 2.40	 2.40	 2.40	 2.40	 2.40	 2.40	
Projected 
Burden of TB 
in Nigeria	
          
A- When there 
is no any 
external 
intervention	
          
Incidence rate 
new ss+ (per 
100 000 pop)	
101	 98	 95	 93	 91	 88	 86	 84	 82	 79	
Incidence rate 
new ss- (per 100 
000 pop)	
138	 135	 131	 128	 124	 121	 118	 115	 112	 109	
Total incidence 
per 100,000 
population	
239	 233	 227	 221	 215	 209	 204	 199	 194	 189	
Proportion of 
MDR-TB in 
population (%)	
1.8	 1.8	 1.8	 1.8	 1.8	 1.8	 1.8	 1.8	 1.8	 1.8	
Number of 
deaths due to all 
forms of TB	
215,34
5	
214,78
0	
214,21
6	
213,65
4	
213,09
4	
212,53
5	
211,97
7	
211,42
1	
210,86
6	
210,31
3	
B- With external 
intervention	           
Incidence rate 
new ss+ (per 
100 000 pop)	
65	 59	 54	 49	 44	 40	 37	 33	 30	 28	
 74 
Incidence rate 
new ss- (per 100 
000 pop)	
89	 81	 74	 67	 61	 55	 50	 46	 42	 38	
Total incidence 
per 100,000 
population	
154	 140	 127	 116	 105	 96	 87	 79	 72	 66	
Proportion of 
MDR-TB in 
population (%)	
1.8	 1.8	 1.8	 1.8	 1.8	 1.8	 1.8	 1.8	 1.8	 1.8	
Number of 
deaths due to all 
forms of TB	
76,087	 70,901	 66,068	 61,565	 57,369	 53,458	 49,815	 46,419	 43,255	 40,307	
Projected 
Disease Control 
indices	
          
A- When there 
is no any 
external 
intervention	
          
• C
ase 
detecti
on rate 
new 
ss+ (%) 
23	 23	 23	 23	 23	 23	 23	 23	 23	 23	
• Case 
detecti
on rate 
new ss- 
(%) 
17	 17	 17	 17	 17	 17	 17	 17	 17	 17	
• Treatm
ent 
success 
rate 
(%) 
76	 76	 76	 76	 76	 76	 76	 76	 76	 76	
B- With external 
intervention	           
• Case 
detecti
on rate 
new 
ss+ (%) 
70	 70	 70	 70	 70	 70	 70	 70	 70	 70	
 75 
• Case 
detecti
on rate 
new ss- 
(%) 
70	 70	 70	 70	 70	 70	 70	 70	 70	 70	
• T
reatme
nt 
success 
rate 
(%) 
80	 80	 80	 80	 80	 80	 80	 80	 80	 80	
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APPENDIX 3: MODELED COST ELEMENTS FOR SCALING UP TB CON-
TROL SERVICES AND PROGRAMME IN NIGERIA OVER A PERIOD OF 20 
YEARS 
 
 
 2012	 2013	 2014	 2015	 2016	 2017	 2018	 2019	 2020	 2021	
A- NO 
INTERVE
NTION	
          
General use 
of health 
services 
including 
labs and x 
rays	
          
Drugs 
sensitive 
patients 
Hospitalizat
ions, 
outpatient 
care, 
investigatio
n and drugs	
20,348,
715	
20,295,
320	
20,242,
065	
20,188,
950	
20,135,
974	
20,083,
137	
20,030,
439	
19,977,
879	
19,925,
457	
19,873,
173	
MDR-TB 
Hospitalizat
ions, 
outpatient 
care, 
investigatio
n and drugs	
5,668,4
07	
5,653,5
34	
5,638,6
99	
5,623,9
03	
5,609,1
46	
5,594,4
27	
5,579,7
47	
5,565,1
06	
5,550,5
03	
5,535,9
39	
           
B- 
INTERVE
NTION	
          
General use 
of health 
services 
including 
labs and x 
rays	
          
 77 
Drugs 
sensitive 
patients 
Hospitalizat
ions, 
outpatient 
care, 
investigatio
n and drugs	
20,348,
715	
32,493,
231	
51,297,
949	
70,157,
866	
67,531,
155	
64,311,
270	
60,586,
361	
56,456,
795	
52,608,
700	
49,022,
891	
MDR-TB 
Hospitalizat
ions, 
outpatient 
care, 
investigatio
n and drugs	
5,668,4
07	
9,051,4
25	
14,289,
732	
19,543,
414	
18,811,
709	
17,914,
767	
16,877,
143	
15,726,
797	
14,654,
859	
13,655,
984	
           
Cost of 
drugs	
          
A- NO 
INTERVE
NTION	
          
First line 
drugs in US 
$	
1,893,6
26	
1,888,6
57	
1,883,7
01	
1,878,7
59	
1,873,8
29	
1,868,9
12	
1,864,0
08	
1,859,1
17	
1,854,2
38	
1,849,3
73	
Second line 
drugs in US 
$	
83,949	 83,729	 83,509	 83,290	 83,072	 82,854	 82,636	 82,419	 82,203	 81,988	
           
B- 
INTERVE
NTION	
          
First line 
drugs in US 
$	
189362
6.06	
302377
9.65	
477372
3.26	
652880
3.61	
628436
5.21	
598472
6.67	
563809
1.30	
525379
9.00	
489570
0.06	
456200
9.15	
Second line 
drugs in US 
$	
83949.
37	
134052
.02	
211631
.57	
289438
.85	
278602
.26	
265318
.50	
249951
.26	
232914
.58	
217039
.12	
202245
.73	
           
National and State TB control programme in US $ (Assumed to be same with and without the external 
intervention)	
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          Staff 
and 
Consultants	
4,359,6
89	
6,961,6
39	
10,990,
528	
15,031,
245	
14,468,
475	
13,778,
618	
12,980,
560	
12,095,
805	
11,271,
355	
10,503,
100	
Routine 
programme 
managemen
t, 
supervision 
activities,m
eetings, 
equipment 
and training	
7,299,9
45	
11,656,
697	
18,402,
745	
25,168,
596	
24,226,
283	
23,071,
174	
21,734,
892	
20,253,
442	
18,872,
967	
17,586,
586	
Private 
Public Mix 
(PPM)	
171,05
4	
178,53
2	
188,59
5	
196,84
6	
196,84
6	
196,84
6	
196,84
6	
196,84
6	
196,84
6	
196,84
6	
Practical 
Approach 
to Lung 
Health 
(PAL)	
207,94
1	
207,94
1	
207,94
1	
207,94
1	
207,94
1	
207,94
1	
207,94
1	
207,94
1	
207,94
1	
207,94
1	
Community 
based TB 
Care 
(CTBC)	
271,35
3	
285,28
8	
299,88
9	
315,17
5	
315,17
5	
315,17
5	
315,17
5	
315,17
5	
315,17
5	
315,17
5	
Advocacy, 
Communica
tion and 
Social 
Mobilizatio
n (ACSM)	
20,143,
067	
21,177,
500	
22,261,
413	
23,396,
071	
23,396,
071	
23,396,
071	
23,396,
071	
23,396,
071	
23,396,
071	
23,396,
071	
Technical 
Assistance 
including 
Country 
based and 
Internationa
l	
320,00
0	
320,00
0	
320,00
0	
320,00
0	
320,00
0	
320,00
0	
320,00
0	
320,00
0	
320,00
0	
320,00
0	
M&E, 
surveillance 
and 
Operational 
Research	
1,012,0
00	
1,000,0
00	
1,058,4
00	
1,101,0
00	
1,101,0
00	
1,101,0
00	
1,101,0
00	
1,101,0
00	
1,101,0
00	
1,101,0
00	
Collaborati
ve TB/HIV 
activities	
62,964,
014	
86,659,
047	
123,04
3,685	
159,54
7,674	
155,17
3,107	
149,68
4,603	
143,25
0,293	
136,06
1,558	
129,42
4,613	
123,30
3,330	
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 2022	 2023	 2024	 2025	 2026	 2027	 2028	 2029	 2030	 2031	
A- NO 
INTERVE
NTION	
          
Drugs 
sensitive 
patients 
Hospitalizat
ions, 
outpatient 
care, 
investigatio
n and drugs	
19,821,
026	
19,769,
015	
19,717,
141	
19,665,
403	
19,613,
801	
19,562,
335	
19,511,
003	
19,459,
806	
19,408,
744	
19,357,
815	
MDR-TB 
Hospitalizat
ions, 
outpatient 
care, 
investigatio
n and drugs	
5,521,4
13	
5,506,9
24	
5,492,4
74	
5,478,0
62	
5,463,6
87	
5,449,3
51	
5,435,0
52	
5,420,7
90	
5,406,5
66	
5,392,3
79	
           
B- 
INTERVE
NTION	
          
Drugs 
sensitive 
patients 
Hospitalizat
ions, 
outpatient 
care, 
investigatio
n and drugs	
45,681,
490	
42,567,
840	
39,666,
416	
36,962,
753	
34,443,
372	
32,095,
712	
29,908,
068	
27,869,
534	
25,969,
947	
24,199,
835	
MDR-TB 
Hospitalizat
ions, 
outpatient 
care, 
investigatio
n and drugs	
12,725,
192	
11,857,
843	
11,049,
612	
10,296,
471	
9,594,6
63	
8,940,6
91	
8,331,2
93	
7,763,4
32	
7,234,2
77	
6,741,1
89	
           
Cost of 
drugs	
          
 80 
A- NO 
INTERVE
NTION	
          
First line 
drugs in US 
$	
1,844,5
20	
1,839,6
80	
1,834,8
53	
1,830,0
38	
1,825,2
36	
1,820,4
47	
1,815,6
70	
1,810,9
05	
1,806,1
54	
1,801,4
14	
Second line 
drugs in US 
$	
81,772	 81,558	 81,344	 81,130	 80,917	 80,705	 80,493	 80,282	 80,071	 79,861	
           
B- 
INTERVE
NTION	
          
First line 
drugs in US 
$	
425106
2.60	
396131
0.18	
369130
7.27	
343970
7.77	
320525
7.29	
298678
6.95	
278320
7.55	
259350
4.13	
241673
0.88	
225200
6.51	
Second line 
drugs in US 
$	
188460
.66	
175615
.19	
163645
.25	
152491
.19	
142097
.39	
132412
.04	
123386
.83	
114976
.79	
107139
.97	
99837.
31	
           
National and State TB control programme in US $ (Assumed to be same with and without the external 
intervention)	
          Staff 
and 
Consultants	
9,787,2
08	
9,120,1
12	
8,498,4
85	
7,919,2
29	
7,379,4
54	
6,876,4
70	
6,407,7
70	
5,971,0
17	
5,564,0
32	
5,184,7
88	
Routine 
programme 
managemen
t, 
supervision 
activities,m
eetings, 
equipment 
and training	
16,387,
884	
15,270,
886	
14,230,
022	
13,260,
104	
12,356,
295	
11,514,
090	
10,729,
290	
9,997,9
81	
9,316,5
19	
8,681,5
05	
Private 
Public Mix 
(PPM)	
196,84
6	
196,84
6	
196,84
6	
196,84
6	
196,84
6	
196,84
6	
196,84
6	
196,84
6	
196,84
6	
196,84
6	
Practical 
Approach 
to Lung 
Health 
(PAL)	
207,94
1	
207,94
1	
207,94
1	
207,94
1	
207,94
1	
207,94
1	
207,94
1	
207,94
1	
207,94
1	
207,94
1	
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Community 
based TB 
Care 
(CTBC)	
315,17
5	
315,17
5	
315,17
5	
315,17
5	
315,17
5	
315,17
5	
315,17
5	
315,17
5	
315,17
5	
315,17
5	
Advocacy, 
Communica
tion and 
Social 
Mobilizatio
n (ACSM)	
23,396,
071	
23,396,
071	
23,396,
071	
23,396,
071	
23,396,
071	
23,396,
071	
23,396,
071	
23,396,
071	
23,396,
071	
23,396,
071	
Technical 
Assistance 
including 
Country 
based and 
Internationa
l	
320,00
0	
320,00
0	
320,00
0	
320,00
0	
320,00
0	
320,00
0	
320,00
0	
320,00
0	
320,00
0	
320,00
0	
M&E, 
surveillance 
and 
Operational 
Research	
1,101,0
00	
1,101,0
00	
1,101,0
00	
1,101,0
00	
1,101,0
00	
1,101,0
00	
1,101,0
00	
1,101,0
00	
1,101,0
00	
1,101,0
00	
Collaborati
ve TB/HIV 
activities	
117,66
4,080	
112,47
5,565	
107,70
8,654	
103,33
6,242	
99,333,
110	
95,675,
797	
92,342,
485	
89,312,
882	
86,568,
123	
84,090,
675	
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APPENDIX 4: PROJECTION OF TB AMONG MIGRANTS COMING TO THE 
UK, 0-15 YEARS OF AGE, (WITH NO ADDITIONAL INTERVENTION IN 
NIGERIA) OVER A PERIOD OF 20 YEARS 
 
 
 
Year	
Smear 
positiv
e rate	
Incidenc
e rate	
ARI
%	
Age 
midpoin
t	
% of 
entrant
s	
Expecte
d 
Number 
of 
entrants	
Expecte
d 
number 
exposed 
to TB	
Number 
of 
Infection
s	
Activ
e TB	
LTB 
<2yr	
LTB 
>2yr	
201
2	 131	 311	 2.620	 8	 8	 7284	 1527	 458	 23	 109	 326	
201
3	 128	 303	 2.552	 8	 8	 7284	 1487	 446	 22	 106	 318	
201
4	 124	 295	 2.486	 8	 8	 7284	 1448	 435	 21	 103	 310	
201
5	 121	 287	 2.421	 8	 8	 7284	 1411	 423	 21	 101	 302	
201
6	 118	 280	 2.358	 8	 8	 7284	 1374	 412	 20	 98	 294	
201
7	 115	 273	 2.297	 8	 8	 7284	 1338	 402	 20	 95	 286	
201
8	 112	 266	 2.237	 8	 8	 7284	 1304	 391	 19	 93	 279	
201
9	 109	 259	 2.179	 8	 8	 7284	 1270	 381	 19	 90	 271	
202
0	 106	 252	 2.122	 8	 8	 7284	 1237	 371	 18	 88	 264	
202
1	 103	 245	 2.067	 8	 8	 7284	 1204	 361	 18	 86	 257	
202
2	 101	 239	 2.013	 8	 8	 7284	 1173	 352	 17	 84	 251	
202
3	 98	 233	 1.961	 8	 8	 7284	 1143	 343	 17	 81	 244	
202
4	 95	 227	 1.910	 8	 8	 7284	 1113	 334	 17	 79	 238	
202
5	 93	 221	 1.860	 8	 8	 7284	 1084	 325	 16	 77	 232	
 83 
6	 91	 215	 1.812	 8	 8	 7284	 1056	 317	 16	 75	 226	
202
7	 88	 209	 1.765	 8	 8	 7284	 1028	 309	 15	 73	 220	
202
8	 86	 204	 1.719	 8	 8	 7284	 1002	 300	 15	 71	 214	
202
8	 84	 199	 1.674	 8	 8	 7284	 976	 293	 14	 70	 209	
203
0	 82	 194	 1.631	 8	 8	 7284	 950	 285	 14	 68	 203	
203
1	 79	 189	 1.588	 8	 8	 7284	 926	 278	 14	 66	 198	
         357	 1714	
514
1	
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APPENDIX 5: PROJECTION OF TB AMONG MIGRANTS COMING TO THE 
UK, 16-24 YEARS OF AGE, (WITH NO ADDITIONAL INTERVENTION IN 
NIGERIA) OVER A PERIOD OF 20 YEARS 
 
 
Year 	 Smear 
positive 
rate	
Incidence 
rate	
ARI%	 Age 
midpoint	
% of 
entrants	
Number	 Total 
number 
expose
d to TB	
Infection	 Active 
TB	
LTB 
<2yr	
LTB 
>2yr	
2012	 131	 311	 2.620	 20	 12	 10926	 5725	 1718	 34	 163	 1469	
2013	 128	 303	 2.552	 20	 12	 10926	 5576	 1673	 33	 159	 1430	
2014	 124	 295	 2.486	 20	 12	 10926	 5432	 1629	 32	 155	 1393	
2015	 121	 287	 2.421	 20	 12	 10926	 5290	 1587	 31	 151	 1357	
2016	 118	 280	 2.358	 20	 12	 10926	 5153	 1546	 31	 147	 1322	
2017	 115	 273	 2.297	 20	 12	 10926	 5019	 1506	 30	 143	 1287	
2018	 112	 266	 2.237	 20	 12	 10926	 4888	 1466	 29	 139	 1254	
2019	 109	 259	 2.179	 20	 12	 10926	 4761	 1428	 28	 136	 1221	
2020	 106	 252	 2.122	 20	 12	 10926	 4637	 1391	 28	 132	 1189	
2021	 103	 245	 2.067	 20	 12	 10926	 4517	 1355	 27	 129	 1159	
2022	 101	 239	 2.013	 20	 12	 10926	 4399	 1320	 26	 125	 1128	
2023	 98	 233	 1.961	 20	 12	 10926	 4285	 1285	 25	 122	 1099	
2024	 95	 227	 1.910	 20	 12	 10926	 4174	 1252	 25	 119	 1071	
2025	 93	 221	 1.860	 20	 12	 10926	 4065	 1220	 24	 116	 1043	
 85 
2026	 91	 215	 1.812	 20	 12	 10926	 3959	 1188	 23	 113	 1016	
2027	 88	 209	 1.765	 20	 12	 10926	 3856	 1157	 23	 110	 989	
2028	 86	 204	 1.719	 20	 12	 10926	 3756	 1127	 22	 107	 963	
2028	 84	 199	 1.674	 20	 12	 10926	 3659	 1098	 22	 104	 938	
2030	 82	 194	 1.631	 20	 12	 10926	 3563	 1069	 21	 102	 914	
2031	 79	 189	 1.588	 20	 12	 10926	 3471	 1041	 21	 99	 890	
    	  	  	  	  	  	 535	 2570	 23133	
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APPENDIX 6: PROJECTION OF TB AMONG MIGRANTS COMING TO THE 
UK, 25-44 YEARS OF AGE, (WITH NO ADDITIONAL INTERVENTION IN 
NIGERIA) OVER A PERIOD OF 20 YEARS 
 
 
Year
 	
Smear 
positiv
e rate	
Incidenc
e rate	
ARI
%	
Age 
midpoin
t	
% of 
entrant
s	
Numbe
r	
Total 
number 
expose
d to TB	
Infectio
n	
Activ
e TB	
LTB 
<2yr	
LTB 
>2yr	
2012	 131	 311	 2.620	 34	 53	 48258	 42988	 12896	 150	 721	 11531	
2013	 128	 303	 2.552	 34	 53	 48258	 41870	 12561	 146	 702	 11231	
2014	 124	 295	 2.486	 34	 53	 48258	 40782	 12234	 142	 684	 10939	
2015	 121	 287	 2.421	 34	 53	 48258	 39721	 11916	 139	 666	 10655	
2016	 118	 280	 2.358	 34	 53	 48258	 38688	 11607	 135	 649	 10378	
2017	 115	 273	 2.297	 34	 53	 48258	 37683	 11305	 132	 632	 10108	
2018	 112	 266	 2.237	 34	 53	 48258	 36703	 11011	 128	 615	 9845	
2019	 109	 259	 2.179	 34	 53	 48258	 35749	 10725	 125	 599	 9589	
2020	 106	 252	 2.122	 34	 53	 48258	 34819	 10446	 122	 584	 9340	
2021	 103	 245	 2.067	 34	 53	 48258	 33914	 10174	 118	 569	 9097	
2022	 101	 239	 2.013	 34	 53	 48258	 33032	 9910	 115	 554	 8860	
2023	 98	 233	 1.961	 34	 53	 48258	 32173	 9652	 112	 539	 8630	
2024	 95	 227	 1.910	 34	 53	 48258	 31337	 9401	 109	 525	 8406	
2025	 93	 221	 1.860	 34	 53	 48258	 30522	 9157	 107	 512	 8187	
 87 
2026	 91	 215	 1.812	 34	 53	 48258	 29728	 8919	 104	 498	 7974	
2027	 88	 209	 1.765	 34	 53	 48258	 28955	 8687	 101	 485	 7767	
2028	 86	 204	 1.719	 34	 53	 48258	 28203	 8461	 98	 473	 7565	
2028	 84	 199	 1.674	 34	 53	 48258	 27469	 8241	 96	 461	 7368	
2030	 82	 194	 1.631	 34	 53	 48258	 26755	 8027	 93	 449	 7177	
2031	 79	 189	 1.588	 34	 53	 48258	 26059	 7818	 91	 437	 6990	
    	  	  	  	  	  	 2364	 1135
2	
18163
6	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	
 88 
APPENDIX 7: PROJECTION OF TB AMONG MIGRANTS COMING TO THE 
UK, 45-64 YEARS OF AGE, (WITH NO ADDITIONAL INTERVENTION IN 
NIGERIA) OVER A PERIOD OF 20 YEARS 
 
Year
 	
Smear 
positiv
e rate	
Incidenc
e rate	
ARI
%	
Age 
midpoin
t	
% of 
entrant
s	
Expecte
d 
number 
of 
entrants	
Expecte
d  
number 
exposed 
to TB	
Number 
of 
Infectio
n	
Activ
e TB	
LTB 
<2yr	
LTB 
>2yr	
2012	 131	 311	 2.620	 54	 23	 20942	 20942	 6283	 65	 221	 5747	
2013	 128	 303	 2.552	 54	 23	 20942	 20942	 6283	 63	 221	 5747	
2014	 124	 295	 2.486	 54	 23	 20942	 20942	 6283	 62	 221	 5747	
2015	 121	 287	 2.421	 54	 23	 20942	 20942	 6283	 60	 221	 5747	
2016	 118	 280	 2.358	 54	 23	 20942	 20942	 6283	 59	 221	 5747	
2017	 115	 273	 2.297	 54	 23	 20942	 20942	 6283	 57	 221	 5747	
2018	 112	 266	 2.237	 54	 23	 20942	 20942	 6283	 56	 221	 5747	
2019	 109	 259	 2.179	 54	 23	 20942	 20942	 6283	 54	 221	 5747	
2020	 106	 252	 2.122	 54	 23	 20942	 20942	 6283	 53	 221	 5747	
2021	 103	 245	 2.067	 54	 23	 20942	 20942	 6283	 51	 221	 5747	
2022	 101	 239	 2.013	 54	 23	 20942	 20942	 6283	 50	 221	 5747	
2023	 98	 233	 1.961	 54	 23	 20942	 20942	 6283	 49	 221	 5747	
2024	 95	 227	 1.910	 54	 23	 20942	 20942	 6283	 47	 221	 5747	
2025	 93	 221	 1.860	 54	 23	 20942	 20942	 6283	 46	 221	 5747	
 89 
2026	 91	 215	 1.812	 54	 23	 20942	 20942	 6283	 45	 221	 5747	
2027	 88	 209	 1.765	 54	 23	 20942	 20942	 6283	 44	 221	 5747	
2028	 86	 204	 1.719	 54	 23	 20942	 20942	 6283	 43	 221	 5747	
2028	 84	 199	 1.674	 54	 23	 20942	 20942	 6283	 42	 221	 5747	
2030	 82	 194	 1.631	 54	 23	 20942	 20942	 6283	 41	 221	 5747	
2031	 79	 189	 1.588	 54	 23	 20942	 20942	 6283	 39	 221	 5747	
    	  	  	  	  	  	 1026	 442
1	
11494
8	
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APPENDIX 8: PROJECTION OF TB AMONG MIGRANTS COMING TO THE UK, 65+  
YEARS OF AGE, (WITH NO ADDITIONAL INTERVENTION IN NIGERIA) OVER A 
PERIOD OF 20 YEARS 
 
 
Year
 	
Smear 
positiv
e rate	
Incidenc
e rate	
ARI
%	
Age 
midpoin
t	
% of 
entrant
s	
Expecte
d 
number 
of 
entrants	
Expecte
d 
number 
exposed 
to TB	
No. of 
infectio
n	
Activ
e TB	
LTB 
<2y
r	
LTB 
>2yr	
2012	 131	 311	 2.620	 65	 4	 3642	 3642	 1093	 11	 32	 1006	
2013	 128	 303	 2.552	 65	 4	 3642	 3642	 1093	 11	 32	 1006	
2014	 124	 295	 2.486	 65	 4	 3642	 3642	 1093	 11	 32	 1006	
2015	 121	 287	 2.421	 65	 4	 3642	 3642	 1093	 10	 32	 1006	
2016	 118	 280	 2.358	 65	 4	 3642	 3642	 1093	 10	 32	 1006	
2017	 115	 273	 2.297	 65	 4	 3642	 3642	 1093	 10	 32	 1006	
2018	 112	 266	 2.237	 65	 4	 3642	 3642	 1093	 10	 32	 1006	
2019	 109	 259	 2.179	 65	 4	 3642	 3642	 1093	 9	 32	 1006	
2020	 106	 252	 2.122	 65	 4	 3642	 3642	 1093	 9	 32	 1006	
2021	 103	 245	 2.067	 65	 4	 3642	 3642	 1093	 9	 32	 1006	
2022	 101	 239	 2.013	 65	 4	 3642	 3642	 1093	 9	 32	 1006	
2023	 98	 233	 1.961	 65	 4	 3642	 3642	 1093	 8	 32	 1006	
2024	 95	 227	 1.910	 65	 4	 3642	 3642	 1093	 8	 32	 1006	
2025	 93	 221	 1.860	 65	 4	 3642	 3642	 1093	 8	 32	 1006	
2026	 91	 215	 1.812	 65	 4	 3642	 3642	 1093	 8	 32	 1006	
 91 
2027	 88	 209	 1.765	 65	 4	 3642	 3642	 1093	 8	 32	 1006	
2028	 86	 204	 1.719	 65	 4	 3642	 3642	 1093	 7	 32	 1006	
2028	 84	 199	 1.674	 65	 4	 3642	 3642	 1093	 7	 32	 1006	
2030	 82	 194	 1.631	 65	 4	 3642	 3642	 1093	 7	 32	 1006	
2031	 79	 189	 1.588	 65	 4	 3642	 3642	 1093	 7	 32	 1006	
    	  	  	  	  	  	 178	 639	 2012
1	
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APPENDIX 9: PROJECTION OF TB AMONG MIGRANTS COMING TO THE 
UK, 0-15 YEARS OF AGE, (WITH THE INTERVENTION, I.E. SCALED UP 
TB SERVICES IN NIGERIA) OVER A PERIOD OF 20 YEARS 
 
 Yea
r	
Smear 
positiv
e rate	
Incidenc
e rate	
ARI
%	
Age 
midpoin
t	
% of 
entrant
s	
Expecte
d 
Number 
of 
entrants	
Expecte
d 
number 
exposed 
to TB	
Infectio
n	
Activ
e TB	
LTB 
<2yr	
LTB 
>2yr	
2012	 131	 311	 2.620	 8	 8	 7284	 1527	 458	 23	 109	 326	
2013	 128	 303	 2.552	 8	 8	 7284	 1487	 446	 22	 106	 318	
2014	 123	 292	 2.460	 8	 8	 7284	 1434	 430	 21	 102	 306	
2015	 117	 279	 2.347	 8	 8	 7284	 1368	 410	 20	 97	 292	
2016	 110	 262	 2.206	 8	 8	 7284	 1286	 386	 19	 92	 275	
2017	 103	 244	 2.052	 8	 8	 7284	 1196	 359	 18	 85	 256	
2018	 94	 224	 1.887	 8	 8	 7284	 1100	 330	 16	 78	 235	
2019	 86	 204	 1.718	 8	 8	 7284	 1001	 300	 15	 71	 214	
2020	 78	 186	 1.563	 8	 8	 7284	 911	 273	 14	 65	 195	
2021	 71	 169	 1.422	 8	 8	 7284	 829	 249	 12	 59	 177	
2022	 65	 154	 1.294	 8	 8	 7284	 754	 226	 11	 54	 161	
2023	 59	 140	 1.178	 8	 8	 7284	 686	 206	 10	 49	 147	
2024	 54	 127	 1.072	 8	 8	 7284	 625	 187	 9	 45	 134	
2025	 49	 116	 0.975	 8	 8	 7284	 568	 171	 8	 40	 121	
2026	 44	 105	 0.888	 8	 8	 7284	 517	 155	 8	 37	 111	
 93 
2027	 40	 96	 0.808	 8	 8	 7284	 471	 141	 7	 34	 101	
2028	 37	 87	 0.735	 8	 8	 7284	 428	 128	 6	 31	 92	
2028	 33	 79	 0.669	 8	 8	 7284	 390	 117	 6	 28	 83	
2030	 30	 72	 0.609	 8	 8	 7284	 355	 106	 5	 25	 76	
2031	 28	 66	 0.554	 8	 8	 7284	 323	 97	 5	 23	 69	
 	  	  	  	  	  	  	  	  	 256	 122
9	
368
8	
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APPENDIX 10: PROJECTION OF TB AMONG MIGRANTS COMING TO 
THE UK, 16-24 YEARS OF AGE, (WITH THE INTERVENTION, I.E SCALED 
UP TB SERVICES IN NIGERIA) OVER A PERIOD OF 20 YEARS 
 
 Yea
r	
Smear 
Positive
s rate	
Incidenc
e rate	
ARI
%	
Age 
midpoin
t	
% of 
entrant
s	
Expecte
d 
Number 
of 
entrants	
Expecte
d 
number 
exposed 
to TB	
Infectio
n	
Activ
e TB	
LTB 
<2yr	
LTB 
>2yr	
2012	 131	 311	 2.620	 20	 12	 10926	 5725	 1718	 34	 163	 1469	
2013	 128	 303	 2.552	 20	 12	 10926	 5576	 1673	 33	 159	 1430	
2014	 123	 292	 2.460	 20	 12	 10926	 5376	 1613	 32	 153	 1379	
2015	 117	 279	 2.347	 20	 12	 10926	 5128	 1539	 30	 146	 1315	
2016	 110	 262	 2.206	 20	 12	 10926	 4821	 1446	 29	 137	 1237	
2017	 103	 244	 2.052	 20	 12	 10926	 4483	 1345	 27	 128	 1150	
2018	 94	 224	 1.887	 20	 12	 10926	 4125	 1237	 24	 118	 1058	
2019	 86	 204	 1.718	 20	 12	 10926	 3753	 1126	 22	 107	 963	
2020	 78	 186	 1.563	 20	 12	 10926	 3416	 1025	 20	 97	 876	
2021	 71	 169	 1.422	 20	 12	 10926	 3108	 932	 18	 89	 797	
2022	 65	 154	 1.294	 20	 12	 10926	 2828	 849	 17	 81	 726	
2023	 59	 140	 1.178	 20	 12	 10926	 2574	 772	 15	 73	 660	
2024	 54	 127	 1.072	 20	 12	 10926	 2342	 703	 14	 67	 601	
2025	 49	 116	 0.975	 20	 12	 10926	 2131	 639	 13	 61	 547	
2026	 44	 105	 0.888	 20	 12	 10926	 1940	 582	 12	 55	 498	
 95 
2027	 40	 96	 0.808	 20	 12	 10926	 1765	 530	 10	 50	 453	
2028	 37	 87	 0.735	 20	 12	 10926	 1606	 482	 10	 46	 412	
2028	 33	 79	 0.669	 20	 12	 10926	 1462	 438	 9	 42	 375	
2030	 30	 72	 0.609	 20	 12	 10926	 1330	 399	 8	 38	 341	
2031	 28	 66	 0.554	 20	 12	 10926	 1210	 363	 7	 34	 310	
    	  	  	  	  	  	 384	 184
4	
1659
6	
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APPENDIX 11: PROJECTION OF TB AMONG MIGRANTS COMING TO 
THE UK, 25-44 YEARS OF AGE, (WITH THE INTERVENTION, I.E SCALED 
UP TB SERVICES IN NIGERIA) OVER A PERIOD OF 20 YEARS 
 
Year
 	
Smear 
positive
s rate	
Incidenc
e rate	
ARI
%	
Age 
midpoin
t	
% of 
entrant
s 	
Expecte
d 
Number 
of 
entrants	
Total 
number 
expose
d to TB	
Infectio
n	
Activ
e TB	
LTB 
<2yr	
LTB 
>2yr	
2012	 131	 311	 2.620	 34	 53	 48258	 42988	 12896	 150	 721	 11531	
2013	 128	 303	 2.552	 34	 53	 48258	 41870	 12561	 146	 702	 11231	
2014	 123	 292	 2.460	 34	 53	 48258	 40363	 12109	 141	 677	 10827	
2015	 117	 279	 2.347	 34	 53	 48258	 38506	 11552	 134	 646	 10329	
2016	 110	 262	 2.206	 34	 53	 48258	 36196	 10859	 126	 607	 9709	
2017	 103	 244	 2.052	 34	 53	 48258	 33662	 10099	 118	 564	 9029	
2018	 94	 224	 1.887	 34	 53	 48258	 30969	 9291	 108	 519	 8307	
2019	 86	 204	 1.718	 34	 53	 48258	 28182	 8455	 98	 472	 7559	
2020	 78	 186	 1.563	 34	 53	 48258	 25646	 7694	 90	 430	 6879	
2021	 71	 169	 1.422	 34	 53	 48258	 23337	 7001	 81	 391	 6260	
2022	 65	 154	 1.294	 34	 53	 48258	 21237	 6371	 74	 356	 5697	
2023	 59	 140	 1.178	 34	 53	 48258	 19326	 5798	 67	 324	 5184	
2024	 54	 127	 1.072	 34	 53	 48258	 17586	 5276	 61	 295	 4717	
2025	 49	 116	 0.975	 34	 53	 48258	 16004	 4801	 56	 268	 4293	
 97 
2026	 44	 105	 0.888	 34	 53	 48258	 14563	 4369	 51	 244	 3906	
2027	 40	 96	 0.808	 34	 53	 48258	 13253	 3976	 46	 222	 3555	
2028	 37	 87	 0.735	 34	 53	 48258	 12060	 3618	 24	 202	 3235	
2028	 33	 79	 0.669	 34	 53	 48258	 10974	 3292	 38	 184	 2944	
2030	 30	 72	 0.609	 34	 53	 48258	 9987	 2996	 35	 167	 2679	
2031	 28	 66	 0.554	 34	 53	 48258	 9088	 2726	 32	 152	 2438	
    	  	  	  	  	  	 1678	 814
4	
13030
8	
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APPENDIX 12: PROJECTION OF TB AMONG MIGRANTS COMING TO 
THE UK, 45-64 YEARS OF AGE, (WITH THE INTERVENTION, I.E SCALED 
UP TB SERVICES IN NIGERIA) OVER A PERIOD OF 20 YEARS 
 
Year 	 Smear 
positive 
rate	
Incidence 
rate	
ARI%	 Age 
midpoint	
% of 
entrants	
Number	 Total 
number 
expose
d to TB	
Infection	 Active 
TB	
LTB 
<2yr	
LTB 
>2yr	
2012	 131	 311	 2.620	 54	 23	 20942	 20942	 6283	 65	 221	 5747	
2013	 128	 303	 2.552	 54	 23	 20942	 20942	 6283	 63	 221	 5747	
2014	 123	 292	 2.460	 54	 23	 20942	 20942	 6283	 61	 221	 5747	
2015	 117	 279	 2.347	 54	 23	 20942	 20942	 6283	 58	 221	 5747	
2016	 110	 262	 2.206	 54	 23	 20942	 20942	 6283	 55	 221	 5747	
2017	 103	 244	 2.052	 54	 23	 20942	 20942	 6283	 51	 221	 5747	
2018	 94	 224	 1.887	 54	 23	 20942	 20942	 6283	 47	 221	 5747	
2019	 86	 204	 1.718	 54	 23	 20942	 20942	 6283	 43	 221	 5747	
2020	 78	 186	 1.563	 54	 23	 20942	 17676	 5303	 39	 187	 4851	
2021	 71	 169	 1.422	 54	 23	 20942	 16085	 4825	 35	 170	 4414	
2022	 65	 154	 1.294	 54	 23	 20942	 14637	 4391	 32	 155	 4017	
2023	 59	 140	 1.178	 54	 23	 20942	 13320	 3996	 29	 141	 3656	
2024	 54	 127	 1.072	 54	 23	 20942	 12121	 3636	 27	 128	 3327	
2025	 49	 116	 0.975	 54	 23	 20942	 11030	 3309	 24	 116	 3027	
2026	 44	 105	 0.888	 54	 23	 20942	 10038	 3011	 22	 106	 2755	
2027	 40	 96	 0.808	 54	 23	 20942	 9134	 2740	 20	 96	 2507	
2028	 37	 87	 0.735	 54	 23	 20942	 8312	 2494	 18	 88	 2281	
2028	 33	 79	 0.669	 54	 23	 20942	 7564	 2269	 17	 80	 2076	
2030	 30	 72	 0.609	 54	 23	 20942	 6883	 2065	 15	 73	 1889	
2031	 28	 66	 0.554	 54	 23	 20942	 6264	 1879	 14	 66	 1719	
    	  	  	  	  	  	 736	 3173	 82498	
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APPENDIX 13: PROJECTION OF TB AMONG MIGRANTS COMING TO THE UK, 
65+ YEARS OF AGE, (WITH THE INTERVENTION, I.E SCALED UP TB SER-
VICES IN NIGERIA) OVER A PERIOD OF 20 YEARS 
 
 Year	 Smear 
positive 
rate	
Incidence 
rate	
ARI%	 Age 
midpoint	
% of 
entrants	
Number	 Total 
number 
expose
d to TB	
Infection	 Active 
TB	
LTB 
<2yr	
LTB 
>2yr	
2012	 131	 311	 2.620	 65	 4	 3642	 3642	 1093	 11	 32	 1006	
2013	 128	 303	 2.552	 65	 4	 3642	 3642	 1093	 11	 32	 1006	
2014	 123	 292	 2.460	 65	 4	 3642	 3642	 1093	 11	 32	 1006	
2015	 117	 279	 2.347	 65	 4	 3642	 3642	 1093	 10	 32	 1006	
2016	 110	 262	 2.206	 65	 4	 3642	 3642	 1093	 10	 32	 1006	
2017	 103	 244	 2.052	 65	 4	 3642	 3642	 1093	 9	 32	 1006	
2018	 94	 224	 1.887	 65	 4	 3642	 3642	 1093	 8	 32	 1006	
2019	 86	 204	 1.718	 65	 4	 3642	 3642	 1093	 7	 32	 1006	
2020	 78	 186	 1.563	 65	 4	 3642	 3642	 1093	 7	 32	 1006	
2021	 71	 169	 1.422	 65	 4	 3642	 3642	 1093	 6	 32	 1006	
2022	 65	 154	 1.294	 65	 4	 3642	 3642	 1093	 6	 32	 1006	
2023	 59	 140	 1.178	 65	 4	 3642	 2788	 837	 5	 24	 770	
2024	 54	 127	 1.072	 65	 4	 3642	 2537	 761	 5	 22	 701	
2025	 49	 116	 0.975	 65	 4	 3642	 2309	 693	 4	 20	 638	
2026	 44	 105	 0.888	 65	 4	 3642	 2101	 630	 4	 18	 580	
2027	 40	 96	 0.808	 65	 4	 3642	 1912	 574	 3	 17	 528	
2028	 37	 87	 0.735	 65	 4	 3642	 1740	 522	 3	 15	 481	
2028	 33	 79	 0.669	 65	 4	 3642	 1583	 475	 3	 14	 437	
2030	 30	 72	 0.609	 65	 4	 3642	 1441	 432	 3	 13	 398	
2031	 28	 66	 0.554	 65	 4	 3642	 1311	 393	 2	 11	 362	
    	  	  	  	  	  	 128	 507	 15963	
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APPENDIX 14: PROJECTION OF FUNDS IN GB £ REQUIRED FOR SCALING UP 
TB CONTROL SERVICES AND PROGRAMME IN NIGERIA OVER A PERIOD OF 
20 YEARS 
 
 
 2012	 2013	 2014	 2015	 2016	 2017	 2018	 2019	 2020	 2021	
INTERVE
NTION: 
TOTAL 
COST in 
GB £	
76,822
,658	
107,83
8,232	
154,54
9,540	
203,89
0,020	
201,31
8,491	
198,73
7,485	
196,15
2,790	
193,56
9,808	
190,99
3,581	
188,42
8,805	
AVAILABL
E 
RESOURC
ES in GB £	
76,822
,658	
84,300,
246	
95,127,
979	
106,50
9,033	
106,70
6,395	
106,83
1,498	
106,88
9,477	
106,88
5,183	
106,82
3,196	
106,70
7,844	
FUNDING 
GAP	 0	
23,537,
986	
59,421,
561	
97,380,
987	
94,612,
096	
91,905,
987	
89,263,
313	
86,684,
626	
84,170,
385	
81,720,
961	
FUNDING 
GAP 
(DISCOUN
TED)	
0	 22,831,846	
57,638,
914	
94,459,
558	
91,773,
733	
89,148,
807	
86,585,
413	
84,084,
087	
81,645,
273	
79,269,
332	
 
	
	
	
 2022	 2023	 2024	 2025	 2026	 2027	 2028	 2029	 2030	 2031	
INTERVE
NTION: 
TOTAL 
COST in 
GB £	
183,12
3,724	
178,04
4,917	
173,18
4,575	
168,53
5,199	
164,08
9,585	
159,84
0,818	
155,78
2,256	
151,90
7,527	
148,21
0,513	
144,68
5,342	
AVAILAB
LE 
RESOURC
ES in GB £	
105,16
5,145	
103,68
0,204	
102,25
0,860	
100,87
5,030	
99,550,
711	
98,275,
975	
97,048,
965	
95,867,
894	
94,731,
042	
93,636,
754	
FUNDING 
GAP	
77,958,
579	
74,364,
713	
70,933,
716	
67,660,
169	
64,538,
874	
61,564,
843	
58,733,
292	
56,039,
634	
53,479,
471	
51,048,
588	
FUNDING 
GAP 
(DISCOUN
TED)	
75,619,
822	
72,133,
772	
68,805,
704	
65,630,
364	
62,602,
708	
59,717,
898	
56,971,
293	
54,358,
445	
51,875,
086	
49,517,
130	
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APPENDIX 15: PROJECTION OF TREATMENT COVERAGE AND TB CON-
TROL WITH AND WITHOUT INTERVENTION IN NIGERIA OVER A PE-
RIOD OF 20 YEARS 
 
Year	 2012	 2013	 2014	 2015	 2016	 2017	 2018	 2019	 2020	 2021	
A- EXPECTED 
NUMBER OF 
TB CASES, 
WITHOUT 
INTERVENTIO
N	
          
Expected 
Number of NEW 
smear Positive 
cases to be 
treated	
50,302	 50,170	 50,038	 49,907	 49,776	 49,645	 49,515	 49,385	 49,255	 49,126	
Expected 
Number of NEW 
smear negative 
cases to be 
treated	
51,086	 50,952	 50,819	 50,685	 50,552	 50,420	 50,287	 50,155	 50,024	 49,893	
Total Number of 
New cases 
expected to be 
treated (SS+ and 
SS-)	
101,38
8	
101,12
2	
100,85
7	
100,59
2	
100,32
8	
100,06
5	
99,802	 99,540	 99,279	 99,019	
Total number of 
New cases 
expected NOT to 
be treated ( 
SS+& SS-)	
417,82
3	
416,72
7	
415,63
3	
414,54
3	
413,45
5	
412,37
0	
411,28
8	
410,20
9	
409,13
2	
408,05
9	
Expected 
Number of total 
NEW smear 
Positive cases in 
year (treated and 
not treated)	
218,70
3	
218,12
9	
217,55
7	
216,98
6	
216,41
7	
215,84
9	
215,28
2	
214,71
8	
214,15
4	
213,59
2	
Expected 
Number of total 
NEW smear 
negative cases in 
year (treated and 
not treated)	
300,50
8	
299,72
0	
298,93
3	
298,14
9	
297,36
6	
296,58
6	
295,80
8	
295,03
2	
294,25
8	
293,48
5	
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Total number of 
new cases in a 
year	
519,21
1	
517,84
9	
516,49
0	
515,13
5	
513,78
3	
512,43
5	
511,09
0	
509,74
9	
508,41
2	
507,07
8	
Estimated 
Number of MDR 
TB cases in year 
(treated and not 
treated)	
9,346	 9,321	 9,297	 9,272	 9,248	 9,224	 9,200	 9,175	 9,151	 9,127	
Expected number 
of new cases to 
be treated per 
100,000 
population	
61	 59	 58	 56	 55	 53	 52	 51	 49	 48	
Expected number 
of new cases 
NOT to be 
treated per 
100,000 
population	
250	 244	 237	 231	 225	 219	 214	 208	 203	 197	
Reduction (from 
2012 rate) in 
incidence 
per100,000 in 
percentage	
0%	 -8%	 -16%	 -24%	 -31%	 -38%	 -45%	 -52%	 -59%	 -66%	
B- EXPECRED 
NUMBER OF 
TB CASES, 
WITH 
INTERVENTIO
N	
          
Expected 
Number of NEW 
smear Positive 
cases to be 
treated	
50302	 71983	 10766
2	
14724
4	
14173
1	
13497
3	
12715
6	
11848
9	
110413	 10288
7	
Expected 
Number of NEW 
smear negative 
cases to be 
treated	
51086	 89916	 14793
2	
20232
0	
19474
5	
18546
0	
17471
8	
16280
9	
15171
2	
14137
1	
Total Number of 
New cases 
expected to be 
treated (SS+ and 
SS-)	
10138
8	
16189
9	
25559
4	
34956
4	
33647
6	
32043
3	
30187
3	
28129
8	
26212
5	
24425
8	
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Total number of 
New cases 
expected NOT to 
be treated 
(SS+&SS-)	
41782
3	
35595
0	
25559
4	
14981
3	
14420
4	
13732
8	
12937
4	
12055
6	
112339	 10468
2	
Expected 
Number of total 
NEW smear 
Positive cases in 
year (treated and 
not treated)	
21870
3	
21812
9	
21532
3	
21034
8	
20247
3	
19281
9	
18165
1	
16927
0	
15773
2	
14698
1	
Expected 
Number of total 
NEW smear 
negative cases in 
year (treated and 
not treated)	
30050
8	
29972
0	
29586
4	
28902
8	
27820
7	
26494
2	
24959
7	
23258
4	
21673
1	
20195
9	
Total number of 
new cases in a 
year	
519211	 51784
9	
511187	 49937
7	
48068
0	
45776
1	
43124
8	
40185
4	
37446
4	
34894
0	
Estimated 
Number of MDR 
TB cases in year 
(treated and not 
treated)	
9346	 9321	 9201	 8989	 8652	 8240	 7762	 7233	 6740	 6281	
Expected number 
of new cases to 
be treated per 
100,000 
population	
61	 95	 146	 195	 183	 170	 157	 143	 130	 118	
Expected number 
of new cases 
NOT to be 
treated per 
100,000 
population	
250	 208	 146	 84	 79	 73	 67	 61	 56	 51	
Reduction (from 
2012 rate) in 
incidence 
per100,000 in 
percentage	
0%	 -8%	 -19%	 -32%	 -49%	 -67%	 -87%	 -107%	 -125%	 -142%	
Mortality and 
morbidity 
averted	
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NUMBER OF 
CASES 
AVERTED FOR 
THE YEAR 	
0	 0	 5,303	 15,758	 33,103	 54,674	 79,843	 107,89
5	
133,94
8	
158,13
7	
CUMMULATIV
E NUMBER OF 
CASES 
AVERTED FOR 
THE YEAR	
0	 0	 5,303	 21,061	 54,164	 108,83
7	
188,68
0	
296,57
5	
430,52
3	
588,66
1	
NUMBER OF 
DEATHS 
AVERTED FOR 
THE YEAR	
0	 23,095	 61,451	 102,48
8	
106,28
8	
111,07
7	
116,70
8	
123,01
5	
128,85
5	
134,26
0	
CUMMULATIV
E NUMBER OF 
DEATHS 
AVERTED FOR 
THE YEAR	
0	 23,095	 84,546	 187,03
5	
293,32
2	
404,39
9	
521,10
7	
644,12
3	
772,97
8	
907,23
8	
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APPENDIX 16: PROJECTION OF TREATMENT COVERAGE AND TB CONTROL 
WITH AND WITHOUT INTERVENTION IN NIGERIA OVER A PERIOD OF 20 
YEARS 
 
Year	 2022	 2023	 2024	 2025	 2026	 2027	 2028	 2029	 2030	 2031	
A- 
EXPECTED 
NUMBER 
OF TB 
CASES, 
WITHOUT 
INTERVENT
ION	
          
Expected 
Number of 
NEW smear 
Positive cases 
to be treated	
48,997	 48,869	 48,740	 48,613	 48,485	 48,358	 48,231	 48,104	 47,978	 47,852	
Expected 
Number of 
NEW smear 
negative cases 
to be treated	
49,762	 49,631	 49,501	 49,371	 49,241	 49,112	 48,983	 48,855	 48,727	 48,599	
Total Number 
of New cases 
expected to be 
treated (SS+ 
and SS-)	
98,759	 98,500	 98,241	 97,984	 97,726	 97,470	 97,214	 96,959	 96,705	 96,451	
Total number 
of New cases 
expected NOT 
to be treated ( 
SS+&SS-)	
406,98
8	
405,92
0	
404,85
5	
403,79
3	
402,73
3	
401,67
6	
400,62
2	
399,57
1	
398,52
3	
397,47
7	
Expected 
Number of 
total NEW 
smear Positive 
cases in year 
(treated and 
not treated)	
213,03
2	
212,47
3	
211,91
5	
211,35
9	
210,80
5	
210,25
1	
209,70
0	
209,14
9	
208,60
1	
208,05
3	
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Expected 
Number of 
total NEW 
smear 
negative cases 
in year 
(treated and 
not treated)	
292,71
5	
291,94
7	
291,18
1	
290,41
7	
289,65
5	
288,89
5	
288,13
7	
287,38
1	
286,62
7	
285,87
5	
Total number 
of new cases 
in a year	
505,74
7	
504,42
0	
503,09
6	
501,77
6	
500,46
0	
499,14
6	
497,83
7	
496,53
0	
495,22
7	
493,92
8	
Estimated 
Number of 
MDR TB 
cases in year 
(treated and 
not treated)	
9,103	 9,080	 9,056	 9,032	 9,008	 8,985	 8,961	 8,938	 8,914	 8,891	
Expected 
number of 
new cases to 
be treated per 
100,000 
population	
47	 45	 44	 43	 42	 41	 40	 39	 38	 37	
Expected 
number of 
new cases 
NOT to be 
treated per 
100,000 
population	
192	 187	 182	 178	 173	 169	 164	 160	 156	 152	
Reduction 
(from 2012 
rate) in 
incidence 
per100,000 in 
percentage	
-72%	 -78%	 -84%	 -90%	 -96%	 -102%	 -107%	 -112%	 -117%	 -122%	
B- 
EXPECRED 
NUMBER 
OF TB 
CASES, 
WITH 
INTERVENT
ION	
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Expected 
Number of 
NEW smear 
Positive cases 
to be treated	
95874	 89339	 83250	 77576	 72288	 67361	 62770	 58491	 54504	 50789	
Expected 
Number of 
NEW smear 
negative cases 
to be treated	
131735	 122756	 114389	 106592	 99327	 92557	 86248	 80370	 74892	 69787	
Total Number 
of New cases 
expected to be 
treated (SS+ 
and SS-)	
227609	 212096	 197639	 184168	 171615	 159918	 149018	 138861	 129396	 120576	
Total number 
of New cases 
expected NOT 
to be treated 
(SS+&SS-)	
97547	 90898	 84703	 78929	 73549	 68536	 63865	 59512	 55455	 51676	
Expected 
Number of 
total NEW 
smear Positive 
cases in year 
(treated and 
not treated)	
136963	 127628	 118929	 110822	 103269	 96230	 89671	 83559	 77864	 72556	
Expected 
Number of 
total NEW 
smear 
negative cases 
in year 
(treated and 
not treated)	
188193	 175366	 163413	 152275	 141896	 132224	 123212	 114814	 106988	 99696	
Total number 
of new cases 
in a year	
325156	 302994	 282342	 263097	 245165	 228454	 212883	 198373	 184852	 172252	
Estimated 
Number of 
MDR TB 
cases in year 
(treated and 
not treated)	
5853	 5454	 5082	 4736	 4413	 4112	 3832	 3571	 3327	 3101	
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Expected 
number of 
new cases to 
be treated per 
100,000 
population	
108	 98	 89	 81	 74	 67	 61	 56	 51	 46	
Expected 
number of 
new cases 
NOT to be 
treated per 
100,000 
population	
46	 42	 38	 35	 32	 29	 26	 24	 22	 20	
Reduction 
(from 2012 
rate) in 
incidence 
per100,000 in 
percentage	
-157%	 -171%	 -184%	 -195%	 -206%	 -215%	 -224%	 -232%	 -239%	 -245%	
Mortality and 
morbidity 
averted	
          
NUMBER OF 
CASES 
AVERTED 
FOR THE 
YEAR 	
180,59
1	
201,42
6	
220,75
5	
238,67
9	
255,29
5	
270,69
2	
284,95
4	
298,15
8	
310,37
6	
321,67
6	
CUMMULAT
IVE 
NUMBER OF 
CASES 
AVERTED 
FOR THE 
YEAR	
769,25
1	
970,67
7	
1,191,4
32	
1,430,1
11	
1,685,4
06	
1,956,0
98	
2,241,0
52	
2,539,2
10	
2,849,5
85	
3,171,2
61	
NUMBER OF 
DEATHS 
AVERTED 
FOR THE 
YEAR	
139,25
9	
143,88
0	
148,14
9	
152,09
0	
155,72
5	
159,07
6	
162,16
2	
165,00
1	
167,61
1	
170,00
6	
CUMMULAT
IVE 
NUMBER OF 
DEATHS 
AVERTED 
FOR THE 
YEAR	
1,046,4
96	
1,190,3
76	
1,338,5
24	
1,490,6
14	
1,646,3
39	
1,805,4
16	
1,967,5
78	
2,132,5
79	
2,300,1
90	
2,470,1
96	
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APPENDIX 17: SENSITIVITY ANALYSIS TABLE FOR VARIABLE ‘PRO-
PORTION OF ENTRANTS/MIGRANTS THAT ARE HIV POSITIVES 
(PPHIV) 
 
ppHI
V	
STRATEG
Y	
COST	 EFF	 CE	 INCRCOS
T	
INCREF
F	
INCRCE	 DOMINATE
D	
0	 NOTHING	 64.8226	 17.2502
8	
3.75777	 0	 0	 0	  
0	 Investment 
in Nigeria 
TB control	
251.4024
8	
17.3041
2	
14.5284
8	
186.57988	 0.05384	 3465.45014	  
0	 Present 
practice 
(Chest x ray 
screening at 
the airport)	
269.2763
2	
17.2660
9	
15.5956
7	
17.87384	 -0.03803	 -469.98846	 (Dominated)	
0	 IGRA	 619.1050
4	
17.3116
5	
35.7623
4	
367.70256	 0.00753	 48847.1948
5	
 
0.025	 NOTHING	 68.43252	 17.2500
1	
3.9671	 0	 0	 0	  
0.025	 Investment 
in Nigeria 
TB control	
253.6275
2	
17.3039
5	
14.6572	 185.19501	 0.05394	 3433.13994	  
0.025	 Present 
practice 
(Chest x ray 
screening at 
the airport)	
285.7366
4	
17.2647
7	
16.5502
8	
32.10912	 -0.03919	 -819.32899	 (Dominated)	
0.025	 IGRA	 668.7791
5	
17.3069
2	
38.6422
9	
415.15162	 0.00297	 139785.740
9	
 
0.05	 NOTHING	 72.02958	 17.2497
4	
4.17569	 0	 0	 0	  
0.05	 Investment 
in Nigeria 
TB control	
255.8446
4	
17.3037
9	
14.7854
7	
183.81506	 0.05405	 3401.06238	  
0.05	 Present 
practice 
(Chest x ray 
screening at 
the airport)	
301.9930
5	
17.2634
5	
17.4932	 46.1484	 -0.04034	 -1144.04	 (Dominated)	
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0.05	 IGRA	 717.7416
6	
17.3022
5	
41.4825
7	
461.89702	 -0.00154	 -
299503.428
6	
(Dominated)	
0.075	 NOTHING	 75.61385	 17.2494
8	
4.38355	 0	 0	 0	  
0.075	 Investment 
in Nigeria 
TB control	
258.0538
8	
17.3036
2	
14.9132
8	
182.44002	 0.05415	 3369.21508	  
0.075	 Present 
practice 
(Chest x ray 
screening at 
the airport)	
318.0482
5	
17.2621
5	
18.4246	 59.99437	 -0.04148	 -
1446.47681	
(Dominated)	
0.075	 IGRA	 766.0024
1	
17.2976
2	
44.2837	 507.94854	 -0.00601	 -
84527.8601
4	
(Dominated)	
0.1	 NOTHING	 79.18541	 17.2492
1	
4.59067	 0	 0	 0	  
0.1	 Investment 
in Nigeria 
TB control	
260.2552
7	
17.3034
6	
15.0406
5	
181.06987	 0.05425	 3337.5957	  
0.1	 Present 
practice 
(Chest x ray 
screening at 
the airport)	
333.9049
3	
17.2608
6	
19.3446
3	
73.64966	 -0.0426	 -
1728.70506	
(Dominated)	
0.1	 IGRA	 813.5711
2	
17.2930
3	
47.0461
9	
553.31585	 -0.01043	 -
53041.9388
6	
(Dominated)	
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APPENDIX 18: SENSITIVITY ANALYSIS TABLE VARIABLE ‘PROPOR-
TION OF ENTRANTS/MIGRANTS THAT HAVE DRUG RESISTANT TB’ 
(PDRA) 
 
        
pDRA	 STRATEGY	 COST	 EFF	 CE	 INCRCOST	 INCREFF	 INCRCE	
0	 NOTHING	 70.36942	 17.24979	 4.07944	 0	 0	 0	
0	 Present practice (Chest 
x ray screening at the 
airport)	
227.90795	 17.2637	 13.20157	 157.53852	 0.01392	 11320.64743	
0	 Investment in Nigeria 
TB control	
254.8257	 17.30382	 14.72656	 26.91775	 0.04011	 671.04742	
0	 IGRA	 717.58383	 17.30225	 41.47344	 462.75813	 -0.00157	 -295685.916	
0.02	 NOTHING	 72.21404	 17.24974	 4.18638	 0	 0	 0	
0.02	 Present practice (Chest 
x ray screening at the 
airport)	
229.11991	 17.26366	 13.2718	 156.90587	 0.01393	 11267.17984	
0.02	 Investment in Nigeria 
TB control	
255.95786	 17.30379	 14.79201	 26.83795	 0.04012	 668.90247	
0.02	 IGRA	 717.7592	 17.30225	 41.48358	 461.80134	 -0.00154	 -
299934.5811	
0.04	 NOTHING	 74.05866	 17.24969	 4.29333	 0	 0	 0	
0.04	 Present practice (Chest 
x ray screening at the 
airport)	
230.33187	 17.26362	 13.34203	 156.27321	 0.01394	 11213.7883	
0.04	 Investment in Nigeria 
TB control	
257.09001	 17.30376	 14.85747	 26.75815	 0.04013	 666.75854	
0.04	 IGRA	 717.93456	 17.30224	 41.49373	 460.84455	 -0.00151	 -
304325.5184	
0.06	 NOTHING	 75.90326	 17.24964	 4.40028	 0	 0	 0	
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0.06	 Present practice (Chest 
x ray screening at the 
airport)	
231.54382	 17.26358	 13.41227	 155.64056	 0.01395	 11160.47263	
0.06	 Investment in Nigeria 
TB control	
258.22216	 17.30373	 14.92292	 26.67834	 0.04014	 664.61563	
0.06	 IGRA	 718.10992	 17.30224	 41.50388	 459.88776	 -0.00149	 -
308866.0086	
0.08	 NOTHING	 77.74786	 17.24959	 4.50723	 0	 0	 0	
0.08	 Present practice (Chest 
x ray screening at the 
airport)	
232.75577	 17.26354	 13.4825	 155.0079	 0.01396	 11107.23267	
0.08	 Investment in Nigeria 
TB control	
259.35431	 17.30369	 14.98838	 26.59854	 0.04015	 662.47375	
0.08	 IGRA	 718.28528	 17.30223	 41.51403	 458.93098	 -0.00146	 -
313563.8231	
0.1	 NOTHING	 79.59246	 17.24954	 4.61418	 0	 0	 0	
0.1	 Present practice (Chest 
x ray screening at the 
airport)	
233.96771	 17.2635	 13.55274	 154.37525	 0.01397	 11054.06825	
0.1	 Investment in Nigeria 
TB control	
260.48645	 17.30366	 15.05383	 26.51874	 0.04016	 660.33288	
0.1	 IGRA	 718.46065	 17.30223	 41.52417	 457.9742	 -0.00144	 -
318427.2851	
0.12	 NOTHING	 81.43704	 17.24949	 4.72113	 0	 0	 0	
0.12	 Present practice (Chest 
x ray screening at the 
airport)	
235.17964	 17.26346	 13.62297	 153.7426	 0.01398	 11000.97923	
0.12	 Investment in Nigeria 
TB control	
261.61859	 17.30363	 15.11929	 26.43894	 0.04017	 658.19303	
0.12	 IGRA	 718.63601	 17.30222	 41.53432	 457.01742	 -0.00141	 -
323465.3116	
0.14	 NOTHING	 83.28162	 17.24944	 4.82808	 0	 0	 0	
0.14	 Present practice (Chest 
x ray screening at the 
airport)	
236.39157	 17.26343	 13.6932	 153.10996	 0.01399	 10947.96543	
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0.14	 Investment in Nigeria 
TB control	
262.75072	 17.3036	 15.18474	 26.35915	 0.04018	 656.0542	
0.14	 IGRA	 718.81137	 17.30222	 41.54447	 456.06065	 -0.00139	 -
328687.4709	
0.16	 NOTHING	 85.12619	 17.24939	 4.93503	 0	 0	 0	
0.16	 Present practice (Chest 
x ray screening at the 
airport)	
237.6035	 17.26339	 13.76344	 152.47731	 0.014	 10895.0267	
0.16	 Investment in Nigeria 
TB control	
263.88285	 17.30357	 15.25019	 26.27935	 0.04019	 653.91639	
0.16	 IGRA	 718.98673	 17.30221	 41.55462	 455.10388	 -0.00136	 -
334104.0493	
0.18	 NOTHING	 86.97075	 17.24934	 5.04198	 0	 0	 0	
0.18	 Present practice (Chest 
x ray screening at the 
airport)	
238.81542	 17.26335	 13.83367	 151.84467	 0.01401	 10842.16288	
0.18	 Investment in Nigeria 
TB control	
265.01497	 17.30354	 15.31565	 26.19955	 0.0402	 651.7796	
0.18	 IGRA	 719.16208	 17.30221	 41.56476	 454.14711	 -0.00134	 -
339726.1067	
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APPENDIX 19: DECISION TREE AND  SENSITIVITY ANALYSES 
	
Model framework and decision tree 
The approach employed is the use of Main decision branches. A decision-analysis model incorpo-
rating multiple Markov processes using TreeAge™ Software. A decision node compares the 
four competing alternative strategies. 
 
Description	 Code	 Estimates	 Rang
e	
Reference	
-Funding gap for scaling up TB control to 100% 
implementation (based on the WHO Stop TB 
strategy) in Nigeria over 20 years	
cInvTBn
g	
£323,198,394 NB: 
In this study only 
25% of this total 
cost is assumed to 
be paid by the UK 
government)	
 Calculated	
-Cost of chest x-ray screening at the airport	 cXraySc	 £28 (2008 £)	  143	
-Cost of IGRA (QuantiFERON) screening at the 
airport	
cIGRAsc	 £45 (2008 £)	 22.5-
90	
143	
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A. Investment in Nigeria TB control 
 
Description	 Code	 Estimates	 Reference	
Initial probability of drug sensitive latent 
TB (Recent)- Alternative 1	
pIn2DSLr	 0.008033389	 Calculated 	
Initial probability of drug sensitive latent 
TB (Longstanding) - Alternative 1 	
pIn2DSLl	 0.134301825	 Calculated	
Initial probability of drug resistant latent 
TB (Recent) - Alternative 1	
pIn2DRLr	 0.000147252	 Calculated	
Initial probability of drug resistant latent 
TB (Longstanding) - Alternative 1	
pIn2DRLl	 0.002461744	 Calculated	
Initial probability of drug sensitive active 
TB- Alternative 1 	
pIn2DSA	 0.001716078	 Calculated	
Initial probability of drug resistant active 
TB- Alternative 1	
pIn2DRA	 0.000031455	 Calculated	
Initial probability of NO TB- Alternative 
1	
pIn2NoTB	 0.853308257	 Calculated	
Initial probability of cured TB- 
Alternative 1	
pIcured	 0	 Assumed	
Initial probability of death from TB- 
Alternative 1	
pIdeath	 0	 Assumed	
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B. Present practice (CXR screening at the airport) 
 
 
CXR screening	   pScr	 0.2162	  
a) True Positives   pTPxRay	 0.0122690081 	 Calculated	
b) False Positives   pFPxRay	 0.5641932951	 Calculated	
c) True Negatives   pTNxRay	 0.3341794321	 Calculated	
d) False Negatives   pFNxRay	 0.0893582647	 Calculated	
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i. True negative, CXR 
 
- For true negative chest x ray screenings, the probability of being active TB is 
‘pTNATB’ 
Chest X ray screening	    
True Negative Active TB	   pTNATB	 1	 Calculated	
True Negative Latent TB	   pTNLTB	 0	 Calculated	
- 	
- 	
 
ii. False negative, chest x ray (Active TB)	
 
Chest X ray screening	    
False  Negative Active TB	   pFTATB	 0	 Calculated	
False  Negative Latent TB	   pFNLTB	 1	 Calculated	
 118 
 
 
 
- For false negative chest x ray screenings, the probability of being active TB is 
‘pFNATB’ 
- Among false negatives active TB, the probability of active drug sensitive TB = 
pIn1DSA/(pIn1DSA+pIn1DRA)  
And  
- probability of active drug resistant TB = pIn1DRA/(pInDSA+pIn1DRA) 
Where 
- ‘pIn1DSA’ is the initial annual probability of drug sensitive active TB and ‘pInDRA’ 
initial annual probability of drug resistant active TB in absence of any significant 
change in Nigeria TB control. 
- The probability of false negative being a cured TB is also assumed to be zero. 
iii. False negative, chest x ray (Latent TB) 
 
- Among false negatives latent TB, the probability of recently acquired drug sensitive 
latent TB = pIn1DSLr/(pIn1DSLr+pIn1DSLl+pIn1DRLr+pIn1DRLl)  
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- probability of longstanding drug sensitive latent TB = 
pIn1DSLl/(pIn1DSLr+pIn1DSLl+pIn1DRLr+pIn1DRLl)  
- probability of recently acquired drug resistant latent TB = 
pIn1DRLr/(pIn1DSLr+pIn1DSLl+pIn1DRLr+pIn1DRLl)  
And 
- probability of longstanding drug resistant latent TB = 
pIn1DRLl/(pIn1DSLr+pIn1DSLl+pIn1DRLr+pIn1DRLl)  
Where  
- ‘pIn1DSA’ is the initial annual probability of drug sensitive active TB and ‘pInDRA’ 
initial annual probability of drug resistant active TB in absence of any significance 
change in Nigeria TB control. 
- The probability of false negative being a cured TB is also assumed to be zero. 
iv. True positive, chest x ray (Active TB) 
 
 
Chest X ray screening	    
True Positive Active TB	   pTPATB	 0.099822921
6	
Calculated	
True Positive Latent TB	   pTPLTB	 0.900177078
4	
Calculated	
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- For true positive chest x ray screenings, the probability of being active TB is 
‘pTPATB’ 
- Among true positive active TB, the probability of active drug sensitive TB = 
pIn1DSA/(pIn1DSA+pIn1DRA)  
And  
- The probability of active drug resistant TB = pIn1DRA/(pInDSA+pIn1DRA) 
Where 
- ‘pIn1DSA’ is the initial annual probability of drug sensitive active TB and ‘pInDRA’ 
initial annual probability of drug resistant active TB in absence of any significant 
change in Nigeria TB control. 
- The probability of true positive being a cured TB is also assumed to be zero. 
v. True positive, chest x ray (Latent TB) 
 
- Among true positive latent TB, the probability of recently acquired drug sensitive 
latent TB = pIn1DSLr/(pIn1DSLr+pIn1DSLl+pIn1DRLr+pIn1DRLl)  
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- probability of longstanding drug sensitive latent TB = 
pIn1DSLl/(pIn1DSLr+pIn1DSLl+pIn1DRLr+pIn1DRLl)  
- probability of recently acquired drug resistant latent TB = 
pIn1DRLr/(pIn1DSLr+pIn1DSLl+pIn1DRLr+pIn1DRLl)  
And 
- The probability of longstanding drug resistant latent TB = 
pIn1DRLl/(pIn1DSLr+pIn1DSLl+pIn1DRLr+pIn1DRLl)  
Where  
- ‘pIn1DSA’ is the initial annual probability of drug sensitive active TB and ‘pInDRA’ 
initial annual probability of drug resistant active TB in absence of any significant 
change in Nigeria TB control. 
- The probability of true positive being a cured TB is also assumed to be zero. 
vi. False positive for chest x ray 
 
Chest X ray screening	    
False  Positive Active TB	     pFPATB	 0.291736610
7	
Calculated	
False  Positive Latent TB	     pFPLTB	 0.708263389
3	
Calculated	
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- For false positives chest x ray screenings, the probability of being active TB is 
‘pFPATB’. 
- It’s assumed that the false positive latent TB is deliberately let to pass without any 
further investigation. 
vii. Migrants’ not screened at the airport 
 
Description	   Code	 Estimates	 Reference	
Initial probability of drug sensitive latent TB 
(Recent)- Scenario 2 (Situation remains same  in 
Nig.)	
  pIn1DSLr	 0.011160324	 Calculated	
Initial probability of drug sensitive latent TB 
(Longstanding) - Scenario 2 (Situation remains same  
in Nig.)	
  pIn1DSLl	 0.186830273	 Calculated	
Initial probability of drug resistant latent TB 
(Recent) - Scenario 2 (Situation remains same  in 
Nig.)	
  pIn1DRLr	 0.000204568	 Calculated	
Initial probability of drug resistant latent TB 
(Longstanding) - Scenario 2 (Situation remains same  
in Nig.)	
  pIn1DRLl	 0.003409924	 Calculated	
Initial probability of drug sensitive active TB- 
Scenario 2 (Situation remains same  in Nig.)	
  pIn1DSA	 0.002405366	 Calculated	
Initial probability of drug resistant active TB- 
Scenario 2 (Situation remains same  in Nig.)	
  pIn1DRA	 0.000044090	 Calculated	
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Initial probability of NO TB- Scenario 2 (Situation 
remains same  in Nig.)	
  pIn1NoTB	 0.796745454	 Calculated	
Initial probability of cured TB- Scenario 2 (Situation 
remains same  in Nig.) 	
  pIcured	 0	 Assumed	
Initial probability of death from TB- Scenario 2 
(Situation remains same in Nig.)	
  pIdeath	 0	 Assumed	
 
For entrants that are not screened at the point of entry, and no scale up of TB control in 
Nigeria. 
- ‘pIn1NoTB’ is the initial annual probability of Nigerian entrant being not infected with 
any form of TB. 
- ‘pIcured’, the initial annual probability of Nigeria entrants being cured for previous TB 
infection. 
- ‘pIn1DSLr’, the initial annual probability of Nigerian entrant having drug sensitive 
latent TB infected less than 2 years (recent infection) before entering the UK. 
- ‘pIn1DSLl’, the initial annual probability of Nigerian entrant having drug sensitive 
latent TB infected more than 2 years (longstanding infection) before entering the UK. 
- ‘pIn1DRLr’, the initial annual probability of Nigerian entrant having drug resistant 
latent TB ‘recently’ infected before entering the UK. 
- ‘pIn1DRLl’, the initial annual probability of Nigerian entrant having ‘longstanding’ 
drug resistant latent TB before entering the UK. 
- ‘pIn1DSA’, the initial annual probability of Nigerian entrant having drug sensitive 
active TB on entering the UK. 
- ‘pIn1DRA’, the initial annual probability of Nigerian entrant having drug resistant 
active TB on entering the UK. 
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- ‘pIdead’ is the probability of been dead on arrival to the UK. 
 
C. Interferon Gamma Release Assay screening 
 
	
	
IGRA screening	   pScrIGRA	 0.90	  
a) True Positives   pTPIGRA	 0.0963866946	 Calculated	
b) False Positives   pFPIGRA	 0.0089837274	 Calculated	
c) True Negatives   pTNIGRA	 0.8893889997	 Calculated	
d) False Negatives   pFNIGRA	 0.0052405783	 Calculated	
 
	
- ‘pScrIGRA’ is the probability of entrant been interferon gamma release assay (IGRA) 
screened at point of entry. 
- ‘pTNIGRA’ the probability of IGRA true negative result for either active or latent 
infections. 
- ‘pTPIGRA’ the probability of IGRA screening result true positive for either active or 
latent infections. 
- ‘pFPIGRA’ the probability of IGRA screening result false positive for either active or 
latent infections. 
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i. True Negative, IGRA 
 
IGRA Screening	    
True Negative Active TB	   pTNATBIGRA	 0.5551985904	 Calculated	
True Negative Latent TB	   pTNLTBIGRA	 0.4448014096	 Calculated	
 
 
 
- For true negative IGRA screenings, the probability of being active TB is 
‘pTNATBIGRA’	
ii. False Negative, IGRA (Active TB) 
	
	
IGRA Screening	    
False Negative Active TB	   pFNATBIGRA	 0.0420661700	 Calculated	
False Negative Latent TB	   pFNLTBIGRA	 0.9579338300	 Calculated	
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- For false negative IGRA screenings, the probability of being active TB is 
‘pFNATBIGRA’ 
- Among false negatives active TB, the probability of active drug sensitive TB = 
pIn1DSA/(pIn1DSA+pIn1DRA)  
And  
- The probability of active drug resistant TB = pIn1DRA/(pInDSA+pIn1DRA) 
Where 
- ‘pIn1DSA’ is the initial annual probability of drug sensitive active TB and ‘pInDRA’ 
initial annual probability of drug resistant active TB in absence of any significance 
change in Nigeria TB control. 
- The probability of false negative being a cured TB is also assumed to be zero.	
iii. False negative (Latent TB) 
		 
 
 
- Among false negatives latent TB, the probability of recently acquired drug sensitive 
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latent TB = pIn1DSLr/(pIn1DSLr+pIn1DSLl+pIn1DRLr+pIn1DRLl)  
- The probability of longstanding drug sensitive latent TB = 
pIn1DSLl/(pIn1DSLr+pIn1DSLl+pIn1DRLr+pIn1DRLl)  
- The probability of recently acquired drug resistant latent TB = 
pIn1DRLr/(pIn1DSLr+pIn1DSLl+pIn1DRLr+pIn1DRLl)  
And 
- The probability of longstanding drug resistant latent TB = 
pIn1DRLl/(pIn1DSLr+pIn1DSLl+pIn1DRLr+pIn1DRLl)  
Where  
- ‘pIn1DSA’ is the initial annual probability of drug sensitive active TB and ‘pInDRA’ 
initial annual probability of drug resistant active TB in absence of any significant 
change in Nigeria TB control. 
- The probability of false negative being a cured TB is also assumed to be zero.	
iv. True positive, IGRA (Active TB) 
	
	
IGRA Screening	    
True Positive Active 
TB	
  pTPATBIGRA	 0.0104192512	 Calculated	
True Positive Latent 
TB	
  pTPLTBIGRA	 0.9895807488	 Calculated	
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- For true positive IGRA screenings, the probability of being active TB is 
‘pTPATBIGRA’ 
- Among true positive active TB, the probability of active drug sensitive TB = 
pIn1DSA/(pIn1DSA+pIn1DRA)  
And  
- The probability of active drug resistant TB = pIn1DRA/(pInDSA+pIn1DRA) 
Where 
- ‘pIn1DSA’ is the initial annual probability of drug sensitive active TB and ‘pInDRA’ 
initial annual probability of drug resistant active TB in absence of any significance 
change in Nigeria TB control. 
- The probability of true positive being a cured TB is also assumed to be zero. 		
v. True Positive, IGRA (Latent TB)		 
 
 
 
- Among true positive latent TB, the probability of recently acquired drug sensitive 
latent TB = pIn1DSLr/(pIn1DSLr+pIn1DSLl+pIn1DRLr+pIn1DRLl)  
- probability of longstanding drug sensitive latent TB = 
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pIn1DSLl/(pIn1DSLr+pIn1DSLl+pIn1DRLr+pIn1DRLl)  
- probability of recently acquired drug resistant latent TB = 
pIn1DRLr/(pIn1DSLr+pIn1DSLl+pIn1DRLr+pIn1DRLl)  
And 
- The probability of longstanding drug resistant latent TB = 
pIn1DRLl/(pIn1DSLr+pIn1DSLl+pIn1DRLr+pIn1DRLl)  
Where  
- ‘pIn1DSA’ is the initial annual probability of drug sensitive active TB and ‘pInDRA’ 
initial annual probability of drug resistant active TB in absence of any significant 
change in Nigeria TB control. 
- The probability of true positive being a cured TB is also assumed to be zero. 
vi. False positive, IGRA		 
 
 
IGRA Screening	    
False  Positive Active TB	   pFPATBIGRA	 0.5551985966	 Calculated	
False  Positive Latent TB	   pFPATBIGRA	 0.4448014034	 Calculated	
 
 
- For false positives IGRA screenings, the probability of being active TB is 
‘pFPATBIGRA’. 
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vii. Migrants not screened at airports for IGRA 
 
 
 
For entrants that are not screened at the point of entry, and no scale up of TB control in 
Nigeria. 
- ‘pIn1NoTB’ is the initial annual probability of Nigerian entrant being not infected with 
any form of TB. 
- ‘pIcured’, the initial annual probability of Nigeria entrant being cured for previous TB 
infection. 
- ‘pIn1DSLr’, the initial annual probability of Nigerian entrant having drug sensitive 
latent TB infected less than 2 years (recent infection) before entering the UK. 
- ‘pIn1DSLl’, the initial annual probability of Nigerian entrant having drug sensitive 
latent TB infected more than 2 years (longstanding infection) before entering the UK. 
- ‘pIn1DRLr’, the initial annual probability of Nigerian entrant having drug resistant 
latent TB ‘recently’ infected before entering the UK. 
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- ‘pIn1DRLl’, the initial annual probability of Nigerian entrant having ‘longstanding’ 
drug resistant latent TB before entering the UK. 
- ‘pIn1DSA’, the initial annual probability of Nigerian entrant having drug sensitive 
active TB on entering the UK. 
- ‘pIn1DRA’, the initial annual probability of Nigerian entrant having drug resistant 
active TB on entering the UK. 
- ‘pIdead’ is the probability of been dead on arrival to the UK. 
 
Description	 Code	 Estimates	 Reference	
Initial probability of drug sensitive latent TB (Recent)- 
Scenario 2 (Situation remains same  in Nig.)	
pIn1DSLr	 0.011160324	 Calculated 	
Initial probability of drug sensitive latent TB 
(Longstanding) - Scenario 2 (Situation remains same  in 
Nig.)	
pIn1DSLl	 0.186830273	 Calculated	
Initial probability of drug resistant latent TB (Recent) - 
Scenario 2 (Situation remains same  in Nig.)	
pIn1DRLr	 0.000204568	 Calculated	
Initial probability of drug resistant latent TB 
(Longstanding) - Scenario 2 (Situation remains same  in 
Nig.)	
pIn1DRLl	 0.003409924	 Calculated	
Initial probability of drug sensitive active TB- Scenario 2 
(Situation remains same  in Nig.)	
pIn1DSA	 0.002405366	 Calculated	
Initial probability of drug resistant active TB- Scenario 2 
(Situation remains same  in Nig.)	
pIn1DRA	 0.000044090	 Calculated	
Initial probability of NO TB- Scenario 2 (Situation remains 
same  in Nig.)	
pIn1NoTB	 0.796745454	 Calculated	
Initial probability of cured TB- Scenario 2 (Situation 
remains same  in Nig.) 	
pIcured	 0	 Assumed	
Initial probability of death from TB- Scenario 2 (Situation 
remains same  in Nig.)	
pIdeath	 0	 Assumed	
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D. Nothing (No screening, no intervention in Nigeria) 
 
Description	 Code	 Estimates	 Reference	
Initial probability of drug sensitive latent TB (Recent)- 
Scenario 2 (Situation remains same  in Nig.)	
pIn1DSLr	 0.011160324	 Calculated 	
Initial probability of drug sensitive latent TB 
(Longstanding) - Scenario 2 (Situation remains same in 
Nig.)	
pIn1DSLl	 0.186830273	 Calculated	
Initial probability of drug resistant latent TB (Recent) - 
Scenario 2 (Situation remains same in Nig.)	
pIn1DRLr	 0.000204568	 Calculated	
Initial probability of drug resistant latent TB 
(Longstanding) - Scenario 2 (Situation remains same in 
Nig.)	
pIn1DRLl	 0.003409924	 Calculated	
Initial probability of drug sensitive active TB- Scenario 2 
(Situation remains same in Nig.)	
pIn1DSA	 0.002405366	 Calculated	
Initial probability of drug resistant active TB- Scenario 2 
(Situation remains same in Nig.)	
pIn1DRA	 0.000044090	 Calculated	
Initial probability of NO TB- Scenario 2 (Situation 
remains same in Nig.)	
pIn1NoTB	 0.796745454	 Calculated	
Initial probability of cured TB- Scenario 2 (Situation 
remains same in Nig.) 	
pIcured	 0	 Assumed	
Initial probability of death from TB- Scenario 2 
(Situation remains same in Nig.)	
pIdeath	 0	 Assumed	
 
When no significant change in TB control in Nigeria is achieved and no any form of screening 
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at the point of entry into the UK. 
- ‘pIn1NoTB’ is the initial annual probability of Nigerian entrant being not infected with 
any form of TB. 
- ‘pIcured’, the initial annual probability of Nigeria entrant being cured for previous TB 
infection. 
- ‘pIn1DSLr’, the initial annual probability of Nigerian entrant having drug sensitive 
latent TB infected less than 2 years (recent infection) before entering the UK. 
- ‘pIn1DSLl’, the initial annual probability of Nigerian entrant having drug sensitive 
latent TB infected more than 2 years (longstanding infection) before entering the UK. 
- ‘pIn1DRLr’, the initial annual probability of Nigerian entrant having drug resistant 
latent TB ‘recently’ infected before entering the UK. 
- ‘pIn1DRLl’, the initial annual probability of Nigerian entrant having ‘longstanding’ 
drug resistant latent TB before entering the UK. 
- ‘pIn1DSA’, the initial annual probability of Nigerian entrant having drug sensitive 
active TB on entering the UK. 
- ‘pIn1DRA’, the initial annual probability of Nigerian entrant having drug resistant 
active TB on entering the UK.  
- ‘pIdead’ is the probability of been dead on arrival to the UK. 
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Health states and transitions 
‘No TB infection’ or ‘No TB’ 
 
This is a health state in which there is absence of TB infection. Both initial and incremental 
costs in this state are zero and the utility is ‘uNormal’ which was assumed to be 1.0 QALY. 
Migrants in this state either die from other causes at the end of a year cycle or return back to 
the next cycle as ‘No TB infection’. 
‘Cured TB’  
 
This is a state of having previously experienced TB infection but fully cured. Both initial and 
incremental costs in this state are zero and utility is 0.95 QALY (144), ‘uCured’. Migrants in 
this state either die from other causes, probability of death from other causes, ‘pDdOther’, 
assumed to be 0.015/cycle (40), or return back to the next cycle as ‘Cured TB’. 
‘Dead’ 
 
This is a state of having died from TB infection or any other cause of death. Both initial and 
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incremental costs as well as utility, ‘uDead’ are zero. This is an absorbing state, once in the 
state remain in that state throughout remaining cycles. 
‘Latent DS TB recent infection’ 
 
 
- This is a state of recent acquisition (less than 2 years) of latent drug sensitive TB 
infection.  
- The initial cost per entrant if investment (by bridging funding gap to scale up TB 
services) in Nigeria was estimated as the total fund to be provided (assumed to be 25% 
of the total funding gap) divided by the expected number of migrants coming into the 
UK from Nigeria over the 20 years period, i.e. ‘cNigTBgap/TotNigMig’, which equals 
‘(£326,167,296.39/1,821,040) = £179.11’   
- For the chest x ray and IGRA screening alternatives, cost of screening at the point of 
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entry, ‘cXraySc’ and ‘cIGRAsc’ were estimated as £25 and £45 respectively (143).  
- Both initial and incremental utility, ‘uDSL’, in all strategies is 0.97 QALY (144). 
- Migrants with latent TB are either detected not detected or die from other causes at the 
end of a year cycle. The annual probability of detection, ‘pDecLT’, in unscreened 
migrants and there contacts is assumed to be 0.10 and the probability of detection in 
entrants that were screened on arrival depends on the sensitivity and specificity of the 
screening test. The cost of detection while in the UK, ‘cDecTBinUK’, is assumed to be 
GB £286 (143).   
- The probability of treatment for latent TB when detected in UK, ‘pRxLTB’, is 0.95 
(144, 145). The costs for drug sensitive and resistant latent TB treatment in the UK, 
‘cRxDSL’ and ‘cRxDRL’ are GB £130 (143) and  GB £780 (146 ) respectively while 
the utility for the treatment of both drug sensitive and resistant latent TB, ‘uLTBrx’ 
was assumed to be 0.95 QALY (144). 
- The probability of adverse effect following treatment for drug sensitive and resistant 
latent TB, ‘pAeDSLTBrx’ and ‘pAeDRLTBrx’, are 0.02 (143) and 0.04 (Assumed) 
respectively. The cost and utility for treating the adverse effect, ‘cAeRx’ and 
‘uAeTBrx’ are GB £362 + £1000, ‘cHospitalization’, when hospitalized (3,4) and 0.75 
QALY or 0.50 QALY, ‘uHosp’, when hospitalized (143). The probability of 
hospitalization due to adverse effect, ‘pAeLTBrxH’, is assumed to be 0.15 (147-149). 
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i) ‘Complete treatment’ 
 
- The probability of treatment completion following latent TB treatment is either 
‘pCrxLTBnAe’ estimated as 0.94 (150-153) when there is no serious treatment adverse 
effect or ‘pCrxLTBAe’ estimated as 0.80 (147,148,153) when there is adverse effect.  
- The probabilities of cure following completion of treatment for drug sensitive latent 
TB, ‘pCurDSLRx’, was estimated at 0.65 (154, 155) and assumed to be 0.325, 
‘pCurDRLRx’ when is drug resistant.  
 
 
ii) ‘Not complete treatment’ or ‘default treatment’ 
 
- The probabilities of cure following treatment default for drug sensitive latent TB, 
‘pCurDSLDfx’, was estimated at 0.21 (154) and assumed to be 0.105, coded 
‘pCurDRLDfx’ when is drug resistant.  
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iii) ‘No treatment’ or ‘No detected’ 
 
- The probability of spontaneous cure for latent TB when not detected or detected but 
not treatment was given for drug sensitive latent TB, ‘pSCurLTB’, is assumed to be 
0.20. 
iv)  ‘Not cured’ 
 
- What follows uncured latent TB is significantly influenced by the patient HIV status. 
The probability of Nigerian migrant being HIV positive, ‘ppHIV’, was estimated at 
0.05 based on the HIV prevalence rate in Nigeria. The probability of reactivation of 
‘uncured’ HIV positives recently acquired latent TB, ‘pRalrHIV’ was estimated as 0.33 
per year (40) which is higher than when the subjects are HIV negative, ‘pRalrneg’, 
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0.05 per year (40). 
- The probability of reactivation of ‘uncured’ HIV positives that have longstanding 
latent TB infection, ‘pRallHIV’ was estimated as 0.034 per year (40, 156-158) which is 
higher than when the subjects are HIV negative, ‘pRallneg’, 0.001 per year (23, 40, 
134). 
- Probability of death from latent TB, ‘pDdTBDSL’ or ‘pDdTBDRL’ are assumed to be 
zero and the probability of becoming drug resistant following completed treatment for 
drug sensitive TB, ‘pDRLfromDSL’, is assumed to be 0.09 (52) and probability of 
drug resistant latent TB remaining resistant if uncured is assumed to be 0.99. The 
probability of subject becoming drug resistant latent TB following treatment default 
for drug sensitive latent TB, ‘pDRLfromDSLDfx’, is assumed to be as high as 0.40. 
- The probability of latent TB being drug resistant, ‘pDRL’, was assumed to be 0.018 
based on the reported prevalence of drug resistance in Nigerian population (52) and the 
probability of a latent TB being recently acquired, ‘pTBr’, is estimated to be 0.046. 
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Active TB  
 
 
- The presumed cost per entrant when UK invests (in bridging funding gap to scale up 
TB services) in Nigeria was estimated as the total fund to be provided by UK (which is 
25% of the total funding gap) divided by the expected number of migrants coming into 
the UK from Nigeria over the 20 years period, i.e. ‘cNigTBgap/TotNigMig’, which 
equals ‘(£326,167,296.39/1,821,040) = £179.11’. 
- Both initial and incremental utilities for active TB, ‘uATB’, are 0.68 (146). 
- For the chest x ray and IGRA screening alternatives, cost of screening at the point of 
entry, ‘cXraySc’ and ‘cIGRAsc’ were estimated at £25 and £45 respectively (143).  
- The annual probability of detection of active TB depends on the sensitivity and 
specificity of the screening test, however, when not screened the probability of 
detection of active TB is assumed to be 0.95. 
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- The cost of detection while in the UK, ‘cDecTBinUK’, is assumed to be GB £286 
(143).   
- The probability of treatment for active TB when detected in UK, ‘pRxATB’, is 
assumed to be 1.0.  
- The costs treatment for drug sensitive and resistant active TB in the UK, ‘cRxDSA’ 
and ‘cRxDRA’ are GB £5522 and  GB £31,329 (157) respectively while the utility for 
the treatment of both drug sensitive and resistant active TB, ‘uATBrx’  was assumed to 
be 0.79 QALY (146, 153). 
- The probability of adverse effect following treatment for drug sensitive and resistant 
active TB, ‘pAeDSATBrx’ and ‘pAeDRATBrx’, are 0.02 (143, 158)  and 0.04 
(Assumed) respectively.  
- The cost for treating the adverse effect, ‘cAeRx’ GB £362 + £1000, ‘cHospitalization’, 
when hospitalized (143) 
- Utility for treating the adverse effect and ‘uAeTBrx’ are and 0.75 QALY or 0.50 
QALY, ‘uHosp’, when hospitalized (144).  
- The probability of hospitalization due to adverse effect, ‘pAeATBrxH’, is 0.9 (40, 
159). 
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(i) ‘Complete treatment’ 
 
 
- The probabilities of completion of active TB treatment with and without adverse 
effect, ‘pCrxATBAe’ and ‘pCrxATBAe’, were assumed to be 0.95 and 0.85 
respectively. 
- The probabilities of cure following completion of treatment for drug sensitive active 
TB, ‘pCurDSARx’, was estimated at 0.80 (160) and for drug resistant active TB, 
‘pCurDRARx’, is 0.48 (161, 162).  
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(ii) ‘Not complete treatment’ or ‘Default treatment’ 
 
- The probabilities of cure following default treatment for drug sensitive active TB, 
‘pCurDSADfx’, was estimated at 0.62 (161-166) and for drug resistant active TB, 
‘pCurDRADfx’, is assumed to be 0.24.  
- Probability of becoming drug resistant following default treatment for drug sensitive 
active TB, ‘pDRAfromDSAdf’, is assumed to be 0.40. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 144 
(iii) ‘No detected’ 
 
- The probability of spontaneous cure for active TB, ‘pSCurATB’, is 0.20 (157) and 
probability of death from active TB without treatment, ‘pDdATB’, 0.23 (157). 
 
Contact infection 
 
- A ‘logical node’ is used to allow contacts infections also be captured in the model.  
- For every single primary active TB case, some contacts are assumed to have been 
infected (Probability of contact infection,’ pContactTB’ assumed to be 1.0). The cost of 
contact tracing coded ‘cContactTB’ was estimated at £482 (143). 
-  The probability of contacts to develop active ‘pCATBa’ or latent TB ‘pCATBl’ 
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following exposure to a primary active TB case is assumed to be 0.20 or 0.18 (143) 
respectively.
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APPENDIX 20:  COST AND EFFECTIVENESS OUTCOMES OF ALL THE CYCLES IN 
THE MONTE CARLO SIMULATION 
 
 
Monte Carlo CE Strategy Values 
Iteration	 Strategy	 Cost	 Eff	 NMB	
1	     
 Investment in Nigeria TB 
control	
259.776	 17.072	 85101.374	
 Present practice (Chest x 
ray screening at the 
airport)	
208.605	 17.086	 85219.395	
 IGRA	 561.639	 17.126	 85067.111	
 NOTHING	 55.324	 17.017	 85027.426	
 
2	
    
 Investment in Nigeria TB 
control	
241.390	 17.357	 86543.560	
 Present practice (Chest x 
ray screening at the 
airport)	
206.779	 17.214	 85865.571	
 IGRA	 575.058	 17.405	 86448.442	
 NOTHING	 73.322	 17.229	 86070.078	
 
3	
    
 Investment in Nigeria TB 
control	
238.192	 17.454	 87030.208	
 Present practice (Chest x 
ray screening at the 
airport)	
211.811	 17.186	 85717.139	
 IGRA	 659.594	 17.136	 85018.206	
 NOTHING	 55.646	 17.429	 87088.454	
 
4	
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Iteration	 Strategy	 Cost	 Eff	 NMB	
 Investment in Nigeria TB 
control	
263.958	 17.351	 86492.142	
 Present practice (Chest x 
ray screening at the 
airport)	
496.769	 17.450	 86752.431	
 IGRA	 567.042	 17.303	 85947.358	
 NOTHING	 91.886	 17.218	 85996.464	
 
5	
    
 Investment in Nigeria TB 
control	
268.055	 17.365	 86555.895	
 Present practice (Chest x 
ray screening at the 
airport)	
339.655	 17.142	 85368.745	
 IGRA	 722.273	 17.224	 85399.427	
 NOTHING	 110.696	 17.256	 86171.004	
 
6	
    
 Investment in Nigeria TB 
control	
251.356	 17.377	 86632.544	
 Present practice (Chest x 
ray screening at the 
airport)	
279.362	 17.452	 86980.088	
 IGRA	 652.759	 17.434	 86518.191	
 NOTHING	 62.604	 17.284	 86358.096	
 
7	
    
 Investment in Nigeria TB 
control	
254.022	 17.384	 86664.828	
 Present practice (Chest x 
ray screening at the 
airport)	
235.388	 17.438	 86955.812	
 IGRA	 602.733	 17.536	 87076.917	
 NOTHING	 61.670	 17.296	 86420.780	
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8	
    
 Investment in Nigeria TB 
control	
388.828	 17.672	 87969.822	
 Present practice (Chest x 
ray screening at the 
airport)	
187.367	 17.493	 87278.833	
 IGRA	 623.339	 17.391	 86331.961	
 NOTHING	 211.792	 17.577	 87671.908	
 
9	
    
 Investment in Nigeria TB 
control	
248.378	 17.204	 85770.372	
 Present practice (Chest x 
ray screening at the 
airport)	
338.938	 17.048	 84899.262	
 IGRA	 669.200	 17.149	 85077.300	
 NOTHING	 70.426	 17.232	 86089.424	
 
10	
    
 Investment in Nigeria TB 
control	
271.549	 17.122	 85337.651	
 Present practice (Chest x 
ray screening at the 
airport)	
181.629	 17.143	 85531.271	
 IGRA	 812.968	 17.247	 85423.382	
 NOTHING	 93.137	 17.033	 85072.413	
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11	     
 Investment in Nigeria TB 
control	
261.554	 17.088	 85176.246	
 Present practice (Chest x 
ray screening at the 
airport)	
246.387	 17.181	 85658.963	
 IGRA	 661.238	 17.345	 86063.962	
 NOTHING	 68.590	 16.981	 84835.760	
     
 
12	
    
 Investment in Nigeria TB 
control	
240.818	 17.491	 87214.932	
 Present practice (Chest x 
ray screening at the 
airport)	
425.647	 17.468	 86913.003	
 IGRA	 625.129	 17.494	 86844.921	
 NOTHING	 40.398	 17.421	 87066.952	
     
 
13	
    
 Investment in Nigeria TB 
control	
268.794	 17.293	 86194.906	
 Present practice (Chest x 
ray screening at the 
airport)	
572.183	 17.342	 86136.717	
 IGRA	 634.009	 17.466	 86696.191	
 NOTHING	 89.724	 17.218	 85999.876	
     
 
14	
    
 Investment in Nigeria TB 
control	
233.838	 17.669	 88109.312	
 Present practice (Chest x 
ray screening at the 
airport)	
502.315	 17.540	 87197.135	
 IGRA	 664.232	 17.459	 86630.018	
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 NOTHING	 39.522	 17.569	 87806.028	
     
 
15	
    
 Investment in Nigeria TB 
control	
251.312	 17.496	 87226.688	
 Present practice (Chest x 
ray screening at the 
airport)	
197.609	 17.384	 86723.241	
 IGRA	 693.991	 17.444	 86524.659	
 NOTHING	 60.374	 17.458	 87231.476	
     
 
16	
    
 Investment in Nigeria TB 
control	
241.700	 17.441	 86962.650	
 Present practice (Chest x 
ray screening at the 
airport)	
204.640	 17.415	 86872.760	
 IGRA	 620.095	 17.441	 86585.055	
 NOTHING	 56.390	 17.390	 86892.960	
     
 
17	
    
 Investment in Nigeria TB 
control	
234.670	 17.202	 85774.930	
 Present practice (Chest x 
ray screening at the 
airport)	
226.381	 17.326	 86405.769	
 IGRA	 661.516	 17.255	 85614.534	
 NOTHING	 29.934	 17.151	 85726.766 
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18	
    
 Investment in Nigeria TB 
control	
273.052	 17.061	 85030.398	
 Present practice (Chest x 
ray screening at the 
airport)	
194.831	 17.087	 85240.769	
 IGRA	 658.450	 17.011	 84399.000	
 NOTHING	 128.723	 16.954	 84640.227	
     
 
19	
    
 Investment in Nigeria TB 
control	
261.506	 17.041	 84943.144	
 Present practice (Chest x 
ray screening at the 
airport)	
452.181	 17.245	 85771.769	
 IGRA	 710.383	 17.073	 84653.517	
 NOTHING	 79.600	 16.986	 84850.100	
     
 
20	
    
 Investment in Nigeria TB 
control	
250.188	 17.148	 85488.912	
 Present practice (Chest x 
ray screening at the 
airport)	
172.140	 17.091	 85280.910	
 IGRA	 501.483	 17.038	 84688.517	
 NOTHING	 55.560	 17.139	 85636.990	
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21	     
 Investment in Nigeria TB 
control	
240.428	 17.253	 86025.072	
 Present practice (Chest x 
ray screening at the 
airport)	
392.568	 17.079	 85002.682	
 IGRA	 673.980	 17.192	 85286.020	
 NOTHING	 69.335	 17.115	 85506.665	
     
	
 
22	
    
 Investment in Nigeria TB 
control	
233.110	 17.467	 87100.940	
 Present practice (Chest x 
ray screening at the 
airport)	
215.886	 17.535	 87460.164	
 IGRA	 562.548	 17.493	 86902.802	
 NOTHING	 39.392	 17.459	 87254.808	
     
 
23	
    
 Investment in Nigeria TB 
control	
380.714	 17.377	 86502.486	
 Present practice (Chest x 
ray screening at the 
airport)	
264.796	 17.513	 87299.854	
 IGRA	 565.553	 17.651	 87689.247	
 NOTHING	 182.488	 17.422	 86926.612	
     
 
24	
    
 Investment in Nigeria TB 
control	
236.402	 17.299	 86256.748	
 Present practice (Chest x 
ray screening at the 
airport)	
317.563	 17.196	 85662.137	
 IGRA	 598.252	 17.391	 86354.948	
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 NOTHING	 53.024	 17.272	 86308.576	
     
 
25	
    
 Investment in Nigeria TB 
control	
234.436	 16.972	 84627.364	
 Present practice (Chest x 
ray screening at the 
airport)	
265.625	 17.258	 86023.075	
 IGRA	 920.500	 17.330	 85728.800	
 NOTHING	 45.762	 16.864	 84272.788 
	
     
 
26	
    
 Investment in Nigeria TB 
control	
234.474	 17.423	 86879.076	
 Present practice (Chest x 
ray screening at the 
airport)	
407.824	 17.491	 87049.226	
 IGRA	 765.673	 17.558	 87023.777	
 NOTHING	 37.964	 17.323	 86575.536	
     
 
27	
    
 Investment in Nigeria TB 
control	
252.772	 17.428	 86887.128	
 Present practice (Chest x 
ray screening at the 
airport)	
243.026	 17.401	 86763.224	
 IGRA	 809.147	 17.447	 86425.353	
 NOTHING	 56.090	 17.362	 86751.510	
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28	
    
 Investment in Nigeria TB 
control	
276.407	 17.474	 87091.643	
 Present practice (Chest x 
ray screening at the 
airport)	
210.691	 17.406	 86817.909	
 IGRA	 846.598	 17.360	 85951.852	
 NOTHING	 79.949	 17.425	 87045.251	
     
 
29	
    
 Investment in Nigeria TB 
control	
277.653	 17.117	 85305.997	
 Present practice (Chest x 
ray screening at the 
airport)	
155.399	 17.081	 85249.251	
 IGRA	 731.505	 17.132	 84928.545	
 NOTHING	 73.087	 17.125	 85549.663 
	
     
 
30	
    
 Investment in Nigeria TB 
control	
240.762	 17.457	 87044.888	
 Present practice (Chest x 
ray screening at the 
airport)	
229.189	 17.311	 86328.161	
 IGRA	 704.765	 17.516	 86877.085	
 NOTHING	 43.378	 17.401	 86961.572	
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31	     
 Investment in Nigeria TB control	 225.692	 16.941	 84481.008	
 Present practice (Chest x ray screening at the 
airport)	
271.719	 16.739	 83423.481	
 IGRA	 670.805	 17.161	 85134.245	
 NOTHING	 27.310	 16.901	 84477.190	
     
 
32	
    
 Investment in Nigeria TB control	 246.330	 17.092	 85214.970	
 Present practice (Chest x ray screening at the 
airport)	
231.079	 17.110	 85317.921	
 IGRA	 737.605	 17.210	 85314.095	
 NOTHING	 59.616	 17.015	 85016.334	
     
 
33	
    
 Investment in Nigeria TB control	 249.216	 17.539	 87446.384	
 Present practice (Chest x ray screening at the 
airport)	
254.503	 17.458	 87033.697	
 IGRA	 643.840	 17.245	 85581.560	
 NOTHING	 110.991	 17.388	 86831.009	
     
	
 
34	
    
 Investment in Nigeria TB control	 297.141	 17.353	 86469.259	
 Present practice (Chest x ray screening at the 
airport)	
201.622	 17.254	 86070.328	
 IGRA	 793.083	 17.392	 86167.617	
 NOTHING	 98.671	 17.276	 86279.479	
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35	
    
 Investment in Nigeria TB control	 243.222	 17.453	 87022.728	
 Present practice (Chest x ray screening at the 
airport)	
166.461	 17.210	 85885.289	
 IGRA	 755.271	 17.155	 85021.729	
 NOTHING	 38.486	 17.373	 86828.564	
     
 
36	
    
 Investment in Nigeria TB control	 254.626	 17.520	 87344.624	
 Present practice (Chest x ray screening at the 
airport)	
240.444	 17.484	 87177.956	
 IGRA	 745.354	 17.607	 87292.096	
 NOTHING	 73.398	 17.475	 87302.302	
     
 
37	
    
 Investment in Nigeria TB control	 276.198	 17.273	 86089.652	
 Present practice (Chest x ray screening at the 
airport)	
175.063	 17.169	 85671.837	
 IGRA	 511.650	 17.256	 85769.850	
 NOTHING	 98.749	 17.178	 85790.101	
     
 
38	
    
 Investment in Nigeria TB control	 238.504	 17.358	 86550.196	
 Present practice (Chest x ray screening at the 
airport)	
267.633	 17.400	 86730.217	
 IGRA	 610.316	 17.420	 86490.334	
 NOTHING	 52.076	 17.331	 86602.124	
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39	
    
 Investment in Nigeria TB control	 238.972	 17.405	 86785.828	
 Present practice (Chest x ray screening at the 
airport)	
311.780	 17.591	 87643.070	
 IGRA	 685.718	 17.598	 87302.632	
 NOTHING	 58.660	 17.321	 86543.990	
     
 
40	
    
 Investment in Nigeria TB control	 246.144	 17.106	 85281.856	
 Present practice (Chest x ray screening at the 
airport)	
315.961	 16.950	 84432.389	
 IGRA	 619.555	 16.999	 84376.395	
 NOTHING	 47.684	 16.945	 84675.766	
     
 
41	
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41	     
 Investment in Nigeria TB 
control	
228.406	 17.395	 86745.394	
 Present practice (Chest x 
ray screening at the 
airport)	
262.096	 17.275	 86111.254	
 IGRA	 677.912	 17.522	 86931.088	
 NOTHING	 27.698	 17.367	 86806.252	
     
 
42	
    
 Investment in Nigeria TB 
control	
249.756	 17.444	 86969.044	
 Present practice (Chest x 
ray screening at the 
airport)	
258.063	 17.426	 86873.437	
 IGRA	 696.841	 17.587	 87240.309	
 NOTHING	 77.802	 17.348	 86663.598	
     
 
43	
    
 Investment in Nigeria TB 
control	
257.460	 17.173	 85608.990	
 Present practice (Chest x 
ray screening at the 
airport)	
231.856	 17.081	 85172.394	
 IGRA	 541.548	 17.142	 85170.802	
 NOTHING	 105.975	 17.152	 85652.825	
     
 
44	
    
 Investment in Nigeria TB 
control	
269.672	 17.635	 87907.578	
 Present practice (Chest x 
ray screening at the 
airport)	
191.702	 17.690	 88259.248	
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 IGRA	 693.297	 17.661	 87613.603	
 NOTHING	 76.446	 17.582	 87831.154	
     
 
45	
    
 Investment in Nigeria TB 
control	
237.982	 17.311	 86316.268	
 Present practice (Chest x 
ray screening at the 
airport)	
226.418	 17.245	 85999.882	
 IGRA	 733.369	 17.249	 85511.381	
 NOTHING	 45.382	 17.206	 85984.968	
     
 
46	
    
 Investment in Nigeria TB 
control	
231.410	 17.222	 85878.240	
 Present practice (Chest x 
ray screening at the 
airport)	
441.625	 16.986	 84490.625	
 IGRA	 680.220	 16.871	 83676.780	
 NOTHING	 26.960	 17.157	 85757.640	
     
 
47	
    
 Investment in Nigeria TB 
control	
257.280	 17.258	 86032.320	
 Present practice (Chest x 
ray screening at the 
airport)	
421.919	 17.135	 85250.581	
 IGRA	 822.713	 17.107	 84712.237	
 NOTHING	 74.892	 17.073	 85291.758	
     
 
48	
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 Investment in Nigeria TB 
control	
258.860	 17.679	 88138.540	
 Present practice (Chest x 
ray screening at the 
airport)	
503.367	 17.621	 87600.783	
 IGRA	 876.581	 17.653	 87386.869	
 NOTHING	 82.152	 17.567	 87753.598	
     
 
49	
    
 Investment in Nigeria TB 
control	
257.332	 17.255	 86018.568	
 Present practice (Chest x 
ray screening at the 
airport)	
355.509	 17.212	 85706.891	
 IGRA	 703.369	 17.061	 84601.531	
 NOTHING	 66.734	 17.242	 86143.216	
     
 
50	
    
 Investment in Nigeria TB 
control	
235.062	 17.190	 85714.338	
 Present practice (Chest x 
ray screening at the 
airport)	
484.848	 17.262	 85823.052	
 IGRA	 536.106	 17.296	 85944.744	
 NOTHING	 50.766	 17.118	 85539.084	
     
	
	
	
	
 
51	
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 Investment in Nigeria TB 
control	
237.224	 17.499	 87258.576	
 Present practice (Chest x 
ray screening at the 
airport)	
381.571	 17.350	 86368.829	
 IGRA	 504.138	 17.320	 86098.162	
 NOTHING	 36.880	 17.452	 87224.870	
     
 
52	
    
 Investment in Nigeria TB 
control	
281.058	 16.877	 84101.792	
 Present practice (Chest x 
ray screening at the 
airport)	
345.447	 16.906	 84187.003	
 IGRA	 527.711	 16.849	 83716.239	
 NOTHING	 114.339	 16.774	 83753.311	
     
 
53	
    
 Investment in Nigeria TB 
control	
263.732	 17.302	 86247.618	
 Present practice (Chest x 
ray screening at the 
airport)	
248.407	 17.085	 85178.143	
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 IGRA	 684.705	 17.109	 84859.545	
 NOTHING	 69.236	 17.305	 86454.014	
     
 
54	
    
 Investment in Nigeria TB 
control	
241.208	 17.314	 86330.492	
 Present practice (Chest x 
ray screening at the 
airport)	
249.752	 17.251	 86003.148	
 IGRA	 676.926	 17.269	 85669.524	
 NOTHING	 35.874	 17.227	 86098.226	
     
 
55	
    
 Investment in Nigeria TB 
control	
263.608	 17.374	 86605.242	
 Present practice (Chest x 
ray screening at the 
airport)	
491.552	 17.153	 85271.248	
 IGRA	 614.301	 17.242	 85594.199	
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 NOTHING	 63.684	 17.288	 86377.066	
     
 
56	
    
 Investment in Nigeria TB 
control	
258.438	 17.184	 85662.112	
 Present practice (Chest x 
ray screening at the 
airport)	
233.071	 17.102	 85274.879	
 IGRA	 997.388	 17.260	 85304.012	
 NOTHING	 72.320	 17.100	 85429.080	
     
 
57	
    
 Investment in Nigeria TB 
control	
237.540	 17.356	 86540.110	
 Present practice (Chest x 
ray screening at the 
airport)	
469.972	 17.152	 85290.428	
 IGRA	 634.141	 17.077	 84752.259	
 NOTHING	 34.102	 17.303	 86479.448	
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58	
    
 Investment in Nigeria TB 
control	
228.552	 17.377	 86658.848	
 Present practice (Chest x 
ray screening at the 
airport)	
263.993	 17.358	 86525.657	
 IGRA	 858.439	 17.348	 85882.611	
 NOTHING	 48.294	 17.364	 86772.656	
     
 
59	
    
 Investment in Nigeria TB 
control	
257.096	 17.367	 86576.354	
 Present practice (Chest x 
ray screening at the 
airport)	
326.042	 17.367	 86509.658	
 IGRA	 1011.760	 17.257	 85270.840	
 NOTHING	 83.429	 17.392	 86876.071	
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60	
    
 Investment in Nigeria TB 
control	
239.320	 17.277	 86144.780	
 Present practice (Chest x 
ray screening at the 
airport)	
318.826	 17.316	 86259.324	
 IGRA	 698.572	 17.414	 86371.478	
 NOTHING	 69.474	 17.216	 86008.926	
     
 
 
 
 
 
61	
    
 Investment in Nigeria TB 
control	
239.230	 17.332	 86420.320	
 Present practice (Chest x 
ray screening at the 
airport)	
264.334	 17.282	 86147.316	
 IGRA	 743.131	 17.427	 86391.819	
 NOTHING	 118.514	 17.293	 86348.536	
     
 
62	
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 Investment in Nigeria TB 
control	
241.936	 17.384	 86679.114	
 Present practice (Chest x 
ray screening at the 
airport)	
539.092	 17.496	 86941.158	
 IGRA	 576.772	 17.500	 86923.278	
 NOTHING	 45.800	 17.247	 86186.700	
     
 
63	
    
 Investment in Nigeria TB 
control	
256.326	 17.395	 86717.274	
 Present practice (Chest x 
ray screening at the 
airport)	
193.040	 17.274	 86174.810	
 IGRA	 917.426	 17.344	 85802.324	
 NOTHING	 99.327	 17.328	 86538.973	
     
 
64	
    
 Investment in Nigeria TB 
control	
305.692	 17.618	 87785.358	
 Present practice (Chest x 
ray screening at the 
airport)	
270.186	 17.426	 86860.464	
 IGRA	 707.461	 17.389	 86236.789	
 NOTHING	 145.118	 17.539	 87548.132	
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65	
    
 Investment in Nigeria TB 
control	
246.626	 17.251	 86009.724	
 Present practice (Chest x 
ray screening at the 
airport)	
301.966	 17.181	 85604.234	
 IGRA	 732.308	 17.205	 85294.142	
 NOTHING	 73.604	 17.170	 85775.046	
     
 
66	
    
 Investment in Nigeria TB 
control	
232.406	 17.230	 85917.394	
 Present practice (Chest x 
ray screening at the 
airport)	
351.207	 17.115	 85222.843	
 IGRA	 652.678	 17.259	 85643.322	
 NOTHING	 34.646	 17.163	 85778.004	
     
 
67	
    
 Investment in Nigeria TB 
control	
229.654	 17.476	 87152.746	
 Present practice (Chest x 
ray screening at the 
airport)	
330.427	 17.314	 86237.773	
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 IGRA	 599.656	 17.469	 86747.144	
 NOTHING	 40.486	 17.409	 87006.964	
     
 
68	
    
 Investment in Nigeria TB 
control	
242.412	 17.540	 87455.788	
 Present practice (Chest x 
ray screening at the 
airport)	
307.439	 17.322	 86300.911	
 IGRA	 575.866	 17.272	 85785.034	
 NOTHING	 73.122	 17.465	 87251.928	
     
 
69	
    
 Investment in Nigeria TB 
control	
303.994	 17.123	 85309.606	
 Present practice (Chest x 
ray screening at the 
airport)	
467.880	 17.188	 85470.120	
 IGRA	 1019.473	 17.368	 85820.527	
 NOTHING	 112.840	 16.972	 84746.860	
     
 
70	
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 Investment in Nigeria TB 
control	
228.422	 17.404	 86790.178	
 Present practice (Chest x 
ray screening at the 
airport)	
199.515	 17.369	 86643.835	
 IGRA	 742.334	 17.485	 86683.366	
 NOTHING	 48.518	 17.302	 86459.832	
     
 
 
 
 
 
71	     
 Investment in Nigeria TB 
control	
277.067	 17.487	 87155.833	
 Present practice (Chest x 
ray screening at the 
airport)	
378.562	 17.490	 87072.338	
 IGRA	 933.497	 17.384	 85984.753	
 NOTHING	 147.153	 17.433	 87019.797	
     
 
72	
    
 Investment in Nigeria TB 
control	
245.454	 17.287	 86190.296	
 Present practice (Chest x 
ray screening at the 
airport)	
230.785	 17.024	 84888.665	
 IGRA	 719.365	 17.034	 84451.485	
 NOTHING	 55.062	 17.272	 86306.888	
     
 
73	
    
 Investment in Nigeria TB 
control	
235.088	 17.303	 86278.212	
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 Present practice (Chest x 
ray screening at the 
airport)	
289.038	 17.388	 86649.662	
 IGRA	 850.792	 17.498	 86641.108	
 NOTHING	 53.102	 17.232	 86109.098	
     
 
74	
    
 Investment in Nigeria TB 
control	
246.472	 17.301	 86258.228	
 Present practice (Chest x 
ray screening at the 
airport)	
256.426	 17.443	 86960.424	
 IGRA	 566.209	 17.707	 87967.391	
 NOTHING	 82.316	 17.337	 86601.684	
     
 
75	
    
 Investment in Nigeria TB 
control	
248.886	 17.416	 86831.164	
 Present practice (Chest x 
ray screening at the 
airport)	
265.160	 17.365	 86560.340	
 IGRA	 533.439	 17.269	 85811.111	
 NOTHING	 65.432	 17.393	 86899.668	
     
 
76	
    
 Investment in Nigeria TB 
control	
239.466	 17.267	 86096.584	
 Present practice (Chest x 
ray screening at the 
airport)	
185.646	 17.201	 85818.154	
 IGRA	 579.233	 17.178	 85310.317	
 NOTHING	 48.712	 17.185	 85873.788	
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77	
    
 Investment in Nigeria TB 
control	
292.120	 17.167	 85543.080	
 Present practice (Chest x 
ray screening at the 
airport)	
238.469	 17.043	 84978.331	
 IGRA	 680.568	 16.943	 84032.582	
 NOTHING	 124.557	 17.156	 85653.293	
     
 
78	
    
 Investment in Nigeria TB 
control	
241.494	 17.611	 87811.506	
 Present practice (Chest x 
ray screening at the 
airport)	
239.049	 17.505	 87283.501	
 IGRA	 921.845	 17.604	 87100.205	
 NOTHING	 67.448	 17.519	 87528.452	
     
 
79	
    
 Investment in Nigeria TB 
control	
247.900	 17.312	 86313.200	
 Present practice (Chest x 
ray screening at the 
airport)	
153.473	 17.224	 85966.377	
 IGRA	 792.412	 17.333	 85873.638	
 NOTHING	 55.324	 17.251	 86198.226	
     
 
80	
    
 Investment in Nigeria TB 
control	
245.768	 17.375	 86628.632	
 Present practice (Chest x 
ray screening at the 
airport)	
209.475	 17.113	 85353.525	
 IGRA	 613.773	 17.061	 84689.127	
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 NOTHING	 44.916	 17.268	 86292.784	
     
 
 
 
 
 
81	     
 Investment in Nigeria TB 
control	
250.170	 17.408	 86789.580	
 Present practice (Chest x 
ray screening at the 
airport)	
474.755	 17.343	 86240.045	
 IGRA	 752.172	 17.432	 86408.028	
 NOTHING	 47.670	 17.284	 86374.130	
     
 
82	
    
 Investment in Nigeria TB 
control	
228.422	 17.781	 88678.778	
 Present practice (Chest x 
ray screening at the 
airport)	
236.379	 17.699	 88256.771	
 IGRA	 613.103	 17.744	 88104.897	
 NOTHING	 51.078	 17.691	 88402.372	
     
 
83	
    
 Investment in Nigeria TB 
control	
238.684	 17.060	 85059.966	
 Present practice (Chest x 
ray screening at the 
airport)	
381.939	 17.141	 85324.711	
 IGRA	 738.518	 17.225	 85386.232	
 NOTHING	 48.918	 16.983	 84866.282	
     
 
84	
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 Investment in Nigeria TB 
control	
242.064	 17.452	 87019.486	
 Present practice (Chest x 
ray screening at the 
airport)	
292.360	 17.559	 87501.840	
 IGRA	 777.961	 17.494	 86694.139	
 NOTHING	 80.168	 17.435	 87092.382	
     
 
85	
    
 Investment in Nigeria TB 
control	
236.154	 17.098	 85254.696	
 Present practice (Chest x 
ray screening at the 
airport)	
233.500	 17.042	 84976.700	
 IGRA	 570.622	 17.339	 86124.078	
 NOTHING	 59.976	 17.122	 85551.874	
     
 
86	
    
 Investment in Nigeria TB 
control	
244.830	 17.639	 87948.620	
 Present practice (Chest x 
ray screening at the 
airport)	
302.831	 17.633	 87860.819	
 IGRA	 646.911	 17.592	 87312.439	
 NOTHING	 75.944	 17.663	 88240.206	
     
 
87	
    
 Investment in Nigeria TB 
control	
225.042	 17.192	 85736.758	
 Present practice (Chest x 
ray screening at the 
airport)	
187.461	 17.088	 85252.689	
 IGRA	 726.697	 17.090	 84724.553	
 NOTHING	 39.974	 17.147	 85697.376	
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88	
    
 Investment in Nigeria TB 
control	
313.010	 17.400	 86688.490	
 Present practice (Chest x 
ray screening at the 
airport)	
194.311	 17.432	 86965.189	
 IGRA	 604.027	 17.346	 86125.273	
 NOTHING	 120.306	 17.380	 86781.344	
     
 
89	
    
 Investment in Nigeria TB 
control	
249.418	 17.236	 85930.232	
 Present practice (Chest x 
ray screening at the 
airport)	
223.690	 17.304	 86294.110	
 IGRA	 597.617	 17.424	 86521.783	
 NOTHING	 67.210	 17.229	 86075.740	
     
 
90	
    
 Investment in Nigeria TB 
control	
275.289	 17.197	 85707.811	
 Present practice (Chest x 
ray screening at the 
airport)	
329.534	 16.886	 84101.916	
 IGRA	 608.793	 17.051	 84644.157	
 NOTHING	 70.187	 17.147	 85665.213	
     
 
 
 
 
 
91	     
 Investment in Nigeria TB 
control	
265.584	 17.353	 86497.166	
 Present practice (Chest x 
ray screening at the 
airport)	
232.497	 17.389	 86714.803	
 175 
SECTION 1 – CLINICAL INFORMATION 
 IGRA	 684.323	 17.334	 85984.777	
 NOTHING	 78.860	 17.310	 86473.440	
     
 
92	
    
 Investment in Nigeria TB 
control	
237.116	 17.196	 85743.984	
 Present practice (Chest x 
ray screening at the 
airport)	
332.493	 17.239	 85862.857	
 IGRA	 741.312	 17.135	 84934.488	
 NOTHING	 42.918	 17.156	 85737.732	
     
 
93	
    
 Investment in Nigeria TB 
control	
259.316	 17.391	 86696.934	
 Present practice (Chest x 
ray screening at the 
airport)	
170.573	 17.385	 86752.927	
 IGRA	 694.106	 17.456	 86584.894	
 NOTHING	 60.750	 17.314	 86507.900	
     
 
94	
    
 Investment in Nigeria TB 
control	
251.654	 17.546	 87479.546	
 Present practice (Chest x 
ray screening at the 
airport)	
520.601	 17.667	 87816.699	
 IGRA	 733.776	 17.546	 86995.974	
 NOTHING	 95.059	 17.499	 87398.041	
     
 
95	
    
 Investment in Nigeria TB 
control	
232.904	 17.281	 86173.196	
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 Present practice (Chest x 
ray screening at the 
airport)	
237.680	 17.157	 85547.220	
 IGRA	 682.032	 17.261	 85621.068	
 NOTHING	 57.328	 17.241	 86146.022	
     
 
96	
    
 Investment in Nigeria TB 
control	
234.122	 17.133	 85433.028	
 Present practice (Chest x 
ray screening at the 
airport)	
454.978	 17.139	 85241.522	
 IGRA	 652.165	 17.231	 85504.885	
 NOTHING	 65.908	 17.156	 85712.642	
     
 
97	
    
 Investment in Nigeria TB 
control	
262.166	 17.402	 86748.434	
 Present practice (Chest x 
ray screening at the 
airport)	
188.463	 17.323	 86424.437	
 IGRA	 534.965	 17.387	 86401.335	
 NOTHING	 67.320	 17.341	 86635.430	
     
 
98	
    
 Investment in Nigeria TB 
control	
247.234	 17.091	 85207.116	
 Present practice (Chest x 
ray screening at the 
airport)	
191.378	 16.960	 84609.872	
 IGRA	 733.587	 17.126	 84896.163	
 NOTHING	 56.388	 16.956	 84725.712	
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99	
    
 Investment in Nigeria TB 
control	
255.978	 17.166	 85576.172	
 Present practice (Chest x 
ray screening at the 
airport)	
479.675	 17.194	 85491.275	
 IGRA	 913.816	 17.307	 85622.384	
 NOTHING	 73.294	 17.149	 85673.256	
     
 
100	
    
 Investment in Nigeria TB 
control	
265.660	 17.280	 86132.090	
 Present practice (Chest x 
ray screening at the 
airport)	
279.283	 17.208	 85758.317	
 IGRA	 629.676	 17.259	 85667.624	
 NOTHING	 89.836	 17.297	 86394.964	
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APPENDIX 21: QUESTIONNAIRES 
Principal	Investigator: 
Dr Nisser Ali Umar 
School of Medicine, Health Policy and Practice, 
Faculty of Health, 
University of East Anglia, Norwich NR4 7TJ 
England 
Tel: +44 7877045785 
E-mail: N.Umar@uea.ac.uk 
February, 2009 
 
 
Date of Interview	 Clinic Name and Place	 Interviewer Name	 Patient Chart Number (or Patient 
Initials)	
    
 
9. COST OF A DAY IN HOSPITAL (EXCLUDING DRUGS, LABORATORY TESTS AND X-RAYS) 
A: NURSING STAFF COSTS 
TYPE OF NURSING 
STAFF WORKING IN 
TB WARD	
NUMBER WHO 
WORK IN TB WARD 
(a)	
ANNUAL COSTS (b)	 AV. PROPORT- 
ION OF TIME SPENT 
ON TB WARDS (c)	
TOTAL ANNUAL 
COSTS =  
(a) x (b) x (c)	
     
     
     
     
 
TOTAL ANNUAL COST OF NURSING STAFF = _________________________ 
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B: MEDICAL STAFF COSTS  
TYPE OF MED. 
STAFF WORKING IN 
TB WARD	
NUMBER WHO 
WORK IN TB WARD 
(a)	
ANNUAL COSTS (b)	 AV. PROPORT- 
ION OF TIME SPENT 
ON TB WARDS (c)	
TOTAL ANNUAL 
COSTS =  
(a) x (b) x (c)	
     
     
 
TOTAL ANNUAL COST OF MEDICAL STAFF = ________________________ 
 
C: SUPPORT STAFF COSTS 
TYPE OF SUPPORT 
STAFF IN TB WARD	
NUMBER WHO 
WORK IN TB WARD 
(a)	
ANNUAL COSTS (b)	 AV. PROPORT- 
ION OF TIME SPENT 
ON TB WARDS (c)	
TOTAL ANNUAL 
COSTS  
(a) x (b) x (c)	
     
     
 
TOTAL ANNUAL COST OF SUPPORT STAFF = _________________________ 
D. BUILDING COST 
REPLACEMENT COST OF THE TB WARD INCLUDING 
THE NEGATIVE PRESURE ROOM (a)	
ANNUALIZED COST OF TB WARD 
 = (a) x 25.73	
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E. STAFF OVERHEAD COST, EXCLUDING KITCHEN, LAUNDRY LABORATORY AND X-RAY STAFF 
TYPE OF STAFF NOT INVOLVED IN DI-
RECT PATIENT CARE EXCLUDING 
KITCHEN/LAUDRY/LAB/ANY SUPPORT 
STAFF AS ABOVE	
ANNUAL COST (a)	 NUMBER EMPLOYED 
(b)	
TOTAL ANNUAL COST= 
(a) x (b) 	
    
    
 
TOTAL ANNUAL STAFF OVERHEAD COST : ________________________________________________________________  
TOTAL ANNUAL NUMBER OF HOSPITAL INPATIENT DAYS ACCOUNTED FOR BY TUBERCULOSIS PATIENTS:  
  ________________________________________________________________________________________________________ 
TOTAL ANNUAL STAFF OVERHEAD COST ACCOUNTED FOR BY TUBERCULOSIS INPATIENT CARE:  
 ________________________________________________________________________________________________________ 
F: KITCHEN AND LAUDRY SERVICE COST 
TYPE OF STAFF EMPLOYED IN THE 
KITCHEN AND LAUDRY	
ANNUAL COST (a)	 NUMBER EMPLOYED 
(b)	
TOTAL ANNUAL COST= 
(a) x (b) 	
    
    
    
 
TOTAL ANNUAL KITCHEN/LAUDRY STAFF COST: _________________________________________________________ 
TOTAL ANNUAL NON-STAFF RECURRENT EXPENDITURE OF KITCHEN AND LAUDRY SERVICES:  
________________________________________________________________________________________________________ 
 
REPLACEMENT COST OF THE KITCHEN AND LAUDRY 
BUILDING (a)	
ANNUALIZED  
 = (a) x 25.73	
  
 
TOTAL ANNUAL COSTS OF STAFF, BUILDINGS AND NON-STAFF RECURRENT EXPENDITURE ASSOCIATED WITH 
KITCHEN AND LAUNDRY FACILITIES:  
 ___________________________________________________________________________________________________________ 
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TOTAL ANNUAL COSTS OF KITCHEN AND LAUNDRY SERVICES TO BE ALLOCATED TO TUBERCULOSIS PATIENTS:  
 
___________________________________________________________________________________________________________ 
G: GENERAL HOSPITAL RECURRENT OVERHEAD COSTS, EXCULUDING STAFF, ITEMS ASSOCIATED WITH DRUGS, 
LABORATORY TESTS, X-RAYS, KITCHEN, LAUNDRY FACILITIES, AND ANY OTHER ITEMS CLEARLY IRRELEVANT 
TO TUBERCULOSIS PATIENTS: ____________________________________________ 
TOTAL ANNUAL COST OF GENERAL NON-PERSONNEL RECURRENT HOSPITAL EXPENDITURE OF ALL ITEMS 
EXCEPT THOSE ASSOCIATED WITH DRUGS, LABORATORY TESTS, X-RAYS, KITCHEN, LAUNDRY FACILITIES, AND 
ANY OTHER ITEMS CLEARLY IRRELEVANT TO TUBERCULOSIS PATIENTS:  ___________________ 
PROPORTION OF TOTAL COSTS CALCULATED ABOVE (i) TO BE ALLOCATED TO INPATIENT SERVICES: 
_______________________________________________________ 
TOTAL NON-PERSONNEL OVERHEAD RECURRENT COST ASSOCIATED WITH INPATIENT SERVICES: 
___________________________________________________________ 
PROPORTION OF INPATIENT DAYS FOR WHICH TUBERCULOSIS PATIENTS ACCOUNT: 
____________________________________ 
TOTAL ANNUAL OVERHEAD NON-PERSONNEL RECURRENT COSTS TO BE ALLOCATED TO TUBERCULOSIS INPA-
TIENT CARE: 
___________________________________________________________________________________________________________ 
H: GENERAL BUILDING AND EQUIPMENT COSTS: 
REPLACEMENT COST OF THE BUILDING USED FOR 
GENERAL SUPPORT SERVICES (a)	
ANNUALIZED COST 
 = (a) x 25.73	
  
 
 
REPLACEMENT COST OF THE FOR GENERAL EQUIP-
MENT USED FOR GENERAL SUPPORT SERVICES (a)	
ANNUALIZED COST 
 = (a) x 25.73	
  
 
TOTAL ANNUALIZED COST OF BUILDING AND EQUIPMENT: 
___________________________________________________________________________________________________________  
PROPORTION OF GENERAL BUILDING AND EQUIPMENT COSTS TO BE ALLOCATED TO INPATIENT SERVICES:  
___________________________________________________________________________________________________________ 
ANNUAL GENERAL BUILDING AND EQUIPMENT COSTS TO BE ALLOCATED TO INPATIENT SERVICES: 
___________________________________________________________________________________________________________  
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PROPORTION OF TOTAL INPATIENT DAYS FOR WHICH TUBERCULOSIS PATIENTS ACCOUNT:  
___________________________________________________________________________________________________________ 
TOTAL GENERAL BUILDING AND EQUIPMENT COSTS TO BE ALLOCATED TO TUBERCULOSIS PATIENTS: 
___________________________________________________________________________________________________________ 
THEREFORE, INPATIENTS CARE OF TUBERCULOSIS PATIENTS: 
 
AVERAGE COST PER DAY : ___________________________________________________________________________________ 
 
ESTIMATED AVERAGE INCREMENTAL COST PER DAY: _______________________________________________________  
 
ESTIMATED MARGINAL COST PER DAY: _____________________________________________________________________ 
 
AVERAGE NUMBER OF INPATIENT DAYS SPENT BY PATIENT WITH DRUG SENSITIVE TB: ______________________  
 
AVERAGE NUMBER OF INPATIENT DAYS SPENT BY A PATIENT WITH MDR-TB: ________________________________  
 
AVERAGE NUMBER OF INPATIENT DAYS SPENT BY A PATIENT WITH XDR- TB: ________________________________ 
 
10. COST OF AN OUTPATIENT DAY (EXCLUDING DRUGS, LABORATORY TESTS AND X-RAYS) 
A: NURSING STAFF COSTS 
TYPE OF NURSING 
STAFF WORKING IN 
TB CLINIC	
NUMBER WHO 
WORK IN TB CLINIC 
(a)	
ANNUAL COSTS (b)	 AV. PROPORT- 
ION OF TIME SPENT 
ON TB CLINIC (c)	
TOTAL ANNUAL 
COSTS =  
(a) x (b) x (c)	
     
     
     
     
 
TOTAL ANNUAL COST OF NURSING STAFF = _________________________ 
B: MEDICAL STAFF COSTS  
TYPE OF MED. 
STAFF WORKING IN 
TB CLINIC	
NUMBER WHO 
WORK IN TB CLINIC 
(a)	
ANNUAL COSTS (b)	 AV. PROPORT- 
ION OF TIME SPENT 
ON TB CLINIC (c)	
TOTAL ANNUAL 
COSTS =  
(a) x (b) x (c)	
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TOTAL ANNUAL COST OF MEDICAL STAFF = ________________________ 
C: SUPPORT STAFF COSTS 
TYPE OF SUPPORT 
STAFF IN TB CLINIC	
NUMBER WHO 
WORK IN TB CLINIC 
(a)	
ANNUAL COSTS (b)	 AV. PROPORT- 
ION OF TIME SPENT 
ON TB CLINIC (c)	
TOTAL ANNUAL 
COSTS  
(a) x (b) x (c)	
     
     
     
     
 
TOTAL ANNUAL COST OF SUPPORT STAFF = _________________________ 
D. BUILDING COST 
REPLACEMENT COST OF THE TB CLINIC (a)	 ANNUALIZED COST OF TB CLINIC 
 = (a) x 25.73	
  
 
E. STAFF OVERHEAD COST, EXCLUDING KITCHEN, LAUNDRY, LABORATORY AND X-RAY STAFF 
TYPE OF STAFF NOT INVOLVED IN DI-
RECT PATIENT CARE EXCLUDING 
KITCHEN/LAUDRY/LAB/ANY SUPPORT 
STAFF AS ABOVE	
ANNUAL COST (a)	 NUMBER EMPLOYED 
(b)	
TOTAL ANNUAL COST= 
(a) x (b) 	
    
    
    
    
    
 
TOTAL ANNUAL STAFF OVERHEAD COST : ________________________________________________________________  
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TOTAL ANNUAL NUMBER OF OUTPATIENT DAYS ACCOUNTED FOR BY TUBERCULOSIS PATIENTS: 
_______________________________________________________ 
PROPORTION OF ALL OUTPATIENT DAYS ACCOUNTED FOR BY TUBERCULOSIS PATIENTS: 
______________________________________________________________ 
TOTAL ANNUAL STAFF OVERHEAD COST ACCOUNTED FOR BY TUBERCULOSIS INPATIENT CARE: 
__________________________________________________________ 
G: GENERAL HOSPITAL RECURRENT OVERHEAD COSTS, EXCULUDING STAFF, ITEMS ASSOCIATED WITH DRUGS, 
LABORATORY TESTS, X-RAYS, KITCHEN, LAUNDRY FACILITIES, AND ANY OTHER ITEMS CLEARLY IRRELEVANT 
TO TUBERCULOSIS PATIENTS:_____________________________________________________ 
TOTAL ANNUAL COST OF GENERAL NON-PERSONNEL RECURRENT HOSPITAL EXPENDITURE OF ALL ITEMS 
EXCEPT THOSE ASSOCIATED WITH DRUGS, LABORATORY TESTS, X-RAYS, KITCHEN, LAUNDRY FACILITIES, AND 
ANY OTHER ITEMS CLEARLY IRRELEVANT TO TUBERCULOSIS PATIENTS: _________________ 
PROPORTION OF TOTAL COSTS CALCULATED ABOVE (i) TO BE ALLOCATED TO OUTPATIENT SER-
VICES:_______________________________________________________ 
TOTAL NON-PERSONNEL OVERHEAD RECURRENT COST ASSOCIATED WITH OUTPATIENT SERVICES: 
________________________________________________________ 
PROPORTION OF OUTPATIENT DAYS FOR WHICH TUBERCULOSIS PATIENTS ACCOUNT: 
___________________________________________________________________ 
TOTAL ANNUAL OVERHEAD NON-PERSONNEL RECURRENT COSTS TO BE ALLOCATED TO TUBERCULOSIS OUTPA-
TIENT CARE: _______________________________ 
H: GENERAL BUILDING AND EQUIPMENT COSTS:  
REPLACEMENT COST OF THE GENERAL BUILDING 
USED FOR GENERAL SUPPORT SERVICES (a)	
ANNUALIZED COST 
 = (a) x 25.73	
  
 
REPLACEMENT COST OF THE FOR GENERAL EQUIP-
MENT USED FOR GENERAL SUPPORT SERVICES (a)	
ANNUALIZED COST 
 = (a) x 25.73	
  
 
TOTAL ANNUALIZED COST OF BUILDING AND EQUIPMENT: 
________________________________________________________________  
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PROPORTION OF GENERAL BUILDING AND EQUIPMENT COSTS TO BE ALLOCATED TO OUTPATIENT SERVICES: 
__________________________________ 
ANNUAL GENERAL BUILDING AND EQUIPMENT COSTS TO BE ALLOCATED TO OUTPATIENT SERVICES: 
_______________________________________________  
PROPORTION OF TOTAL OUTPATIENT DAYS FOR WHICH TUBERCULOSIS PATIENTS AC-
COUNT:________________________________________________________ 
TOTAL GENERAL BUILDING AND EQUIPMENT COSTS TO BE ALLOCATED TO TUBERCULOSIS PA-
TIENTS:__________________________________________________ 
THEREFORE, OUTPATIENTS CARE OF TUBERCULOSIS PATIENTS: 
AVERAGE COST PER VISIT:__________________________________________________________________________________ 
ESTIMATED AVERAGE INCREMENTAL COST PER DAY: _______________________________________________________  
ESTIMATED MARGINAL COST PER DAY: _____________________________________________________________________ 
 11: COST OF DRUGS 
COST OF DRUGS FOR THE INTENSIVE  PHASE (1-2MTHS) TUBERCULOSIS PATIENT: 
________________________________________________________________________ 
 COST OF DRUGS FOR THE MAINTAINANCE PHASE (2-9 MTHS) TUBERCULOSIS PA-
TIENT:________________________________________________________________ 
 
COST OF DRUGS FOR MULTI DRUG RESISTANT TUBERCULOSIS (MDR-TB) PATIENT TREATMENT: 
__________________________________________________________ 
 COST OF DRUGS FOR EXTENSIVELY DRUG RESISTANT TUBERCULOSIS (XDR-TB) PATIENT TREAT-
MENT:_____________________________________________________ 
COST OF DRUGS FOR RE-TREATMENT OF TUBERCULOSIS PA-
TIENT:____________________________________________________________________________________  
12: COST OF A SPUTUM SMEAR: 
QUOTED AVERAGE COST OF SPUTUM SMEAR: __________________________________________________________ 
 SOURCE OF QUOTATION: _____________________________________________________________ 
AVERAGE NUMBER OF SPUTUM SMEAR TESTS REQUIRED BY A PATIENT WITH DRUG SENSITIVE TB: 
______________________________________________________ 
AVERAGE NUMBER OF SPUTUM SMEAR TESTS REQUIRED BY A PATIENT WITH MDR-TB: 
__________________________________________________________  
AVERAGE NUMBER OF SPUTUM SMEAR TESTS REQUIRED BY A PATIENT WITH XDR- TB: 
_________________________________________________________________ 
13: COST OF A SPUTUM CULTURE: 
QUOTED AVERAGE COST OF SPUTUM CULTURE (OR ESTIMATED AVERAGE COST OF SPUTUM CULTURE = AVER-
AGE COST OF A SPUTUM SMEAR x 1.6) :_________ 
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 SOURCE OF QUOTA-
TION____________________________________________________________________________________________________________
_ 
AVERAGE NUMBER OF SPUTUM CULTURE TESTS REQUIRED BY A PATIENT WITH DRUG SENSITIVE 
TB:_____________________________________________________ 
AVERAGE NUMBER OF SPUTUM CULTURE TESTS REQUIRED BY A PATIENT WITH MDR-TB: 
_________________________________________________________________  
AVERAGE NUMBER OF SPUTUM CULTURE TESTS REQUIRED BY A PATIENT WITH XDR- 
TB:_________________________________________________________________ 
14:  COST OF AN X-RAY: 
QUOTED AVERAGE OF AN X-RAY:  ______________________________________________________________________________  
SOURCE OF QUOTATION: ______________________________________________________________________________ 
AVERAGE NUMBER OF X RAY REQUIRED BY A PATIENT WITH DRUG SENSITIVE TB: 
______________________________________________________________________  
AVERAGE NUMBER OF X RAY REQUIRED BY A PATIENT WITH MDR-TB: 
__________________________________________________________________________  
 
AVERAGE NUMBER OF X RAY REQUIRED BY A PATIENT WITH XDR- 
TB:_____________________________________________________________________________________  
15:  COST OF OUTPATIENT SUPERVISIONS/VISITS OF PATIENTS BY HEALTH WORKERS/SUPPORT WORKERS:  
STAFF COSTS:  
TYPES OF STAFF IN-
VOLVE/PARTICIPATE IN SU-
PERVISION	
ANNUAL COST  
(a)	
PROPORTION OF TIME 
SPENT  
(b)	
TOTAL ANNUAL COST  
(c)	
    
    
    
 
TOTAL ANNUAL COST OF STAFF INVOLVED/PARTICIPATE IN SUPERVISION: 
______________________________________________________________________________ 
ESTIMATED	TOTAL	ANNUAL	COST	(MILES*RATE)	OF	TRANSPORTATION	FOR	THE	SUPERVISION	OF	PATIENTS	AND	THEIR	SURPERVI-
SORS:________________________________________________ 
	AVERAGE	COST	FOR	SUPERVISIONS/VISITS	TO	PATIENT	BY	HEALTH	WORKERS/SUPPORT	WORKERS:		
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Ii Assessing Patient Costs due to Tuberculosis (TB) 
 
 
 
 
 
 
 
 
SECTION	1	:	Clinical	Information	
1.	Date	of	Birth	 2.	Sex	 3.Ethnicity/	Country	of	
Origin	
3a.	Legal	Status	 4.	What	was	the	date	and	loca-
tion	of	diagnosis	for	this	episode	
of	TB?	
5.	Classifica-
tion	
Date of Interview	 Clinic Name and Place	 Interviewer Name	 Patient Chart Number (or Patient 
Initials)	
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Write	date:	
	
____/																
/_______	
day	/					month		/			
year	
	
(write	month	in	full	
	
ex.	17/August/2004)	
Circle:	
	
Male	
	
Female	
Country	of	Origin:		
	
Born	in	
______________	
	
	
Country	of	current	resi-
dence:	
	
____________________	
	
AND	(if	applicable)	
	
Year	arrived__________	
Circle:	
	
Accepted	refugee	
	
Citizen	
	
Immigrant	applicant	
	
Landed	immigrant	
	
Refugee	claimant	
	
Student	
	
Visitor	
	
Work	visa		
	
Other	__________	
Write	date:	
	
	
____/																														/_____	
day	/					month														/			year	
	
(write	month	in	full)	
	
Name	of	Facility	where	diag-
nosed	
	
___________________	
	
Type	of	Health	Facility:	
	
Public	Hospital	(as	inpatient)	
	
Private	Hospital	(as	inpatient)	
	
Clinic	at	Public	Hospital	(as	out-
patient)	
	
Clinic	at	Private	Hospital	(as	out-
patient)	
	
Public	Clinic	
	
Private	Clinic		
	
Other		
Circle:		
	
New	Case	
	
(if	new	case	
go	to	Q7)	
	
OR	
	
Retreatment	
	
																			
Failure	
	
																			Re-
lapse	
	
																			
Default	
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(Specify)_______________	
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6.	If	re-treatment	
case,	what	was	the	
date	of	the	patients	
prior	TB?	
7.	Was	this	patient	
referred	to	this	clinic,	
from	immigration,	a	
hospital	or	another	
clinic?		
8.	Has	the	patient	
been	admitted	into	
hospital?	
9.	Form/Site	of	
TB	
10.		Smear	 11.	Culture	 12.	Culture	
sensitivity?	
	
Write	date:	
	
	
____/________/_____	
day	/			month		/			year	
	
(write	month	in	full)	
	
OR	
	
Don’t	know	
	
Circle:	
	
Yes		
	
	
No	
	
If	Yes:	
	
Circle	source:	
	
Hospital	
	
Clinic	at	Hospital	
	
Clinic	
	
Immigration	
	
Circle:	
	
Yes		
	
	
No	
	
If	Yes:	
	
Name	of	Hospital:	
	
________________	
	
Type	of	Hospital:	
(i.e.	public/private)	
	
________________	
	
Circle:	
	
Pulmonary	
	
Extra-Pulmo-
nary	
	
Both	
	
	
*	If	not	pulmo-
nary	or	both,	
do	not	pro-
ceed.	
	
Circle:	
	
Any	Positive	
	
All	Negative	
	
Circle:	
	
Any	Positive	
	
All	Negative	
	
Not	Done	
	
Circle:	
	
Not	done	
	
Sensitive	All	
	
OR	
	
Resistant	to:	
	
INH	(H)	
	
RIF	(R)	
	
PZA	(Z)	
	
EMB	(E)	
	
STREP	(S)	
	
*	At	least	one	of	the	above	
must	be	positive	in	order	
for	the	patient	to	be	eligi-
ble	for	this	study	
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13.	What	
treatment	is	
the	patient	
on?	
14.	When	did	the	patient	
start	treatment?	
15.	Treatment	Supervision	
(current)	
16.	Does	
the	patient	
have	private	
insurance?	
17.	Co	morbidity?	
	
(Circle	all	that	apply)	
	
Circle	:	
	
INH	(H)	
	
RIF	(R)	
	
PZA	(Z)	
	
EMB	(E)	
	
STREP	(S)	
	
	
Write	Date:	
	
____/																													
/_______	
day	/					month													/			
year	
	
(write	month	in	full)	
	
Circle:	
	
Directly	Observed	Therapy	
(DOT)	
	
OR	
	
Self	Administered	Treat-
ment	(SAT)	
	
	
			
	If	DOT											OR									If	SAT	
	
Circle:	
	
Yes	
	
No	
	
Circle:	
	
Asthma/COPD	
Cancer	
Diabetes	
Diarrhea	
Fracture	
Gonorrhea	
Heart	Disease	
HIV/AIDS	
Intestinal	Parasites	
	
Syphilis	
Typhoid	
Urinary	Infection	
Other	STD	(Specify)	
_________________	
	
Other	Illness	(Specify)	
__________________	
	
Other	Injury	(Specify)	
	
__________________	
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OR	
	
WHO	
Scheme	1	
	
	
WHO	
Scheme	2	
	
Location:													
	
Health	Post	
	
Home	
	
Clinic	
	
Hospital	
	
Clinic	in	hos-
pital	
	
Other	(Spec-
ify)	
	
Frequency	
of	Med.	Pick	
up:	
	
Weekly	
	
Bi	Weekly	
	
Monthly	
	
	
Kidney	(renal)	di-
sease	
Malaria	
Malnutrition	
Measles	
Meningitis	
Poisoning	
	
	
Don’t	Know	
	
OR	
	
None	
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SECTION	2:	General	Questions		
	
Explain	to	the	patient	that	you	will	now	ask	them	a	few	general	questions	about	their	household,	education	and	employment	history.	
	
18.	How	many	people	
live	in	your	household?	
	
(i.e.	family	or	persons	
with	whom	you	share	
costs)	
19.	What	is	the	highest	
level	of	education	that	
you	have	completed?	
20.	What	type	(s)	of	work	do	you	do?	 21.	If	NOT	WORKING,	Please	provide	a	
reason	
Circle:	
	
One	
	
Two		
	
Three	
	
Four		
	
Five	or	more	
	
(Specify	number)		
	
________	
	
OR	
	
Lives	Alone	
Circle:	
	
None	
	
Primary	school	
	
Some	high	school	
	
Finished	high	school	
	
Above	high	school	
Write	Main	Type	of	work:	
	
	
	
	
Additional	Work:	
	
	
	
	
OR								
	
	Student	
	
OR									
	
Not	Working	
	
Circle:	
	
Unemployed											
	
Fired	
	
Contract	Ended						
	
Retired	
	
Other:	
	
	
	
	
Is	the	reason	for	Not	Working	related	
to	the	patient’s	TB	illness?	(please	
check	one)	
Yes	□						No	□	
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22.	What	is	YOUR	average	to-
tal	MONTHLY	take	home	earn-
ings	(after	tax)	&/or	the	TOTAL	
amount	of	financial	support	
you	receive	NOW?	
	
(includes	welfare,	disability,	or	
other	social	support,	but	not	
loans	due	to	illness)	
23.	What	was	YOUR	average	
total	MONTHLY	take	home	
earnings	(after	tax)	&/or	the	
TOTAL	amount	of	financial	sup-
port	you	received	PRIOR	TO	
YOUR	DIAGNOSIS?	
	
(includes	welfare,	disability,	or	
other	social	support)	
24.	What	is	your	HOUSEHOLD	
average	total	MONTHLY	take	
home	earnings	(after	tax)	&/or	
the	total	amount	of	financial	
support	your	household	receives	
NOW?	
	
(including	government	assis-
tance	and	money	sent	from	
overseas)		
	
*	Skip	this	question	if	the	patient	
lives	alone	
25.	What	was	your	HOUSEHOLD	
average	total	MONTHLY	take	
home	earnings	(after	tax)	&/or	
the	total	amount	of	financial	sup-
port	your	household	received	
PRIOR	TO	YOUR	DIAGNOSIS	WITH	
TB?	
	
(including	government	assistance	
and	money	sent	from	overseas)		
	
*	Skip	this	question	if	the	patient	
lives	alone	
	
Circle	Amount:	
	
Under	100$/month	
	
100-500$/month	
	
500-1000$/month	
	
More	than	1000$/month	
	
Circle	Amount:	
	
Under	100$/month	
	
100-500$/month	
	
500-1000$/month	
	
More	than	1000$/month	
	
Circle	Amount:	
	
Under	100$/month	
	
100-500$/month	
	
500-1000$/month	
	
More	than	1000$/month	
	
Circle	Amount:	
	
Under	100$/month	
	
100-500$/month	
	
500-1000$/month	
	
More	than	1000$/month	
	
*	Is	the	change	in	earnings	related	to	the	patient’s	TB	illness		
(please	check	one)	
Yes	□						No	□	
	
*	Is	the	change	in	earnings	related	to	the	patient’s	TB	illness		
(please	check	one)	
Yes	□						No	□	
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SECTION	3A:	Pre-Diagnostic	Period	–	History	of	Pre-Diagnostic	Medical	Visits	
	
Explain	to	the	patient	that	you	will	now	ask	them	some	questions	about	their	health	and	experiences	PRIOR	to	their	TB	diagnosis.			
	
26.	Which	of	the	following	
symptoms	did	you	have	
preceding	your	TB	diagno-
sis?	
27.	If	symptomatic:	
How	long	did	you	have	these	
symptoms	before	seeking	help?		
(health	facility	or	other	doc-
tor/expert)		
28.	Where	did	you	first	go	to	seek	
help	because	of	these	symptoms?	
29.	When	did	you	first	visit	this	fa-
cility/person	to	seek	help	for	your	
symptoms?	(month/year)	
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Circle:	
	
Cough	
	
Wheezing	or	asthma	like	
symptoms	
	
Sputum/phlegm	produc-
tion		
	
Blood	in	sputum	
	
Fatigue		
	
Fever/sweats	
	
Loss	of	appetite	
	
Weight	loss	
	
OR	
	
None/	Asymptomatic		
	
Write	amount	of	time	between	
first	symptoms	and	first	consulta-
tion:	
	
___________		
	
weeks	
	
months	
	
Name	of	first	location	(person)	
visited	
	
	
	
Type	of	facility	
	
Public	Clinic	
	
Private	Clinic		
	
Public	Hospital	
	
Private	Hospital	
	
Clinic	at	Public	Hospital		
	
Clinic	at	Private	Hospital		
	
Private	Doctor	
	
Health	Post	
	
Spiritual	Healer	
	
Pharmacy	
	
Other	_______________	
	
Date	of	first	visit:	
	
	
	
												(month/year)	
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*	Begin	by	reciting	to	the	patient	the	dates	of	their	TB	diagnosis	and	treatment	start	date	that	you	have	obtained	from	their	chart.	Check	
with	the	patient	that	they	agree	with	their	diagnosis	and	start	dates,	and	record	this	information	in	question	27a	before	beginning.	
	
30.	Starting	with	the	first	location,	please	list	ALL	the	locations	visited	PRIOR	to	the	TB	diagnosis	(for	any	respiratory	or	TB	related	symp-
toms)	
	
(Please	include	all	hospitals,	clinics,	pharmacies,	spiritual	healers,	and	other	sites	visited	because	of	TB	related	symptoms)	
*	Only	include	visits	made	up	to	one	year	ago	
Name	of	facility/person	 Type	of	facility/person	
(select	from	list	in	Q25)	
How	many	months	BEFORE	TB	
DIAGNOSIS	did	the	patient	
visit	this	facility/person?	
Was	the	patient	hospitalized	at	this	fa-
cility?	
	
If	YES,	fill	in	Section	5	–	Hospitalization	
If	NO,	fill	in		Section	3	–	Pre-Diagnosis	
1)	  months	 Yes	□						No	□	
2)	  months	 Yes	□						No	□	
3)	  months	 Yes	□						No	□	
4)	  months	 Yes	□						No	□	
5)	  months	 Yes	□						No	□	
6)	  months	 Yes	□						No	□	
7)	  months	 Yes	□						No	□	
8)	  months	 Yes	□						No	□	
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31.	Where	were	you	officially	diagnosed	with	TB?		
	
			Write	name	of	location:	
When	were	you	officially	diag-
nosed	with	TB?		
	
	
	
												(month/year)	
Were	you	hospitalized	during	diagno-
sis?	
Yes	□						No	□	
	
If	NO	fill	in	the	details	in	Section	4	–	Di-
agnosis	
If	YES	fill	in	the	details	in	Section	5	–	
Hospital.	
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32.	Did	you	visit	anywhere	else	because	of	these	symptoms	or	because	you	were	instructed	to	do	so?	
	
Circle:	
	
Yes		
	
If	YES	return	to	the	previous	questions	and	complete	the	missing	information	
	
No	
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SECTION	3B:	Pre	Diagnostic	Period	–	Establishments	visited	(excluding	hospitalizations)	
	
	
3.1	First	Location	Visited	Prior	to	Diagnosis	(if	hospitalized,	fill	in	details	in	SECTION	5	–	Hospitalization	Period)	
	
33.	Name	of	First	Location	visited	pre-diagno-
sis,	listed	in	Q30,	excluding	hospitalizations.	
		
34.	Type	of	Facility	 35.	Were	you	diagnosed	at	
this	location?		
36.	How	many	times	did	
you	visit	this	place?	
	
Name	of	first	location/facility:	
	
Circle:	
	
Public	Clinic	
	
Private	Clinic		
	
Clinic	at	Public	Hospital		
	
Clinic	at	Private	Hospital		
	
Private	Doctor	
	
Health	Post	
	
Spiritual	Healer	
	
Pharmacy	
	
Other		
(Specify)_______________	
	
Circle:	
	
Yes		
	
	If	YES,	skip	this	section	and	
go	to	Section	4	(DIAGNOSIS)	
	
	
No	
	
Circle:	
	
One	
	
Two		
	
Three	
	
Four	
	
Five	or	more	
	
(Specify	number)		
	
		___________	
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37.	How	long	on	average	did	
you	spend	traveling	to	and	
from	the	facility?		
38.	How	long	on	average	did	
one	of	these	visits	take?		
	
(include	waiting	time,	consulta-
tion	and	tests)	
39.	Did	any	family	or	friend	ac-
company	you	on	these	visits?	
40.	How	many	visits	did	your	family	
member/friend	accompany	you	
for?	
	
Write	total	travel	time:		
	
	
																													
	
Hours	
	
Minutes	
	
Write	total	consultation	time:		
	
	
																													
	
Hours	
	
Minutes	
Circle:	
	
Yes		
	
No	
Circle:	
	
None	
	
Almost	none	
	
Some	
	
Most	
	
All	
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41.	What	did	you	or	your	accompanier	have	to	pay	for	at	this	establishment	or	following	your	appointments?	
	
WRITE	ZERO	here	if	patient	had	no	expenditures:__________	
	
WRITE	TOTAL	if	patient	only	knows	total	amount:_________$	
 Amount	 Per	Visit	 Total	
Parking	    
Travel	    
Registration	fee	    
Paperwork	fee	    
Consultation	    
Blood	Tests	    
Medication	(TB	or	Non-TB)	    
X-ray	    
Food	    
Other	(Specify	
__________________	
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3.2	Second	Location	Visited	Prior	to	Diagnosis	(if	hospitalized,	fill	in	details	in	SECTION	5	–	Hospitalization	Period)	
42.	Name	of	Second	Location	visited	pre-di-
agnosis	listed	in	Q30,	excluding	hospitaliza-
tions	
43.	Type	of	Facility	 44.	Were	you	diagnosed	at	
this	location?		
45.	How	many	times	did	
you	visit	this	place?	
	
Name	of	second	location/facility:	
	
Circle:	
	
Public	Clinic	
	
Private	Clinic		
	
Clinic	at	Public	Hospital		
	
Clinic	at	Private	Hospital		
	
Private	Doctor	
	
Health	Post	
	
Spiritual	Healer	
	
Pharmacy	
	
Other	
(Specify)_______________	
	
Circle:	
	
Yes		
	
	If	YES,	skip	this	section	and	
go	to	Section	4	(DIAGNOSIS)	
	
	
No	
	
Circle:	
	
One	
	
Two		
	
Three	
	
Four	
	
Five	or	more	
	
(Specify	number)		
	
		___________	
	
	
	
	
	
 205 
SECTION 3 – PRE DIAGNOSTIC PERIOD – Second Location 
	
	
46.	How	long	on	average	did	
you	spend	traveling	to	and	
from	the	facility?		
47.	How	long	on	average	did	
one	of	these	visits	take?		
	
(include	waiting	time,	consulta-
tion	and	tests)	
48.	Did	any	family	or	friend	ac-
company	you	on	these	visits?	
49.	How	many	visits	did	your	family	
member/friend	accompany	you	
for?	
	
Write	total	travel	time:		
	
	
																													
	
Hours	
	
Minutes	
	
Write	total	consultation	time:		
	
	
																													
	
Hours	
	
Minutes	
Circle:	
	
Yes		
	
No	
Circle:	
	
None	
	
Almost	none	
	
Some	
	
Most	
	
All	
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50.	What	did	you	or	your	accompanier	have	to	pay	for	at	this	establishment	or	following	your	appointments?	
	
WRITE	ZERO	here	if	patient	had	no	expenditures:__________	
	
WRITE	TOTAL	if	patient	only	knows	total	amount:_________$	
 Amount	 Per	Visit	 Total	
Parking	    
Travel	    
Registration	fee	    
Paperwork	fee	    
Consultation	    
Blood	Tests	    
Medication	(TB	or	Non-TB)	    
X-ray	    
Food	    
Other	(Specify)	
__________________	
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3.3	Third	Location	Visited	Prior	to	Diagnosis	(if	hospitalized,	fill	in	details	in	SECTION	5	–	Hospitalization	Period)	
51.	Name	of	Third	Location	visited	pre-di-
agnosis,	listed	in	Q30,	excluding	hospitali-
zations	
52.	Type	of	Facility	 53.	Were	you	diagnosed	at	
this	location?		
54.	How	many	times	did	
you	visit	this	place?	
	
Name	of	third	location/facility:	
	
Circle:	
	
Public	Clinic	
	
Private	Clinic		
	
Clinic	at	Public	Hospital		
	
Clinic	at	Private	Hospital		
	
Private	Doctor	
	
Health	Post	
	
Spiritual	Healer	
	
Pharmacy	
	
Other		
(Specify)_______________	
	
Circle:	
	
Yes		
	
	If	YES,	skip	this	section	and	
go	to	Section	4	(DIAGNOSIS)	
	
	
No	
	
Circle:	
	
One	
	
Two		
	
Three	
	
Four	
	
Five	or	more	
	
(Specify	number)		
	
		___________	
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55.	How	long	on	average	did	
you	spend	traveling	to	and	
from	the	facility?		
56.	How	long	on	average	did	
one	of	these	visits	take?		
	
(include	waiting	time,	consulta-
tion	and	tests)	
57.	Did	any	family	or	friend	ac-
company	you	on	these	visits?	
58.	How	many	visits	did	your	family	
member/friend	accompany	you	
for?	
	
Write	total	travel	time:		
	
	
																													
	
Hours	
	
Minutes	
	
Write	total	consultation	time:		
	
	
																													
	
Hours	
	
Minutes	
Circle:	
	
Yes		
	
No	
Circle:	
	
None	
	
Almost	none	
	
Some	
	
Most	
	
All	
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59.	What	did	you	or	your	accompanier	have	to	pay	for	at	this	establishment	or	following	your	appointments?	
	
WRITE	ZERO	here	if	patient	had	no	expenditures:__________	
	
WRITE	TOTAL	if	patient	only	knows	total	amount:_________$	
 Amount	 Per	Visit	 Total	
Parking	    
Travel	    
Registration	fee	    
Paperwork	fee	    
Consultation	    
Blood	Tests	    
Medication	(TB	or	Non-TB)	    
X-ray	    
Food	    
Other	(Specify)	
__________________	
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3.4	Fourth,	Fifth,	and	Sixth	Location	Visited	Prior	to	Diagnosis	(if	hospitalized,	fill	in	details	in	SECTION	5	–	Hospitalization	Period)	
60.	How	many	VISITS	did	you	
make	to	additional	health	estab-
lishments	prior	to	your	diagno-
sis?	
	
(Include	all	visits	made	to	the	
fourth,	fifth	and	sixth	sites	listed	
in	Q30,	excluding	hospitaliza-
tions)	
61.	What	did	you	or	your	accompanier	have	to	pay	for	at	all	of	these	additional	visits?	
	
WRITE	ZERO	here	if	patient	had	no	expenditures:__________	
	
WRITE	TOTAL	if	patient	only	knows	total	amount:_________$	
	
Circle:	
	
One	
	
Two		
	
Three	
	
Four	
	
Five	or	more	
	
(Specify		number)		
	
_____________	
 Amount	 Per	Visit	 Total	
Parking	    
Travel	    
Registration	fee	    
Paperwork	fee	    
Consultation	    
Blood	Tests	    
Medication	(TB	or	Non-TB)	    
X-ray	    
Food	    
Other	(Specify)	
__________________	
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62.	Where	were	you	diag-
nosed	for	Tuberculosis	
(TB)?	
	
(If	diagnosed	while	hospi-
talized,	write	HOSPITAL	
below,	skip	the	remainder	
of	this	section	and	collect	
information	about	the	stay	
in	SECTION	5)	
63.	How	many	
times	did	you	
visit	this	clinic	
during	your	di-
agnosis	period?	
	
(including	all	ini-
tial	visit(s),	spu-
tum	inductions	
and	visit	where	
patient	was	in-
formed	of	diag-
nosis)	
64.	How	long	on	average	
did	you	spend	traveling	
to	and	from	the	facility?		
65.	How	long	on	average	
did	one	of	these	visits	
take?		
	
(including	waiting	time,	
consultation	and	tests)	
66.	Did	any	
family	or	
friend	accom-
pany	you	on	
these	visits?	
67.	How	many	
visits	did	your	
family/friend	ac-
company	you	
for?	
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SECTION	4:	Diagnosis	Period	
Explain	to	the	patient	that	the	following	sec-
tion	collects	information	on	the	establishment	
in	which	their	diagnosis	was	made.	
			
	
Write	location:	
	
______________________	
	
Circle:	
	
One	
	
Two		
	
Three	
	
Four	
	
Five	or	more	
	
(Specify	num-
ber)		
	
Write	total	travel	time:		
	
	
																													
	
Hours	
	
Minutes	
	
Write	total	consultation	
time:		
	
	
																													
	
Hours	
	
Minutes	
	
Circle:	
	
Yes		
	
No	
	
Circle:	
	
None	
	
Almost	none	
	
Some	
	
Most	
	
All	
 214 
SECTION 4 – DIAGNOSIS PERIOD  
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68.	What	did	you	or	your	accompanier	have	to	pay	for	at	the	establishment	that	you	were	diagnosed	at,	or	following	your	appointments?	
	
WRITE	ZERO	here	if	patient	had	no	expenditures:__________	
	
WRITE	TOTAL	if	patient	only	knows	total	amount:_________$	
 Amount	 Per	Visit	 Total	
Parking	    
Travel	    
Registration	fee	    
Paperwork	fee	    
Consultation	    
Blood	Tests	    
Medication	(TB	or	Non-TB)	    
X-ray	    
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Other	Tests		    
Food	    
Other	(Specify)	
__________________	
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SECTION	5	Hospitalization	periods:		
	
Explain	to	the	patient	that	the	following	section	collects	information	about	the	period	when	they	were	hospitalized.	It	is	only	for	patients	
who	have	been	ADMITTED	into	hospital	FOR	ANY	REASON	for	at	least	ONE	NIGHT	due	to	their	illness	(including	any	hospitalization	in	the	SIX	
MONTHS	leading	up	to	their	TB	diagnosis).	If	the	patient	was	not	admitted	into	hospitals	then	SKIP	THIS	SECTION.	
69.	Were	you	hospitalized	
for	any	illness	in	the	6	
months	leading	up	to	your	
diagnosis	of	TB?	
70.	Were	you	diagnosed	
for	any	of	the	following	
conditions?	
71.	Where	were	you	hospitalized	for	these	conditions?	
	
Circle:	
	
Yes		
	
	
No	
	
If	NO	skip	to	SECTION	6	
	
Circle:	
	
Pneumonia	
	
Bronchitis	
	
Asthma	
	
Respiratory	problems	
	
Lung	conditions	
	
Weight	loss	
	
Other	
	
Specify____________	
	
Write	hospital	name(s):	
(please	check	correct	period	for	each	
stay)	
	
Duration	of	hospital	stay:	
(please	circle	units)	
	
1)	Name:	______________________	
Pre-diagnosis	
During	diagnosis	
Post-diagnosis	
	
	
	
											
							days										weeks											months	
	
2)	Name:	______________________	
Pre-diagnosis	
During	diagnosis	
Post-diagnosis	
	
	
	
											
							days										weeks											months	
	
3)	Name:______________________	
Pre-diagnosis	
During	diagnosis	
Post-diagnosis	
	
	
	
											
							days										weeks											months	
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5.1	–	Information	pertaining	to	the	Most	Recent	Hospitalization	
The	following	questions	relate	ONLY	to	the	most	recent	hospital	stay.	Make	sure	the	patient	is	only	giving	information	related	to	the	most	
recent	hospitalization.	
72.	On	your	MOST	RE-
CENT	stay	did	any	fam-
ily/friends	STAY	with	you	
while	in	hospital?	
	
(i.e.	sleep	in	the	hospital	
with	you)	
73.	For	how	many	days?	 74.	On	your	most	recent	
stay	did	any	fam-
ily/friends	VISIT	you	
while	you	were	in	hospi-
tal?	
75.	How	long	on	average	
did	ONE	visit	last?		
76.	On	how	many	days	
did	you	have	friends	or	
family	visiting	you?	
	
Circle:	
	
Yes		
	
No	
	
If	NO	skip	to	Q74	
	
Circle:	
	
None	
	
Almost	none	
	
Some	
	
Most	
	
All	
	
Circle:	
	
Yes		
	
No	
	
If	NO,	skip	to	Q77	
	
Write	time:	
	
	
	
	
Minutes	
	
Hours		
	
Circle:	
	
None	
	
Almost	none	
	
Some	
	
Most	
	
All	
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77.	On	your	MOST	RECENT	hospital	stay,	what	did	you	have	to	pay	for?	
WRITE	ZERO	here	if	patient	had	no	expenditures:__________	
WRITE	TOTAL	if	patient	only	knows	total	amount:_________$	
 Amount	 Per	Day	 Total		
Parking	    
Travel	    
Registration	fee	    
Paperwork	fee	    
Consultation	    
Blood	Tests	    
Medication	(TB	or	Non-TB)	    
X-ray	    
Food	    
Sheets	    
Other	(Specify)	
____________________	
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SECTION	6:	DOT/DOSSETTE	pill	collection	visits			
Carefully	explain	that	the	following	questions	are	for	pill	collection	visits.	This	section	is	ONLY	APPLICABLE	TO	PATIENTS	WHO	HAVE	CLINIC	
VISITS	THAT	ARE	EXCLUSIVELY	FOR	THE	COLLECTION	OF	TB	PILLS.	This	strictly	means	clinic	visits	to	collect	one	dose	of	TB	pills,	and	does	NOT	
INCLUDE	VISITS	WHERE	ANYTHING	ELSE	IS	DONE.		If	the	patient’s	treatment	is	SELF	ADMINISTERED	or	if	a	pill	collection	visit	is	combined	
with	follow	up/monitoring	activities	(ex.	taking	blood,	or	looking	at	side	effects)	by	a	nurse	or	doctor,	skip	this	section	and	record	this	infor-
mation	the	next	section,	SECTION	7.	
78.	How	often	do	you	go	to	
the	clinic	for	DOT	to	pick	up	
pills	ONLY?	
79.	How	long	does	it	
take	you	to	travel	to	
and	from	the	facility	
to	collect	your	pills?		
80.	How	long	does	it	
take	to	pick	up	your	
pills?	
81.	Do	any	family	members	or	
friends	accompany	you	on	
these	visits?	
82.	How	many	visits	
do	your	friends	or	
family	member	ac-
company	you	for?	
	
Circle:	
	
Daily	
	
Once	per	week	
	
Twice	per	week	
	
3	times	per	week	
	
Write	total	time:	
	
_______________	
	
	
Hours	
	
Minutes	
	
Write	total	time:	
	
_____________minutes	
	
Circle:	
	
Yes		
	
No	
	
Circle:	
	
None	
	
Almost	none	
	
Some	
	
Most	
	
All	
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83.	What	did	you	or	your	accompanier	have	to	pay	for	during	DOT	(pill	collection	visits)?	
	
WRITE	ZERO	here	if	patient	had	no	expenditures:__________	
 Amount	 Per	Visit	
Parking	   
Travel	   
Medication	(TB	or	Non-TB)	   
Food	   
Other	(Specify)	
__________________	
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SECTION	7:	TB	Follow-up	visits			
Explain	to	the	patient	that	this	section	collects	information	on	all	visits	made	to	the	clinic	during	TB	follow	up.	This	includes	monthly	TB	fol-
low	up	visits	to	the	doctor,	or	more	frequent	visits	for	combined	visits	to	collect	medication	and	have	blood	tests	etc.	This	section	includes	
all	visits	except	for	strict	DOT	visits	that	have	already	been	discussed	in	SECTION	6.	
84.	Where	do	you	go	for	
your	TB	follow	up	appoint-
ments?	
85.	How	regularly	do	you	
go	to	see	the	doctor	who	
is	following	you	for	TB	
since	you	were	diagnosed?	
	
(To	see	nurse/doctor	for	
any	TB	related	medical	
evaluation,	tests	etc.)	
86.	How	long	on	aver-
age	does	one	of	these	
follow	up	visits	take	
(including	travel	time,	
all	waiting	time	and	
seeing	the	doctor)?	
87.	Do	any	family/friends	ac-
company	you	on	these	visits?	
88.	How	many	visits	
have	your	family	
member/	friend	ac-
companied	you	for?	
Write	Location:	
	
________________	
Circle:	
	
Monthly	
	
Twice	a	month	
	
Weekly	
Write	total	time:	
	
_______________	
	
	
Hours	
	
Minutes	
Circle:	
	
Yes	
	
No	
Circle:	
	
None	
	
Almost	none	
	
Some	
	
Most	
	
All	
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89.	With	these	follow	up	visits	in	mind,	what	did	you	or	your	accompanier	have	to	pay	for	at	the	Doctors	office	and	EACH	VISIT?	
WRITE	ZERO	here	if	patient	had	no	expenditures:__________	
 Amount	 Per	Visit	
Parking	   
Travel	   
Registration	fee	   
Paperwork	fee	   
Consultation	   
Blood	Tests	   
Medication	(TB	or	Non-TB)	   
X-ray	   
Food	   
Other	(Specify)	
__________________	
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SECTION	8:	Events	throughout	Illness		
Explain	to	the	patient	that	the	following	questions	pertain	to	events	that	have	occurred	throughout	their	illness,	and	how	they	feel	their	TB	
has	affected	their	daily	activities	and	their	family.	The	questions	at	the	end	of	this	section	are	slightly	more	general	than	previous	questions.	
The	patient	may	need	to	be	reminded	of	some	of	the	disruptions	that	they	mentioned	earlier	in	the	interview,	or	that	you	may	have	picked	
up	on	at	any	point	throughout	the	interview.		
90.	Have	you	missed	any	addi-
tional	time	from	your	principal	
daily	activities	(work/school)	be-
cause	of	your	TB	illness?		
	
(Excluding	visits	to	see	the	doc-
tor	or	hospitalization,	which	
have	been	captured	in	previous	
sections)		
91.	Have	you	needed	to	borrow/	
been	given	any	extra	money	be-
cause	of	your	TB	illness?	
92.	Has	your	TB	illness	af-
fected	your	ability	to	com-
plete	your	household	chores	
and	activities?	
93.	Which	of	the	following	has	
your	TB	caused	you	to	have	
problems	completing?		
	
Circle:	
	
Yes	
	
No	
	
IF	Yes,	
	
How	long	in	total		
	
TOTAL:___________	
	
Days	
	
Weeks	
		
Months	
	
Circle:	
	
Yes	
	
No	
	
IF	Yes,	
	
Write	TOTAL:		$_______	
	
Circle:	
	
Yes	
	
No	
	
If	NO,	skip	to	Q96	
	
Circle:	
	
Child	care	
	
Laundry	
	
Cooking	or	meal	preparation	
	
Shopping	
	
House	maintenance	
	
Carrying	loads	
	
Other___________	
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94.	Have	you	received	any	extra	
help	(PAID	or	UNPAID)	because	
your	illness	has	affected	your	
ability	to	complete	these	chores?		
95.	Please	specify	the	kind(s)	and	duration	of	help	the	patient	(or	family)	has	received	due	to	the	pa-
tient’s	illness:	
	
Circle:	
	
Yes	
	
No	
	
If	NO,	skip	to	Q96	
Type	of	Help	
	
Circle:	
Time	and	Cost	
(complete	the	information	for	the	relevant	time	period)	
	
Paid	
	
Pre-diagnosis	
How	much	did	you	pay	for	this	extra	help	PER	WEEK?		$___________/week 
For	how	many	weeks:		____________weeks	
	
Post-diagnosis	
How	much	did	you	pay	for	this	extra	help	PER	WEEK?		$___________/week	
For	how	many	weeks:		____________weeks	
	
Unpaid	-	Family		
	
Pre-diagnosis	
Average	number	of	additional	hours	per	week	spent	with	or	for	the	patient	
______hours	
For	how	many	weeks:		____________weeks	
	
Post-diagnosis	
Average	number	of	additional	hours	per	week	spent	with	or	for	the	patient	
______hours	
For	how	many	weeks:		____________weeks		
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Unpaid	–	other	
	
Specify	
____________	
	
Pre-diagnosis	
Average	number	of	additional	hours	per	week	spent	with	or	for	the	patient	
______hours	
For	how	many	weeks:		____________weeks	
	
Post-diagnosis	
Average	number	of	additional	hours	per	week	spent	with	or	for	the	patient	
______hours	
For	how	many	weeks:		____________weeks		
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96.	Are	you	currently	
buying	any	supplements	
(e.g.	energy	drink,	vita-
mins,	medicine…)	due	to	
your	illness?	
	
(not	including	costs	al-
ready	captured	in	previ-
ous	sections)	
97.	How	much	do	you	spend	on	
these	items	per	month?	
98.	Throughout	your	illness,	how	
has	your	household	routine	
changed	since	you	have	been	diag-
nosed	with	TB?	(This	includes	
changing	rooms	to	sleep,	using	dif-
ferent	utensils	and	dishes	)	
99.	How	has	TB	affected	your	fam-
ily	(your	children	or	between	you	
and	your	partner)?	
	
		
Circle:	
	
Yes	
	
No	
 
If	NO,	skip	to	Q98	
Item	 Extra	cost	
/month	
Please	explain:	
	
	
_____________________________
___	
_____________________________
___	
_____________________________
___	
_____________________________
___	
_____________________________
___	
_____________________________
___	
_____________________________
___	
_____________________________
___	
_____________________________
___	
Please	explain:	
	
	
____________________________
____	
____________________________
____	
____________________________
____	
____________________________
____	
____________________________
____	
____________________________
____	
____________________________
____	
____________________________
____	
____________________________
____	
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100.	How	does	TB	affect	you	physically	
today?	
101.	How	does	TB	affect	you	socially	
today?	
	
(This	includes	effects	related	to	stigma-
tization	isolation,	rejection	and	fear)	
102.	How	do	you	feel	that	TB	will	impact	you	and	
your	family	in	the	future?	
Please	explain:	
	
	
________________________________	
________________________________	
________________________________	
________________________________	
________________________________	
________________________________	
________________________________	
________________________________	
________________________________	
Please	explain:	
	
	
________________________________	
________________________________	
________________________________	
________________________________	
________________________________	
________________________________	
________________________________	
________________________________	
________________________________	
Please	explain:	
	
	
________________________________	
________________________________	
________________________________	
________________________________	
________________________________	
________________________________	
________________________________	
________________________________	
________________________________	
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Extra	question:	Do	you	have	any	other	concerns	about	your	medical	visits,	your	experiences	with	TB	or	the	effect	that	TB	has	had	on	you	
and	your	family?	
__________________________________________________________________________________________________________________
__________________________________________________________________________________________________________________
__________________________________________________________________________________________________________________
_________________________________________________________________________________________	
	
Extra	Pages	for	Longer	Answers:			
__________________________________________________________________________________________________________________
__________________________________________________________________________________________________________________
__________________________________________________________________________________________________________________
______		
Please note that if the patient provides you with information that 
makes you think that they may be carrying out activities that are 
affecting their TB treatment or may be damaging their health, or if the 
patient expresses fears and doubts about their illness, please ask the 
patient if they would mind if you relayed some of their concerns to 
the nurse in charge of their care for further follow up. 
 
